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Abstract 
 
Effective clinical audit can contribute to the maintenance and improvement of clinical 
performance through the opportunity for timely analysis, reflection and action to 
address perceived deficiencies or learn from exceptional performance. The 
importance of these systems has been highlighted by a marked increase in public 
demand for transparency in health care due to investigations such as the 2001 inquiry 
into paediatric cardiac surgery at the Bristol Royal Infirmary and the Queensland 
Public Hospitals Commission of Inquiry in 2005.  
 
Both inquiries provided a retrospective examination of the respective health care 
systems which highlighted the absence of adequate mechanisms to appropriately 
monitor performance. Arising from these inquiries was a series of recommendations 
on how the standard of patient care could be enhanced, including the need for the 
establishment of effective and efficient clinical governance frameworks.   
 
ix 
To address this issue, this thesis explores the development and implementation of a 
systematic approach to the use of risk adjusted statistical process control tools for the 
monitoring and improvement of clinical outcomes in interventional cardiology. To 
achieve this goal, three objectives are dealt with; the identification of a suite of 
clinical outcome indicators (with risk adjustment) to characterise performance of the 
service, the development of charting tools suitable for monitoring the various 
indicators and implementation and validation of a governance process to maintain, if 
not improve, clinical standards.   
 
The contribution this thesis makes is to extend the use of statistical process control 
techniques from the monitoring of isolated single measures of performance through 
the use of univariate control charts to deliver a structured process capable of 
monitoring and improving the performance of a clinical service. As such the major 
contribution made by this work goes to the development, validation and application of 
statistical techniques to support a structured clinical governance processes. 
x 
xi 
 
 
 
 
 
 
 
 
 
 
 
List of Publications 
This thesis is comprised of 12 papers that have been published, accepted or submitted 
for publication to journals or have been presented at conferences. Details of the papers 
and their current status is provided below: 
Chapter 3: Smith IR, Rivers JT, Mengersen KL, Cameron J. Performance 
Monitoring in Interventional Cardiology: Application of Statistical 
Process Control to a Single-Site Database. Eurointervention, 2011 
Mar;6(8):955-62.  
Chapter 4:  Lavercombe PS, Bentley GJ, Smith IR. Site Specific Recalibration of 
APACHE II: Issues for Sequential Performance Monitoring. ANZICS 
Scientific Meeting on Intensive Care Medicine. Rotorua, NZ, 2007. 
Abstract published in Anaesthesia and Intensive Care 2007 35(6): 
1004-1005. 
xii 
 
 
Chapter 5:  Smith IR, Rivers JT, Mengersen KL, Cameron J. Performance An 
Exponentially Weighted Moving Average Chart for Monitoring Low 
Event Rate Outcomes: Application to Lesion Treatment Failure in PCI. 
Submitted to BMJ Quality & Safety, Dec 2012. 
Chapter 6: Stevens NT, Steiner SH, MacKay RJ, Smith IR. Monitoring Radiation 
Use in Cardiac Fluoroscopy Imaging Procedures. Med Phys. 2011 
Jan;38(1):317-26 
Chapter 7: Smith IR, Cameron J., Mengersen KL, Foster KA, Rivers JT 
Monitoring Lesion Treatment Failure Rate in Percutaneous Coronary 
Interventions. Accepted to Heart Lung Circ., Oct 2012. 
Chapter 8: Waterhouse MA, Smith IR, Assareh H, Mengersen K. Implementation 
of multivariate control charts in a clinical setting, International Journal 
for Quality in Health Care, 2010 22 (5): 408-414. 
Chapter 9: Assareh H, Smith I, Mengersen K. Bayesian Change Point Detection in 
Monitoring Cardiac Surgery Outcomes. Quality Management in 
HealthCare 2011 Vol. 20, No. 3, pp. 227–232 
Chapter 10: Smith IR, Foster KA, Brighouse RD, Cameron J, Rivers JT. The role 
of quantitative feedback in coronary angiography radiation reduction.  
International Journal for Quality in Health Care. 2011 Jun;23(3):342-
8. Epub 2011 Apr 19. 
Chapter 11: Smith IR, Cameron J, Brighouse RD, Ryan C, Foster KA, Rivers JT 
Impact of quantitative feedback and benchmark selection on radiation 
use by cardiologists performing cardiac angiography. Radiation 
Projection Dosimetry. 2012 Oct 18. [Epub ahead of print] 
xiii 
Chapter 12: Smith IR, Cameron J, Mengersen KL, Rivers JT. Evaluation of 
coronary angiographic projections to balance the clinical yield with the 
radiation risk. Br J Radiol. 2012 85, e722-e728.  
Chapter 13: Smith IR., Garlick B, Gardner MA, Brighouse RD, Foster KA, Rivers 
JT. Use of Graphical Statistical Process Control Tools to Monitor and 
Improve Outcomes in Cardiac Surgery. Heart Lung Circ. 2012 Oct 11. 
[Epub ahead of print] 
Chapter 14: Smith IR, Garlick B, Gardner MA, Brighouse RD., Foster KA, Rivers 
JT. Validation of the Use of Cardiopulmonary Bypass Duration as a 
Marker for Cardiac Surgical Performance. Submitted to International 
Journal for Quality in Health Care, September 2012.  
 
 
 
  
  
  
  
  
  
  
  
  
  
xiv 
 
xv 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
I would like to acknowledge my academic supervisor, Professor Kerrie Mengersen. It 
was a privilege and an inspiration to have worked with her. This thesis would not 
have been possible without her immense patience, gentle guidance and tireless 
encouragement. 
 
Thanks must also go to Dr David Cook, who in the early phases of this work provided 
valuable guidance on not only the technical and clinical aspects of research but also 
the need to maintain a healthy work/life balance. To Drs Hassan Assareh and Mary 
Waterhouse of QUT, I very much appreciated the opportunity to collaborate with you 
on various papers.  
 
I am indebted to my colleagues at the St Andrew’s Medical Institute for their tireless 
encouragement. Whilst individually acknowledging the contributions of Dr John 
Rivers, Mr Russell Brighouse and Dr Kelley Foster, who freely offered their well 
xvi 
considered thoughts and comments, it would be remiss of me not to emphasise that 
every member of the SAMI team deserves my gratitude for their tireless dedication to 
ensuring that good quality data was available for my work. Special thanks also goes to 
Janet Collins for her assistance in preparation this thesis. 
 
Appreciation must also go to the administration, visiting medical officers and staff of 
St Andrew’s War Memorial Hospital and Uniting Care Health for supporting and 
encouraging me to undertake this work. In particular I am grateful to Dr James 
Cameron, Dr Peter Lavercombe, Dr Ian Brandon and Dr Michael Gardner for giving 
their time and encouragement in support of my endeavours.  
 
I must also thank my parents Beth and Keith for encouraging me throughout my life 
to follow my dreams.  
 
Last but by no means least, to Susan, Madeline and Lucas, words cannot express my 
thanks. Your unshakable love and support was the essential fuel that allowed me to 
finish this journey. 
 
xvii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
Keywords ......................................................................................................................... v 
Abstract ......................................................................................................................... viii 
List of Publications ........................................................................................................ xi 
Acknowledgements ....................................................................................................... xv 
Contents ....................................................................................................................... xvii 
List of Figures ............................................................................................................ xxvii 
List of Tables .......................................................................................................... xxxviii 
Statement of Original Authorship .............................................................................. xlii 
xviii 
1. Introduction ................................................................................................................. 1 
1.1   Motivation ............................................................................................. 1 
1.2   Clinical Background .............................................................................. 5 
1.3   Research Aim ........................................................................................ 7 
1.4   Research Objectives .............................................................................. 9 
1.4.1 Objective 1: Performance Measures for PCI ................................ 9 
1.4.2 Objective 2: Control Charts for Monitoring PCI Outcomes ....... 10 
1.4.3 Objective 3: Use of SPC in Clinical Governance ....................... 11 
1.5   Research Contribution ......................................................................... 12 
1.5.1 Contribution to Application ........................................................ 12 
1.5.2 Contribution to Method .............................................................. 13 
1.6   Thesis Structure ................................................................................... 14 
1.7   Thesis Outline...................................................................................... 14 
Bibliography ................................................................................................ 20 
2. Literature Review ..................................................................................................... 21 
2.1   Introduction ......................................................................................... 21 
2.2   Clinical Registries in Quality Improvement ........................................ 22 
2.3   Performance Management Processes .................................................. 26 
2.4   SPC in Interventional Cardiology ....................................................... 27 
2.5   Statistical Tools: Control Charts ......................................................... 28 
2.5.1 CUmulative SUM (CUSUM) Charts .......................................... 29 
2.5.2 Cumulative Observed – Expected (O-E) Charts ......................... 31 
2.5.3 Exponentially Weighted Moving Average Charts: ..................... 33 
2.5.4 Funnel Plots ................................................................................ 36 
2.5.5 Multivariate SPC Charts ............................................................. 38 
2.6   Performance Indicators........................................................................ 40 
2.7   Risk Adjustment Algorithms in PCI ................................................... 43 
Bibliography ................................................................................................ 46 
3. Performance Monitoring in Interventional Cardiology ........................................ 54 
Preamble ...................................................................................................... 54 
3.1   Abstract ............................................................................................... 58 
xix 
3.2   Introduction ......................................................................................... 59 
3.3   Methods ............................................................................................... 60 
3.3.1  Data Collection: .......................................................................... 60 
3.3.2 Performance Measures: ............................................................... 62 
3.3.3 Choice of SPC methods: ............................................................. 65 
3.3.4 Chart Design: .............................................................................. 67 
3.4   Results ................................................................................................. 67 
3.5   Discussion ........................................................................................... 71 
3.5.1 Performance Measures: ............................................................... 72 
3.5.2 Governance Issues: ..................................................................... 74 
Bibliography ................................................................................................ 77 
4. Adaptation of Existing Risk Adjustment Models .................................................. 82 
Preamble ...................................................................................................... 82 
4.1   Abstract ............................................................................................... 86 
4.2   Introduction ......................................................................................... 87 
4.3   Materials & Methods: .......................................................................... 88 
4.4   Results ................................................................................................. 90 
4.5   Discussion ........................................................................................... 95 
4.6   Conclusion ........................................................................................... 99 
Bibliography .............................................................................................. 100 
5. Site Specific Risk Adjustment Models .................................................................. 103 
Preamble .................................................................................................... 103 
5.1   Abstract ............................................................................................. 106 
5.2   Introduction ....................................................................................... 106 
5.3   Methods ............................................................................................. 108 
5.3.1 Patients ...................................................................................... 108 
5.3.2 Control Chart Methodology ...................................................... 109 
5.3.3 Outcome Measure ..................................................................... 109 
5.3.4 Model Factors ........................................................................... 111 
5.3.5 Bayesian Model ........................................................................ 111 
5.3.6 Risk Factor Selection ................................................................ 112 
5.3.7 Application to Performance Monitoring ................................... 113 
xx 
5.4   Results ............................................................................................... 114 
5.5   Discussion ......................................................................................... 118 
5.5.1 RA Algorithm: .......................................................................... 121 
5.5.2 Outcomes Monitoring: .............................................................. 123 
5.5.3 Limitations: ............................................................................... 125 
Appendix: .................................................................................................. 126 
Bibliography .............................................................................................. 130 
6. Monitoring Radiation Use In Cardiac Fluoroscopy Imaging Procedures ......... 133 
Preamble .................................................................................................... 133 
6.1   Abstract ............................................................................................. 137 
6.2   Introduction ....................................................................................... 138 
6.2.1 Motivation ................................................................................. 138 
6.2.2 Goals ......................................................................................... 140 
6.3   Materials And Methods ..................................................................... 141 
6.3.1 Data ........................................................................................... 141 
6.3.2 Regression model building ....................................................... 144 
6.3.3 Control chart methodology ....................................................... 146 
6.3.4 Phase I analysis ......................................................................... 148 
6.4   Results ............................................................................................... 151 
6.4.1 Phase II Analysis ...................................................................... 151 
6.5   Discussion ......................................................................................... 153 
6.6   Conclusions ....................................................................................... 156 
Appendix ................................................................................................... 157 
Bibliography .............................................................................................. 163 
7. An Exponentially Weighted Moving Average Chart for Monitoring Low Event 
Rate Outcomes: Application to Lesion Treatment Failure in PCI ................ 165 
Preamble .................................................................................................... 165 
7.1   Abstract ............................................................................................. 169 
7.2   Introduction ....................................................................................... 170 
7.3   Method............................................................................................... 171 
7.3.1 EWMA Control Charts ............................................................. 171 
7.3.2 Alternative EWMA Control Limits .......................................... 172 
xxi 
7.3.3 Issues with Wilson’s Limits ...................................................... 173 
7.3.4 EWMA Design ......................................................................... 173 
7.3.5 CUSUM Chart .......................................................................... 174 
7.3.6 Chart Comparison ..................................................................... 174 
7.4   Results ............................................................................................... 175 
7.4.1 Comparison of Confidence Intervals ........................................ 175 
7.4.2 Chart Performance .................................................................... 175 
7.5   Discussion: ........................................................................................ 177 
7.6   Conclusion: ........................................................................................ 181 
Bibliography .............................................................................................. 182 
Appendix ................................................................................................... 184 
8. Implementation of Multivariate Control Charts in a Clinical Setting............... 191 
Preamble .................................................................................................... 191 
8.1   Abstract ............................................................................................. 194 
8.2   Introduction ....................................................................................... 194 
8.3   Methods ............................................................................................. 195 
8.3.1   Description of case study data .................................................. 195 
8.3.2  A general framework for multivariate monitoring ................... 196 
8.3.3   Control chart construction ........................................................ 198 
8.3.4   Outline of simulation study ....................................................... 200 
8.4   Results ............................................................................................... 202 
8.4.1   Case study ................................................................................. 202 
8.4.2   Simulation Study ....................................................................... 203 
8.5   Discussion ......................................................................................... 205 
Bibliography .............................................................................................. 209 
9. Bayesian Change Point Detection in Monitoring Cardiac Surgery Outcomes . 211 
Preamble .................................................................................................... 211 
9.1   Abstract ............................................................................................ 214 
9.2   Introduction ....................................................................................... 214 
9.3   Cardiac Surgery Data ........................................................................ 217 
9.3.1 Data Description ....................................................................... 217 
9.3.2 Process Monitoring ................................................................... 217 
xxii 
9.3.3 Change Point Detection ............................................................ 221 
9.4   Angioplasty Data ............................................................................... 229 
9.4.1  Data Description ....................................................................... 229 
9.4.2  Process Monitoring ................................................................... 229 
9.4.3  Change Point Detection ............................................................ 233 
9.5   Conclusion ......................................................................................... 236 
Appendix ................................................................................................... 238 
Bibliography .............................................................................................. 239 
10. Use of Quantitative Feedback to Drive Change in Clinical Practice ............... 242 
Preamble .................................................................................................... 242 
10.1   Abstract ........................................................................................... 246 
10.2   Introduction ..................................................................................... 247 
10.3   Methods ........................................................................................... 249 
10.3.1 Radiation Safety Interventions: ................................................ 249 
10.3.2 Study Data ................................................................................. 250 
10.3.3 Data Analysis ............................................................................ 252 
10.3.4 Statistical Notes ........................................................................ 253 
10.4   Results ............................................................................................. 254 
10.5   Discussion ....................................................................................... 256 
Bibliography .............................................................................................. 260 
11. Impact of Quantitative Feedback and Benchmark Selection On Radiation 
Use By Cardiologists Performing Cardiac Angiography ............................... 264 
Preamble .................................................................................................... 264 
11.1   Abstract ........................................................................................... 269 
11.2   Introduction ..................................................................................... 270 
11.3   Methods And Patients ..................................................................... 272 
11.3.1 Study population ....................................................................... 272 
11.3.2 Study design .............................................................................. 272 
11.3.3 Feedback mechanism ................................................................ 273 
11.3.4 Radiation metrics ...................................................................... 275 
11.3.5 Monitoring radiation use ........................................................... 277 
11.3.6 Motivation to change radiation use ........................................... 278 
xxiii 
11.3.7 Ethical statement ....................................................................... 278 
11.4   Results ............................................................................................. 279 
11.5   Discussion ....................................................................................... 282 
11.6   Conclusion ....................................................................................... 286 
Bibliography .............................................................................................. 288 
12. Optimising Clinical Practice ................................................................................ 291 
Preamble .................................................................................................... 291 
12.1   Abstract ........................................................................................... 295 
12.2   Introduction ..................................................................................... 296 
12.3   Methods ........................................................................................... 298 
12.3.1 Image Quality Information: ...................................................... 299 
12.3.2 Radiation Data: ......................................................................... 299 
12.3.3 Algorithm Description. ............................................................. 301 
12.4   Results ............................................................................................. 303 
12.5   Discussion ....................................................................................... 307 
12.6   Conclusion ....................................................................................... 311 
Bibliography .............................................................................................. 312 
13. Use of Graphical Statistical Process Control Tools to Monitor and Improve 
Outcomes in Cardiac Surgery ........................................................................... 315 
Preamble .................................................................................................... 315 
13.1   Abstract ........................................................................................... 319 
13.2   Introduction ..................................................................................... 320 
13.3   Methods ........................................................................................... 321 
13.3.1 Data: .......................................................................................... 321 
13.3.2 Blood Product Use & Reoperation for Bleeding (BP/Reop): ... 322 
13.3.3 SPC Charts: ............................................................................... 323 
13.3.4 EWMA Chart Design Parameters: ............................................ 324 
13.3.5 Risk Adjustment: ...................................................................... 325 
13.3.6 Analysis of TXA: ...................................................................... 326 
13.4   Results ............................................................................................. 327 
13.5   Discussion ....................................................................................... 330 
13.6   Conclusion ....................................................................................... 332 
xxiv 
Acknowledgments: .................................................................................... 332 
Appendix: .................................................................................................. 333 
Bibliography .............................................................................................. 335 
14. Validation of the Use of Cardiopulmonary Bypass Duration as a Marker for 
Cardiac Surgical Performance .......................................................................... 339 
Preamble .................................................................................................... 339 
14.1   Abstract ........................................................................................... 343 
14.2   Introduction ..................................................................................... 344 
14.3   Methods ........................................................................................... 345 
14.3.1 Data: .......................................................................................... 345 
14.3.2 Monitored Variable: .................................................................. 347 
14.3.3 Control Chart Paradigm: ........................................................... 348 
14.3.4 Monitoring Process: .................................................................. 349 
14.3.5 Regression Model for CPBD’: .................................................. 350 
14.3.6 Design of Charts: ...................................................................... 350 
14.3.7 Change Point Detection: ........................................................... 351 
14.3.8 Cardiac Surgery Process Changes: ........................................... 352 
14.3.9 High CPBD Residual: ............................................................... 352 
14.4   Results ............................................................................................. 353 
14.5   Discussion ....................................................................................... 360 
14.5.1 CPBD as a Performance Indicator: ........................................... 360 
14.5.2 Monitoring CPBD: .................................................................... 362 
14.5.3 Impact of IO-TOE Use: ............................................................ 363 
14.6   Conclusion ....................................................................................... 364 
Bibliography .............................................................................................. 365 
15. Conclusion ............................................................................................................. 370 
15.1   Research Findings ........................................................................... 371 
15.1.1 Objective 1: Performance Measures for PCI ............................ 371 
15.1.2 Objective 2: Control Charts for Monitoring PCI Outcomes ..... 373 
15.1.3 Objective 3: Use of SPC in Clinical Governance ..................... 375 
15.1.4 Contribution to Method ............................................................ 378 
15.1.5 Contribution to Application ...................................................... 380 
xxv 
15.2   Future Research ............................................................................... 382 
15.2.1 Data Quality .............................................................................. 382 
15.2.2 Control Charting Methods ........................................................ 384 
15.2.3 Clinical Governance ................................................................. 386 
15.2.4 Health Services Resarch ........................................................... 387 
Bibliography: ............................................................................................. 389 
Full Bibliography ........................................................................................................ 391 
 
xxvi 
xxvii 
 
 
 
 
 
 
 
 
 
 
List of Figures 
3.1  CUSUM for monitoring the occurrence of Major Adverse Cardiac Events at 12 
months. The upper and lower graphs have been designed to detect a doubling 
and a halving of the odds of MACE with ‘h’ values of 3.6 (ARL0 ~ 2,500, 
ARL1 ~ 200) and -3.6 (ARL0 ~ 2,500, ARL1 ~ 450) respectively. The chart 
indicates that the MACE rate steadily increased from July 2005 and eventually 
signalled in February 2006. .................................................................................... 68 
3.2  Cumulative Expected – Observed (O-E) chart for monitoring the occurrence of 
Major Adverse Cardiac Events at 12 months Chart includes 95% confidence 
intervals. The Expected event rate for the chart was set to the average rate for the 
period from the 1st January 2003 to the 31st December 2005 (4.1%). The chart 
demonstrates that the MACE rate has been increasing since July 2005 and at 
present indicates that the unit has recorded approximately 15 events more than 
expected. ................................................................................................................. 68 
xxviii 
3.3  Funnel Plot comparing the 2006 12 month MACE rates associated with 
individual cardiologists to the overall average performance for the from the 1st 
January 2003 to the 31st December 2005 (4.1%). The chart demonstrates that the 
MACE rate for all clinicians is greater than the benchmark level but no 
clinician’s performance was in excess of the 99% upper threshold (taken to 
indicate performance significantly different to the benchmark). ........................... 69 
3.4  Graph depicting the relationship between Average Run Length (ARL), ‘h’ (left 
side of the graph) and odds ratio shift (right side of the graph) for the double 
sided CUSUM (benchmark MACE rate of 4.1%). A ‘h’ value of 3.6 provides an 
ARL0 of ~2500 (or a false alarm on average every 5 years) and ARL1 values of 
~200 and ~450 for odds shifts of x2 and x0.5 respectively (as shown in the curve 
on the right that links run lengths to odds shift). .................................................... 71 
4.1  EWMA (λ=0.05) of APACHE II predicted ROD by first admission date for 
patients admitted to the SAWMH ICU between January 2003 and December 
2007. Death events are indicated by vertical bars at date of initial admission to 
ICU. ........................................................................................................................ 91 
4.2  Calibration curve relating APACHE II predicted ROD to observed patient 
mortality rates for patients admitted to the SAWMH ICU between January 2003 
and December 2007. The 95% confidence intervals were calculated according to 
the ‘scores’ method with correction for continuity (Newcombe 1998). The 
sample cumulative density function describing the distribution of expected risk 
probabilities is also shown. .................................................................................... 92 
4.3  Graph of the prediction error (Expected – Observed deaths) for the APACHE II, 
Power Function and Odds Correction models. Analysis relates to each model’s 
performance across the full 2954 admissions (97 deaths) to the SAWMH ICU 
between January 2003 and December 2007.Model Predicted Risk is the ROD 
decile into which the respective model allocates an admission. ............................ 93 
4.4  Graph depicting the result of the cross validation analysis of the use of an odds 
correction and a simple power function based recalibration of the APACHE II 
xxix 
score. An average H-L statistic of 15.5 or less is taken as the acceptance level for 
adequate calibration. ............................................................................................... 94 
4.5  RA CUSUM derived using the odds correction model. The upper and lower 
graphs have been designed to detect a doubling and a halving of the odds of 
death with ‘h’ values of 4.2 (ARL0 = 5,250, ARL1 = 250) and -3.3 (ARL0 = 
1,750, ARL1 = 400) respectively. .......................................................................... 96 
4.6  RA CUSUM derived using the power function recalibration model. The upper 
and lower graphs have been designed to detect a doubling and a halving of the 
odds of death with ‘h’ values of 4.0 (ARL0 = 5,250, ARL1 = 270) and -3.1 
(ARL0 = 1,750, ARL1 = 430) respectively............................................................ 96 
5.1  Graph demonstrating calibration of the risk adjustment model based on the 
identified combination of factors. Performance of the model on Phase 1 data is 
shown as closed dots AUC=0.847, SE=0.015 and H-L p=0.65). The results for 
Phase 2 evaluation of the model is shown as open dots (AUC=0.765, SE=0.038 
and H-L p=0.11). .................................................................................................. 118 
5.2(a) Double sided CUSUM assuming constant risk for each lesion of 1.85%. The 
upper and lower graphs have been designed to detect a doubling and a halving of 
the odds of lesion failure. A ‘h’ value of 3.16 has been used resulting in CUSUM 
charts that exhibits an ARL0 of 3260 lesions (~ 5 years) and ARLs of 380 
(OR=2.0) and 880 (OR=0.5). The open dots indicate signal events at which time 
the charts reset. ..................................................................................................... 119 
5.2(b) Double sided CUSUM using the risk prediction algorithm to adjust for each 
lesion attempted. The upper and lower graphs have been designed to detect a 
doubling and a halving of the odds of lesion failure. A ‘h’ value of 3.11 has been 
used resulting in CUSUM charts that exhibits an ARL0 of 3260 lesions (~ 5 
years) and ARLs of 365 (OR=2.0) and 580 (OR=0.5). The open dots indicate 
signal events at which time the charts reset. ........................................................ 120 
xxx 
5.3  EWMA Chart tracking observed incidence of lesion failure against predicted 
risk of lesion failure. Confidence limits have been set to achieve similar ARL0 
to RA CUSUM. EWMA (Exp) and EWMA (Obs) are the graphs of expected 
failure rate (based on lesion risk) and observed failure rate (based on actual 
success or failure). ................................................................................................ 120 
5.4  Funnel Plot evaluating outcomes achieved by clinicians performing PCI 
procedures. This analysis examines outcomes for the Phase 2 period (Oct-09 to 
Sep-11). Upper and lower control limits have been set at 3 standard deviations 
(99%) level and a benchmark rate of 2.1% (the unit average for the period) has 
been used. Open and solid dots show the unadjusted and adjusted lesions 
attempted lesion failure rates for each clinician. The adjusted failure rate is 
derived by multiplying the overall group failure rate by the observed number of 
failures divided by the expected number of failures for each clinician. ............... 121 
6.1  Individuals and EWMA control charts from original Toshiba phase I data. ....... 149 
6.2  Individuals and EWMA control charts from reduced Toshiba phase I data ........ 150 
6.3  Individuals and EWMA control charts of Toshiba phase II residuals. ................ 152 
6.4  Individuals and EWMA control charts of Philips phase II residuals. .................. 153 
6.5  Average run length as a function of mean shift for different values of λ. ............ 158 
6.6  Optimal smoothing constant λ to detect different sized mean ln(DAP) shifts. .... 159 
6.7 Comparison of the average run length for two monitoring approaches. Solid 
line—Individuals chart on raw ln(DAP). Dashed line—Combined individuals 
and EWMA chart on residuals. ............................................................................ 161 
7.1(a) & (b) Shows the detection response of the various charting methods when 
designed to have an ARL0 of 1000. Charts demonstrates the EWMA using 
modified Wilson’s limits (solid line) versus (a) CUSUM and (b) Wald (dashed 
red) and unadjusted Wilson’s (dashed blue) limits. ............................................. 177 
xxxi 
7.2(a-c) Demonstrate application of the three intervals when used on clinical data 
(only the first 5000 lesions treated have been shown). Charts have been designed 
with an ARL0 of 1000. ......................................................................................... 178 
7A.1(a) & (b) Distribution of Eobs resulting from the monitoring of a process with 
event rates of 2% and 8% respectively. The curves shown correspond to λ values 
ranging from 0.001 to 0.018. ................................................................................ 184 
7A.2(a)-(d) Graphical comparison of the 95% (top) and 99% (bottom) confidence 
limits derived using the Wald, unadjusted Wilson and modified Wilson methods 
compared to the corresponding symmetrical bounds for the distribution of Eobs 
resulting from the monitoring of a process with event rates of 2% (left) and 8% 
(right). ................................................................................................................... 185 
7B.1 Graph of odds correction (C) vs. proportion of negative signals for run length 
constant (k) ranging from 1 to 3. In this example, lesion treatment failure is 
simulated (E: 1.85%) to generate the EWMA with λ=0.01. ................................ 187 
7B.2 Graphical representation of the relationship between the odds correction (Ck) 
and the run length constant (k), In this example, lesion treatment failure is 
simulated (event rate: 1.85%) to generate the EWMA with λ=0.01. ................... 188 
8.1  Hotelling’s T2 chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005. .................................................................. 200 
8.2  MEWMA chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005. .................................................................. 200 
8.3  MCUSUM chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005. .................................................................. 201 
8.4  Plot of ARL1 versus ||δ|| for the T2, MEWMA and MCUSUM charts, given ρ12 = 
ρ13 = ρ23 = 0.2. Results are shown for the cases where no data are missing (γ = 0) 
and when γ = 0.2. In the latter case, MI has been used to impute for missing 
values. ................................................................................................................... 204 
xxxii 
9.1  Exponentially weighted moving average graphs (with smoothing constant of 
0.01) tracking the incidence of patients returning to theatre for re-operation for 
bleeding related issues and cases requiring excess blood product utilisation (>10 
units)in the first 24 hours post CABG surgery. Data is drawn from cardiac 
surgical procedures performed at SAWMH in the period 2002-2010 ................. 218 
9.2  Bernoulli CUSUM and EWMA control charts for the re-operation (a1-2) and the 
use of blood products (b1-2) variables over 1072 patients underwent CABG 
surgery during 2006-2010. ................................................................................... 222 
9.3  Posterior distributions of the time 1- (1) and the magnitude 8 (2) of the change in 
the rate of re-operation detected by the Bernoulli EWMA control chart at the 
32nd patient who underwent CABG surgery. ........................................................ 224 
9.4  Exponentially weighted moving average graph (with smoothing constant of 
0.01) for rates of patients for whom Aprotinin was used in CABG surgery during 
2006-2010 at SAWMH. ....................................................................................... 227 
9.5  Exponentially weighted moving average graphs (with smoothing constant of 
0.01) for rates of patients who underwent CABG or PTCA on the lesion target of 
the angioplasty procedure (TLR) and the rate of patients who experienced either 
TLR or heart attack or died (MACE). Data is drawn from cardiac surgical 
procedures performed at SAWMH in the period 2002-2006. .............................. 231 
9.6  Bernoulli CUSUM and EWMA control charts for TLR (a1-2) and MACE (b1-2) 
variables over 982 patients underwent angioplasty during 2005-2006. ............... 232 
9.7  Exponentially weighted moving average graph (with smoothing constant of 
0.01) for rates of patients who DES was used for in angioplasty procedure 
during 2005-2006 at SAWMH ............................................................................. 234 
10.1  Cumulative E-O chart showing FT for all cardiologists over a period of nine 
years (January 1997 to December 2005). Also shown are the trends in FTs for 
Cardiologists 3, 6 and 8. The mandatory radiation safety training course 
xxxiii 
occurred in October 2001 (dotted line). Timing of provision of personalised 
feedback is indicated by the letter ‘A’ .................................................................. 255 
10.2  Double sided CUSUM chart monitoring changes in rate of FTs exceeding the 
entire cardiologist group benchmark time (75th percentile). Radiation safety 
training course indicated by the vertical dotted line with timing of personalised 
feedback indicated by the letter ‘A’. Solid dots indicate that the alarm limits 
have been reached, at which point the chart has been reset to zero and 
monitoring continued. .......................................................................................... 255 
11.1  Example of the detailed feedback provided to cardiologists at the conclusion of 
each case. Data in the top half of the form; Patient and Procedural Details was 
provided to all cardiologists in Groups 1 and 2, while the lower half of the form; 
Radiation Details and Risk Estimates, was provided to only those cardiologists 
assigned to Group 2. ............................................................................................. 274 
11.3  EWMA control charts monitoring impact of the various levels of feedback on 
the normalised Digital Acquisition Time for the three groups of cardiologists 
(Group 1: patient and procedural data, Group 2: radiation data + patient and 
procedural data, Group 3: no feedback). Feedback provided in Phase 2 only. 
Phase 1 – pre study period used to establish monitoring baselines, Phase 2 – 
study phase during which participants received feedback described in Figure 
11.1, Phase 3 – post feedback period ................................................................... 280 
11.4  EWMA control charts monitoring impact of the various levels of feedback on 
the normalised Weighted Radiation Time ( FT + 10 * DAT) for the three groups 
of cardiologists (Group 1: patient and procedural data, Group 2: radiation data + 
patient and procedural data, Group 3: no feedback). Feedback provided in Phase 
2 only. Phase 1 – pre study period used to establish monitoring baselines, Phase 
2 – study phase during which participants received feedback described in Figure 
11.1, Phase 3 – post feedback period. .................................................................. 280 
11.5  Plot for WRT showing change in radiation use against category of individual 
cardiologist initial (Phase 1) average radiation use. Initial use categories are 
xxxiv 
defined as; ‘Low’ - clinicians with Phase 1 average results < 25th percentile of 
overall Phase 1 data, ‘Intermediate’ - clinicians with Phase 1 average between 
25th and 75th percentile of overall Phase 1 data and ‘High’ - clinicians with 
Phase 1 average > 75th percentile of overall Phase 1 data. Change in radiation 
use is expressed as the proportion of Phase 2 procedures with a radiation record 
more or less than the Phase 1 average for individual cardiologists. A 95% 
confidence interval is shown for each proportion. ............................................... 283 
12.1  Graphs of Q Score against E Score (a measure related to effective dose) for the 
Left and Right coronary systems. Highlighted is the view set recommended as 
being optimal for imaging of the Left and Right coronary systems (corresponds 
respectively to the ‘*’ and ‘+’ sets in Table 12.4). ............................................... 304 
12.2  Graphs of Q Score against Scatter Score (a measure related to operator scatter 
dose) for the Left and Right coronary systems. Highlighted is the view set 
recommended as being optimal for imaging of the Left and Right coronary 
systems (corresponds respectively to the ‘*’ and ‘+’ sets in Table 12.4). ........... 304 
13.1  Chart showing the proportion of surgeries involving a transfusions of >10 units 
and or reoperation (BP/Reop) compared against the proportion of patients 
receiving aprotinin or TXA. The graph shows an initial rate of BP/Reop of 5% 
with aprotinin used in approximately 80% of surgeries to October 2007. Key 
events impacting on the use of aprotinin and TXA at SAWMH are shown. 
Reference to Mangano relates to publication of the paper by Mangano et al. 
dealing with the risk associated with aprotinin in cardiac surgery (Mangano, 
Tudor et al. 2006). The withdrawal of aprotinin was associated with the (BART) 
study (Fergusson, Hebert et al. 2008). .................................................................. 328 
13.2  EWMA Control chart for BP/Reop using RA Model1. Shown on the graph is the 
observed rate of BP/Reop (solid black line) overlaying the expected rate of 
BP/Reop defined by the risk model. Control limits for the expected rate of 
BP/Reop have been set to deliver an ARL0 of 1000 cases. Boundaries of the data 
for establishing RA Model1 are shown. ................................................................ 329 
xxxv 
13.3  EWMA Control chart for BP/Reop using RA Model2. Shown on the graph is the 
observed rate of BP/Reop (solid black line) overlaying the expected rate of 
BP/Reop defined by the risk model. Control limits for the expected rate of 
BP/Reop have been set to deliver an ARL0 of 1000 cases. Boundaries of the data 
for establishing RA Model2 are shown. ................................................................ 329 
13.4  Propensity score based analysis of intra- & post- operative adverse events in 
cases involving TXA compared to cases in which TXA was not used. ............... 330 
13.5  Signal investigation process – adapted from Mohammed et al. 2004 
(Mohammed, Rathbone et al. 2004). .................................................................... 331 
14.1(a) & (b) Left plot is the distribution of raw CPBD values. Right plot shows the 
normalised CPBD distribution along with the distribution of residuals. ............. 348 
14.2 Plot of predicted (using the regression model) versus observed CPBD’. ............ 353 
14.3  Odds ratio comparison of outcomes for surgeries with residual CPBD’ in Q4 vs. 
Q1-3 for Phase I procedures (95% confidence intervals are shown). Shown are 
comparisons for peri- and post- procedural events as well as major process 
changes. Open diamonds indicate no significance found while closed diamonds 
indicate significance at p<0.05, p<0.01 and p<0.001 using (*), (**) and (***) 
respectively. Also compared are the EuroSCORE predicted risks for the two 
groups (p=0.082, Mann-Whitney U test). ............................................................ 355 
14.4  Shewhart Control Chart of CPBD’ residuals for individual Phase I and Phase II 
surgeries. Upper and Lower control limits are set at ± 3 σr of the Phase I data 
(+/- 0.227). Open dots represent surgeries with CPBD’ falling outside the control 
limits or where no bypass time was recorded (in which case the CPBD’ is shown 
as 0). Short dashed line is at the 19th December 2009 and corresponds to the 
point in time identified as the statistical change point for CPBD’. ...................... 356 
xxxvi 
14.5  EWMA of CPBD’ residuals. Control limits are based on Phase I data (+/- 
0.019). Short dashed line is at the 19th December 2009 and corresponds to the 
point in time identified as the statistical change point for CPBD’. ...................... 356 
14.6  EWMA chart tracking variations in TXA use, use of IO-TOE and incidence of 
intra-operative variations during the period of monitoring. Also highlighted on 
the graph is the change point for CPBD (19th December 2009) and the date on 
which the possibility of a link between CPBD and IO-TOE was first discussed 
with senior clinicians ............................................................................................ 357 
14.7  EWMA of CPBD’ residuals following inclusion of IO-TOE as a factor in the 
regression model. Control limits are based on Phase I data. Short dashed line is 
at the 19th December 2009 and corresponds to the point in time identified as the 
statistical change point for CPBD’ ....................................................................... 358 
14.8  Result of propensity score matched analysis. OR (with 95% confidence 
intervals) shown for peri- and post- outcomes for cases involving IO-TOE 
compared with those where IO-TOE was not used. Open diamonds indicate no 
significance found while closed diamonds indicate significance at p<0.05, 
p<0.01 and p<0.001 using (*), (**) and (***) respectively. ................................ 359 
 
xxxvii 
xxxviii 
 
 
 
 
 
 
 
 
 
 
 
List of Tables 
2.1  Performance measures used in defining the quality of performance of a 
angioplasty service. Measures marked with * are measures of process while all 
others can be considered as measures of outcome. ................................................ 42 
3.1 Patient population ( n = 2417 ) clinical variables. .................................................. 61 
3.2  Patient population angiographic and procedural variables. (ACC/AHA – 
American College of Cardiology / American Heart Association). ........................ 63 
5.1 Characteristics of the Phase 1 and Phase 2 patient populations and procedural 
details. ................................................................................................................... 110 
5.2  Table of factors considered for inclusion in the risk model. ................................ 116 
xxxix 
6.1 Summary of procedure types performed by the SAWMH Cardiac Imaging 
Service from January 2, 2008 to March 29, 2010. ............................................... 142 
6.2 Standard deviations of raw data and residual values for both imaging systems. . 151 
6.3 ARL for various shifts in the mean DAP value for the Toshiba CA data with λ = 
0.1 ......................................................................................................................... 159 
7.1 Comparison of performance of intervals delivered using alternative methods for 
deriving control limits. Event rate of 2% used. Wald limits have been derived 
using the method described in Cook at al (Cook, Coory et al. 2011), Unadjusted 
Wilson limits have been derived using the actual event rate and Modified Wilson 
includes an odds correction factor for the event rate to compensate for interval 
centre bias to 0.5. .................................................................................................. 176 
9.1  Posterior distributions (mode, sd.) and incredible intervals (CI) of the change 
point parametersr and 8 following signals from the Bernoulli CUSUM (h± = 
(3.37,2.87) and h± = (3.22, 2.68)) and EWMA (λ= 0.05, A± = 4.15 and A± = 
4.25) charts on the rate of re-operation and the use of blood products over 1072 
patients who underwent CABG surgery during 2006-2010. Standard deviations 
are shown in parentheses. ..................................................................................... 225 
10.1 Summary of personalised feedback provided to cardiologists. Current year’ 
refers to analysis of data for procedures performed in the 12 months prior to the 
feedback report while ‘Previous year’ relates to the 12 months prior to that. The 
radiation metrics comprised summaries of fluoroscopy time (FT), digital 
acquisition frame count (DA), and dose area product (DAP). ............................. 251 
10.2 Analysis of radiation use by individual clinicians pre- and post-radiation safety 
training course. Conducted in November 2001. FT (min) are expressed as the 
median and inter-quartile range. ........................................................................... 254 
12.2 Image quality scores for each coronary anatomical segments by projection. 
These data are drawn from the work of Di Mario and Sutaria (Di Mario and 
xl 
Sutaria 2005). The system used by Di Mario and Sutaria translates to the 
classification of a view that is not recommended as 0, occasionally useful as 1, 
very useful as 2 and the ideal view is rated as 3. .................................................. 300 
12.3 Radiation weighting factors by projection. Data for the Time-Adjusted Radiation 
Exposure (DAP Rate in mGy.cm2.s-1) and Mean Operator Radiation Exposure 
(Scatter Rate in µSv.h-1) has been derived from the work of Kuon et al. (Kuon, 
Dahm et al. 2004) using linear interpolation. Data for the relative weights 
converting DAP Rate to E (Units) has been derived from the work of Stern et al. 
(Stern, Rosenstein et al. 1995). ............................................................................. 301 
12.4 Table summarising the top 5 ranked view set combinations in order of 
decreasing efficiency (Q Score) for patient effective dose and cardiologist scatter 
dose for imaging of the left and right coronary systems. The number in brackets 
after the rank shows the ranking of that view set in the list for the alternative 
radiation measure. Vmax represents the number of segments visualised with at 
least one view rated as ideal (out of 8 for the Left and 5 for the Right). The core 
set of views recommended for the Left coronary system is identified with a 
‘*’.the core set of views recommended for the Right coronary system is 
identified with a ‘+’. .............................................................................................. 306 
13.1 Logistic regression (β) coefficients used in the two risk models. Age at 
Operation and Pre-Operative Haemoglobin are continuous variables, the 
remainder are binary with a 1 allocated when the characteristic is present and a 0 
otherwise. ............................................................................................................. 328 
14.1 Patient characteristics and operative details ......................................................... 346 
xli 
xlii 
 
 
 
 
 
 
 
 
 
 
Statement of Original Authorship  
The materials contained in this thesis have not been published before or presented by 
the candidate for any other programme or degree at any other higher education 
institution. Where the publications and presentations included in this thesis were the 
product of research activities undertaken jointly with others, the name of such 
collaborators or co-authors has been listed immediately following the statement of 
original authorship page for each chapter. In each case a short description of the 
nature of the contribution made by each author, including the candidate has been 
provided. Particular attention is drawn to Chapters 4, 6, 8 and 9 in which the 
candidate is not listed as lead author. In these chapters, the candidate has been 
instrumental in the conception of the work, statistical content and technical analysis 
of the results. 
 Signature:       
 Ian Robert Smith 
 Date:   16th August 2013 
xliii 
  
 
 
 
CHAPTER 1 
 
 
 
Introduction 
 
1.1   Motivation 
 
The 1999 United States (US) Institute of Medicine’s publication, ‘To Err is Human: 
Building a Safer Health System’ (Kohn, Corrigan et al. 2000) raised significant 
concerns with the extent and cost of errors in the US health care system and was a call 
to health care providers, governments, consumers, and stakeholders to strive to 
achieve a substantial reduction in the rate of adverse events. The identification of 
systemic failings leading to unacceptable clinical performance is not limited to the US 
health system with similar performance issues being reported in the 2001 Bristol 
Royal Infirmary Inquiry (The Royal Infirmary Enquiry 2001) in the United Kingdom 
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and the 2005 Queensland Public Hospitals Commission of Inquiry (Queensland 
Government 2005) in Australia. As a result of the publicity generated by these reports 
and reviews there is increased emphasis on the establishment of systems aimed at 
ensuring that the delivery of clinical services is of an acceptable standard.  
 
However, interest in the monitoring of health care quality is not solely limited to 
dealing with the detection and reduction of medical errors and unacceptably poor 
clinical performance. In 2003 the Centers for Medicare & Medicaid Services (Centers 
for Medicare & Medicaid Services 2008) went further by demanding that hospitals 
develop programs aimed at improving the overall quality of care. The potential 
benefits to be gained from efforts aimed at improving the overall quality of care is 
emphasized by Atul Gawande in his book ‘Better: A Surgeon 's Notes on 
Performance’(Gawande 2007), in which he states: 
 
“The scientific effort to improve performance in medicine – an effort that 
at present gets only a miniscule portion of scientific budgets – can 
arguably save more lives in the next decade than bench science, more lives 
than research on the genome, stem cell therapy, cancer vaccines, and all 
the other laboratory work we hear about in the news.” 
 
In combination, therefore, the recommendations of the various inquiries and reports 
advocate the development and deployment of systems not only capable of identifying 
and managing underperformance but also systems that identify and encourage 
excellence. Both the Bristol and Queensland inquiries provided retrospective 
examination of the respective health care systems which highlighted the absence of 
adequate mechanisms to appropriately monitor performance. From these inquiries 
arose a series of recommendations on how the standard of patient care could be 
enhanced, including the need for the establishment of complaint management and 
clinical governance frameworks.   
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The Queensland Inquiry (Queensland Government 2005) specifically emphasized the 
importance of clinical audits as an ongoing evaluation tool for assessing performance 
of medical practitioners: 
 
“All hospitals must have effective clinical audit systems. As a minimum 
these systems should include monthly audit of all mortalities and 
significant morbidities. Hospitals must ensure that their clinical audit 
systems are independent and transparent.”  
 
Adequate audit would almost certainly have identified clinical performance issues at 
an early stage at both the Bristol Royal Infirmary and Bundaberg Hospital (the 
catalyst for the Queensland inquiry) and thus limited the number of serious adverse 
outcomes ultimately documented in both instances.  
 
The use of statistical methods to monitor and detect changes in performance of 
manufacturing processes was pioneered in the 1920s by Walter Shewhart. Although 
continuous quality improvement is a shared goal of both manufacturing and 
healthcare, one of the major differences impacting on the translation of Shewhart’s 
principles to the monitoring of clinical outcomes is the highly variable nature of the 
‘inputs’(Alemi and Oliver 2001). Naïve application of manufacturing methods to 
healthcare monitoring without due regard for the underlying nature and causes of 
variation has the potential to render the use of these methods ineffective or worse, 
misleading (Alemi and Oliver 2001; Morton 2003). In particular, a fundamental 
assumption in the application of Shewhart’s methods is that the factors influencing the 
process of interest are “stable”. In healthcare practice, this is rarely the case.  
 
Effective clinical audit programs can contribute to the maintenance and improvement 
of clinical performance through the opportunity for timely analysis, reflection and 
action to address perceived deficiencies or learn from exceptional performance. The 
potential power of statistical process control (SPC) charts in supporting these 
programs is now being recognised (Tennant, Mohammed et al. 2007) with the 
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Queensland Health Public Reporting Ministerial Advisory Panel (Queensland 
Government 2006) noting that: 
 
"The healthcare industry has been slow to adopt statistical process control 
methodology that has been used to monitor and improve performance in 
industry for many years. Fortunately this is now changing - partly in 
recognition of the power of these techniques to display adverse clinical 
performance trends well in advance, sometimes by decades, of other 
methods of detection." 
 
 
In most medical disciplines, raising the standards of performance and ensuring the 
delivery of optimal care through robust and informed clinical monitoring and analysis, 
is expected to lead to a significant improvement in patient outcomes with a flow on 
benefit to improved financial performance.  
 
Although the benefits to be obtained through the use of SPC methodology have been 
recognised and these tools are now finding acceptance in a variety of clinical 
applications (Morton, Whitby et al. 2001; Novick, Fox et al. 2001; Cook, Steiner et al. 
2003; Grigg, Farewell et al. 2003; Spiegelhalter, Grigg et al. 2003; Rogers, Reeves et 
al. 2004; Rogers, Ganesh et al. 2005; Woodall 2006; Thor, Lundberg et al. 2007), 
application to performance monitoring and improvement in interventional cardiology 
has not been extensively explored. Recent work by Kunadian et al. (Kunadian, 
Dunning et al. 2008) and Matheny et al. (Matheny, Ohno-Machado et al. 2008) 
provide examples of how SPC can be used to monitor specific performance measures 
associated with Percutaneous Coronary Intervention (PCI), including in-hospital 
major adverse cardiovascular and cerebrovascular events and in-hospital mortality. 
Historically, PCI is also associated with additional adverse events post hospital 
discharge including significant complications such as restenosis and stent thrombosis, 
which may require repeat angiography and revascularisation procedures and also 
result in additional morbidity and mortality. 
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The relevance of the work described in this thesis was recently underlined by both 
Australian and United States professional bodies responsible for those delivering 
interventional cardiology services. In 2011 the Society of Cardiovascular 
Angiography and Interventions (SCAI) published position statements (Klein, Ho et al. 
2011; Klein, Uretsky et al. 2011) proposing a framework for the design and 
implementation of programs to proactively drive continuous quality improvement in 
interventional cardiology.  While these documents provide sound guidance on the 
structure of these programs including the choice of outcome indicators and suitable 
benchmarks, one aspect not adequately addressed are the tools to be used to monitor 
for performance variations. More recently (July 2012) the Cardiac Society of 
Australia and New Zealand (CSANZ) sought expressions of Interest (EOI) for the 
development, and ongoing management of a high quality Cardiac Procedures 
Registry. The intended use of this registry is to document and measure outcomes for 
patients undergoing cardiovascular procedures in Australia and New Zealand with the 
aim to improve cardiovascular outcomes for patients.  
 
Both professional societies have therefore identified the importance of a structured 
approach to quality monitoring and improvement in interventional cardiology. 
Examination of the scope of work outlined in this thesis will show close alignment 
with the requirements and intent of the SCAI position statements and CSANZ EOI. 
This therefore provides a sound justification for the work presented herein. 
 
1.2   Clinical Background 
 
Coronary heart disease (CHD) also referred to as ischaemic heart disease (ICD-10 
I20-I25) is the most common form of heart disease in Australia and the largest single 
cause of death of Australians. In 2006, CHD accounted for 22,983 deaths (17% of all 
deaths) and was also listed most frequently as an associated cause in 21,848 deaths. 
Male CHD death rates in Australia have consistently been nearly twice those of 
females, a finding common to most Western societies (AIHW 2008). 
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The primary feature of CHD is a lack of sufficient blood supply to the muscle of the 
heart itself. The common underlying problem affecting the blood flow is 
atherosclerosis. This is a complex process where build-ups called plaques form on the 
inside surface of the artery. When advanced, plaques can narrow the channel through 
which the blood flows. Plaques can be single or multiple and can affect one or more 
of the heart’s three main arteries as well as the minor branches. The two major clinical 
manifestations of CHD are heart attack (severe chest pain and cardiac arrest and 
arrhythmia usually associated with the blockage of the coronary arteries) and angina 
(pain associated with significant narrowing of the coronary arteries). If left untreated 
CHD can result in significant and irreversible damage to the heart tissue, culminating 
in the death of the patient.  
 
For patients who have persistent blockage of the coronary arteries, either in the case 
of angina or after a heart attack, there are several procedures to re-establish blood 
flow to the heart’s muscle. This involves either removing or bypassing the blockage. 
Revascularisation procedure options include percutaneous transluminal coronary 
angioplasty (PTCA) and coronary artery bypass grafting (CABG).  
 
Typically, a PTCA procedure involves inserting a balloon tipped catheter via an artery 
in the groin or arm into the point where a coronary artery has been narrowed by a 
plaque. Once in place the balloon is inflated to force open the obstruction. In most 
instances, once the lesion is dilated a stent is expanded within the artery at the site of 
the lesion to hold the site open. A CABG procedure is a far more invasive process 
which entails opening the patient’s chest and using blood vessel grafts to bypass 
blockages in the coronary arteries to restore adequate blood supply to the heart 
muscle. AIHW data shows there were 35,600 angioplasty and 26,717 CABG 
procedures performed in Australia in 2007/08 (AIHW 2008). 
 
The choice of revascularisation procedure is usually made based on the procedural 
risks faced by the patient in undergoing the procedures as well as an assessment by 
the clinicians concerned regarding which procedure has the potential to achieve the 
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best long term outcome for the patient. Factors taken into consideration include the 
patient’s age and co-morbidities, the coronary arteries involved and how many, the 
extent of the blockages, the general function of the heart and whether there is other 
concomitant cardiovascular disease requiring treatment (e.g. valvular disease).   
 
Whilst undergoing a PTCA or CABG procedure may result in a significant 
improvement in a patient’s quality of life, these procedures are associated with risks 
both during the conduct of the procedures itself as well as in the recovery and post 
hospital discharge phases. According to a study conducted by the Mayo Clinic in the 
United States (Jacobson, Hall Long et al. 2007), 13.2% of patients experienced some 
degree of complications (major adverse cardiac events or bleeding) as an outcome 
during hospitalisation associated with a PTCA procedure. The enhancement of 
medical care through adoption of clinical governance processes using quantitative 
outcomes monitoring would help to optimise the quality of life of patients undergoing 
revascularisation procedures by contributing to a reduction in the number of 
complications and also lead to improvement in the overall cost effectiveness of health 
care delivery. This is borne out by the results of the Mayo Clinic study that suggested 
the adjusted mean costs of hospitalisations was approximately $7,000 higher for 
procedures in which a complication occurred.  
 
1.3   Research Aim 
 
This research focuses on the development of a systematic scientific process for 
ensuring the delivery of excellence in interventional cardiology. It is intended that the 
primary output from this research will be a system that will allow and encourage 
openness in objectively assessing and improving clinical performance. Thus, built into 
the system are elements that allow known causes of risk and outcome to be taken into 
account when monitoring and comparing performance. Although the major goal of 
similar initiatives such as those proposed by the Queensland Inquiry is the 
development of systems to detect failings or deterioration in clinical performance, this 
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will not be the sole focus of this project. To provide a comprehensive, effective and 
efficient process that facilitates continuous improvement the structure proposed will 
also identify instances of superior performance and propose systems allowing this 
aspect of performance to be reviewed. 
 
The primary aim of this research is to develop and validate a governance system, 
supported by SPC tools, to monitor both overall institutional and individual clinician 
performance in the delivery of PCI services. These tools are proposed as an adjunct to 
the traditional case based morbidity and mortality (M&M) peer review processes 
commonly used to manage and deal with major adverse events. This research will 
explore the role of these techniques in contributing to a system of feedback to clinical 
teams to drive service quality improvement.  
 
The stated primary aim will be achieved through addressing three main objectives: 
1. Identification of a concise suite of clinical outcome indicators (COIs) that can 
be used to describe or quantify the quality of performance of the clinical 
service and clinicians being monitored.   
2. Development of a system of control charts that can be used to monitor for 
variations in the identified COIs over time and between clinicians. 
3. Implementation and validation of the impact of a clinical governance process 
that is informed by the various control charts to monitor and improve clinical 
outcomes. 
 
Although this work will focus on pursuit of these aims in the context of a quality 
monitoring and improvement activity linked to an angioplasty service located at a 
single clinical site, development of the tools and techniques will be undertaken 
mindful of the potential application to other clinical specialties and a wider, including 
national, scope. To this end, a number of the applications used to demonstrate these 
techniques will draw upon data, and be applied to COIs, dealing with cardiac surgery 
and coronary angiography. These areas have been chosen due to their close 
association with PCI and the availability of extensive pre-existing data sets and 
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governance structures which enable the fast tracking of evaluation of the various tools 
and techniques developed in this research.        
 
 
1.4   Research Objectives 
 
To achieve the stated goal, the program of research has been divided into three main 
objectives. These are briefly discussed in the following section. 
 
1.4.1 Objective 1: Performance Measures for PCI 
 
This component of research deals with the development of a set of clinical outcome 
measures that can be used to quantify the quality of clinical performance of a PCI 
service. This component of research involves 3 main aspects: 
 
1(a) Performance Measures: Identification of a suite of performance indicators 
appropriate for characterising the quality of service delivery in the practice of 
interventional cardiology. This aspect of the project will, in consultation with the 
clinical end users explore the various commonly used process and outcome 
performance measures used in interventional cardiology and define a subset that is 
appropriate to the task.  
 
1(b) Risk Adjustment: Risk adjustment algorithms will be adapted or developed for 
the various performance indicators to account for known sources of variation in 
clinical performance and allow focus to be squarely placed on unaccounted for 
deviation from expected outcomes.  
 
1(c) Clinical Data: Data for this project is being drawn from the St Andrew’s War 
Memorial Hospital (SAWMH) cardiac angioplasty data register. This register is 
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currently being migrated from a legacy database (that has been in use from 2003) to a 
new system. This provides the opportunity to modify the new database structure and 
implement processes to optimise data quality. Where possible, data validation 
processes, in the form of intelligent filtering, will be built into the register to ensure 
the quality of information used in the register is of an appropriate standard. 
Furthermore, signal response processes will include review of data quality as a first 
step.   
 
1.4.2 Objective 2: Control Charts for Monitoring PCI Outcomes 
 
This component of research deals with the development and validation of the tools to 
be used to monitor clinical performance in PCI. Work in this area deals with 3 main 
activities: 
 
2(a) Control Chart Selection: This aspect of research will involve a review of the 
range of control charts in common use to identify the most suitable control chart or 
system of control charts appropriate for the task of efficiently detecting changes in 
group performance and comparing performance of individual units (e.g. clinicians or 
clinical teams). Evaluation of control charts for this project will extend to include the 
possibility of development and validation of innovative charting methods such as risk 
adjusted exponentially weighted moving average charts tracking the difference 
between observed and expected outcomes. 
 
2(b) Issues of Multiple Testing: With the potential for the monitoring process to 
involve the use of a number of control charts the issue of multiple testing must be 
considered. A balance must therefore be struck between the desire to implement a 
broad based monitoring program and the increased likelihood of falsely signalling a 
change in performance through over testing. Investigation of appropriate techniques 
for dealing with control charts monitoring processes involving multiple (correlated) 
measures of performance will draw upon methods developed for industrial 
applications and surveillance.  
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1.4.3 Objective 3: Use of SPC in Clinical Governance 
 
This component of research deals with how the analysis and interpretation of 
information obtained through the monitoring process can be used to maintain and 
improve clinical performance in PCI.  
 
Clinical governance is a broad term that encompasses the collection of activities 
dealing with the promotion, review, measurement and monitoring of the quality of 
patient care. It has been defined (Scally and Donaldson 1998) as “a systematic and 
integrated approach to assurance and review of clinical responsibility and 
accountability that improves quality and safety resulting in optimal patient 
outcomes.” 
 
Therefore, having addressed the issues of what tools to use to monitor performance 
the question remains of how these tools are to be best used. This aspect of the project 
will deal with the development of recommendations on the inculcation of these tools 
into existing clinical governance structures. Issues to be addressed include: 
• How best to use the information provided from these charts to monitor and 
positively influence clinical performance in PCI.  
• The actions to be taken when significant changes in performance (both 
positive and negative) are detected for individual clinicians or the group.  
• Consideration of the design parameters for the various charts. While the 
selection of chart parameters forms a key aspect of chart design, this is heavily 
influenced by the consequences of variation in clinical care and the severity of 
actions to be taken when performance variation is detected. 
• How frequently the charts are to be updated and provided to governance 
authorities and participating clinicians. 
 
This aspect of research is core to the activities of a grant from the Queensland 
Government Research Industry Partnerships Program to the St Andrew’s Medical 
Institute. The grant titled “Applied Medical Intelligence: Developing a Structured 
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Process for the Delivery of Excellence in Clinical Medicine” covers work on the 
development of improved methods for the audit and monitoring of clinical 
performance to enhance the quality of care and safety of patients, specifically in the 
area of cardiac services. 
 
1.5   Research Contribution 
 
Substantial work has been done by others to demonstrate the utility of statistical 
process control tools in isolated clinical applications. This has largely focussed on the 
monitoring of single measures of performance through the use of univariate control 
charts with most instances demonstrating how underperformance can be identified. 
This project, however, is concerned with performance monitoring and improvement 
of an overall system of care. In broad terms, the contribution made by pursuing the 
objectives outlined in Section 1.4 can be broken into two categories; Application and 
Methods: 
 
1.5.1 Contribution to Application 
 
This work will contribute to the development of a set of meaningful and actionable 
clinical outcome indicators that can be used to monitor the overall quality of delivery 
of angioplasty services (Objective 1(a)). As this aim involves the use of a number of 
charts to simultaneously monitor multiple performance measures, there is a risk of 
increasing the false detection rate due to multiple testing. To address this issue, we 
investigate the implementation of multivariate SPC charts in a clinical setting 
(Objective 2(b)). The use of risk adjustment has been shown to enhance the 
functionality of SPC charts in the monitoring of clinical performance. In 
interventional cardiology, however, there is a limited number of validated risk 
adjustment algorithms with those available not adequately addressing the needs of this 
project. This project will therefore investigate the development of risk adjustment 
algorithms for the measures identified (Objective 1(b)).  
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Whilst it is important to ensure that statistically robust tools are available for 
application to the monitoring of meaningful outcome indicators, it is important that 
they be incorporated into a system of governance which both guards against poor 
performance and identifies opportunities for learning from excellence to drive 
performance improvement. In this work we will propose a governance structure and 
evaluate the impact of quantitative performance measures in achieving these 
outcomes, exploring factors that enhance (or inhibit) the uptake of change to 
improved performance (Objective 3). 
 
1.5.2 Contribution to Method 
 
Whilst a major component of this project involves developments in the application of 
statistical process control techniques to quantitatively inform clinical governance 
processes, this also identified a number of areas in which methods were advanced. In 
particular, the need to employ control charts that were both statistically robust and 
easily interpretable for non-statistically oriented clinicians saw an emphasis placed in 
identifying suitable charting techniques that would satisfy this dual requirement. To 
this end, the role of Exponentially Weighted Moving Average charts has been 
extended to deal with both continuous data in the clinical setting as well as low event 
rate binary outcomes. In both cases, utility of the charts has been enhanced through 
the application of techniques to adjust for known sources of variation (Objective 2(a)). 
A by-product of this work is the development of an intelligent filtering system that 
can be used to identify possible data errors at the point of data entry into the register 
(Objective 1(c)). Whilst it is important to be able to track and compare performance 
over time and between clinicians, for outcomes improvement to occur it must be 
possible to offer alternatives in the way they perform their tasks that support them in 
achieving this goal. This thesis includes an analysis of the way cardiac imaging 
procedures are conducted, identifying a core set of views that has the potential for 
optimising the (radiation) risk versus clinical benefit (diagnosis) balance (Objective 
3). 
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1.6   Thesis Structure 
 
This thesis is written in publication form since the research objectives are met by a 
series of research components outlined in independent papers either submitted or 
accepted to journals and conferences. Chapters are therefore presented in this thesis in 
the form in which they were submitted to, or accepted by, journals or are based on 
manuscripts derived from presentations delivered at conferences. These articles are 
presented in Chapters 3 to 14. Each chapter has its own relevant literature review and 
references and there is necessarily some overlap and repetition across chapters. 
Furthermore due to limitations placed by journals on the volume and scope of material 
submitted for review the references cited in the published literature is by necessity, 
brief. However a more complete literature review is presented in Chapter 2 and the 
references for all chapters are compiled into a bibliography that appears at the end of 
the thesis. 
 
 
1.7   Thesis Outline 
 
To facilitate review of this thesis, the order of chapters has been structured around the  
stated objectives. There is, however, some overlap in how the chapters align with the 
objectives and in these instances related chapters will also be noted:  
 
Objective 1:  Performance Measures for PCI - Chapter 3 describes the establishment 
of a concise suite of clinical outcome indicators suitable for monitoring 
the performance of a clinical service activity or procedure such as one 
performing PCI. Chapters 4 and 5 deal with the adaptation and 
development of risk adjustment for the indicators identified in Chapter 
3. Elements of Chapter 6 deals with issues related to the development 
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and use of an outcome indicator related to radiation use in cardiac 
imaging procedures and proposes a form of ‘risk model’ to improve the 
sensitivity of a monitoring process using a continuous variable. 
Chapters 13 and 14 demonstrate application of the methodology 
described in Chapters 3 and 5 to the development of outcome 
indicators and associated risk adjustment models in cardiac surgery.   
 
Objective 2:  Control Charts for monitoring PCI - Chapter 3 and Chapters 6-9 deal 
with the development and refinement of statistical tools, including 
control charts and change point indicators, which can be used to 
efficiently and effectively monitor for changes in clinical outcomes and 
clinician performance. Chapters 13 and 14 provide illustrations of how 
the control charts can be used to identify and support the investigation 
of significant performance variations associated with outcome 
indicators developed for cardiac surgery.   
 
Objective 3:  Use of SPC & Quantitative Feedback in Clinical Governance – 
Chapters 3 and 13 outline the basis for a governance structure that can 
be informed by a system of control charts to monitor and, if necessary, 
act upon significant variations in clinical outcome. Chapters 10 and 11 
provide evidence that quantitative feedback can be used to drive a 
quality monitoring and improvement agenda, but emphasise the need 
for caution in the selection of benchmarks. Chapter 12 describes the 
development of a clinical technique benchmark that defines a 
minimum set of angiographic projections to be used in diagnosing 
cardiovascular disease.   
 
Having placed into context the alignment of each chapter with the three main 
objectives of this research, the remainder of this section offers a more detailed 
description of the contents and contribution of each chapter.   
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Chapter 2 comprises a literature review focussing mainly on the application of 
statistical process control tools to the monitoring of clinical outcomes. Some 
differences between the reviewed body of literature in this chapter with cited 
references within Chapters 3 to 14 are expected due to the time frame over which the 
published work has been prepared and presented . 
 
Chapter 3 puts into context the overall work presented in this thesis. In this chapter an 
overview is provided of the development and application of an SPC informed clinical 
governance process for the monitoring of outcomes of the interventional cardiology 
service at SAWMH. Included in this work is discussion of the factors to be considered 
in determining the validity of clinical outcome indicators (COI) to be used in the 
monitoring program and proposes a meaningful set of indicators satisfying these 
criteria. To monitor variations in clinical outcome delivered by the service over time 
as well as to enable comparison between individual practitioners, a suite of SPC 
monitoring tools is proposed. Characteristics of these tools, such as speed of 
detection, statistical robustness and ease of interpretation are described. Also 
discussed in this chapter is the need to employ charting techniques that take into 
account known sources of variation in the complexity of clinical procedures. Known 
as risk adjustment, this is an aspect of the application of SPC to interventional 
cardiology that required particular attention due to the lack of suitable algorithms. 
 
Chapters 4 and 5 further address the issue of how to improve the performance of SPC 
charts by accommodating variations in case complexity and expected outcome 
associated with patient related factors and co-morbidities. In Chapter 4, issues 
concerning the application of a commonly accepted risk adjustment algorithm to the 
SPC monitoring of clinical performance is explored. This chapter emphasises that 
such models can be useful provided they are evaluated and adapted for the patient 
cohort and clinical service being monitored. To illustrate this topic, intensive care unit 
outcome data from SAWMH is analysed. Using an APACHE II risk model (shown to 
have good discrimination but poor calibration for the patient cohort) a simple 
correction is proposed and evaluated to enable this model to function acceptably in an 
SPC application for this unit. With regards the application of risk adjustment for SPC 
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in interventional cardiology, Chapter 5 includes an evaluation of the literature 
highlighting the lack of suitable risk models for use with the COIs identified in 
Chapter 3. As such, Chapter 5 describes the development of a suitable risk adjustment 
algorithm for the monitoring of lesion treatment failure, a COI identified as important 
in interventional cardiology. Application of this model is demonstrated using data 
from the SAWMH interventional cardiac procedures register. 
 
In Chapter 3 it was highlighted that the SPC charting tools used must not only be 
statically robust but should also be easily interpretable by clinicians. For this reason, 
use of both CUSUM (statistical robustness) and VLAD (intuitive interpretation) 
charts in tandem have been advocated. However, in the intervening period since 
publishing Chapter 3, appropriately designed EWMA charts have been shown to have 
characteristics fulfilling both criteria. In addition, EWMA charts can be readily 
adapted for the monitoring of both binary outcome and continuous variable data. In 
Chapters 6 and 7 use of EWMA charts to monitor clinical performance is explored. In 
Chapter 6, the use of EWMA charts to monitor the performance of cardiac imaging 
systems is developed and described. In this application, characteristics of the patient 
and imaging procedure are used to monitor the underlying stability in performance of 
the imaging system. In so doing, a charting system sensitive to subtle changes in the 
characteristics of the imaging platform is provided, thereby ensuring improved 
surveillance of radiation use. A limitation of the use of EWMA charts developed to 
monitor binary outcomes is the event rate of the process being monitored 
(recommended for rates in excess of 5%). In Chapter 7, a modification is proposed to 
the method for deriving the control limits for EWMA charts that enables them to be 
used with event rates of the order of 1% , thereby allowing use of this chart to monitor 
the COI of lesion treatment failure. 
 
An issue identified in Chapter 3 concerns the problem of multiple testing. While it is 
tempting to implement a monitoring program involving multiple COIs, in the context 
of monitoring clinical performance such a system would potentially generate an 
unacceptably high rate of false signals. To address this issue in industry, multivariate 
SPC techniques have been developed. These tools, however, have not been widely 
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explored in the clinical domain. In Chapter 8, the use of multivariate control charts to 
monitor clinical performance is explored. In this chapter multivariate control charts 
are developed to monitor radiation use in the imaging of patients undergoing coronary 
angiography. 
 
Whilst it is important to identify that the outcome of a clinical process has changed, it 
is potentially just as important to identify the point at which a change took place. In 
Chapter 9 a Bayesian approach is proposed as a new method for change point 
estimation. In this chapter the development of the change point method is described 
and evaluated in the context of known significant changes in clinical practice 
including one discrete and one linear. In the first example, patients undergoing cardiac 
surgery at SAWMH are analysed to study the impact of known (forced) changes in 
the use of antifibrinolytic drugs. In the second example, the impact of gradual changes 
in the use of a new clinical technology (drug eluting stents) on patient 12 month 
outcomes is explored. In both cases, the benefit in expediting potential signal 
investigations through accurately identifying the point at which patient outcomes 
changed is emphasised. 
 
While a primary goal of the use of SPC is to identify instances of underperformance, 
an important aspect is how best to employ the analysis provided through the use of 
SPC charts to modify clinical practice; this is the subject of Chapters 10 and 11. In 
Chapter 10, evidence contained within the data recorded for cardiac imaging 
procedures at SAWMH is extracted to demonstrate the effectiveness of quantitative 
feedback in modifying clinician practice. In Chapter 11, this work is extended to 
explore issues surrounding the frequency of feedback and the selection of 
performance benchmarks. This chapter is based on work analysing the comparative 
response of two groups of cardiologists, one selected to receive only clinical data at 
the end of each angiography case while the other was provided with benchmarked 
radiation use feedback in addition to the clinical data. Whilst it can be shown that 
audit and feedback are important components of a clinical outcomes quality 
improvement programs, clinicians must also be provided with clear expectations of 
performance standards and strategies targeted at assisting them to optimise their 
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performance. Chapter 12 describes the development of an imaging information 
gathering strategy that is optimised for deriving the required clinical information at 
the lowest radiation risk to both patients and the clinician.   
 
In Chapters 13 and 14, the combined use of the tools developed is demonstrated 
through their application to monitoring of performance in cardiac surgery. Chapter 13 
describes application of risk adjusted control charts to inform clinical governance 
processes in cardiac surgery. To illustrate this application an example of the 
monitoring of a compound clinical outcome indicator tracking the rate of excess blood 
product utilisation and/or reoperation for bleeding is given. These two events share 
the common aetiology of technical and/or coagulopathic factors. As both blood 
product utilisation and reoperation for bleeding carry increased risk to the patient the 
monitoring of an increase in the incidence of either or both is cause for concern, 
requiring further investigation. Presentation of these charts at the cardiac surgical 
M&M meetings stimulated a number of fruitful discussions on the impact of changing 
patterns in the use of antifibrinolytic drugs and blood products and the consequent 
impact on patient outcomes. Chapter 14 describes the development and 
implementation of a process around the monitoring of total elapsed time a patient is 
on cardiopulmonary bypass. Prolonged bypass duration may act as a ‘near miss 
marker’ linked to changes in clinical practice and is also known to contribute to 
damage to the blood resulting in increased adverse outcomes of patients undergoing 
cardiac surgery. Use of this system identified a significant shift to prolonged bypass 
time which could be linked to a number of potential factors. Change point analysis 
was used to identify the likely cause of the increase, which when communicated to the 
users resulted in a change in clinical practice.  
 
In Chapter 15 the thesis is concluded and findings from each chapter are restated and 
mapped to the raised objectives of the research. Areas in which the research can be 
advanced are also outlined. 
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CHAPTER 2 
 
 
 
Literature Review 
 
2.1   Introduction 
 
Despite accounting for in excess of 30% of all academic publications relating to the 
application of SPC charts (second only to engineering, industrial and environmental 
applications at 43%) (MacCarthy and Thananya 2002), healthcare has been 
comparatively slow to adapt these tools into widespread routine use (Queensland 
Government 2005). Although Lim (Lim 2003) suggests that healthcare’s resistance to 
the use of SPC tools is related to a lack of evidence or a lack of conviction regarding 
their utility, this is a relatively simplistic view that does not consider in detail the 
characteristics of the people involved (clinicians) the nature of the processes being 
monitored (healthcare services) and the capacity of SPC tools to be adapted to address 
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the unique requirements inherent in the healthcare setting (Thor, Lundberg et al. 
2007). The broader issue of why clinical care does not reliably and rapidly translate 
research into daily use has been explored by a number of authors who have used 
schemas such as the diffusion of innovation theory (Berwick 2003, Plsek 2003, 
Sanson-Fisher 2004, Dalrymple, Lehmann et al. 2010) to better understand and 
explain the challenges the healthcare setting poses in the adoption of new techniques 
and technology.  A thorough and detailed analysis of why SPC has been slow to be 
incorporated into routine clinical practice is beyond the scope of this thesis; however, 
this is a fertile area for further research as although the topic is extremely complex, 
the benefits to be gained through their adoption are potentially substantial. 
 
The primary purpose of this Chapter is to provide an overview of the body of 
knowledge relevant to the research objectives and goals of the work described in this 
thesis. This chapter begins by introducing the relevance of quality data registries in 
clinical governance and quality improvement (Section 2.2). Attention is then given to 
systems for performance management (Section 2.3) including a review of the use of 
these tools in interventional cardiology (Section 2.4). The major control chart types 
most commonly used in monitoring for clinical performance variations is then 
discussed (Section 2.5). By necessity, this review is only brief as the variety of charts 
described in the literature on control charts in the clinical context is extensive. Having 
described the charts considered for use, attention is then devoted to the performance 
indicators that might be considered in a governance program for interventional 
cardiology (Section 2.6). The Chapter concludes with a discussion of the issue of 
adjusting for known sources of variation when evaluating and comparing 
performance.   
 
2.2   Clinical Registries in Quality Improvement 
The process of outcomes monitoring and quality improvement in clinical care is 
inexorably linked to building clinical data registries and collecting quantitative 
information (Porter 2008; Porter, Baron et al. 2010; Porter and Molander 2010; 
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Spertus, Bonow et al. 2010). Developments in information technology and 
requirements for accountability have led to an increase in the creation and use of 
governance processes incorporating clinical registries at the local, state and national 
level. There has been growing acceptance of the role of high quality clinical data 
registries (Porter and Molander 2010) such as the National Cardiovascular Data 
Registry (NCDR) (https://www.ncdr.com/webncdr/), Society of Thoracic Surgeons 
(STS) (http://www.sts.org/national-database), Swedish Coronary Angiography and 
Angioplasty Register (SCAAR) (http://www.ucr.uu.se/scaar/ (Lagerqvist, James et al. 
2007), in providing quality information to health system providers, clinicians, funders 
and patients as an essential step to inform subsequent outcome improvement 
processes. Outcomes data may also be used to inform clinical governance and 
credentialing systems (Smith, Rivers et al. 2011). Although the creation of data 
registries has in some instances been prompted by underperformance at healthcare 
institutions (Department of Health 2001; Davies 2005), observational registry data has 
the great potential to be deployed as a routine but powerful tool for both quality 
assurance and improved patient outcomes. Analysis of data from these registries 
provides an alternative monitoring system for real world experience of procedures and 
devices, beyond that provided by the tightly specified randomised clinical trial phase 
(Bhatt 2010; McNamara 2010). Due to the inclusion of large numbers of patients, 
registries enable clinicians to perform subgroup analyses, which provides them 
information on widely varying sub-categories of patients.  
 
With any registry, however, the quality of the analyses is constrained by the quality of 
the data entered. In order to draw useful conclusions from registry data, the data must 
be credible and therefore must be of consistently high quality. Improved data 
management practices increase clinicians’ confidence in the data and therefore their 
engagement with response to the analysis. The guarantee of quality relies on the 
regular application of quality assurance and quality control procedures. Achieving this 
goal requires the development and testing of procedures for more thorough data 
acquisition, analysis and utilization. Quality assurance frameworks, systematic audits 
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and correction procedures have been proposed in the past to enhance accuracy and 
completeness of databases (Arts, Keizer et al. 2002).  
 
In Australia, recent policy changes have urged the reporting of performance data 
(National Health and Hospitals Reform Commission 2008; National Health and 
Hospitals Reform Commission 2008). Several clinical registries now exist in Australia 
that collect data to inform healthcare performance. Evans et al. (Evans, Bohensky et 
al. 2009) conducted a survey to assess the types of registries in use, the data collected, 
the governance structures involved and the quality of the data. The study found that 
46% of the registries (at state or national level) were not supported by clinical or 
professional groups. In terms of data quality, it was noted that 13 of the 28 registries 
(46%) recruited less than 80% of the eligible population or did not formally assess 
completeness of recruitment. The 15 registries that did assess recruitment 
completeness, compared their data with other data sources (e.g. hospital, state or 
national databases, pharmaceutical company data or international benchmarks). The 
study found that the majority of registries used data definitions, had rules for coding 
data and quality assurance techniques (e.g. data validation and range checks). 
However, only 5 of the registries employed audit techniques to ensure that the entered 
data was accurate and reliable. 
 
The power of well thought out quality monitoring and performance review processes 
to improve the quality of service delivery in interventional cardiology has been well 
recognised in the United Kingdom (UK), The United States (US) and Australia. In 
each of these countries processes have been developed or are in the process of being 
developed to collect and audit the performance of PCI services.  
 
Since 1991, the British Cardiovascular Intervention Society (BCIS) has been 
collecting, auditing and providing analysis of clinical performance in PCI across UK 
centres (see: http://www.bcis.org.uk/). The information provided through this process 
relates to an analysis of performance across the entire health service, including both 
public and private facilities, in the UK. As such it features little in the way of 
outcomes analysis that can be extrapolated to the performance at individual sites and 
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performance comparisons with other facilities. However, use of the BCIS supported 
software for collection and analysis of data at individual sites appears to be both 
supported and encouraged, although no specific direction is given on how this is to be 
done.  
 
In the US, the American College of Cardiology (ACC) and the Society of 
Cardiovascular Angiography and Interventions (SCAI) have collaborated on the 
establishment of the National Cardiovascular Data Registry (NCDR) to facilitate the 
collection and reporting of performance metrics related to PCI. Known as the NCDR 
CathPCI registry (http://www.ncdr.com/), this registry has been in operation since 
1997 and is currently in its fourth iteration of data definitions. In its current form, the 
NCDR claims to support generation, on a quarterly basis, of risk-adjusted 
benchmarked reports of the outcomes of diagnostic and PCI procedures. These reports 
seem to offer internal performance analysis of individual facilities and enable 
comparison to comparable facilities and national data. The basis of analysis appears to 
therefore be block data analysis, with limited use of statistically robust methods for 
evaluation and comparison of performance. Furthermore, the reporting frequency 
suggests there is at least 3 months delay between the delivery of care and evaluation 
of outcome, as such the possibility of prompt response to significant performance 
changes is limited. Recently, the SCAI signalled a heightened commitment to a 
quality agenda with the publication of two position statements (Klein, Ho et al. 2011; 
Klein, Uretsky et al. 2011) that propose a sound framework for the design and 
implementation of programs to proactively drive continuous quality improvement in 
interventional cardiology. Interestingly, while these documents provide sound 
guidance on the quality program’s structure including choice of outcome indicators 
and suitable benchmarks, they again do not adequately address the tools to be used to 
monitor for performance variations.  
 
While the programs just outlined in the UK and US have been underway for more 
than a decade, efforts to establish a national registry for quality monitoring and 
improvement in PCI in Australia has only recently commenced. In July 2012 the 
Cardiac Society of Australia and New Zealand (CSANZ) went to the market with an 
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expression of Interest (EOI) for the development, and ongoing management of a high 
quality Cardiac Procedures Registry. The intended use of this registry is to document 
and measure outcomes for patients undergoing cardiovascular procedures in Australia 
and New Zealand with the aim to improve cardiovascular outcomes for patients. At 
the time of writing this thesis, exact specification of the registry and associated 
analysis and reporting processes have not been defined.    
 
2.3   Performance Management Processes 
 
As a consequence of a number of major recent reviews into health-care service quality 
(Department of Health 2001; Queensland Government 2005), there has been a general 
strengthening of structures and processes within hospitals that focus on the 
management and improvement of clinical performance. A key element in achieving 
this objective is the development of transparent systems of accountability for 
effective, safe, high quality care, measurement of clinical outcomes, and appropriate 
management of any deficiencies. In this regard, recommendations from the 
Queensland Health Systems Review have identified (Queensland Government 2005) 
the role of statistical process monitoring techniques. 
 
Spiegelhalter (Spiegelhalter 2004) identifies that it is impossible to meaningfully 
design and implement a control chart based quality monitoring process unless the 
actions to be taken in response to the detection of outlier performance are thoroughly 
considered when the system is constructed. It is vital that these actions be considered 
at the design stage to avoid a statistical monitoring system becoming discredited 
through inappropriate use. 
 
Successful development of the tools outlined in this thesis will assist healthcare 
providers to safeguard and maintain the highest level of clinical care through the 
ability to empirically monitor clinical performance and identify areas of sub-optimal 
clinical outcomes. These tools will form a bridge between the delivery of healthcare at 
Chapter 2:  Literature Review  27  
 
the patient/clinician level and the structures within the health service responsible for 
monitoring and driving quality clinical performance.  
 
The implementation of a real time alarm and response system for clinical under and 
over performance will lead to a reduction in the socio-economic cost of mortality, 
disability and extended recovery times associated with sub-optimal clinical practice. 
The system will allow areas in which clinical performance is below the benchmark to 
be quantitatively and proactively identified and appropriate interventions actioned to 
improve clinical outcomes.  
 
2.4   SPC in Interventional Cardiology 
 
The use of statistical process control techniques to identify performance issues in 
cardiac surgery has been extensive. Substantial components of this work have 
included the use of data from Bristol (Department of Health 2001) to demonstrate the 
use of these tools. A review of the literature, however, reveals that despite the 
apparent similarities in nature of CABG and PTCA procedures (acknowledging that 
CABG procedures are more likely associated with clinically more complex cases), 
comparatively little research appears to have been done in developing and applying 
SPC techniques to PTCA.  
 
To date, the use of SPC tools in Interventional Cardiology for the monitoring of 
performance in PTCA reveals comparatively few instances. Kunadian et al. 
(Kunadian, Dunning et al. 2008) has used Cumulative Funnel Plots to monitor in-
hospital major complications while Matheny et al. (Matheny, Ohno-Machado et al. 
2008) has reported on use of the Sequential Probability Ratio test to detect significant 
discrepancies in mortality rates. The British Cardiovascular Intervention Society 
(BCIS) has indicated in their report on the analysis of 2005 data (Ludman 2005) that 
they intend developing the use of VLAD charts for use in monitoring in-hospital 
Major Adverse Cardiovascular and Cerebrovascular Events. 
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2.5   Statistical Tools: Control Charts 
 
The use of statistical methods to monitor and detect changes in performance of 
manufacturing processes was pioneered in the 1920s by Walter Shewhart. Initially 
designed for use in monitoring industrial processes, in 1942 Deming proposed their 
potential use in health care.  
 
Presently, statistical process control techniques are used in many applications in 
health-care monitoring and public-health surveillance (Woodall 2006) with the charts 
employed taking on various forms depending upon: 
• The type of data: 
o Continuous - blood loss, delay to commencement of intervention, 
length of hospital stay, etc. 
o Binary – mortality, procedural success, etc. 
o Count data – number of complications per month  
• The quantity of interest  
o average performance or  
o variability in performance 
• The primary objective of the monitoring procedure 
 
 Charts in general use for monitoring in health care applications include:  
• Shewhart Charts (Shahian, Williamson et al. 1996; Mohammed, Cheng et al. 
2001),  
• Exponentially Weighted Moving Average Charts (EWMA) (Benneyan and 
Borgman 2003),  
• CUmulative SUM (CUSUM) Charts (Grigg, Farewell et al. 2003; Rogers, 
Reeves et al. 2004),  
• Charts based on Sequential Probability Ratio Tests (SPRT) (Grigg, Farewell et 
al. 2003; Spiegelhalter, Grigg et al. 2003), and  
• Charts monitoring Cumulative Observed – Expected (O-E) (Rogers, Reeves et 
al. 2004), or inverse variable life-adjusted display (VLAD) (Lovegrove, 
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Valencia et al. 1997) or cumulative risk adjusted mortality/morbidity (CRAM) 
(Poloniecki, Valencia et al. 1998). 
 
2.5.1 CUmulative SUM (CUSUM) Charts  
 
Use of CUSUM charts, in their various forms, have been widely used in monitoring 
applications in health care. Their use has been demonstrated in applications ranging 
from cardiac surgery (Novick, Fox et al. 2001; Grigg, Farewell et al. 2003; Rogers, 
Reeves et al. 2004; Rogers, Ganesh et al. 2005), intensive care (Cook, Steiner et al. 
2003) and infection control (Morton, Whitby et al. 2001). 
 
The CUSUM chart is quick to detect small persistent shifts in a process. The chart is 
constructed by cumulatively summing a series of weights (wt) based on the difference 
between the observed and expected outcomes of a series of successive observation (t) 
for the parameter being monitored. In its simplest form the running CUSUM score 
(Xt) is:  
 
ttt wXX += −1  
 
The resultant sum is compared to a predefined decision threshold (‘h’) and is said to 
signal when the threshold is crossed. This normally triggers a review of the factors 
contributing to the outcome change. After a signal the CUSUM is reset to zero and 
monitoring continued.  
 
The particular CUSUM used in this work is based around the charting method 
proposed by Steiner et al. (Steiner, Cook et al. 2000). This method employs double 
sided CUSUM charts based on the cumulative log likelihood ratio. These charts 
simultaneously test the hypotheses that the odds of an event occurring has increased 
or decreased by defined amounts (commonly factors of 2x and 0.5x have been used).  
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Construction of the double sided CUSUM chart is described as follows. For each 
successive observation (t) with an estimated outcome probability of pt and having 
outcome yt (1 for an event of significance and 0 for no event) a risk adjusted weight 
(wt) is calculated using the log-likelihood formula:  
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Where, RO and RA represent the odds ratios under the null hypothesis (H0: odds ratio = 
R0) and the alternate hypotheses (HA: odds ratio = RA) respectively.  
 
The running CUSUM score (Xt) is derived by successively adding wt for each new 
observation to the accumulated score for the prior observations. In the CUSUM 
method described by Steiner et al, the cumulative sum of the weighted scores for the 
chart detecting an increase in the rate of an event of significance (RA>R0) is 
constrained to non-negative values. This has the effect of limiting the accumulation of 
‘credit’ for long runs of favourable outcomes (an advantage of this technique over 
charts using the Risk Adjusted SPRT). The resulting calculation for the running 
CUSUM score (Xt) is: 
 
( )ttt wXX += −1,0max  
 
After each calculation, Xt is compared to the decision threshold ‘h’. If Xt exceeds ‘h’ 
the chart is said to ‘signal’ indicating there is a high likelihood the event rate has 
increased from RO to RA.  
 
CUSUM charts intended for the detection of improved performance (RA<R0) operate 
in a similar manner, however, the accumulation of weighted scores is constrained to 
non-positive values and the chart ‘signals’ when the CUSUM decreases below the 
defined ‘h’. The resulting calculation of the running CUSUM score (Zt) is: 
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( )ttt wZZ −= −1,0min  
 
Using this method, two charts are constructed simultaneously for each performance 
measure. The upper CUSUM (Xt) to detect a doubling in the event rate (RA=2*R0) 
while the lower CUSUM (Zt) to signal when the event rate halves (RA=0.5*R0). It is 
not uncommon to use a two chart system as the lower chart provides useful 
information about the performance of the risk adjustment model as well as acting as a 
tool to detect actual improved performance (Steiner, Cook et al. 2000).  
 
The value of ‘h’ is critically important in determining the run lengths expected before 
a chart ‘signals’. The performance of a CUSUM chart is described in terms of the 
average number of observations that are monitored (average run length or ARL) 
before the chart ‘signals’. For each CUSUM chart, the choice of ‘h’ is a trade-off 
between the ARL to signal when the process is in-control (ARL0) and when the 
process is out-of-control (ARL1). Under ideal circumstances the chart should have a 
very low false alarm rate (long ARL0) while rapidly detecting true change (short 
ARL1). Various methods can be used to determine ‘h’ including the use of empirical 
equations, Markov Chain methods and simulations (Grigg, Farewell et al. 2003). 
 
2.5.2 Cumulative Observed – Expected (O-E) Charts  
 
The VLAD chart was first described by Lovegrove et al. (Lovegrove, Valencia et al. 
1997) in 1997 and was modified by Poloniecki et al. (Poloniecki, Valencia et al. 1998) 
in 1998 (with an attempt to apply control limits to the graph) and described as the 
CRAM. Sherlaw-Johnson et al. (Sherlaw-Johnson 2005) has subsequently introduced 
a scheme for applying control limits from CUSUM charts onto the VLAD and this 
charting scheme has been adopted by Queensland Health. The cumulative O-E chart 
can be used with binary and count data and is good for visual inspection as it shows 
how many events more or less have been observed compared to that expected. 
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In construction, the O-E chart is a special form of CUSUM chart where wt for 
successive observations (t) is calculated as the difference between the observed (yt) and 
predicted probability (pt) of the series of observations, expressed as:  
 
ttt pyw −=  
 
The resultant value of the O-E chart (Vt) after a run of t observations is given by: 
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In its original form, as proposed by Lovegrove et al. (Lovegrove, Valencia et al. 1997) 
in 1997, the VLAD chart was not seen as a formal statistical test and as such 
confidence limits were not seen as being appropriate as this would imply that a 
decision had been made regarding what is or is not acceptable performance. 
 
Subsequently, Sherlaw-Johnson et al. developed the ‘Rocket Tail’ VLAD (Sherlaw-
Johnson, Gallivan et al. 2004), a charting technique that incorporates limits (around 
the x-axis) relating to the exact distribution of outcomes (number of deaths and 
individual patient risks). These limits are updated after each observation and provide 
the probability associated with the current value of the VLAD. More recently, 
Sherlaw-Johnson has combined the VLAD chart with control limits derived using the 
CUSUM (Sherlaw-Johnson 2005).  
 
An alternative approach to the issue of ‘confidence limits’ has been provided by 
Morton (Morton 2006; Morton, Clements et al. 2008). Instead of applying control 
limits to these charts, Bayesian updating is applied to derive credible limits for the O-
E chart.    
 
The cumulative O-E chart is the up-side-down version of the VLAD/CRAM. As the 
test statistic plotted  in constructing the VLAD/CRAM chart is a direct measure of the 
number of target events more or less than expected over the duration of monitoring, 
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the main advantage these charts have over the Steiner CUSUM (which charts the 
cumulative log likelihood ratio) is its ease in interpretation. Although there have been 
various attempts to apply decision thresholds around the VLAD it is not uncommon 
for both charts to still be used for more robust statistical analysis.  
 
2.5.3 Exponentially Weighted Moving Average Charts: 
 
As with CUSUM charts, EWMA control charts are well suited for detecting small 
sustained shifts in a processes (Montgomery 1991). The chart is derived by 
calculating a weighted average of sequential observations with the current observation 
given a weight or smoothing constant, λ (where 0<λ≤1), and previous observations 
given geometrically decreasing weights. Appropriate selection of the design 
parameters for the EWMA chart will result in a system with performance 
characteristics similar to that of the CUSUM (Montgomery 1991). Sonesson 
(Sonesson 2003) provides a review of basic EWMA methods for monitoring 
applications.  
 
 
Construction of the basic EWMA chart is described as follows. For each successive 
observation (xt) the current value of the EWMA (Xt) involves the previous value (X t-1) 
and is derived using:  
 
1)1( −λ−+λ= ttt XxX  
 
To monitor the process, the EWMA chart is a plot of Xi vs. t. If the EWMA chart 
signals, i.e., falls outside some prespecified control limits, we suspect a systematic 
and persistent change in the process being monitored. 
 
A number of forms of EWMA chart have been proposed, all with the same basic form 
but differing in the values for the observations (xt). Charts have been based on:  
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• the weights used in the VLAD (i.e. the difference between the observed (yt) 
and predicted outcome (pt) of a series of observations, where yt is either 0 or 1 
(for success or fail) and pt is the probability associated with the outcome 
provided by the risk model),  
• the time or number of cases/procedures between adverse events, or  
• the value of observations (e.g. the time between admission and first inflation 
of a balloon in an angioplasty procedure).  
 
When used in the latter context, if the observations can be considered as having a 
continuous distribution, the upper and lower limits for the control chart are derived 
using (Crowder 1989; Montgomery 2008), 
[ ]tkx 20 )1(12 λ−−λ−
λ
σ±      
 
where, k is a constant determined by the user to deliver the desired in control run 
length, λ is the smoothing constant, and x0 and σ are the mean and standard deviation 
of the observations used to construct the chart (Montgomery 1991). For simplicity it is 
usual to assume that t is large, in which case the control limits converge to: 
λ−
λ
σ±
20
kx  
 
In the form proposed by Cook et al. (Cook, Coory et al. 2011) for the risk adjusted 
monitoring of binary outcomes, two charts are effectively run. One EWMA chart is 
constructed based on the sequential observation of the expected results (provided by 
the risk adjustment algorithm). This EWMA is ‘wrapped’ with control limits derived 
using: 
)2( λ−
λ
σ± tt kX  
where σt2 is the estimated variance associated with the current expected event rate as 
described by the EWMA (given by Xt(1-Xt)). An anomaly of this formulation is that, 
under certain circumstances, it can deliver a chart with a negative lower control limit. 
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In the clinical domain this result is non-sensible and under these circumstances (if a 
lower control limit is required) a small finite value is used lest the chart never signal a 
reduction (which would be the case if 0 was used). The EWMA chart of expected 
outcomes with control limits, is then overlaid with the EWMA of observed events. 
The process being monitored is then considered as performing within expectation 
while the EWMA of observed outcomes lies between the control limits for the 
EWMA chart of expected outcomes. A caveat on use of the EWMA as described by 
Cook et al. concerns its performance when used to monitor extreme event rates. When 
rates fall outside the 5-95% range, the distribution of observed and expected events 
cease to be sufficiently normal for the Wald based limits to apply.    
 
The development of EWMA charts in the clinical context has tended to lag behind the 
other methods previously mentioned. EWMA charts have been proposed and 
developed for a range of applications including the monitoring of time between 
occurrence of significant events (Spliid 2007), process characteristics (e.g. infection 
rates (Morton, Whitby et al. 2001)) and observed versus predicted outcomes for 
binary events (death or survival following cardiac surgery (Cook, Duke et al. 2008)). 
Development of these charts has also seen them enhanced to account for variations in 
patient risk (Grigg and Spiegelhalter 2007; Cook, Duke et al. 2008; Cook, Coory et al. 
2011). Most recently, Steiner et al. (Steiner and Jones 2009) and Sego et al. (Sego, 
Reynolds et al. 2009) have both explored the use of EWMA charts to monitor survival 
times. 
 
Unlike the CUSUM chart proposed by Steiner et al. (Steiner, Cook et al. 2000), where 
the plotted value is based on the cumulative log likelihood ratio (an abstract value not 
easily interpreted by clinicians), the EWMA chart can be adapted to directly chart a 
measure of performance (e.g. ICU mortality rate (Cook, Duke et al. 2008; Cook, 
Coory et al. 2011). In this regard the EWMA chart has the potential to be more readily 
accepted by clinicians when used as part of a routine, clinician driven quality 
improvement program. 
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2.5.4 Funnel Plots 
 
The application of Funnel Plots to monitor performance quality in healthcare has been 
described by Speigelhalter (Spiegelhalter 2002; Spiegelhalter 2005) and their 
application to interventional cardiology has been demonstrated by Kunadian et al. in 
both ‘conventional’ (Kunadian, Dunning et al. 2009) and ‘cumulative’ (Kunadian, 
Dunning et al. 2008) forms. It should be noted that Speigelhalter (Spiegelhalter 2005) 
has raised questions about this latter use of Funnel Plots in sequential monitoring 
applications due to the issue of repeated testing. Funnel Plots are a useful technique 
for comparison across a number of units (clinicians, clinical teams or institutions), 
however, Speigelhalter notes that usually the only allowance for multiple comparisons 
is use of small p-values for the control limits.  
 
Fundamentally, the funnel plot has four components; an indicator of observed 
performance, a parameter that determines the accuracy with which the indicator is 
measured, an overall target for performance, and a set of control limits that define the 
bounds of acceptable variation. Chart construction plots the performance indicator 
against the measure of variation and then overlays this with a plot of the performance 
target (across the range of variation) and corresponding control limits. Performance is 
deemed as being consistent with expectation when the result falls within the bounds of 
the control limit. 
 
Funnel plots have been used to compare a number of characteristics including; 
proportions, changes or differences in proportions, ratios of proportions, standardised 
rates, changes in standardised rates, ratios of standardised rates (e.g. ratios of 
standardised mortality ratios), directly standardises rates, and means and differences 
in means of continuous data. 
 
In the clinical setting, if the performance measure used to compare unit performance 
is the proportion of patients experiencing an event (r events in a sample size of n), it is 
usual for these four components to comprise; (1) the observed proportion of cases for 
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each unit (i) experiencing the outcome (yi = ri/ni), (2) the number of observations 
attributed to each unit (ni), (3) the expected population proportion experiencing the 
outcome (ϑ0) and (4) the exact binomial limits associated with the expected 
proportion. The graph is constructed by plotting the measure of performance for each 
unit (yi), against the number of observations for that unit (ni). This graph is then 
overlayed with a plot of the expected population performance (as a horizontal line at  
y = ϑ0) and the control limits plotted at the desired level(s) for all possible values of 
the x-axis. Control limits for proportions can be derived using any of a number of 
approaches, including the use of a normal approximation to the binomial (Dover and 
Schopflocher 2011) or the inverse binomial distribution (Spiegelhalter 2002). The 
resultant chart has a characteristic ‘‘funnel’’ shape which is statistically intuitive for 
clinicians to interpret as it shows how the variation due to ‘‘chance’’ reduces with 
increasing sample sizes. Unit performance is deemed as being consistent with 
expectation when the result falls within the funnel. If the chart is used to compare 
proportions relating to adverse outcomes, results below the funnel relate to superior 
performance while results above the funnel indicate poorer than accepted outcomes. It 
is customary to use a system of dual limits on the funnel plot to represent an ‘alert’ 
level (2 standard deviations) and an ‘alarm’ level (3 standard deviations), with the 
response appropriate to the level of limits exceeded. Funnel plots have been advocated 
as a replacement for league tables which can be misleading in that a naïve 
interpretation of the ordinal presentation of outcome results can lead to an inference of 
differences in performance where none exists (Adab, Rouse et al. 2002).  
 
Funnel plots have evolved to include risk adjustment (Gale, Roberts et al. 2006; 
Mayer, Bottle et al. 2009; Noyez 2009). To accommodate risk adjustment, the 
performance measure used is based on the standardised ratio (number of observed 
events divided by the number of expected events). Although a viable option is to 
construct a chart using the standardised ratio directly (Spiegelhalter 2005; Morton, 
Mengersen et al. 2011) it is common to chart the risk adjusted event rate which is 
obtained by multiplying the standardised ratio for each unit by the overall population 
event rate (Spiegelhalter 2005).  
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One issue that needs to be considered when using the Funnel Plot is the possibility 
that the variability in the in-control units is not fully explained by the distribution used 
to determine the control limits. Known as overdispersion (Spiegelhalter 2005; 
Mohammed and Laney 2006), this issue is particularly apparent when sample sizes 
are very large and as a consequence, the resultant control limits are very close to the 
target value. A characteristic of charts exhibiting overdispersion is the presence of a 
disproportionately large number of units signalling special cause variation. A number 
of approaches have been described for handling overdispersion (Spiegelhalter 2005; 
Mohammed and Laney 2006). 
 
2.5.5 Multivariate SPC Charts 
 
While control charts have become more widely accepted in the health domain as a 
means of monitoring processes and outcomes, attention has mainly focused on the 
application of univariate control charts. In most clinical governance settings, however, 
it is usual to track more than one quality characteristic. Unless care is taken in 
configuring these charts the overall probability of a false alarm may be inflated 
(unless the control limits are adjusted accordingly) since any correlation between the 
variables is ignored. A potential solution to this issue is the use multivariate 
techniques (Bersimis, Psarakis et al. 2007; Montgomery 2009). In the industrial 
context, charts used in this application include one based on Hotelling’s T2, the 
multivariate exponentially weighted moving average (MEWMA), and the multivariate 
cumulative sum (MCUSUM) charts. These charts are extensions of univariate charts 
commonly used to monitor clinical data, namely the Shewhart, the exponentially 
weighted moving average (EWMA) and the cumulative sum (CUSUM) charts.  
 
As opposed to univariate charts, where each observation is an individual measure of 
performance or outcome, the dataset used in multivariate charting is based on vectors 
of observations at each time point. If Xi is the ith vector of observations for the p 
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variables being monitor, when the process is in-control, it is assumed that Xi follows a 
multivariate normal distribution, with mean vector µ0 and covariance matrix Σ, 
independent of other observations. That is, )(~ ,Σop
iid
i NX µ . There will be many 
occasions, however, where clinical data do not satisfy this assumption. Although the 
MEWMA chart can be designed to be robust against deviations from normality 
(Stoumbos and Sullivan 2002; Testik, Runger et al. 2003) and there exists a non-
parametric version of the MCUSUM chart (Qiu and Hawkins 2003), the T2 chart is 
highly sensitive to the normality assumption (Stoumbos and Sullivan 2002). When 
normality cannot be assumed, it may be required to transform one or more of the 
variables being monitored to correct for this.  
 
The baseline parameters defining acceptable performance (µ0 and Σ) can either be 
specified by management or estimated using a sample from a stable process. The 
objective is to detect a shift from µ0 to µ1 (some level indicting a significant shift in 
performance). The T2, MEWMA and MCUSUM charts all consider only the 
magnitude of any shift and not its direction. As such, they use only an upper control 
limit (UCL). If a statistic exceeds the UCL, the chart is said to ‘signal’, and the 
process should be investigated using the defined signal investigation protocol.  
The T2 chart plots Ti2 = (Xi − µ0)′Σ−1(Xi − µ0) (Hotelling 1947). If µ0 and Σ have been 
estimated using a sufficiently large sample (in excess of 100 observations), then the 
UCL is 2, pαχ (Seber 2004), however, if they are based on a “small” sample, the UCL 
depends upon whether the researcher is performing a retrospective (Phase I) analysis 
or wants to monitor future values (Phase II). The Phase I and II UCLs are 
βα,p/2,(n−p−1)/2[(n−1)
2/n] and Fα,p,n−p[p(n+1)(n−1)/(n2−np)], respectively (Tracy N 1992), 
where n is the sample size.  
Construction of the MEWMA chart (Lowry, Woodall et al. 1992) requires 
specification of a weight λ, (0<λ≤1) that is used to assign importance to current 
observations. Letting Zi = λ(Xi−µ0)+(1−λ) Zi−1, where Z0 = 0, it plots Zi′Σ−1Zi Zi, where 
ΣZi = λ/2-λ [1−(1−λ)2i]Σ. Prabhu and Runger (Prabhu and Runger 1997) determined the 
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optimal weight and corresponding UCL for selected combinations of p, the size of the 
shift to be detected, and the desired ARL0. For cases not considered, the UCL can be 
obtained through simulation in order to achieve a desired in control run length.  
Several versions of the MCUSUM chart have been proposed (Crosier 1988). This 
chart plots (L′iΣ−1Li)1/2, where  
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and Ci = ((Li−1 + Xi −µ0)′Σ−1(Li−1 + Xi −µ0))1/2 . Crosier recommended setting L0 = 0 
and k = (δ′Σ−1δ)1/2/2 with UCL derived by simulation `to achieve a desired ARL0. 
 
2.6   Performance Indicators 
 
In establishing a quality monitoring system, the definition of what constitutes a 
suitable measure to monitor is the subject of substantial debate. Questions have been 
raised concerning the relative merits of using measures of outcomes (e.g. those 
experienced by the patient) vs. measures of process/structure (those inherent in the 
system delivering care) (Lilford, Brown et al. 2007; Shahian, Edwards et al. 2007). 
Shahian et al. (Shahian, Edwards et al. 2007) identified nine principles to consider 
when selecting performance measures for quality monitoring in adult cardiac surgery. 
Although the clinical focus of this project concerns PTCA, some of the principles 
outlined by Shahian et al. can broadly be applied to the selection of measures for 
monitoring PTCA. These include: 
• The measures selected should monitor all relevant temporal domains of a 
patient’s encounter: pre-procedural, procedural, and post-procedural 
(including long-term measures of outcome) 
• The measures should satisfy multiple criteria for validity, that is, they must 
appear 
o reasonable for their intended purpose 
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o encompass all relevant aspects of the function being monitored, 
o accurately reflect the performance they are designed to measure ,  
o adequately reflect quality of care and not be influenced by case mix 
(this may necessitate the use of risk adjustment) 
• The measures should be easily interpretable and actionable by providers.  
 
In addition to these criteria, frequency of occurrence and likelihood of evidence of 
measurement and monitoring have also been used to assess the applicability of 
indexes for inclusion in a program for monitoring surgical performance (Bruce, 
Russell et al. 2001). In regard to this criterion the application of statistical process 
control techniques to monitor performance, places particular limitations on the 
selection of measurements (i.e. a minimum acceptable event rate of approximately 3-
5% is considered to apply). A review of the measures commonly used to assess 
performance in PTCA (Scanlon, Faxon et al. 1999; Laskey, Kimmel et al. 2000; 
Bashore, Bates et al. 2001; Klein, Ho et al. 2011; Klein, Uretsky et al. 2011) suggests 
that the pool of individual or aggregated measures from which those can be drawn as 
part of a clinical performance monitoring program is quite extensive. A summary of 
the measures sited is provided in Table 2.1. 
 
Most of these measures are currently being collected and audited as part of the clinical 
quality monitoring of interventional cardiology at St Andrew’s War Memorial 
Hospital (SAWMH). This data will be used extensively in the course of this project.  
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Table 2.1: Performance measures used in defining the quality of performance of a angioplasty 
service. Measures marked with * are measures of process while all others can be considered 
as measures of outcome.  
Pre procedural/Procedural measure of service delivery: 
• Delay time from presentation to commencement of intervention (acute procedures)* a 
• Use and administration of appropriate drug therapy (acute procedures)* 
• Radiation usage* a 
• Lesion Treatment Failure (failure to successfully re-establish flow in a lesion)  
• Procedural Failure (failure to achieve a success in all lesions intended to treat)  
• Major Procedural complications, including: 
o Death a 
o Emergency CABG a 
o Anaphylaxis (contrast reactions) a 
o Arrhythmia requiring cardioversion a 
o Cardiac Tamponade a 
o Myocardial Infarction a 
o Stroke a 
o Major Vascular Complications a   
Acute Post Procedure (pre-discharge) 
• Puncture Site Complications a 
o Bleeding  
 Requiring blood transfusion a 
 Excessive nursing intervention  
o Haematoma a 
• Acute Post-procedure Complications, including  
o Death a 
o Emergency Revascularisation (CABG/Angioplasty) a 
o Anaphylaxis 
o Tamponade 
o Myocardial Infarction a 
o Stroke a 
o Use of Intra-aortic Balloon Pump 
Follow-up Outcomes (30 Day & 12 Month) 
• Repeat Angiogram 
• Repeat PTCA  
o Target Vessel 
o Target Lesion 
o New Vessel 
• CABG  
• Death a  
• Stroke a  
• Myocardial Infarction 
• Puncture Site Complications 
• Target Lesion Revascularisation: (TLR: any repeat PTCA on the target lesion or any 
CABG procedure in the follow-up period )  
• Major Adverse Cardiac Event (MACE: any Death, Myocardial Infarction or TLR event). 
• Major Adverse Cardiac & Cerebrovascular Event (any MACE, Stroke, Transient 
Ischemic Attack or Neurological Event). 
a Denotes core measures identified by Klein et al. (Klein, Ho et al. 2011) 
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2.7   Risk Adjustment Algorithms in PCI 
 
When, in 1864, William Farr published one of the first statistical comparisons of 
death rates across English hospitals it was greeted with criticism based on two fronts; 
the statistical methods used in performing the comparison was questionable and he 
failed to take into account the differences in patient characteristics (Iezzoni 1997). 
Although continuous quality improvement is a shared goal of both manufacturing and 
healthcare, one of the major differences impacting on the translation of Shewhart’s 
principles to the monitoring of clinical outcomes is the highly variable nature of the 
‘inputs’ (Alemi and Oliver 2001). The incorporation of risk adjustment (RA) 
techniques into statistical process control (SPC) tools used for healthcare quality 
improvement has therefore been crucial for their success. In adjusting for risk, some 
confounding factors beyond the control of the clinician or service being monitored 
can be controlled in the analysis, maintaining focus on measurement of performance 
of the process under scrutiny (Steiner, Cook et al. 2000; Steiner, Cook et al. 2001; 
Benneyan and Borgman 2003; Grigg, Farewell et al. 2003; Spiegelhalter, Grigg et al. 
2003; Grigg and Farewell 2004). However, poorly calibrated risk adjustment is known 
to introduce bias into the monitoring process (Steiner, Cook et al. 2000; Cook, Steiner 
et al. 2003; Grigg, Farewell et al. 2003; Woodall 2006). Great care therefore needs to 
be exercised in the choice and use of risk adjustment tools to ensure that they are 
relevant and have adequate performance in the patient sample under scrutiny. 
 
A review of the literature regarding risk prediction algorithms developed for use with 
PCI reveals that the most common algorithms involve determining the risk of death of 
the patient following PCI. Of these, the majority relate to death within the hospital 
admission associated with the PCI (Ellis, Weintraub et al. 1997; O’Connor, Malenka 
et al. 1999; Holmes, Berger et al. 2000; Moscucci, Kline-Rogers et al. 2001; Resnic, 
Ohno-Machado et al. 2001; Shaw, Anderson et al. 2002; Maynard, Goss et al. 2003; 
Qureshi, Safian et al. 2003; Wu, Hannan et al. 2006; Singh, Rihal et al. 2007; 
Chowdhary, Ivanov et al. 2009). The remaining algorithms deal with predicting the 
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probability of death as an isolated event at varying discrete times after PCI such as 30 
days (Halkin, Singh et al. 2005) and 12 months (Halkin, Singh et al. 2005). These 
intervals are of interest in this research as they match with the reference intervals used 
in reporting outcomes associated with PCI (Hill, Bagust et al. 2004; Lord, Howard et 
al. 2005). Work by MacKenzie et al. (MacKenzie, Malenka et al. 2009) and Mehta et 
al. (Mehta, O'Neill W et al. 2006) dealt with mortality prediction at other time 
intervals such as 0-90 days (short-term), 90-days to 18 months (mid-term), and more 
than 18 months (long-term) as well as one-year mortality among 30-day survivors, 
however, these time intervals do not tend to match with any reference intervals 
commonly used.  
 
Other prediction algorithms developed for use in PCI look at the risk of suffering a 
major adverse cardiovascular events (MACE) defined as one or more of in-hospital 
death, Q-wave MI, urgent CABG (Ellis, Weintraub et al. 1997; Grayson, Moore et al. 
2006; Madan, Elayda et al. 2008) or if cerebrovascular accidents are included the term 
MACCE can be used (Singh, Rihal et al. 2007). Contrast media associated renal 
dysfunction has also been put forward as a measure of interest and hence has been the 
centre of research on risk prediction models (Rihal, Textor et al. 2002; Bartholomew, 
Harjai et al. 2004; Mehran, Aymong et al. 2004; Brown, DeVries et al. 2008). 
 
Of particular interest in this project, due to the choice of proposed performance 
measures, is a set of algorithms designed to predict Lesion Success and Procedure 
Success (Ellis, Vandormael et al. 1990) as well as late lesion restenosis (Hausleiter, 
Kastrati et al. 2002; Lee, Shih et al. 2007). 
 
A closer examination of these algorithms, however, shows a range of complexities 
and issues of data definitions (of input variables and outputs). Herein lies one of the 
major limitations with the adoption of an external risk measure. Unless it has been 
widely adopted for a particular area (e.g. as is the case the APACHE score for ICU 
(Knaus, Draper et al. 1985) and the EUROScore for cardiac surgery (Roques, Nashef 
et al. 1999)) matching the input data and outcome definitions is problematic. 
Although these models use commonly available metrics such as age and gender, a 
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number of the co-morbidities and outcomes have study specific definitions which 
make it difficult when attempting to apply these tools to an existing data set.   
 
An example of this problem is provided in the four studies dealing with renal 
dysfunction, with the outcomes of interest being variously defined as:   
• serious renal dysfunction, typified by onset of dialysis, ≥2.0 mg/dl absolute 
increase in creatinine from baseline, or ≥50% increase in creatinine from baseline 
(Brown, DeVries et al. 2008) 
• serum creatinine concentration of > 0.5 mg/dl from pre-procedure values (Rihal, 
Textor et al. 2002)  
• nephropathy typified by a >1.0 mg/dl increase in serum creatinine from the 
baseline level, and  
• nephropathy was defined as an increase of ≥25% or ≥0.5 mg/dl in pre-PCI serum 
creatinine at 48 hours after PCI. (Mehran, Aymong et al. 2004) 
 
The issue of standardisation of risk prediction algorithms, along with data collection 
and endpoints, is raised in an editorial by Ludman (Ludman 2008) published in Heart 
in 2008 in which it is suggested that no one prediction tool has yet been adopted for 
widespread use although, as is highlighted here, a large number of different systems 
have been developed. Of the risk prediction tools reviewed, reference can only be 
found to the adoption of an algorithm by the BCIS for the prediction of MACCE 
following PCI (Grayson, Moore et al. 2006). This prediction tool, described and used 
in BCIS 2005 audit for the production of VLAD charts, is currently being used to 
generate Funnel Plots for the comparison of unit performance in centres performing 
PCI in the United Kingdom.  
 
It is therefore likely that to enable the application of risk adjustment to the various 
control charts proposed in this project, in-house, algorithms will need to be developed  
and validated for the various performance measures identified. Should this be the 
case, there is an abundance of examples of how this might be done (in the references 
quoted) using a variety of Bayesian and Logistic regression techniques.    
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CHAPTER 3 
 
 
 
Performance Monitoring in Interventional 
Cardiology 
 
Preamble 
 
Scientifically based quality improvement tools, such as statistical process control 
(SPC) charts, have demonstrated their worth in the industrial context since being 
introduced in the 1920s. Although the translation from industry to health care has 
taken some time, the power of these techniques to display adverse clinical 
performance trends well in advance of other methods of detection has seen them find 
growing acceptance in a variety of clinical applications. To date, however, their 
application to performance monitoring in interventional cardiology has not been 
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extensively explored.  
 
In this chapter we propose a system of clinical outcome indicators and SPC tools to 
monitor both total institutional and individual clinician performance in the delivery of 
PCI services within a single clinical site, inclusive of outcomes up to 12 months post 
procedure. To optimize effectiveness and efficiency of the monitoring process, we 
explore the criteria for selection of clinical outcome indicators and identify a concise 
suite of metrics, including in-hospital outcomes and outcomes at 30 days and 12 
months, for use in a governance application. We then propose and illustrate through 
clinical application, a set of SPC charting tools as a means of quantitatively tracking 
consistency in the delivery of clinical care. These tools are suggested as an adjunct to 
the traditional case based review processes commonly used to deal with major adverse 
events. A secondary purpose of this paper is to explore the role of these techniques in 
developing a system of feedback processes to clinical teams in a clinician driven 
model of quality improvement.  
 
This chapter outlines the overall scope of the thesis and as such touches upon all three 
research objectives. In this chapter an overview is provided of the development and 
application of an SPC informed clinical governance process for the monitoring of 
outcomes of the interventional cardiology service at SAWMH. Included in this work 
is discussion of the factors to be considered in determining the validity of clinical 
outcome indicators (COI) to be used in the monitoring program and proposes a 
meaningful set of indicators satisfying these criteria. To monitor variations in clinical 
outcome delivered by the service over time as well as to enable comparison between 
individual practitioners, a suite of SPC monitoring tools is proposed. Characteristics 
of these tools, such as speed of detection, statistical robustness and ease of 
interpretation are described.   
 
This chapter also serves to highlight a number of potential gaps in existing tools, 
thereby opening areas of possible research touched upon in subsequent chapters. 
These areas include the desirability of employing techniques that take into account 
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known sources of variation in the complexity of clinical procedures. Known as risk 
adjustment, this is an aspect of the application of SPC to interventional cardiology 
that requires particular attention due to the lack of suitable algorithms. 
 
This chapter has been written as a journal paper for which I am the principal author. It 
is reprinted here in the form accepted for publication. I was responsible for the 
conception and conduct of research, design and implementation of statistical analysis, 
preparation of the manuscript and modification of the manuscript to meet the 
requirements of the papers co-authors and journal reviewers. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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3.1   Abstract 
 
Graphical Statistical Process Control (SPC) tools have been shown to promptly 
identify significant variations in clinical outcomes in a range of health care settings, 
but as yet have not been widely applied to performance monitoring in Percutaneous 
Coronary Intervention (PCI). We explored the application of these techniques to a 
prospective PCI registry at a single site. 
 
Baseline clinical and procedural data along with one and twelve month Major 
Adverse Cardiac Event (MACE) details were prospectively collected in relation to 
2697 consecutive PCI procedures (2417 patients) performed between the 1st January 
2003 and the 31st December 2007. We investigated outcome measures which were 
both clinically relevant and occurred at a sufficient frequency (> 1%) to allow valid 
application of SPC techniques, and found procedural and lesion failure, major post 
procedural complications, and one and 12 month MACE to be suitable endpoints. 
Cumulative Sum (CUSUM) charts, Variable Life-adjusted Display (VLAD) charts 
and Funnel Plots were employed in combination to evaluate both group and individual 
performance on a near “real time “basis. We found the use of these charts provided 
complimentary prospective audit of clinical performance to identify variations in 
group and individual operator performance and to clarify these as either systemic or 
individual operator-related. We propose a system of integrating SPC tools as a 
component of the audit function of a PCI unit. 
 
SPC tools have the potential to provide near “real-time” performance monitoring and 
may allow early detection and intervention in altered performance for both the group 
and individual operator. A clinically-integrated system of SPC tools may thus 
complement and enhance effectiveness of the traditional case-based Morbidity and 
Mortality audit.  
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3.2   Introduction 
 
The 1999 United States (US) Institute of Medicine’s publication, ‘To Err is Human: 
Building a Safer Health System’ (Kohn, Corrigan et al. 2000) raised significant 
concerns with the extent and cost of errors in the US health care system and called for 
health care providers, government, consumers, and others to strive to achieve a 
substantial reduction in the rate of adverse events. The identification of systemic 
failings leading to unacceptable clinical performance was also the subject of the 2001 
Bristol Royal Infirmary Inquiry (The Bristol Royal Infirmary Inquiry 2001) in the 
United Kingdom and the 2005 Queensland Public Hospitals Commission of Inquiry 
(Queensland Government 2005) in Australia. As a result of the publicity generated 
from these reports and reviews there has been an increased emphasis on the 
establishment of systems to ensure the delivery of clinical services is of an acceptable 
quality. However, interest in the quality of health care is not limited to dealing only 
with the detection and reduction of medical errors and unacceptable clinical 
performance. In 2003 the Centers for Medicare & Medicaid Services (2008) went 
further by instituting a rule that required hospitals to develop quality assessment and 
performance improvement programs. 
 
Scientifically based quality improvement tools, such as statistical process control 
(SPC) charts, have been used in manufacturing since the 1920s and have a proven 
history of success in quality monitoring and improvement. Although the translation 
from industry to health care has taken some time, the power of these techniques to 
display adverse clinical performance trends well in advance of other methods of 
detection (Queensland Government 2006) sees them now finding widespread 
acceptance in a variety of clinical applications (Morton, Whitby et al. 2001; Novick, 
Fox et al. 2001; Cook, Steiner et al. 2003; Grigg, Farewell et al. 2003; Spiegelhalter, 
Grigg et al. 2003; Rogers, Reeves et al. 2004; Rogers, Ganesh et al. 2005; Woodall 
2006; Thor, Lundberg et al. 2007). To date, however, their application to performance 
monitoring in interventional cardiology has not been extensively explored. Recent 
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work by Kunadian et al. (Kunadian, Dunning et al. 2008) and Matheny et al. 
(Matheny, Ohno-Machado et al. 2008) provide examples of how SPC can be used to 
monitor specific performance measures associated with Percutaneous Coronary 
Intervention (PCI), including in-hospital major adverse cardiovascular and 
cerebrovascular events and in-hospital mortality. Historically, PCI is also associated 
with additional adverse events post hospital discharge including important 
complications such as restenosis and stent thrombosis, which may require repeat 
angiography and revascularisation procedures and also result in additional morbidity 
and mortality.  
 
The primary purpose of this paper is to propose a system of SPC tools to monitor both 
total institutional and individual clinician performance in the delivery of PCI services 
within a single clinical site, inclusive of outcomes up to 12 months post procedure. 
These tools are proposed as an adjunct to the traditional case based review processes 
commonly used to deal with major adverse events. We therefore investigated 
appropriate parameters to monitor not only in-hospital outcomes but also outcomes at 
30 days and 12 months. Our secondary purpose was to explore the role of these 
techniques in developing a system of feedback to clinical teams in a clinician driven 
model of quality improvement.  
 
 
3.3   Methods 
 
3.3.1  Data Collection: 
 
Ethical approval was gained to undertake collection of data from patients undergoing 
PCI procedures at St Andrew’s War Memorial Hospital (SAWMH), as part of an 
ongoing performance monitoring process. 
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For each patient, demographic and co-morbidity data along with angiographic 
findings and outcomes from the hospital admission for PCI were collected. Patients 
were contacted at 30 days and 12 months post procedure and data on a number of 
outcomes were collected. All data were entered prospectively into a purpose-designed 
database. 
 
Data for this study were drawn from 2,697 consecutive procedures performed in the 
Cardiac Catheterisation Theatres at SAWMH between the 1st January 2003 and the 
31st December 2007. The procedures involved 2,417 patients (74.1% male) with a 
median age of 67.1 years (range: 21.1 to 91.2 years). Follow-up of eligible procedures 
at 30 days was 90.2% and at 12 months was 87.9%. A description of the patient 
population characteristics is provided in Table 3.1 while angiographic and procedural 
details are summarised in Table 3.2.    
 
Table 3.1: Patient population ( n = 2417 ) clinical variables. 
Variable Incidence 
Male (%) 74.1% 
Median age (range) years 67.4  (21.1-91.2) 
Risk Factors (%)  
 • Hypertension 62.3% 
 • Diabetes 18.9% 
 • Hyperlipidaemia 56.0% 
 • Smoking history 14.5% 
Indications (%)  
 • Stable angina 45.9% 
 • Unstable angina (and Non STEMI) 47.0% 
 • Acute STEMI 4.0% 
 • Rescue MI (including cardiogenic shock) 0.3% 
 • Positive non-invasive test 5.6% 
Prior Procedures (%)  
 • PCI 23.0% 
 • CABG 13.7% 
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3.3.2 Performance Measures: 
 
In establishing a quality monitoring system, the choice of suitable quality measures to 
monitor is the subject of substantial debate. Questions have been raised concerning 
the relative merits of using measures of outcomes (e.g. those experienced by the 
patient) vs. measures of process/structure (those inherent in the system delivering 
care)(Lilford, Brown et al. 2007; Shahian, Edwards et al. 2007). Based on the 
principles identified by the Shahian et al. (Shahian, Edwards et al. 2007) the measures 
selected should: 
• monitor all relevant temporal domains of a patient’s encounter (including 
long-term measures of outcome), 
• satisfy multiple criteria for validity, that is, they must appear  
o reasonable for their intended purpose , 
o encompass all relevant aspects of the function being monitored,  
o accurately reflect the performance they are designed to measure ,  
o adequately reflect the quality of care, and  
• be easily interpretable and actionable by providers.  
 
In addition to these criteria, frequency of occurrence and likelihood of evidence of 
measurement and monitoring have also been used to assess the applicability of indices 
for inclusion in a program for monitoring surgical performance (Bruce, Russell et al. 
2001). In regard to this criterion the application of statistical process control 
techniques to monitor performance places particular limitations on the selection of 
measurements. For example the event rate has to be high enough to meaningfully 
monitor and have a known, stable distribution. Webster (Webster 2008) has suggested 
that event rates should be in excess of at least 1%.  
 
The measures commonly used to assess performance in PCI (Scanlon, Faxon et al. 
1999; Laskey, Kimmel et al. 2000; Bashore, Bates et al. 2001) were reviewed and 
compared to measures collected as part of the existing hospital based quality 
monitoring program. Through this process a range of appropriate measures was 
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identified and these were assessed against the selection criteria for their suitability for 
inclusion in a performance monitoring program. These measures relate to in-hospital 
procedural and post procedural complications and outcomes and extend into the post 
discharge period with data collection at 30 days and 12 months.  
 
Table 3.2: Patient population angiographic and procedural variables. (ACC/AHA – 
American College of Cardiology / American Heart Association). 
Variable Incidence 
Vessels (%)  
 • Left main 1.3% 
 • Left anterior descending 39.0% 
 • Left circumflex 21.3% 
 • Right coronary 30.7% 
 • Graft 7.7% 
ACC/AHA Lesion Type (%)  
 • Type A 6.5% 
 • Type B 58.3% 
 • Type C 35.2% 
Normal left ventricular function (%) 74.5% 
Stent Type (%)  
 • Drug eluting 89.3% 
 • Bare metal 7.6% 
 • Balloon only 3.0% 
 
Table 3.3: Procedure performance and patient outcome data. 
Clinical Measure Procedure Patient Follow-up 30 Day 12 Month 
Follow-up Rate  90.2% 87.9% 
Procedure Measures    
 Lesion Failure 2.04%   
 Procedure Failure 2.63%   
Acute Post Procedure Measures:    
 Major Complications 1.71%   
 Prolonged Puncture Site Bleeding  5.79%   
Outcome Measures:    
 Mortality 0.19% 0.71% 2.37% 
 Myocardial Infarction 0.12% 0.25% 0.35% 
 Bypass Surgery 0.12% 0.50% 1.36% 
 Stroke 0.04% 0.34% 0.66% 
 Target Lesion Revascularisation 0.12% 0.75% 2.62% 
 Major Adverse Cardiac Event 0.31% 1.68% 5.00% 
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The range of potential performance measures identified from the hospital’s PCI 
database along with their event rates is provided in Table 3.3. This table includes both 
individual and aggregated performance measures covering the procedural, acute post-
procedural and post discharge phases of care.  
 
We selected the following performance measures based on their clinical relevance, 
applicability to a monitoring program and event rate (> 1%): 
Procedural measures of service delivery:  
o Lesion failure: failure to successfully re-establish a final residual stenosis of 
less than 50% as determined by visual estimation,  
o Procedural failure: failure to achieve a success in all lesions intended to treat. 
Acute Post Procedure Outcome Measures (pre-discharge):  
o Major post procedural complications: any instance of major events such as 
mortality, myocardial infarction (MI) , emergency coronary artery bypass graft 
(CABG) surgery, intra-aortic balloon pump use, transfusion, tamponade, 
repeat angioplasty, ventilation, arrhythmia or shock. 
o Puncture site complications excess puncture site bleeding defined as instances 
of where nursing intervention for the management of bleeding exceeded 2 
hours. 
Follow-up Outcomes (30 day and 12 month):  
o Target Lesion Revascularisation (TLR): any repeat PCI or CABG on the target 
lesion in the follow-up period. 
o Major Adverse Cardiac Event (MACE): any mortality, MI or TLR event. 
 
For the purposes of this project, mortality has been defined as being due to any cause. 
At our facility the procedural mortality rate is 0.19% and reflects a relatively low 
proportion of acute MI and cardiogenic shock patients. At this event rate the 
application of SPC techniques is not recommended and therefore mortality has not 
been used as an isolated performance indicator. In other institutions dealing with a 
more acute patient population, however, mortality may be of a sufficient rate (>1.0%) 
that would make it suitable to monitor as an isolated measure using SPC techniques. 
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3.3.3 Choice of SPC methods: 
 
Many types of statistical process control charts have been used in clinical 
performance monitoring applications including Shewhart charts, CUSUM charts (and 
variants such as the Sequential Probability Ratio Test and Sets Method or Grass Plot), 
Cumulative Expected Observed Minus Expected (O-E) charts (or VLAD and CRAM 
charts), Funnel Plots and Exponentially Weighted Moving Average charts. Most 
authors propose a selection of charts to optimise the monitoring process (Rogers, 
Reeves et al. 2004; Spiegelhalter 2004). CUSUM and SPRT charts provide a more 
statistically robust analysis of performance (Rogers, Reeves et al. 2004) while VLAD 
and CRAM plots provide a more intuitive overview of variation in performance that is 
easier to interpret from a “lay” perspective. A strength of sequential monitoring using 
these charts is the ability to construct a system that senses changes in outcome on a 
“near real time” basis (provided data are entered and analysed promptly). As such 
they are suitable for use in an “alarm” or “early warning” system.  Funnel Plots 
provide analysis of individual operator performance and can often clarify whether 
performance variation relates to individual or systemic variations. The following 
outline provides a more detailed explanation of the different charts and a rationale for 
their use in this study. 
 
3.3.3.1 Cumulative Sum (CUSUM Charts): The use of CUSUM charts has been 
demonstrated in applications ranging from cardiac surgery (Novick, Fox et al. 2001; 
Grigg, Farewell et al. 2003; Rogers, Reeves et al. 2004; Rogers, Ganesh et al. 2005), 
intensive care (Cook, Steiner et al. 2003) and infection control (Morton, Whitby et al. 
2001). This form of chart has the advantage over the conventional Shewhart type 
control chart that it is quick to detect small persistent shifts in a process. The charts 
used in this study follow the methodology proposed by Steiner et al. (Steiner, Cook et 
al. 2000), and are based on the cumulative sum of the log likelihood ratio. The 
resultant sum is compared to a predefined decision threshold (‘h’) and is said to signal 
when the threshold is crossed. After a signal the CUSUM is reset to zero and 
monitoring continued. The method proposed in this study involves the use of double 
Chapter 3:  Performance Monitoring in Interventional Cardiology 66  
 
sided CUSUM charts that simultaneously test the hypotheses that the odds of an event 
occurring has increased or decreased (commonly factors of 2x and 0.5x are used). 
Establishment of the decision threshold ‘h’ for these charts is a balance between the 
need to rapidly signal a shift in performance against the rate of false alarms that arise 
due to chance.   
 
3.3.3.2 Cumulative Observed Minus Expected (O-E) Charts: The cumulative O-E 
chart is the inverted version of the Variable Life Adjusted Display (VLAD) 
(Lovegrove, Valencia et al. 1997) or Cumulative Risk Adjusted Morbidity (CRAM) 
(Poloniecki, Valencia et al. 1998) charts. Confidence limits can be calculated and 
plotted on this type of chart while Sherlaw-Johnson et al. (Sherlaw-Johnson, Morton 
et al. 2005) has proposed a scheme for applying CUSUM derived control limits onto 
the VLAD. This chart can be used with binary and count data and is good for visual 
inspection as it shows how many events more or less have been observed compared to 
that expected. The main advantage of the VLAD/CRAM over the CUSUM is its ease 
in interpretation; however, the use of both charts is proposed as the CUSUM 
contributes the more definitive statistical analysis. In this project, this type of chart (in 
the form of the VLAD/CRAM) has been used for institution wide monitoring and 
when required, to review individual cardiologist performance. 
 
3.3.3.3 Funnel Plots: The application of Funnel Plots to monitor performance 
quality in health care has been described by Speigelhalter (Spiegelhalter 2002; 
Spiegelhalter 2005) and their application to interventional cardiology has been 
demonstrated by Kunadian et al. (Kunadian, Dunning et al. 2008). Funnel Plots are a 
useful technique for comparison across a number of time periods, operators or 
institutions. The graph is constructed by plotting the measure of performance 
(numerator) for each unit in this application under review, against the number of cases 
performed (denominator), expressed as a percentage. The performance benchmark 
and exact binomial limits are calculated and plotted for all possible values for the 
number of cases and used to create the familiar Funnel Plot appearance. This chart 
was used for individual cardiologist review. Cardiologist performance is deemed as 
being consistent with the benchmark when their result falls within the ‘funnel’. 
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Results below the ‘funnel’ relate to performance that is significantly under the defined 
benchmark while results above the ‘funnel’ indicate performance significantly above 
the benchmark.  
 
3.3.4 Chart Design:  
 
With all SPC charts, the choice of design parameters (e.g. benchmark rates, ‘h’ 
values, confidence limits etc) is established in consultation with the users and after 
careful consideration of the actions to be taken should an alarm be signalled. In this 
study, performance benchmarks for each chart were based on the group performance 
for the period 2003 to 2006 for the analysis of 2007 performance while the 12 month 
follow-up analysis used outcomes for patients treated between 2003 and 2005 as a 
reference. Data relating to patients lost to follow-up have been omitted from the charts 
of post discharge outcomes. For the CUSUM charts, a false alarm every 5 years was 
considered acceptable and this was used to determine the ‘h’ value for the respective 
charts. 
 
 
3.4   Results 
 
As the number of charts generated in this review totals more than 30 discrete plots 
(including additional plots to review questions arising from the main analysis) we 
have provided an illustrative example of graphs relating to 12 month MACE. Figure 
3.1 is the group CUSUM plot, Figure 3.2 the group VLAD plot and Figure 3.3 the 
individual clinician Funnel Plot.  
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Figure 3.1: CUSUM for monitoring the occurrence of Major Adverse Cardiac Events at 12 
months. The upper and lower graphs have been designed to detect a doubling and a halving of 
the odds of MACE with ‘h’ values of 3.6 (ARL0 ~ 2,500, ARL1 ~ 200) and -3.6 (ARL0 ~ 
2,500, ARL1 ~ 450) respectively. The chart indicates that the MACE rate steadily increased 
from July 2005 and eventually signalled in February 2006. 
 
Figure 3.2: Cumulative Expected – Observed (O-E) chart for monitoring the occurrence of 
Major Adverse Cardiac Events at 12 months Chart includes 95% confidence intervals. The 
Expected event rate for the chart was set to the average rate for the period from the 1st 
January 2003 to the 31st December 2005 (4.1%). The chart demonstrates that the MACE rate 
has been increasing since July 2005 and at present indicates that the unit has recorded 
approximately 15 events more than expected. 
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Figure 3.3: Funnel Plot comparing the 2006 12 month MACE rates associated with 
individual cardiologists to the overall average performance for the from the 1st January 2003 
to the 31st December 2005 (4.1%). The chart demonstrates that the MACE rate for all 
clinicians is greater than the benchmark level but no clinician’s performance was in excess of 
the 99% upper threshold (taken to indicate performance significantly different to the 
benchmark). 
 
The CUSUM and VLAD plots monitoring MACE at 12 months (Figure 3.1 and 3.2) 
have been configured using a benchmark expected rate of 4.1% (the average rate 
across the period from 1st January 2003 to 31st December 2006). The graphs indicate 
that the rate of events declined noticeably from December 2003 until April 2004 
(although no signal resulted on the CUSUM). From April 2004 until August 2005 the 
MACE rate appears to settle to around the benchmark rate (the VLAD suggests that 
the cumulative outcome at this time is around 6 events less than expected). From 
August 2005 until February 2006 the graphs indicate that the rate of events steadily 
increased before a cluster of events resulted in a signal on the CUSUM indicating the 
odds of an event was well above the benchmark rate. The nature of the graphs in 
Figures 3.1 and 3.2 tend to indicate that the event rate from March 2006 is above the 
benchmark rate (the VLAD showing a steady negative slope) with an analysis of this 
data suggesting the rate is greater than 7%. It is important to note that as the trend 
seen in the VLAD may be due to a sequence of chance events, it emphasises the 
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importance of supporting the qualitative information provided by this type of chart 
with an objective, statistically defined signal process such as the CUSUM. By the end 
of December 2006, the VLAD suggests that cumulative outcomes were at 15 events 
more than expected (a marked turnaround from July 2005). The Funnel Plot (Figure 
3.3) comparing the MACE rate for 2006 with the expected benchmark indicates that 
no individual cardiologists' performance can be identified as substantively different 
from the others with respect to this outcome. This suggests that it is likely that the 
increase in MACE is attributable to a systemic change rather than a deviation in 
performance by an individual clinician. In this specific instance, a review suggested 
that a reduction in use of drug-eluting stents by the whole cardiology group may have 
been responsible for the deterioration in MACE. 
 
Figure 3.4 shows the result of the simulation to determine the value of ‘h’ used in the 
CUSUM of Figure 3.1. From this graph an ‘h’ value of 3.6 delivers an in-control 
average run length (ARL0) of ~ 2,400 procedures (or a false alarm every 5 years) 
while the out of control average run length (ARL1) for a doubling in the odds of 
MACE is ~ 200 procedures. Use of the same ‘h’ value in the chart monitoring for a 
halving in the odds of MACE results in an ARL1 for this process of ~450 procedures. 
Also shown in Figure 3.4 is the relationship between the change in odds ratio and the 
rate at which the CUSUM will respond. 
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Figure 3.4: Graph depicting the relationship between Average Run Length (ARL), ‘h’ (left 
side of the graph) and odds ratio shift (right side of the graph) for the double sided CUSUM 
(benchmark MACE rate of 4.1%). A ‘h’ value of 3.6 provides an ARL0 of ~2500 (or a false 
alarm on average every 5 years) and ARL1 values of ~200 and ~450 for odds shifts of x2 and 
x0.5 respectively (as shown in the curve on the right that links run lengths to odds shift). 
 
3.5   Discussion 
 
The introduction of SPC systems to monitor the clinical performance of individual 
practitioners and clinical services has been brought about through public demand for 
transparency in health care. A common thread in reviews into quality failings has 
been the absence of systems to actively and appropriately monitor performance. The 
role of performance monitoring, however, should not be the sole domain of 
government authorities charged with maintaining professional standards. 
Appropriately run institution centred programs, used as an adjunct to the more 
traditional case based mortality and morbidity review processes for major adverse 
events (Bruce, Russell et al. 2001), can enhance these broader based programs by 
removing the delays imposed in the reporting of data off site for analysis and review. 
The opportunity also exists for clinician led teams to leverage these tools for 
optimising clinical performance rather than simply demonstrating minimum 
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acceptable standards of performance. This has the benefit of improving the link 
between changes in clinical practice and defined outcome measures. 
 
To this end we have applied SPC retrospectively to a prospectively collected database 
to begin to develop a system for performance monitoring of PCI outcomes. In 
establishing this system three main issues were considered. These comprised: 
1. The selection of measures appropriate to the task of monitoring variations in 
quality of the service, 
2. The design and establishment of a set of tools with the sensitivity to detect 
meaningful variations in performance, and 
3. The establishment and empowerment of a governance structure to influence 
design of the tools and manage performance issues (both good and poor) 
arising from the monitoring program.  
 
3.5.1 Performance Measures: 
 
In assessing the available performance measures, consideration was given to not only 
whether the measures were clinically meaningful (fulfilling the criteria defined by 
Shahian et al. (Shahian, Edwards et al. 2007)) but also whether they occurred at a 
sufficient frequency to be useful for inclusion in a control chart based clinical 
performance monitoring scheme. For example, in our database, procedural mortality 
is a low frequency event (occurring at a rate of 0.19% across the period under 
review). This rate most likely reflects the low number of cardiogenic shock 
(Hochman, Sleeper et al. 1999) presentations in our current practice. Consequently, 
for our institution, monitoring procedural mortality is best dealt with via a more 
traditional mortality review process as SPC tools are technically suited to event rates 
>1% . In other facilities having a higher rate of acute ST elevation Myocardial 
Infarction and Cardiogenic Shock, the procedural mortality rate may be high enough 
to enable independent monitoring of this outcome with SPC techniques.  
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In our application, we found Procedural Failure (event rate 2.63%) to be a more 
readily useful marker of “in hospital” performance. Similarly, we found TLR and 
MACE to be better measures of performance variation at 30 days and 12 months, 
rather than isolated measures of mortality, MI and target lesion CABG or PCI. 
Although the choice of measures (individual and aggregated) for inclusion in a 
performance monitoring program at our facility has been limited by event rate to 
mainly aggregated measures, use of these parameters might not be the sole options 
when these charting techniques are applied to a database which incorporates patients 
who are at high risk for adverse outcomes.  
 
However, one of the challenges in extending data capture and monitoring into the post 
discharge period is the issue of incomplete patient follow-up. This is particularly an 
issue for a supra-regional tertiary referral hospital where patients may return to remote 
rural and regional location and are not routinely followed up by the treating 
cardiologists at 12 months post discharge from the hospital. The facility under study 
currently runs at an overall follow-up rate at 12 months of 87.9%. A consequence of 
incomplete follow-up is that signals (positive and negative) arising from charts 
monitoring this phase of a patient’s recovery may be due to bias in data capture rather 
than actual changes in patient outcomes. A solution to this would be to monitor and 
potentially correct for this bias in the characteristics of patients captured in the follow-
up period. The methodology for achieving this is the subject of current research which 
will draw upon the experience gained by others in dealing with incomplete follow-up 
data sets associated with, for example, longitudinal studies (Dufouil, Brayne et al. 
2004; Kristman, Manno et al. 2005). 
 
Whilst it may be attractive to establish a seemingly comprehensive system of control 
charts to track all available parameters to monitor technical and clinical performance, 
developers of these systems must be aware of the issue of multiple testing (Bland and 
Altman 1995). Put simply, the more comparisons applied to testing a hypothesis, the 
more likely at least one of the tests will result in a significant finding. A balance must 
therefore be struck between the desire to implement a broad based monitoring 
program and the increased likelihood of falsely signalling a change in performance 
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through over testing. Investigation of appropriate techniques for dealing with control 
charts monitoring processes involving multiple (correlated) measures of performance 
is an area of active research which will draw upon methods developed for industrial 
applications (Bersimis, Psarakis et al. 2007) and surveillance (Rolka, Burkom et al. 
2007). 
 
3.5.2 Governance Issues: 
 
As shown in Figures 3.1-3.3, for each parameter monitored, CUSUM charts (for their 
statistical analysis) and VLAD charts (for their intuitive feedback), were constructed 
to review group performance over time. Funnel Plots and VLAD charts were 
constructed to monitor outcomes linked to individual clinicians. This combination of 
charts has been decided upon due to the relatively low event rates associated with 
these procedures and the modest procedural volumes of some of the individual 
operators.   
 
As the intent of this paper is to primarily demonstrate the viability of the use of SPC 
to monitor the delivery of PCI services, we do not intend to provide a critical review 
of any significant variations in individual clinician or group performance. It is 
important, however, to discuss the broader issues associated with the implementation 
of this type of system .  
 
In any performance review of individuals, the process of monitoring must be 
associated with a process of engagement of the individuals themselves, in this case 
clinicians, such that there is an agreement to participate in a monitoring process. This 
engagement is important for two reasons. Firstly, the choice of parameters to monitor 
and the fundamental design specifications of the monitoring process (magnitude of 
parameter change to detect and tolerance to false signals) should be predetermined 
through consultation with the physicians themselves with a clear understanding of the 
actions to be taken in the event a signal arises (these clinically based decisions will 
then be used to inform the technical design of the charts). Secondly, cooperative 
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participation of physicians should be with an understanding that the results will not 
only be part of an accreditation audit process but will also provide helpful educational 
feedback for all concerned. If used in such a manner, SPC might complement 
traditional “Mortality and Morbidity” reviews, which are by their nature retrospective, 
with the potential for SPC to provide near “real-time” analysis of performance. 
 
We would suggest the following clinician led algorithm (based broadly on the 
approach described by Mohammed et al. (Mohammed, Rathbone et al. 2004)) for 
action in response to a chart “signal”: 
1. Audit of accuracy of data collection which led to the signal “event”. A 
limitation of our study, and of any registry study, is that a number of the 
measures are sensitive to data collection completeness, interpretation and 
accuracy, and therefore, a critical part of the process concerns both the 
relevance and utility of the database fields and the accuracy of prospective 
data collection. 
2. Examination of risk parameters for the patient population over the time 
leading up to the signal to determine if an adverse outcome has arisen due to a 
marked change in the underlying risk factors of the patients being monitored. 
An appropriately calibrated risk adjustment tool for the population could be 
incorporated into the various charting schemes to reduce this effect.  
3. Feedback report of any valid signal (not attributable to data error or variation 
in risk) to the clinical group or individual operator and the institution clinical 
quality control body. A system might include more than one "h" level to 
indicate varying degrees of certainty associated with performance changes. 
 
Use of this algorithm would provide clinicians with prompt notification of a change in 
outcomes associated with variations in performance or changes (intended or 
otherwise) to clinical practice.  
 
Risk adjustment could also be incorporated into the charts proposed in this paper. It is 
highly desirable that common-cause sources of variation should be taken into account 
in this manner, to allow focus on special-cause variation only. Outcome is dependant 
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on pre-procedural risk variables and a number of risk models (Singh, Rihal et al. 
2005; Singh, Rihal et al. 2005; Thune, Hoefsten et al. 2005; Wu, Jin et al. 2006; Lee, 
Shih et al. 2007; Singh, Rihal et al. 2007; Tang, Steinhubl et al. 2007) have been 
developed for PCI, although the majority of these relate to “in hospital” risk rather 
than 30 day and 12 month outcome. To be effective, however, the risk adjustment 
used must be well calibrated to the population being monitored as poorly calibrated 
risk adjustment can render the use of SPC techniques unreliable. For the purposes of 
this paper, we note that the demographics for our study population and the known 
measure of procedure complexity were relatively stable through the period of 
observation and include a population which is at relatively low risk for adverse PCI 
outcomes, according to current risk models. Hence risk adjustment of our population 
is not as critical as it would be in a population with high risk features or significant 
risk variations. We are exploring the incorporation of prospective risk models into the 
database and this may further refine our ability to discriminate performance quality 
variations, including not only “in hospital” outcomes but also 30 day and 12 month 
outcomes.  
 
Medical informatics and decision support can play an important role in outcomes 
monitoring and quality improvement in the delivery of healthcare services, 
particularly through the provision of rapid feedback of accurate and reliable SPC 
information to those working at the patient. We have developed and are implementing 
a statistical process control based system to monitor clinical performance and patient 
outcomes in-hospital, at 30 days and at 12 months. The ability to critically evaluate 
variations in patient outcomes at 12 moths is particularly relevant for patients 
undergoing PCI. The system we propose has the potential to promptly detect and 
signal real changes in clinical performance relating to PCI procedures within an 
institution. Strengthening the link between changes in clinical practice and patient 
outcomes via a rapid and sensitive feedback system, combined with a structured 
management system at both clinical and institutional levels, can contribute to 
significantly enhanced patient care. 
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CHAPTER 4 
 
 
      Adaptation of Existing Risk 
Adjustment Models 
 
 
 
 
Preamble 
 
One of the major factors that has impacted upon the adaptation of industrial quality 
improvement techniques to the health care area is the highly variable nature of the 
complexity of cases being attended to by clinicians. Marked differences in case 
complexity can potentially obscure analysis exploring differences or changes in 
clinical outcome. This variability is related to a wide range of patient related factors 
and co-morbidities. To address this issue, algorithms taking into account known 
sources of variation, have been developed to provide an estimate of likelihood of an 
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outcome being observed (whether that be an adverse event such as death or a positive 
outcome such as the reestablishment of flow in a previously occluded coronary 
artery). The inclusion of risk adjustment into SPC based monitoring applications has 
markedly improved the ability of these tools to detect differences or variations in 
clinical outcome. To be effective, however, these algorithms must be capable of 
providing an expectation of outcome that is both discriminatory and well calibrated 
for the result being monitored as well as the clinical setting and patient cohort in 
which they are applied.  
 
In this chapter we explore issues concerning the application of a commonly accepted 
risk adjustment algorithm to the SPC monitoring of clinical performance. To illustrate 
this topic, intensive care unit outcome data from St Andrew’s War Memorial Hospital 
(SAWMH) is analysed. Using an APACHE II risk model (shown to have good 
discrimination but poor calibration for the patient cohort) a simple correction is 
proposed and evaluated which enables this model to function acceptably in an SPC 
application for this unit. This chapter emphasises that such models can be useful, 
provided they are evaluated and adapted for the patient cohort and clinical service 
being monitored.  
 
The focus of this chapter relates to the first objective of the thesis in that it relates to 
the selection and adaptation for use of clinical outcome indicators for SPC 
monitoring. Although the need for recalibration of risk models for SPC applications 
has been previously identified by others, this chapter contributes by highlighting the 
need for care to be taken in how the recalibration impacts risk estimates across the 
entre range of the algorithm.   
 
This chapter has been written based on a conference paper for which I am a co-author. 
It is reprinted here in the form of a manuscript based on the expansion and refinement 
of analysis undertaken in the preparation of the conference paper. I was responsible 
for the conception and conduct of research, design and implementation of statistical 
analysis, preparation of the manuscript and modification of the manuscript to meet the 
requirements of the papers co-authors. 
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Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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4.1   Abstract 
 
Statistical process control (SPC) tools have been applied to monitoring patient 
outcomes in a range of clinical settings including intensive care. The usefulness of 
these tools, however, is governed by the capacity of the risk adjustment (RA) 
algorithms they employ to reliably account for variations in confounding factors not 
directly under the influence of clinicians. The purpose of this study is to evaluate two 
strategies for recalibrating a potentially poorly performed RA model and compare the 
performance of the resultant outputs in an SPC based outcomes monitoring 
application in a single clinical unit setting. 
 
Records relating to 2954 admissions to the intensive care unit (ICU) from the 1st 
January 2003 to the 31st December 2007 were reviewed. The Acute Physiology and 
Chronic Health Evaluation (APACHE) II algorithm was used to generate probability 
of death estimates for these admissions. This algorithm was shown to have good 
discrimination (area under the curve: 0.90) but poor calibration (Hosmer-Lemeshow C 
Statistic: 128 (df=8, p<0.001)) for the patient population under study. Linear 
recalibration of the predicted APACHE II odds of death and a non-linear (power 
function) recalibration of the predicted APACHE II risk of death were employed to 
improve the RA model’s performance. The resultant recalibrated risk estimates were 
used to generate Cumulative Sum (CUSUM) charts for longitudinal performance 
monitoring.  
 
Both recalibration techniques markedly improved calibration of the APACHE II 
algorithm although the non-linear technique performed better for death estimates less 
than 20% (where the majority of patients in the study population were found). For RA 
CUSUM charts in ICU, the non-linear recalibration method demonstrated superior 
performance. 
 
An ill-fitting risk of death estimate model can be locally recalibrated and is suitable 
for longitudinal, sequential monitoring of outcomes in the ICU. 
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4.2   Introduction 
 
Statistical process control (SPC) may be used to monitor the outcomes of an Intensive 
Care Unit (ICU) over time, by sequentially monitoring deaths or mortality rate. Raw 
mortality rates take no account of changes in the effects of patient related factors on 
the rate of deaths. A risk adjustment (RA) method can balance some of the effects of 
confounding factors such as severity of illness, patient case mix and other factors not 
directly under the influence of clinicians (Steiner, Cook et al. 2000; Steiner, Cook et 
al. 2001; Benneyan and Borgman 2003; Grigg, Farewell et al. 2003; Spiegelhalter, 
Grigg et al. 2003; Grigg and Farewell 2004), but an ill fitting RA is known to 
introduce bias into the monitoring process (Steiner, Cook et al. 2000; Cook, Steiner et 
al. 2003; Grigg, Farewell et al. 2003; Woodall 2006).  
 
Existing RA methods introduce a generalisation error whereby the fit of the risk 
estimates differ between the developmental data and the geographically and 
temporally distant application. It is not practical to develop unique RA tools for each 
individual application. Development is expensive and time consuming and requires 
collection of a large developmental data set often beyond the resources of a single unit 
particularly where there is a low mortality rate. An alternative option, is to recalibrate 
an existing model to the required local application.  
 
The purpose of this study is to explore simple options for the recalibration of a 
potentially poorly performed risk adjustment model and compare the performance of 
the resultant outputs in an SPC based outcomes monitoring application. The RA 
model used for the purposes of this analysis is the Acute Physiology and Chronic 
Health Evaluation (APACHE) II (Knaus, Draper et al. 1985) algorithm.  
 
APACHE II has been widely employed for RA and quality assurance monitoring in 
Australian and New Zealand hospitals such as the St Andrew’s War Memorial 
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Hospital (SAWMH). This ICU adopted the Australian and New Zealand Intensive 
Care Society (ANZICS) Adult Database (Pfadt and Wheeler 1995; Stow, Hart et al. 
2006) in 2000. Although APACHE III (Knaus, Wagner et al. 1991) (introduced into 
the ANZICS Adult Database in 2004) can be used with cardiac surgical cases and has 
been shown to perform better for the Australian population (Cook, Joyce et al. 2002), 
an assessment of fit with appropriate recalibration would have to be performed on this 
(or any other) algorithm’s output before it could be confidently used in a site specific 
RA SPC outcomes monitoring program.  
 
To illustrate a suitable assessment and recalibration process, two simple methods have 
been used to improve the fit of the APACHE II predicted risk of death; an odds 
correction (Steiner, Cook et al. 2000) and a non-linear power recalibration. The 
effectiveness of these recalibration methods and the usefulness of the resultant outputs 
in a monitoring application using a pair of RA Cumulative Sum (CUSUM) charts will 
be demonstrated through retrospective application to the available dataset. A case will 
also be made for the use of a well calibrated and locally relevant RA based SPC tool 
to monitor performance at an individual unit level.  
 
 
4.3   Materials & Methods: 
 
The analysis was performed on data collected in the SAWMH ICU (1st January 2003 
to the 31st December 2007). It is a medical and surgical ICU in a 286 bed adult 
metropolitan private hospital in Brisbane, Australia admitting 1000 patients per year. 
The APACHE II system (provided by the ANZICS Adult Database) estimated 
hospital risk of death (ROD). Readmissions and non-predictive diagnoses, such as 
cardiac surgical cases following bypass surgery were excluded. UnitingCare Health 
Human Research Ethics Committee approval was gained prior to commencement of 
this study (Reference Number: 200813A). 
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Mortality prediction models were assessed by discrimination (the model’s ability to 
distinguish survivors from non-survivors by assigning a higher ROD to patients who 
die than to those who survive) and calibration (the agreement between the expected 
and observed ROD). Discrimination was tested using the area under the receiver 
operating characteristic (ROC) curve (Hanley and McNeil 1982). Calibration was 
assessed using the Hosmer-Lemeshow (H-L) goodness of fit C statistic (Hosmer and 
Lemeshow 1989).  
 
The odds recalibration approach in this paper uses a feature of the RA CUSUM chart 
method defined by Steiner et al. (Steiner, Cook et al. 2000) that permits the testing of 
any OR under the null hypothesis. It can be shown that use of an OR other than one 
under the null hypothesis is similarly achieved by correcting each patient’s individual 
odds by the same OR and then testing as if the OR under the null hypotheses is one. 
The OR correction factor applied was derived after comparing the actual odds of 
death to the odds predicted using the APACHE II model. 
 
The non-linear model used for the recalibration of APACHE II ROD prediction was 
determined after analyzing the relationship between observed mortality and predicted 
risk. Observed mortality rates were calculated for each decile of predicted risk and the 
parameters for a simple power function recalibration curve resulting from the plot of 
observed vs. expected mortality rates was determined using weighted least squares 
regression. The weighting scheme used was designed to adjust for the marked 
variation in population density across the range of predicted risk values. Three 
weighting schemes based on absolute count, log count and square root of count within 
each decile were considered. Based on an evaluation of the observed variation and 
effect of each of these schemes, the square root of the count in each decile was 
adopted as the weight. 
 
A cross validation analysis was used to test the performance of the two risk prediction 
recalibration strategies dividing the full data set into two groups in a 70:30 split. The 
larger sample was used to develop the risk prediction recalibration models. The 
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smaller sample was used to test the performance of the resultant model and 1000 
iterations were performed. 
 
The application of RA CUSUM charts (Steiner, Cook et al. 2000) to monitor in-ICU 
and in-hospital mortality has previously been described by Cook et al. (Cook, Steiner 
et al. 2003). A summary of the RA CUSUM chart method and estimation of the 
decision threshold (‘h’) appears in Steiner et al. (Steiner, Cook et al. 2000). The 
detection of statistical anomalies by RA CUSUM charts can be described in terms of 
the average run length (ARL) of observations before signalling a likely shift in the 
odds ratio (OR) referenced to a prediction model such as the APACHE II estimate of 
probability of in-hospital death. The choice of ‘h’ at which the chart signals is a trade-
off between the ARL when the process is in-control (ARL0) and when the process is 
out-of-control (ARL1). ARL0 and ARL1 can be thought of as being similar to 
measures of specificity and sensitivity (Cook, Steiner et al. 2003). Under ideal 
circumstances the chart should have a very low false alarm rate (long ARL0) while 
rapidly detecting true change (short ARL1).  
 
The selection of ‘h’ values was made after reviewing the results of the simulations of 
the RA CUSUM charts for various OR shifts. Consideration was made in clinically 
plausible scenarios, given the context of the event rate being monitored, the rate of 
admissions to ICU and the number of deaths likely to occur before a change was 
signalled.  
 
4.4   Results 
 
Between the 1st January 2003 and the 31st December 2007 there were 4842 hospital 
admissions to the ICU. Of these, 2954 admissions were eligible for analysis 
comprising; 90.9% elective; median age 66.6 years (interquartile range of 55.8 to 76.0 
years); 59.8% males and median length of stay of 2 days (interquartile range of 1 to 2 
days, overall range of 1 to 77 days). An Exponentially Weighted Moving Average 
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(EWMA) graph of the APACHE II predicted ROD estimates for patients admitted to 
ICU over the period of this analysis is provided in Figure 4.1.   
 
Prior to using the outcome data to explore the effectiveness of the two recalibration 
strategies and subsequent use of their outputs in a RA CUSUM application it was first 
necessary to established that the performance of the ICU was stable and in-control. 
This was done through examination of the departmental management records which 
includes a routine Mortality and Morbidity review and an analysis of the quarterly 
Standardized Mortality Ratio (SMR) estimates. This review indicated that 
performance of the unit was sufficiently consistent to allow use of the data for the 
intended purpose.  
 
Figure 4.1: EWMA (λ=0.05) of APACHE II predicted ROD by first admission date for 
patients admitted to the SAWMH ICU between January 2003 and December 2007. Death 
events are indicated by vertical bars at date of initial admission to ICU.  
 
The observed mortality rate was 3.28% (97 deaths in 2954 admissions) compared to 
the APACHE II model predicted mortality rate of 8.61% (254 expected deaths). The 
APACHE II model had an area under the ROC curve of 0.90 (95% confidence 
interval 0.87 - 0.94) indicating good discrimination. The H-L goodness of fit C 
statistic was 128 (df=8, p<0.001) indicating that the APACHE II predicted ROD was 
not well calibrated in this application. The relationship between observed death rate at 
discharge from hospital and APACHE II predicted ROD is shown in Figure 4.2.  
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Figure 4.2 displays the cumulative density function representing the distribution of 
admissions by predicted risk. Approximately 90% of the patients admitted to the 
SAWMH have an APACHE II predicted ROD of less than 0.2 (observed risk of 
0.075). Figure 4.3 shows that the APACHE II model over-estimates the total number 
of deaths by 157.4 while the power function and odds correction recalibration 
strategies have prediction errors of -5.9 and 15.4 deaths respectively. 
 
 
Figure 4.2: Calibration curve relating APACHE II predicted ROD to observed patient 
mortality rates for patients admitted to the SAWMH ICU between January 2003 and 
December 2007. The 95% confidence intervals were calculated according to the ‘scores’ 
method with correction for continuity (Newcombe 1998). The sample cumulative density 
function describing the distribution of expected risk probabilities is also shown. 
 
The weighted least squares regression fit to the data resulted in a power function 
model with a scalar of 1.0503 and a power term of 1.6352. Based on the observed 
death rate and the rate predicted by the APACHE II model, an odds correction factor 
of 0.3603 was used to adjust the ROD estimates for each patient. The H-L statistics 
for these models using the power function and odds correction models on the full 
dataset (n=2954) is 19.5 (p=0.012) and 26.3 (p<0.001) respectively. 
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Figure 4.3: Graph of the prediction error (Expected – Observed deaths) for the APACHE II, 
Power Function and Odds Correction models. Analysis relates to each model’s performance 
across the full 2954 admissions (97 deaths) to the SAWMH ICU between January 2003 and 
December 2007.Model Predicted Risk is the ROD decile into which the respective model 
allocates an admission. 
 
Figure 4.2 displays the cumulative density function representing the distribution of 
admissions by predicted risk. Approximately 90% of the patients admitted to the 
SAWMH have an APACHE II predicted ROD of less than 0.2 (observed risk of 
0.075). Figure 4.3 shows that the APACHE II model over-estimates the total number 
of deaths by 157.4 while the power function and odds correction recalibration 
strategies have prediction errors of -5.9 and 15.4 deaths respectively. 
 
Figure 4.4 plots the change in calibration achieved through the use of the odds 
correction and power function recalibration processes. The graphs shown relate to the 
distributions of the pre and post recalibration H-L C statistic resulting from the cross 
validation analysis. After recalibration, both models demonstrated improved fit.  
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Evaluation of the CUSUM designed to detect a doubling of the odds of ICU mortality 
using the power function recalibration showed that an ‘h’ value of 4.0 delivers an 
ARL0 of ~5,250 and an ARL1 of ~270. This equates to a false alarm every 7.5 years 
while signalling a true doubling of the odds of ICU mortality within 5 months (or 7 
excess deaths). For the RA CUSUM designed to detect a halving of the mortality 
odds, an ‘h’ value of 3.1 delivers an ARL0 of ~1,750 (2.5 years) and an ARL1 of ~430 
(7 months). The corresponding ARL0 criterion for the odds correction model delivers 
an ARL1 of 250 (doubling of mortality odds) and 400 (halving of mortality odds) with 
‘h’ values of 4.2 and 3.3 respectively. 
 
 
Figure 4.4: Graph depicting the result of the cross validation analysis of the use of an odds 
correction and a simple power function based recalibration of the APACHE II score. An 
average H-L statistic of 15.5 or less is taken as the acceptance level for adequate calibration.  
 
Figures 4.5 and 4.6 are the CUSUM charts resulting from the use of the odds 
correction and power function recalibration methods. These charts highlight the effect 
the discrepancies in predictive ability of the two models had on performance of the 
respective CUSUM charts. The more conservative ROD estimates of the power 
function recalibration model resulted in the CUSUM detecting a doubling in the odds 
of death being more willing to indicate a deterioration in unit performance than the 
equivalent chart of the odds correction technique. This is particularly apparent in the 
period after April 2006 where the EWMA graph in Figure 4.1 shows a period of 
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relatively low APACHE II predicted ROD, a range for which the odds correction 
model has been shown to deliver an over-prediction of risk.  
 
The only common signal identified by both techniques occurs in June 2003. The 
EWMA chart of APACHE II predicted ROD and observed death events (Figure 4.1) 
indicates that this is a period of moderately high risk admissions but few death events. 
The difference in performance between the two models in this region results in the 
odds correction technique signalling twice in the space of 6 months for lower than 
expected mortality. In comparison the power function model appears to return to a 
‘normal’ state after the first signal. This is most likely due to the difference in 
calibration of the two systems in this region of operation where the odds correction 
technique over-predicts risk compared to the power function model.  
 
4.5   Discussion 
 
The APACHE II estimated probability of in-hospital death is a poor tool to use for 
risk adjustment in the SAWMH ICU. Although it reliably discriminates between 
survivors and non-survivors (AUC of 0.90), in its unmodified form it is poorly 
calibrated, over-estimating the probability of death particularly for low risk patients. 
Recalibration on the SAWMH data markedly reduces this problem. After applying the 
odds correction technique, the 157 excess deaths predicted using the unmodified tool 
is reduced to 15 excess deaths. Recalibration with the power function method under-
estimates the outcomes by 6 deaths with most of the discrepancy occurring in the 10-
20% range.  
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Figure 4.5: RA CUSUM derived using the odds correction model. The upper and lower 
graphs have been designed to detect a doubling and a halving of the odds of death with ‘h’ 
values of 4.2 (ARL0 = 5,250, ARL1 = 250) and -3.3 (ARL0 = 1,750, ARL1 = 400) 
respectively.  Dots indicate signal events and are associated with a reset of the relevant 
CUSUM.  
 
Figure 4.6: RA CUSUM derived using the power function recalibration model. The upper 
and lower graphs have been designed to detect a doubling and a halving of the odds of death 
with ‘h’ values of 4.0 (ARL0 = 5,250, ARL1 = 270) and -3.1 (ARL0 = 1,750, ARL1 = 430) 
respectively. Dots indicate signal events and are associated with a reset of the relevant 
CUSUM.  
 
 
Chapter 4:  Adaption of Existing Risk Adjustment Models 97 
 
The H-L cross validation analysis, (Figure 4.4) underscores the improvement in 
calibration achieved using both recalibration strategies. This analysis also 
demonstrates that the power function recalibration is superior to the odds correction 
technique with over 70% of the model assessments in the simulation achieving scores 
below the defined acceptance threshold compared to 27% of simulations for the odds 
correction method. 
 
In this study monitoring using two RA CUSUM charts is used to detect different 
plausible scenarios regarding changes in performance. Different information (and 
responses) arise from monitoring in this way. For a system of charts monitoring a 
significant outcome such as patient death, there are major implications associated with 
signalling a deterioration in performance. Under the investigation model proposed by 
Mohammed et al. (Mohammed, Rathbone et al. 2004) a signal suggesting a significant 
increase in the odds of death would trigger systematic and extensive reviews of data 
quality, risk predication performance, clinical practice and clinician performance. The 
cost and disruption associated with a false alarm has to be balanced against the need 
to rapidly detect and respond to an unexpected increase in patient deaths (which could 
relate to an indication of a change in risks associated with the process as well as a 
deterioration in the quality of the care delivered). 
 
In contrast, a signal arising from the chart monitoring for improved performance in 
this application has a different focus. A similar review process is likely to follow, 
commencing with a review of the data. A suggestion that a unit is performing better 
than expected has a different implication as potentially a genuine reduction in patient 
mortality may have been achieved. As such, it may be acceptable for a much shorter 
false positive ARL and a longer true positive ARL as the consequences of an 
erroneous signal are less onerous. 
 
We contend that local unit based monitoring with a locally relevant and calibrated risk 
adjustment tool can allow longitudinal analysis of performance in a single institution. 
This is potentially an effective audit technique which can contribute to improvement 
of clinical performance. Being local and relevant, there is the opportunity for timely 
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analysis and feedback, reflection and action to address deficiencies or learn from 
exceptional performance.  
 
Most commentators on the need and use of SPC in the clinical domain have stressed 
the role of central oversight and accountability in monitoring the outcomes of 
healthcare processes. The retrospective case studies where the use of sequential 
techniques may have detected true anomalies of care have not necessarily been 
advocating for local use to favourably modify the quality of clinical services. A far 
more convoluted population surveillance paradigm has been promoted. The methods 
that we describe will not stop someone who intentionally sets out to injure or kill 
patients, nor do they constitute a complete quality program in isolation. Their use will, 
however, assist in the relevant and timely assessment of outcomes. 
 
A driver for the introduction of sequential monitoring systems has been the marked 
increase in public demand for transparency in health care which has been fuelled by 
investigations such as the 2001 inquiry into paediatric cardiac surgery at the Bristol 
Royal Infirmary (The Bristol Royal Infirmary Inquiry 2001) and the Queensland 
Public Hospitals Commission of Inquiry 2005 (Queensland Government 2005). 
Findings from these inquiries highlighted an absence of systems to appropriately 
monitor performance in the respective healthcare services.  
 
Recommendations arising from these reviews included requirements designed to 
improve the standard of clinical practice. The Queensland Inquiry specifically 
emphasized the importance of clinical audits as an ongoing evaluation tool for 
assessing performance of medical practitioners and services (Queensland Government 
2005) with the associated Queensland Health Systems Review (Queensland 
Government 2005) recommending the use of appropriate statistical techniques such as 
CUSUM charts as a means of performing this function. Retrospective evaluations of 
clinical performance at Bristol (Mohammed, Cheng et al. 2001; Grigg, Farewell et al. 
2003; Spiegelhalter, Grigg et al. 2003) suggest that the use of adequate audit 
methodologies and surveillance techniques would almost certainly have detected 
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underperformance at an early stage and if acted on would thus have prevented the 
serious adverse outcomes that were seen. 
 
Medical informatics and decision support can play an important role in performance 
monitoring and quality improvement in the ICU (Garland 2005), particularly with 
rapid feedback of accurate and reliable SPC information to those working at the 
patient (Thor, Lundberg et al. 2007). The use of these tools for driving quality 
improvement should not be the sole domain of national or state level monitoring 
programs. 
 
A great benefit can be achieved with carefully designed and calibrated performance 
monitoring at the local unit level. Longitudinal trends in RA outcomes focus on 
improvement with respect to within institution benchmarks, supplement the broader 
based programs used in a secondary tier quality assurance role. Monitoring at this 
secondary level has less ability to detect and respond to within institution process 
variations. Such a system would potentially detect real performance changes within an 
institution more reliably and improve responsiveness by removing the delays imposed 
in the reporting of data off site to broad based national or state based services (Afessa, 
Keegan et al. 2005). From the clinical quality improvement perspective this type of 
system is eminently practical and will reduce feedback delays by linking outcomes 
with changes in clinical practice (Thor, Lundberg et al. 2007).   
 
4.6   Conclusion 
 
This paper describes the recalibration of an ill-fitting in-hospital mortality model for 
incorporation into risk adjusted statistical process control techniques at the individual 
unit level. Such a system has the potential to improve the responsiveness and quality 
of care by minimising the delays inherent in aggregating and exporting data for 
analysis to organisations or agencies remote from the point of care, thereby 
facilitating a tighter link between actions and outcomes.  The method of recalibration 
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can substantially impact on the information delivered by the process. It is 
recommended that routine reassessment of the RA model performance take place to 
ensure its ongoing utility. Interpretation of these charts (and any signals arising) 
requires a detailed understanding of the RA model and its interaction with the SPC 
technique employed.  
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CHAPTER 5 
 
 
Site Specific Risk Adjustment Models 
 
Preamble 
 
In the previous chapter, the need for inclusion of risk adjustment to improve the 
performance of SPC monitoring of clinical outcomes was demonstrated and a case 
made for care to be taken in the evaluation and potential calibration of an ‘off the 
shelf’ risk model for use in this task. In cardiac surgery (EuroSCORE, Parsonnet) and 
intensive care (APACHE II, III and IV), extensive work has been done on the 
development and validation of generalized risk models dealing with the adverse 
outcome of death and these models are widely accepted and used in clinical audit 
applications. Unfortunately, as identified in Chapters 2 and 3, there is presently no 
consensus on outcome indicators in interventional cardiology (this may be changing, 
however, with the release in 2011 of two position statements on "Quality assessment 
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and improvement in interventional cardiology” by the Society of Cardiovascular 
Angiography and Interventions) with the result that there are no risk models that can 
be viewed as having widespread acceptance.  
 
Therefore to optimize monitoring of the suite of outcome indictors proposed in 
Chapter 3 it has been necessary to develop risk adjustment algorithms in-house using 
data available in the SAWMH prospectively collected interventional cardiology 
registry.  
 
The focus of this chapter relates to the first objective of the thesis in that it considers 
factors impacting on the selection and adaptation for use of clinical outcome 
indicators for SPC monitoring. The work undertaken in this chapter contributes 
through the development of a unique risk adjustment algorithm predictive of the 
likelihood successfully reestablishing flow in an occluded coronary vessel of using 
percutaneous coronary intervention. 
 
This chapter has been written based on a journal paper for which I am the principal 
author. It is reprinted here in the form accepted for publication. I was responsible for 
the conception and conduct of research, design and implementation of statistical 
analysis, preparation of the manuscript and modification of the manuscript to meet the 
requirements of the papers co-authors and journal reviewers. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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5.1   Abstract 
This paper describes the development of a risk adjustment (RA) model predictive of 
individual lesion treatment failure in percutaneous coronary interventions (PCI) for 
use in a quality monitoring and improvement program.  
Prospectively collected data for 3972 consecutive revascularization procedures (5601 
lesions) performed between January 2003 and September 2011 were studied. Data on 
procedures to September 2009 (n=3100) were used to identify factors predictive of 
lesion treatment failure. Factors identified included lesion risk class (p<0.001), 
occlusion type (p<0.001), patient age (p=0.001), vessel system (p<0.04), vessel 
diameter (p<0.001), unstable angina (p=0.003) and presence of major cardiac risk 
factors (p=0.01). A Bayesian RA model was built using these factors with predictive 
performance of the model tested on the remaining procedures (area under the receiver 
operating curve: 0.765, Hosmer-Lemeshow p value: 0.11). CUmulative SUM, 
Exponentially Weighted Moving Average and Funnel Plots were constructed using 
the RA model and subjectively evaluated. 
A RA model was developed and applied to SPC monitoring for lesion failure in a PCI 
database. If linked to appropriate quality improvement governance response protocols, 
SPC using this RA tool might improve quality control and risk management by 
identifying variation in performance based on a comparison of observed and expected 
outcomes. 
 
5.2   Introduction 
Recent position statements (Klein, Ho et al. ; Klein, Uretsky et al.) of the Society of 
Cardiovascular Angiography and Interventions (SCAI) provide a framework for the 
design and implementation of programs to proactively drive continuous quality 
improvement in interventional cardiology. While these documents provide sound 
guidance on the structure of these programs including the choice of outcome 
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indicators and suitable benchmarks, one aspect not adequately addressed are the tools 
to be used to monitor for performance variations. We have previously described the 
development and deployment of such a monitoring program in a single unit 
performing percutaneous coronary intervention (PCI) (Smith, Rivers et al. 2011). In 
this program we have made extensive use of graphical statistical process control tools 
to quantitatively inform quality assurance and improvement activities. 
 
A point well made in the SCAI documents is the need to take into account known 
patient related factors when assessing performance variations. The incorporation of 
risk adjustment (RA) into SPC tools for healthcare quality improvement has been 
crucial for their success (Alemi and Oliver 2001). In adjusting for risk, confounding 
factors beyond the control of the clinician or service being monitored can be 
accounted for in the analysis, improving focus on measurement of performance of the 
process under scrutiny by comparing achieved outcomes against those expected 
(Steiner, Cook et al. 2000; Steiner, Cook et al. 2001; Benneyan and Borgman 2003; 
Grigg, Farewell et al. 2003; Spiegelhalter, Grigg et al. 2003; Grigg and Farewell 
2004). Poorly calibrated RA, however, is known to introduce bias into the monitoring 
process (Steiner, Cook et al. 2000; Cook, Steiner et al. 2003; Grigg, Farewell et al. 
2003; Woodall 2006). Great care therefore needs to be exercised in the choice and use 
of RA tools to ensure that they are relevant and have adequate performance on the 
patient sample under scrutiny. 
 
An outcome measure proposed for inclusion in the program we have developed 
concerns the failure to re-establish a final residual stenosis of less than 50% in lesions 
being treated (termed lesion failure). A review of the literature for a suitable RA 
algorithm for this measure yielded work by Ellis et al. (Ellis, Vandormael et al. 1990) 
published in 1990 which deals with refinement of the American College of 
Cardiology and the American Heart Association (ACC/AHA) stenosis classification 
system. Evaluation of the validity of this classification system to the stratification of 
outcomes for the clinicians and unit being monitored revealed that although it 
demonstrated modest capacity to discriminate risk (area under the Receiver Operating 
Characteristic curve (AUC) =0.658) it was not well calibrated for this patient cohort 
Chapter 5:  Risk Modelling in Quality Clinical Registries 108 
 
(Hosmer-Lemeshow (H-L) statistic p<0.001). This index was therefore considered of 
limited utility in an RA-SPC application for the service under review. A finding that 
this classification system is no longer calibrated for a contemporary patient cohort is 
not unexpected as significant advances in clinical practice and technology over the 
past 20 years (including the use of coronary stents) are known to have had a marked 
effect on outcomes (Roberts, Grayson et al. 2010; Krone, Shaw et al. 2003). More 
contemporary risk assessment tools such as the SYNTAX Score (Sianos, Morel et al. 
2005) were also considered. However, this algorithm was rejected as although it 
includes a comprehensive range of lesion characteristics its primary outcome 
(functional significance of disease) was not specific to an individual lesion and hence 
not considered appropriate for purpose.   
 
In the absence of an appropriate contemporary algorithm we explored the 
development of a RA scheme tailored to the unit’s specific patient characteristics and 
performance. Data for the development of this model was drawn from a registry of 
retrospectively collected data acquired as part of an ongoing quality monitoring 
program. The model we have developed uses a Bayesian approach to combine 
available evidence to provide an assessment of the risk of lesion failure. This 
approach has been used in other risk prediction applications in PCI and cardiac 
surgery (L'Italien, Paul et al. 1996; de Belder, Jewitt et al. 2001).  
 
In this study we therefore aimed to develop and validate a Bayesian prediction 
algorithm for lesion treatment failure in PCI for the purpose of improving the 
sensitivity of SPC charts used to monitor variations in overall unit outcomes as well 
as the outcomes achieved by individual clinicians working within the unit. 
  
5.3   Methods 
5.3.1 Patients 
This study involved the retrospective analysis of prospectively collected data acquired 
as part of an ongoing quality monitoring program conducted by the angioplasty 
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service of St Andrew’s War Memorial Hospital, Brisbane, Australia. Ethical approval 
was gained to undertake collection of these data.  
 
In total, data for 3972 consecutive revascularization procedures (5601 lesions) 
performed on 3426 patients in the period from 1st January 2003 to 30th September 
2011 were available for analysis. All data were entered into a purpose-designed 
database. Procedures were performed by 5 experienced consultant cardiologists. Data 
recorded included patient demographic information, along with procedural details and 
outcomes including major adverse cardiac events during the admission of the 
procedure, at 30 days and at 12 months.  
 
5.3.2 Control Chart Methodology 
Control charting for process monitoring has two phases (Montgomery 2008). In Phase 
1, the dataset is retrospectively examined to build the charts and derive the control 
limits. In Phase 2, the charts are used to monitor the process in real time and take 
action if the charts signal that the process has changed. Phase 2 data was also used to 
undertake an evaluation of the RA model to confirm performance. Data collected up 
until the end of September 2009 (the first 3100 procedures) was used as Phase 1. This 
date has been chosen as it marked the commissioning of a new cardiac imaging 
facility (including new angioplasty registry) at the hospital. Analysis of Phase 2 
outcomes therefore provides an assessment of the stability of clinical practice and the 
data acquisition processes. A description of the patient population and lesion 
characteristics for the two phases is provided in Table 5.1. 
 
5.3.3 Outcome Measure 
The outcome of interest in this study is failure to successfully re-establish a final 
residual stenosis of less than 50% in the treated lesion (termed lesion failure). The 
status of flow, hence the outcome, is determined visually by the cardiologist at the 
time of the imaging procedure. Entry of information into the registry is based in the 
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intention to treat, that is, an outcome is recorded for each lesion attempted. In Phase 1 
a total 81 of the 4387 lesions attempted were noted as failures (1.85%).   
 
 
Table 5.1: Characteristics of the Phase 1 and Phase 2 patient populations and procedural details. 
Parameter 
Incidence 
Phase 1 Phase 2 
Patients 2764 662 
Procedures 3100 872 
Lesions 4387 1214 
Male (% procedures) 74.6% 73.4% 
Median age at time of procedure (range) years 67.2 (26.1-92.8) 69.5 (32.2-94.1) 
Risk Factors (% patients)   
 • Hypertension 63.1% 61.8% 
 • Diabetes 19.2% 29.0% 
 • Hyperlipidaemia 56.6% 71.9% 
Indications (% procedures)   
 • Unstable angina (and Non STEMI) 30.3% 26.0% 
 • Primary AMI 3.8% 3.6% 
 • Rescue MI (including cardiogenic shock) 0.3% 0.5% 
Prior Procedures (% procedures)   
 • PCI 23.6% 35.8% 
 • CABG 13.2% 23.0% 
Procedure Type (% lesions)   
 • Primary Stent 23.7% 27.3% 
 • Balloon Angioplasty Only 5.4% 4.7% 
 • Balloon Angioplasty + Stent 69.8% 66.9% 
 • Rotablator +/- Stent 0.9% 0.9% 
 • Other 0.2% 0.2% 
Vessels (% lesions)   
 • Left main 1.7% 2.8% 
 • Left anterior descending 40.0% 39.3% 
 • Left circumflex 22.4% 19.3% 
 • Right coronary 27.0% 31.3% 
 • Graft 9.0% 7.4% 
Lesion Type (% lesions)   
 • Type A/B1 43.6% 34.7% 
 • Type B2/C 56.4% 65.3% 
Normal left ventricular function (%) 78.6% 77.5% 
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Whilst this definition of lesion failure may not align with more contemporary 
definitions covering the success or failure of treatment, it was the classifications 
criterion used in the early phase of collection of data for the registry. As we do not 
have the capacity to retrospectively reclassify lesion success using alternative 
definitions, for consistency in tracking performance, it has been necessary to maintain 
the pre-existing coding system throughout analysis. 
 
5.3.4 Model Factors 
Factors available for inclusion in the risk model comprised a range of patient 
demographic details, cardiac risk factors and co-morbidities, along with details 
describing characteristics and location of the treated lesion. A summary of the factors 
considered for inclusion in the model are provided in Table 5.2. A factor identified in 
some studies as being linked to procedural outcome is vessel size (De Luca, 
Suryapranata et al. 2009; Wykrzykowska, Serruys et al. 2009), however, as this 
measure was not specifically captured in our data registry it was imputed using the 
size of stents and balloons as well as relevant vessel characteristics. Factors linked to 
the outcome with a p-value of 0.25 or less were considered for inclusion in the RA 
model. 
 
5.3.5 Bayesian Model 
Bayesian methods provide a way of estimating the posterior odds of a hypothesis (H) 
regarding a future event is true (OC) based on knowledge of the prior odds of the 
event (Op) and the association of the outcome with a number of related risk factors. In 
this study, the H being considered concerns failure to re-establish flow in a lesion 
while the factors or evidence (ei) being combined are the factors identified as being 
independently predictive of this outcome. Although the particular Bayesian algorithm 
used in this study is based upon the technique described in Shinghal (Shinghal 1992), 
the approach used is similar to that described in other papers dealing with the 
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development of risk models using Bayesian techniques (L'Italien, Paul et al. 1996; de 
Belder, Jewitt et al. 2001).   
 
Using Bayesian methods, the equation linking the odds the hypothesis is true with the 
prior odds and the evidence is given by: 
p
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Where Ei (referred to as the effective influence measure associated with ei) is given 
by: 
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5.3.6 Risk Factor Selection 
To develop the RA model, a retrospective survey of the available Phase 1 data was 
performed to identify factors predictive of the outcome. Although analysis identified 
10 factors in our dataset as being potentially suitable for inclusion in the model it does 
not necessarily follow that a model using all of these factors would achieve the best 
predictive result. One reason for this concerns the Bayes theorem requirement of 
independence of the constituent factors. Any marked correlation between the risk 
factors used has the potential of producing a model that significantly overestimates 
risk (de Belder, Jewitt et al. 2001).  
 
To identify the optimum combination of factors a two stage process was used:  
• In stage one all possible combinations of candidate factors were evaluated using 
all available data. Performance of the various combinations was assessed using 
measures of discrimination (the model’s ability to distinguish success from failure by 
assigning a higher probability to lesions where flow was not successfully 
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reestablished) and calibration (the agreement between the expected and observed 
probabilities of failure). Discrimination was tested using the area under the Receiver 
Operating Characteristic curve (AUC with standard error (SE)) while calibration was 
assessed using the Hosmer-Lemeshow (H-L) goodness of fit statistic.  
• In stage 2 of the process, a cross validation technique (N=100) was then used to 
evaluate performance of the ten factor combinations identified as achieving the best 
compromise between discrimination and calibration (defined as the highest AUC 
values for H-L p values > 0.75). This involved randomly dividing the full data set into 
two groups in a 70:30 split. The larger sample was used to develop the risk prediction 
model while the smaller sample was used to test the resultant model’s performance. 
For each iteration, performance of the factor combination on the test data was 
documented using the resultant AUC and H-L values.  
 
Discrimination and calibration of the risk prediction model developed using this 
process was evaluated via AUC and H-L values for Phase 2 data.  
 
5.3.7 Application to Performance Monitoring 
In this study the resultant RA model was evaluated in a performance monitoring 
application using risk adjusted Cumulative Sum (RA CUSUM) and exponentially 
weighted moving average (RA EWMA) charts to monitor unit level outcomes. 
Comparison of individual clinician outcomes was accomplished via use of a risk 
adjusted funnel plot (Spiegelhalter 2002; Spiegelhalter 2005). A brief description of 
the charts used for monitoring group performance is provided below while a more 
detailed description of the various charts is provided in the Appendix.  
 
RA CUSUM Chart: The form of RA CUSUM chart used in this study is described by 
Steiner (Steiner, Cook et al. 2000). Use of this type of chart in outcomes monitoring 
in healthcare has been well documented (Grigg, Farewell et al. 2003; Rogers, Reeves 
et al. 2004; Rogers, Ganesh et al. 2005). In this study double sided CUSUM charts 
have been used. The statistic used in these charts is based on the likelihood of the 
outcome associated with the treatment of each lesion and whether or not treatment is 
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successful. Failure of a high risk lesion carries only a small penalty compared to the 
failure of a lesion where the expectation of success is considerably higher. 
Conversely, success in treating a high risk lesion is associated with a large ‘reward’ 
when the chart is updated as this outcome is positive and comparatively unexpected. 
These charts simultaneously test the hypotheses that the odds of an event occurring 
has increased (2x) or decreased (0.5x).  
 
RA EWMA Chart: The RA EWMA chart in this study follows the methodology 
described by Cook (Cook, Coory et al. 2011). In the form described, overlays the 
EWMA of observed events on the EWMA of predicted risk (describing expected 
outcome). Control limits are then wrapped around the expected outcome to define the 
range of ‘acceptable’ performance. An advantage of the EWMA chart over the 
CUSUM is that offers the ability to simultaneously visualize variations in both risk 
and outcome. 
 
Benchmarks for the CUSUM and EWMA charts were based on the documented group 
performance over the Phase 1 period. Establishment of the decision threshold ‘h’ and 
confidence limits for the CUSUM and EWMA charts was via simulation with an “in 
control run length” (ARL0) false alarm every 5 years being considered acceptable  
 
5.4   Results 
 
A summary of the factors evaluated for inclusion in the risk model is provided in 
Table 5.2. For each characteristic stratification, the probability of lesion failure is 
provided along with the effective influence value. The p value associated with for 
each characteristic’s association with lesion failure is also provided. Application of a 
threshold p-value of 0.25 or less resulted in eleven factors being considered for 
evaluation in the risk model. With regards the performance of the ACC/AHA risk 
classification system in describing the risk of failure we found rates of 0.3%. 0.7%, 
1.1% and 4.3% for A, B1, B2 and C class lesions. When applied to the full data set, 
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this risk model has an AUC of 0.658 while the H-L statistic (using the original 
ACC/AHA outcome results) has a p-value of <0.001 confirming poor calibration.  
 
Stage 1 analysis of factor combinations identified a number of combinations that 
achieved good discrimination (high AUC values) but with very poor calibration (H-L 
statistic with p-values < 0.05). An example of this is the model which included all 
eleven factors (AUC=0.848, and H-L p<0.001). While it is tempting to use all 
available factors to build a model, this approach is fundamentally flawed as any 
marked correlation between the factors used has the potential of producing a model 
that significantly overestimates risk (de Belder, Jewitt et al. 2001). This issue is well 
illustrated in our analysis where the risk model involving all eleven factors achieves 
excellent discrimination but significantly over predicts risk, exhibiting very poor 
calibration. The cross validation approach we have used to develop our risk model 
overcomes this issue by taking into account both discrimination and calibration of the 
various models constructed. 
 
Cross validation analysis of the ten combinations selected via Stage 1 identified two 
clear candidate combinations with the ultimate decision being based on the 
combination achieving the best goodness of fit (lowest median H-L statistic). The 
selected combination (AUC=0.847, SE=0.015 and H-L p=0.65) involved six factors: 
patient age, history of unstable angina, documented hypertension, vessel diameter, 
vessel system and lesion occlusion type. When tested using Phase 2 data, the 
discrimination and calibration of the model remained acceptably high (AUC=0.765, 
SE=0.038 and H-L p=0.11). Performance of the resultant model is graphically 
demonstrated in Figure 5.1.  
 
Application of the RA model to unit level outcomes monitoring is shown in Figures 
5.2(a) and 5.2(b). In Figure 5.2(a) a constant risk of 1.85% (average unit failure rate 
during Phase 1) is assigned to all lesions attempted. The chart demonstrates two signal 
events the first occurring in September 2005 (suggesting a significant reduction in 
lesion failure rate) and the second in March 2009 (attributed to an increase in the odds 
of lesion failure of more than a factor of 2). 
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Table 5.2: Table of factors considered for inclusion in the risk model.  
Evidence (ei) nfail ntotal Pc(H|ei) Ei p-Value 
Patient Demographics:      
 Gender Male 65 3272 1.99% 1.08 0.237 
  Female 16 1115 1.43% 0.77  
 Age <60 14 1158 1.21% 0.65 0.001 
  60-69 23 1398 1.65% 0.89  
  70-79 22 1261 1.74% 0.94  
  >=80 22 570 3.86% 2.13  
 Prior PTCA Y 14 993 1.41% 0.76 0.245 
  N 67 3394 1.97% 1.07  
 Prior CABG Y 11 603 1.82% 0.99 0.965 
  N 70 3784 1.85% 1.00  
Co-morbidities / Cardiac Risk Factors:      
 History of Stable Angina Y 38 2000 1.90% 1.03 0.809 
  N 43 2387 1.80% 0.98  
 History of Unstable Angina Y 14 1342 1.04% 0.56 0.009 
  N 67 3045 2.20% 1.20  
 Left Ventricular Function Normal 64 3442 1.86% 1.00 0.972 
  Impaired 17 923 1.84% 0.99  
 Prior History of MI Y 17 863 1.97% 1.07 0.764 
  N 64 3524 1.82% 0.98  
 Documented Hypertension Y 48 2884 1.66% 0.90 0.215 
  N 33 1503 2.20% 1.19  
 Family History of CVD Y 18 1315 1.37% 0.74 0.124 
  N 63 3072 2.05% 1.11  
 Documented Diabetes Y 16 899 1.78% 0.96 0.868 
  N 65 3488 1.86% 1.01  
 Documented Hyperlipidaemia Y 45 2614 1.72% 0.93 0.456 
  N 36 1773 2.03% 1.10  
 History of Smoking Y 11 659 1.67% 0.90 0.714 
  N 70 3728 1.88% 1.02  
 Any Risk Factor Y 59 3779 1.56% 0.84 <0.001 
  N 22 608 3.62% 2.00  
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When the Bayesian RA model is used to account for lesion complexity the control 
charts do not exhibit any signals. This suggests that the signal events identified in 
Figures 5.2(a) and 5.2(b) were likely driven by increased complexity in lesion 
characteristics rather than a significant decline in unit level performance. 
Furthermore, the RA weighted analysis, has markedly altered appearance of the chart 
between September 2005 and June 2006 when the chart came close to signalling. 
Variations in both the rate of lesions failure and risk is graphically demonstrated in 
the RA EWMA chart of Figure 5.3. This chart graphically demonstrates the gradual 
drift to higher risk lesions suggested in the comparison of Phase 1 and Phase 2 
baseline data. Comparison of individual clinician performance with and without RA is 
depicted in the funnel plot of Figure 5.4. This analysis shows that for the period under 
review (Oct-09 to Sep-11) no clinician recorded a failure rate (unadjusted or adjusted) 
that was significantly above the group average rate over the review period (the 
benchmark for comparison). However, when adjusted for case risk, clinician C2 
achieved a failure rate that is statistically lower than the group benchmark.    
Table 5.2 (Cont): Table of factors considered for inclusion in the risk model. 
Evidence (ei) nfail ntotal Pc(H|ei) Ei p-Value 
Lesion Details:      
 Vessel Diameter <2.5mm 35 551 6.35% 3.61 <0.001 
  >=2.5mm 46 3836 1.20% 0.65  
 Vessel System LAD 22 1754 1.25% 0.68 0.037 
  LCX 23 984 2.34% 1.27  
  RCA 31 1183 2.62% 1.43  
  LM 1 73 1.37% 0.74  
  Graft 4 393 1.02% 0.55  
 ACC/AHA Lesion Class A or B1 11 1965 0.56% 0.30 <0.001 
  B2 or C 70 2421 2.89% 1.58  
 Lesion Type Partial Occlusion 48 4133 1.16% 0.62 <0.001 
  Total Occlusion (<3 months) 11 193 5.70% 3.21  
  Total Occlusion (>3 months) 22 61 36.07% 29.99  
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Figure 5.1: Graph demonstrating calibration of the risk adjustment model based on the 
identified combination of factors. Performance of the model on Phase 1 data is shown as 
closed dots AUC=0.847, SE=0.015 and H-L p=0.65). The results for Phase 2 evaluation of the 
model is shown as open dots (AUC=0.765, SE=0.038 and H-L p=0.11). 
 
5.5   Discussion 
 
We and others have explored and described the application of graphical SPC tools to 
the monitoring of outcomes in Percutaneous Coronary Intervention (Kunadian, 
Dunning et al. 2008; Matheny, Ohno-Machado et al. 2008; Kunadian, Dunning et al. 
2009). These tools are seen as a valuable complement to the more traditional case 
based “morbidity and mortality” peer-review approach often undertaken by 
institutions in monitoring clinical performance. When used prospectively, SPC has the 
potential to provide continuous monitoring for variations in clinical performance with 
the ability to detect emerging trends both positive and negative as they develop. Thus 
they may provide an “early warning” of deteriorating systemic or individual 
practitioner performance and therefore allow early remediation in response to an 
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emerging adverse trend. Conversely, the ability to detect instances of performance in 
excess of expectation provides a valuable tool for identifying changes in factors or 
care patterns that can be used to improve overall group performance in a broader 
clinical context. 
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Figure 5.2(a): Double sided CUSUM assuming constant risk for each lesion of 1.85%. The 
upper and lower graphs have been designed to detect a doubling and a halving of the odds of 
lesion failure. A ‘h’ value of 3.16 has been used resulting in CUSUM charts that exhibits an 
ARL0 of 3260 lesions (~ 5 years) and ARLs of 380 (OR=2.0) and 880 (OR=0.5). The open 
dots indicate signal events at which time the charts reset. 
 
 
Chapter 5:  Risk Modelling in Quality Clinical Registries 120 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
03
-J
an
-0
3
03
-A
pr
-0
3
02
-J
ul
-0
3
30
-S
ep
-0
3
29
-D
ec
-0
3
28
-M
ar
-0
4
26
-J
un
-0
4
24
-S
ep
-0
4
23
-D
ec
-0
4
23
-M
ar
-0
5
21
-J
un
-0
5
19
-S
ep
-0
5
18
-D
ec
-0
5
18
-M
ar
-0
6
16
-J
un
-0
6
14
-S
ep
-0
6
13
-D
ec
-0
6
13
-M
ar
-0
7
11
-J
un
-0
7
09
-S
ep
-0
7
08
-D
ec
-0
7
07
-M
ar
-0
8
05
-J
un
-0
8
03
-S
ep
-0
8
02
-D
ec
-0
8
02
-M
ar
-0
9
31
-M
ay
-0
9
29
-A
ug
-0
9
27
-N
ov
-0
9
25
-F
eb
-1
0
26
-M
ay
-1
0
24
-A
ug
-1
0
22
-N
ov
-1
0
20
-F
eb
-1
1
21
-M
ay
-1
1
19
-A
ug
-1
1
CU
SU
M
 H
1:O
R=
2.
0
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
03
-J
an
-0
3
03
-A
pr
-0
3
02
-J
ul
-0
3
30
-S
ep
-0
3
29
-D
ec
-0
3
28
-M
ar
-0
4
26
-J
un
-0
4
24
-S
ep
-0
4
23
-D
ec
-0
4
23
-M
ar
-0
5
21
-J
un
-0
5
19
-S
ep
-0
5
18
-D
ec
-0
5
18
-M
ar
-0
6
16
-J
un
-0
6
14
-S
ep
-0
6
13
-D
ec
-0
6
13
-M
ar
-0
7
11
-J
un
-0
7
09
-S
ep
-0
7
08
-D
ec
-0
7
07
-M
ar
-0
8
05
-J
un
-0
8
03
-S
ep
-0
8
02
-D
ec
-0
8
02
-M
ar
-0
9
31
-M
ay
-0
9
29
-A
ug
-0
9
27
-N
ov
-0
9
25
-F
eb
-1
0
26
-M
ay
-1
0
24
-A
ug
-1
0
22
-N
ov
-1
0
20
-F
eb
-1
1
21
-M
ay
-1
1
19
-A
ug
-1
1
CU
SU
M
 H
1:O
R=
0.
5
 
 
Figure 5.2(b): Double sided CUSUM using the risk prediction algorithm to adjust for each 
lesion attempted. The upper and lower graphs have been designed to detect a doubling and a 
halving of the odds of lesion failure. A ‘h’ value of 3.11 has been used resulting in CUSUM 
charts that exhibits an ARL0 of 3260 lesions (~ 5 years) and ARLs of 365 (OR=2.0) and 580 
(OR=0.5). The open dots indicate signal events at which time the charts reset. 
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Figure 5.3: EWMA Chart tracking observed incidence of lesion failure against predicted risk 
of lesion failure. Confidence limits have been set to achieve similar ARL0 to RA CUSUM. 
EWMA (Exp) and EWMA (Obs) are the graphs of expected failure rate (based on lesion risk) 
and observed failure rate (based on actual success or failure).  
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Figure 5.4: Funnel Plot evaluating outcomes achieved by clinicians performing PCI 
procedures. This analysis examines outcomes for the Phase 2 period (Oct-09 to Sep-11). 
Upper and lower control limits have been set at 3 standard deviations (99%) level and a 
benchmark rate of 2.1% (the unit average for the period) has been used. Open and solid dots 
show the unadjusted and adjusted lesions attempted lesion failure rates for each clinician. The 
adjusted failure rate is derived by multiplying the overall group failure rate by the observed 
number of failures divided by the expected number of failures for each clinician. 
 
5.5.1 RA Algorithm: 
 
Having previously identified lesion failure as an important performance metric in the 
monitoring of clinical outcomes in interventional cardiology (Smith, Rivers et al. 
2011) we proposed the use of RA SPC charts to monitor both group and individual 
clinician performance using this measure. As highlighted above, the capacity to 
adequately adjust for known factors influencing this outcome is a fundamental 
requirement in meaningfully monitoring for variations in outcome.   
 
Building a risk prediction algorithm to support this analysis required careful 
consideration and assessment of the factors available for potential inclusion in the 
model. Results of the univariate analysis exploring the link between lesion failure and 
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patient demographics, co-morbidities, cardiac risk factors and lesion characteristics is 
provided in Table 5.2. This analysis indentifies a strong link between all of the 
available individual lesion characteristics (vessel diameter, vessel system, lesion class 
and lesion type) and outcome of treatment. Of the remaining patient characteristics 
and co-morbidities/risk factors, only patient age (increasing failure rate with 
increasing age), history of unstable angina (higher failure rate when there is no 
history) and presence of any cardiac risk factors (higher failure rate when no risk 
factors are present) were independently linked to outcome. 
 
Inclusion of non-lesion specific factors in the development of a RA algorithm for 
lesion failure is in contrast to the approach taken by others where lesion 
characteristics only were considered. Roberts at al (Roberts, Grayson et al. 2010) 
justifies this decision, making note that the exclusion of non-lesion characteristics was 
a conscious decision so as to drive development of an index based on predictors of 
outcome specific to each individual lesion, independent of factors “that might have 
had an impact on several lesions or one lesion but not another in the same 
interventional procedure”. Whilst acknowledging the restrictions imposed by others, 
as the dataset we have access to does not include a comprehensive suite of lesion 
characteristics, we have opted to also consider inclusion of patient characteristics, co-
morbidities and cardiac risk factors in our model. Our decision to undertake this 
course of action is based upon the potential for correlations to exist between these 
factors and lesion characteristics (not available in our dataset) important in 
determining the outcome of treatment. For example, our analysis highlights an 
apparent significant association between age and lesion failure. As severe calcification 
is one of the factors identified as predictive of failure by Roberts et al. (Roberts, 
Grayson et al. 2010) and as there is a known link between age and presence/extent of 
calcification in the coronary arteries (Hoff, Chomka et al. 2001), patient age at time of 
treatment may indirectly act as a surrogate for this measure. Similarly, the known link 
between unstable angina and presence of soft plaque (Hodgson, Reddy et al. 1993; 
Rasheed, Nair et al. 1994) when coupled with the comparative degree of success in 
dealing with soft plaque lesions may account for the documented association between 
unstable angina and lesion success. 
Chapter 5:  Risk Modelling in Quality Clinical Registries 123 
 
 
Using the available factors (including those with comparatively weak statistical links 
to lesion failure) the multivariate analysis and evaluation we have performed has 
identified a risk model based on six factors that is optimised for this particular patient 
cohort. Three of these factors; vessel diameter, vessel system and lesion type are 
characteristics of the lesion while the remaining factors include patient age, history of 
unstable angina and hypertension. It is of note that although the ACC/AHA lesion 
class is statistically linked to lesion failure, it has not been identified as being one of 
the independent factors in the model. The cross validation analysis we have applied 
results in a model with a median AUC of 0.823 (IQ range 0.786-0.852) and 
corresponding HL statistic p value of 0.32 (with a p value IQ range from 0.04 to 0.59) 
when evaluated using the Phase 1 data.   
 
5.5.2 Outcomes Monitoring: 
 
Impact of the application of this Bayesian RA index to improve control chart based 
outcomes monitoring is demonstrated for unit level monitoring in Figures 5.2(a), 
5.2(b) and 5.3 while comparison of individual practitioner performance is depicted in 
Figure 5.4. Analysis of the sequential charts of unit level outcomes demonstrates that 
incorporation of RA would have altered the process of outcomes monitoring by 
avoiding the two signal events (linked to lesion failure risk variations using the RA 
analysis) noted on the non-RA charts. In both cases the circumstances associated with 
these signal events were reviewed. Retrospective analysis of the case records leading 
up to the first signal event in the non-RA chart confirmed that there were no missing 
(failed) lesion records and that the pattern trending towards a signal indicating a 
significant reduction in lesion failure rate on the RA chart was due to a run of 
successful outcomes on low risk lesions. With the March 2009 signal on the non-RA 
chart, analysis of the RA index derived using the records for these cases suggests the 
pattern shown on both the RA and non-RA chart was most likely associated with a 
sequence of lesions of higher complexity. This may account for the signal recorded on 
the non-RA chart not being apparent on the corresponding RA chart.   
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It is also interesting to review the circumstances in the period from September 2005 to 
June 2006. While the non-RA chart provides no evidence suggesting altered 
performance, both the RA CUSUM and RA EWMA charts came close to signalling. 
Review of the data for this period using the RA EWMA shows that it reflects a 
succession of cases of lower average predicted risk coupled with a higher than usual 
observed rate of failure. Although not achieving a signal on either chart, over time this 
situation showed improvement. The capacity of the RA EWMA to facilitate direct 
comparison of predicted risk versus observed outcome highlights one of the 
advantages of this chart over the RA CUSUM.   
 
These examples demonstrate that caution must be exercised when monitoring 
performance and investigating signal events. We have adopted an investigation 
process based on the schema proposed by Mohammed et al. (Mohammed, Rathbone 
et al. 2004). This suggests that initial reactions to a signal event should focus on 
ensuring the data surrounding the event is correct with subsequent investigation 
focussing on factors relating to case mix and risk. Only after considering these issues 
and addressing any identified concerns should investigation proceed, if necessary, to 
evaluation of the process of care and clinician performance. Although the two 
‘signals’ identified in the RA chart have been attributed to issues of risk (which is 
evident when RA is applied to the control charts) it must be remembered that a signal 
may still arise due to the random clustering of adverse outcomes (the likelihood and 
consequence associated with this must be considered when setting the signal 
thresholds). 
 
We chose lesion failure as our measured outcome but other outcomes should also be 
considered and these might be chosen both for their clinical relevance. Clinically 
important outcomes for PCI are well established and include mortality, myocardial 
infarction, requirement for repeat revascularisation and combined outcome measures 
such as MACE (Major Adverse Cardiac Events). Care must be taken when 
considering the use of these outcomes, however, to ensure they are fundamentally 
suitable for monitoring via SPC. For example, Webster et al. suggests that the event 
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rate of the outcome being monitored should be greater than 1% and have a known 
stable distribution.  
 
A key requirement for use of SPC monitoring as a risk management tool is a low 
incidence of false positive signals, while still reliably detecting true variations in unit 
or individual performance. “Alarm signals” are likely to generate substantial 
investigation with a data audit, care review and root cause analysis, culminating in a 
governance report, whereas trends that do not cross the statistical boundary i.e. “alert 
signals” will generate appropriate but less intense investigations. For clinicians to 
accept SPC monitoring, the process needs to have minimal false alarms while still 
reliably detecting adverse performance. Application of our RA model to SPC charts of 
lesion failure modified the signal process by removing 2 false alarms including one 
“under” and one “over” performance during the test period. There were no alarms for 
“true” performance deterioration in our data set.  
 
In summary, RA applied to SPC monitoring of the failure to successfully re-establish 
flow in a treated lesion in PCI provides a robust tool for monitoring of unit and 
individual clinician performance with early detection of either adverse or favourable 
changes in outcome. If linked to appropriate quality improvement governance 
response protocols, this tool might improve quality control and risk management. 
 
5.5.3 Limitations: 
 
We acknowledge certain limitations to this analysis. First, the data and outcomes used 
in the development and testing of this risk model and risk adjusted control charts were 
drawn from a register established for the purposes of internal quality control. These 
data were not subject to systematic external independent validation. Second, the 
analysis uses data from a single institution with contribution from five experienced 
interventional cardiologists with differing volume throughput. It is therefore possible 
that individual clinician expertise and patterns of clinical practice could have 
influenced those factors that were associated with an angiographic result.  
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Appendix: 
 
Risk Adjusted CUSUM Charts: 
 
The particular CUSUM proposed in this work is based around the charting method 
proposed by Steiner et al. (Steiner, Cook et al. 2000). This method uses double sided 
CUSUM charts based on the cumulative log likelihood ratio. For each successive 
lesion (t) treated having an estimated risk of failure (pt) and outcome (yt: 1 for failure 
and 0 for success) a risk adjusted weight (wt) is calculated using the log-likelihood 
formula:  
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Where, RO and RA represent the odds ratios under the null hypothesis (H0: odds ratio = 
R0) and the alternate hypotheses (HA: odds ratio = RA) respectively.  
 
The running CUSUM score (Xt) is derived by successively adding wt for each new 
patient to the accumulated score for the prior lesions. In the CUSUM method 
implemented in this study, the cumulative sum of the weighted scores for the chart 
detecting an increase in the rate of failure (RA>R0) is constrained to non-negative 
values. This has the effect of limiting the accumulation of ‘credit’ for long runs of 
favourable outcomes. The resulting calculation for the running CUCUM score (Xt) is: 
 
( )ttt wXX += −1,0max  
 
After each calculation, Xt is compared to a decision threshold ‘h’. If Xt exceeds ‘h’ the 
chart is said to ‘signal’ indicating there is a high likelihood that the treatment failure 
rate has increased from RO to RA.  
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CUSUM charts intended for the detection of improved performance (RA<R0) operate 
in a similar manner, however, the accumulation of weighted scores is constrained to 
non-positive values and the chart ‘signals’ when the CUSUM decreases below the 
defined ‘h’. The resulting calculation of the running CUCUM score (Zt) is: 
 
( )ttt wZZ −= −1,0min  
 
In this study two charts have been constructed for each model. The upper CUSUM 
(Xt) to detect a doubling in the treatment failure rate while the lower CUSUM (Zt) to 
signal when the treatment failure rate halves. It is not uncommon to use a two chart 
system as the lower chart provides useful information about the performance of the 
risk adjustment model as well as acting as a tool to detect actual improved 
performance.  
 
The value of ‘h’ is critically important in determining the run lengths expected before 
a chart ‘signals’. The performance of a CUSUM chart is described in terms of the 
average number of encounters that are monitored (average run length or ARL) before 
the chart ‘signals’. For each CUSUM chart, the choice of ‘h’ is a trade-off between 
the average run length to signal when the process is in-control (ARL0) and when the 
process is out-of-control (ARL1). Under ideal circumstances the chart should have a 
very low false alarm rate (long ARL0) while rapidly detecting true change (short 
ARL1). Various methods can be used to determine ‘h’ including the use of empirical 
equations, Markov Chain methods and simulations. 
 
 
Exponentially Weighted Moving Average Charts: 
 
As with CUSUM charts, EWMA control charts are good for detecting small sustained 
shifts in a processes (Montgomery 1991). The particular version of EWMA used in 
this study is described by Cook et al. (Cook, Coory et al. 2011). The basic EWMA 
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chart is derived by calculating a weighted average of sequential observations with the 
current observation given a weight, λ, and previous observations given geometrically 
decreasing weights.   
 
Construction of the EWMA chart is described as follows. For each successive 
observation (xt) the current value of the EWMA (Xt) involves the previous value (X t-1) 
and is derived using:  
 
1)1( −⋅−+⋅= ttt XxX λλ  
 
As described by Cook, two concurrent EWMA charts are calculated, one where the 
values for the observations (xt) are based on the observed outcomes of procedures (yt), 
the other using the predicted outcome (pt). Control limits for the EWMA chart of 
expected outcomes are then derived using: 
 
)2(
)1(
λ
λ
−
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Where L is a constant that defines the in-control run length (ARL0) of the chart. 
Selection of ARL0 is a balance between the need to rapidly detect true shifts in 
performance while minimizing the incidence of false alarms. The EWMA chart of 
expected outcomes (and control limits) is then overlaid with the EWMA of observed 
events. The process being monitored is then considered as performing within 
expectation while the EWMA of observed outcomes lies between the expected chart’s 
control limits. 
 
 
Funnel Plots:  
 
The application of Funnel Plots to monitor performance quality in healthcare has been 
described by Speigelhalter (Spiegelhalter 2002; Spiegelhalter 2005). Funnel Plots are 
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a useful technique for comparison across a number of units (clinicians or institutions). 
In its basic form, the funnel plot is constructed by plotting the measure of 
performance (as a percentage) for each unit under review against the number of cases 
performed (the denominator for the percentage). The performance benchmark (in 
most cases the overall average performance of the group) and exact binomial limits 
are calculated and plotted for all possible values for the number of cases and used to 
create the familiar funnel plot appearance. Unit performance is deemed as being 
consistent with the benchmark when their result falls within the funnel. Results below 
the funnel relate to superior performance (significantly lower failure rate) while 
results above the funnel indicate poorer than accepted outcomes (significantly higher 
failure rate). To accommodate risk adjustment, the standardised ratio for each 
clinician is calculated (total number of observed failures divided by the total number 
of expected failures) and then is then multiplied by the overall group average failure 
rate. The resulting value is the risk adjusted failure rate for an individual clinician and 
this is used in the funnel plot. As implemented in this study we have plotted both the 
unadjusted and adjusted failure rates for each clinician and compared this to the 
overall average failure rate and confidence interval derived for each clinician (based 
on the number of lesions they have contributed to the sample). 
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CHAPTER 6 
 
 
Monitoring Radiation Use In Cardiac 
Fluoroscopy Imaging Procedures  
 
Preamble 
 
Whilst it is essential for the SPC charting tools used in clinical monitoring and 
improvement applications to be statistically robust, Chapters 2 and 3 also highlight the 
requirement for the analysis provided by these tools to be easily interpretable by 
clinicians. The RA-CUSUM chart proposed by Steiner et al., for example, is one of 
the most robust and efficient methods for detecting small sustained shifts in clinical 
performance, however, the charted statistic (log likelihood ratio) is neither intuitive 
nor directly interpretable by clinicians. Alternative control charts such as the VLAD 
and CRAM charts overcome this drawback (through use of a statistic based directly 
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on the accumulation of expected minus observed outcomes), however, the 
implementation of control limits for these charts pose problems for interpretation. 
Therefore to achieve the dual goal of a monitoring process that is accessible by the lay 
clinician and statistical robustness, most authors propose use of the double sided 
CUSUM in tandem with VLAD charts.  
 
Since publishing Chapter 3, appropriately designed EWMA charts have been shown 
to have characteristics fulfilling both criteria. In addition, EWMA charts can be 
readily adapted for the monitoring of both binary outcome and continuous variable 
data.   
 
In this chapter the use of EWMA charts to monitor the stability of output of cardiac 
imaging systems is developed and described. Current radiation safety monitoring 
practices require the imaging system to undergo an annual assessment of 
performance. The risk with current practice is that small changes in performance of 
the imaging system or changes in clinical practice that result in either an increase or 
decrease in radiation use may go undetected. In this application, characteristics of the 
patient and imaging procedure, collected as part of the routine documentation 
associated with the operation of the imaging systems, are used to continuously 
monitor the underlying stability in performance of the imaging system (and clinical 
practice). In so doing, a charting system sensitive to subtle changes in the 
characteristics of the imaging process (primarily the performance of the imaging 
system) is provided, thereby ensuring improved surveillance of radiation use.  
 
The focus of this chapter relates primarily to the second objective of the thesis in that 
it explores development and validation of an innovative charting method (based on 
the EWMA) that tracks the difference between observed and expected radiation use 
associated in cardiac angiography studies. The result of this charting technique is a 
process that is markedly more sensitive to subtle changes in imaging system 
performance. An additional benefit of the charting process is the development of a 
‘smart’ data filtering process that when implemented at the point of data entry can 
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detect possible data errors, thereby improving the quality of information entered and 
the sensitivity of the analysis provided. This goes to objective 1(c).    
 
This chapter has been written based on a journal paper for which I am the third author. 
It is reprinted here in the form accepted for publication. I participated in the study 
design and development of the radiation models, provided input into the technical 
aspects of the work and participated in the preparation and editing of the manuscript. 
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6.1   Abstract 
 
Timely identification of systematic changes in radiation delivery of an imaging 
system can lead to a reduction in risk for the patients involved. However, existing 
quality assurance programs involving the routine testing of equipment performance 
using phantoms are limited in their ability to effectively carry out this task. To address 
this issue, the authors propose the implementation of an ongoing monitoring process 
that utilizes procedural data to identify unexpected large or small radiation exposures 
for individual patients, as well as to detect persistent changes in the radiation output of 
imaging platforms. 
 
Data used in this study were obtained from records routinely collected during 
procedures performed in the cardiac catheterization imaging facility at St. Andrew’s 
War Memorial Hospital, Brisbane, Australia, over the period January 2008–March 
2010. A two stage monitoring process employing individual and exponentially 
weighted moving average (EWMA) control charts was developed and used to identify 
unexpectedly high or low radiation exposure levels for individual patients, as well as 
detect persistent changes in the radiation output delivered by the imaging systems. To 
increase sensitivity of the charts, we account for variation in dose area product (DAP) 
values due to other measured factors (patient weight, fluoroscopy time, and digital 
acquisition frame count) using multiple linear regression. Control charts are then 
constructed using the residual values from this linear regression. The proposed 
monitoring process was evaluated using simulation to model the performance of the 
process under known conditions. 
 
Retrospective application of this technique to actual clinical data identified a number 
of cases in which the DAP result could be considered unexpected. Most of these, upon 
review, were attributed to data entry errors. The charts monitoring the overall system 
radiation output trends demonstrated changes in equipment performance associated 
with relocation of the equipment to a new department. When tested under simulated 
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conditions, the EWMA chart was capable of detecting a sustained 15% increase in 
average radiation output within 60 cases (<month 1 of operation), while a 33% 
increase would be signalled within 20 cases. 
 
This technique offers a valuable enhancement to existing quality assurance programs 
in radiology that rely upon the testing of equipment radiation output at discrete time 
frames to ensure performance security 
 
6.2   Introduction 
6.2.1 Motivation 
Recent reports concerning the accidental overexposure of stroke patients undergoing 
brain perfusion CT studies have highlighted the need for increased vigilance in the 
conduct of practices involving the use of ionizing radiation (Wintermark and Lev 
2010). This issue, however, is not limited to CT scans alone but is of general concern, 
especially for modalities and procedures involving significant individual patient 
radiation risks, such as fluoroscopy procedures and nuclear medicine imaging exams 
(U.S. Food and Drug Administration). 
 
Radiation exposures arising from diagnostic and interventional cardiac catheterization 
procedures are among the highest routinely delivered in any ionizing radiation-based 
imaging procedure with the effective dose (E) for diagnostic coronary angiography 
procedures being reported to be of the order of 5–10 mSv, while for complex coronary 
angioplasty procedures, E can exceed 35 mSv (Einstein, Moser et al. 2007; Smith and 
Rivers 2008; Topaltzikis, Rountas et al. 2009). Due to the magnitude and frequency of 
these types of studies, efforts aimed at maintaining exposures at the minimum 
required to achieve an effective outcome have the potential to benefit both individual 
patients and the population as a whole. 
 
To ensure optimal performance of the imaging equipment, minimum performance 
standards are mandated (American College of Radiology 1999; Diagnostic X-ray 
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Imaging Committee Task Group #12 2002; Causer, Einsiedel et al. 2005). These 
standards cover factors related to image quality and radiation dose delivery and 
stipulate a testing frequency for the verification of defined performance measures. For 
equipment such as that used in cardiac catheterization, the testing interval is 
commonly set at 12 months. 
 
A flaw in this testing process concerns the potential for equipment performance to 
unexpectedly drift or shift discreetly at some point within the test interval either 
through the development of a fault in the imaging system or as an unintended change 
in the mode of operation of the equipment (default selection of a high or low dose 
mode of operation). Under certain circumstances, this change could result in patients 
and clinical personnel receiving radiation exposures higher than expected. Depending 
on the cause and magnitude of the variation in exposures being delivered, no marked 
effect on imaging performance may be detected, and therefore no corrective action to 
resolve the problem might be taken until the next scheduled preventive maintenance 
or mandatory test. In the example of the incident involving patients undergoing brain 
perfusion imaging, the problem does not appear to have been due to a malfunction of 
the imaging equipment but instead was linked to a process failure in the use of the CT 
scanner. In total, the scanner was used in more than 200 cases over some 18 months 
before the error was detected (Wintermark and Lev 2010). 
 
Quality issues concerning dose delivery exist in the radiation therapy domain where a 
subtle drift in the performance of the equipment may result in the under- or 
overdelivery of radiation to a tumor. This change in radiation delivery can have 
significant consequences for the patient being treated. To manage this problem, a 
system of control charts using individual case data has been evaluated and deemed 
effective in detecting unacceptable drift in the delivery of treatment (Pawlicki, 
Whitaker et al. 2005; Gerard, Grandhaye et al. 2009). In general, control charts are 
more effective in detecting process changes than is a simple review of the data 
because they provide clear rules concerning when to look for process changes and 
also when there is no reason to undertake this search. In this paper, we extend the 
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works of Pawlicki et al. (Pawlicki, Whitaker et al. 2005) and Gerard et al. (Gerard, 
Grandhaye et al. 2009) in a number of ways. 
 
6.2.2 Goals  
The goal of this project was to develop and describe the use of a radiation exposure 
monitoring scheme in the cardiac catheterization facilities at St. Andrew’s War 
Memorial Hospital (SAWMH) in Brisbane, Australia. 
The proposed ongoing performance monitoring method is capable of  
• Identifying unusually high or low exposure levels for individual patients and 
• Detecting persistent changes in the average radiation dose applied by the 
imaging system. 
 
We achieve these two goals by monitoring the process using two control charts: A 
chart for individuals and an exponentially weighted moving average (EWMA) chart 
(Matthews and Farewell 2007). EWMA control charts are known to be more sensitive 
than Shewhart type charts to small to medium persistent process changes or slow 
drifts. We found the simultaneous use of the two control charts particularly useful in 
this context because often large individual outliers flagged by the individuals chart 
were found, upon further investigation, to be due to human error, such as a 
transcription error. By filtering these erroneous values, we are better able to detect 
real changes in the imaging equipment. 
 
An obvious and overly simple way to monitor the radiation exposure arising from the 
imaging process is to chart the raw dose area product (DAP) values associated with 
each imaging procedure. However, using such a plot can result in a loss of sensitivity 
to changes in the functionality of the imaging systems because there is a substantial 
variation in the DAP values due to known factors. These include equipment related 
factors (e.g., the type of imaging equipment and the dose rate it is configured to 
deliver in the various modes of operation), as well as factors related to how the 
equipment is used (e.g., how much imaging is used, number of high dose frames 
acquired to document the case, number and selection of views employed, beam 
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collimation, and field size), and finally various patient characteristics (e.g., patient 
size, disease state). 
 
To increase the sensitivity of the charts, we adopt two strategies. First, we stratify the 
charting by imaging system and procedure type. In our example, we built separate 
charts for the two imaging systems and used only the data from the most commonly 
occurring procedure, an exploration of the coronary arteries. Second, we account for 
variation in DAP values due to other measured factors using multiple linear regression 
(Montgomery 2009). We then construct control charts using the residual values 
(actual DAP−predicted DAP), which have far less variability and hence are more 
sensitive to process changes than the raw DAP measurements. 
 
This paper describes the implementation, the interpretation, and the advantages of this 
technique. Further discussion about the differences and advantages of our approach 
compared to previously suggested approaches is given in Appendix A. 
 
6.3   Materials And Methods 
6.3.1 Data 
The data used in this study were obtained from records routinely collected during 
procedures performed in the cardiac catheterization imaging facility at St. Andrew’s 
War Memorial Hospital, Brisbane, Australia, over the period January 2008–March 
2010. The service deals with a comprehensive range of cardiac and peripheral 
vascular conditions. Procedures can be broadly divided into four categories: 
Diagnostic and interventional cardiac procedures (cardiovascular disease), 
electrophysiology and device implant procedures (cardiac rhythm related issues), 
miscellaneous cardiac procedures (valvuloplasties, defect closures, and pacemaker 
lead screening), and noncardiac procedures (embolizations, peripheral angiography, 
and angioplasty). A breakdown of the procedure types along with volumes is provided 
in Table 6.1. This analysis demonstrates that as a subgroup, diagnostic coronary 
Chapter 6:  Monitoring Radiation Use in Cardiac Angiography 142 
 
angiography (CA) is the most common single study type, accounting for 
approximately 42% of the service’s total workload. 
 
The service operates three imaging systems and we provide a demonstration of the 
monitoring for two of them, a Philips Allura Xper FD10 system (Philips Medical 
Systems, Best, The Netherlands) and a Toshiba Infinix CCi–FPD system (Toshiba 
Medical Systems Corporation, Tokyo, Japan). These two systems account for 
approximately 70% of all the records. The third imaging system, a Toshiba KXO-80 
system (Toshiba Medical Systems Corporation, Tokyo, Japan), is not used for CA 
procedures and therefore was not included in subsequent analysis. As one of our 
purposes is to detect persistent changes in the imaging process, we monitor each 
imaging system separately. 
 
 
Table 6.1: Summary of procedure types performed by the SAWMH Cardiac Imaging 
Service from January 2, 2008 to March 29, 2010. 
Procedure classification Volume % of total 
Cardiovascular disease related procedures   
• Diagnostic coronary angiogram (only) procedures 2656 42 
• Coronary angioplasty procedures 1004 16 
• Coronary artery bypass graft studies 456 7 
Rhythm related procedures   
• Electrophysiology procedures (diagnostic and ablation) 803 13 
• Device implants (pacemakers and defibrillators) 1246 20 
Miscellaneous cardiac procedures   
• Other cardiac procedures (valvuloplaties, defect closures, etc.) 69 1 
Non-cardiac imaging procedures   
• Diagnostic and interventional peripheral procedures 83 1 
Total case load 6317  
 
Control charting for process monitoring has two phases (Montgomery 2009). In phase 
I, we retrospectively examine a set of data to build the charts and derive the control 
limits. In phase II, we use the charts to monitor the process in real time and take 
action if the charts signal that the process has changed. To demonstrate in our 
example, we have divided the existing data into phase I and phase II for each system 
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and have used the relocation of each of the imaging systems to a new facility as the 
delineation between the two phases. 
 
For the Philips system, the period January 2008 until August 25, 2009 was selected as 
phase I. The start date was chosen to coincide with a revision to the doses as 
prescribed by Philips. The end date corresponds to the movement of the imaging 
system to a new location. There are 1098 case records in phase I. Phase II started on 
September 28, 2009 when the imaging system began operation at its new location and 
continued until March 25, 2010. There are 422 case records in phase II. During 
relocation of this equipment, all cardiologists were required to use the Toshiba system 
for non rhythm related procedures. 
 
For the Toshiba system, the period February 2008 until September 25, 2009 was 
selected as phase I. The start date for this imaging system coincided with a major 
revision of the unit’s dose algorithm. The end date corresponds to the day when the 
Toshiba system was moved to a new location. Phase I includes 2248 case records. 
Phase II started on October 20, 2009 when the imaging system began operation at its 
new location and continued to March 29, 2010. There are 584 case records in phase II. 
During relocation of this equipment, all cardiologists were required to use the Philips 
system for non rhythm related procedures. 
 
For each procedure, many factors were routinely recorded including patient 
characteristics such as height, weight, body mass index, and resting heart rate as well 
as procedural factors such as cardiologist, imaging system, fluoroscopy time, digital 
acquisition (DA) frame count, and total case DAP. Of particular interest were patient 
weight, number of fluoroscopy frames, and number of digital acquisition frames, as 
these factors were expected to be the main determinants of DAP, an expectation that 
arose from a physical understanding of the procedure. 
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6.3.2 Regression model building 
In developing the monitoring process, we decided to focus on CA procedures only, 
the most frequently occurring procedure that accounts for approximately 60% of the 
non rhythm related cardiac procedures on the two imaging systems. Including other 
procedures would have increased the volume of available data but would also have 
greatly increased the variability in DAP values. When we tried to include data from 
many procedure types, we were unable to build a regression model that could 
sufficiently compensate for this additional variability. By focusing only on a single 
(common) procedure, we were able to more quickly detect systematic changes in the 
imaging systems than if we included the additional DAP variation generated by 
uncommon procedures. Note that this choice also excludes all procedures other than 
CA in phase II. 
 
Radiation delivery in CA procedures occurs due to two components; the first involves 
imaging while the cardiologist manipulates a catheter into position in the patient’s 
heart prior to injecting a radio-opaque dye into the coronary arteries (to enable 
visualization of vessel disease). This component typically involves a low radiation 
exposure rate mode of operation (fluoroscopy). The second component involves 
documentation of the injection of contrast agent down the arteries. This commonly 
involves acquiring low noise, high resolution images at a higher radiation exposure. 
This stage is quantified by the DA frame count. The total study DAP is then a 
measure of the total radiation exposure resulting from the fluoroscopy and DA modes 
of operation. 
 
With this in mind, we tried to build a good regression model using the phase I CA 
procedure data for each of the two imaging systems. This involved considerable trial 
and error, not all of which we describe here in detail. We considered transformations 
of the DAP score, the inclusion of various factors, and possible interactions among the 
selected factors. In Appendix B, we provide a brief description of the regression 
model building and some helpful references. 
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Preliminary regression using DAP as the response suggested a systematic “funnel-
shaped” pattern in the residual values, where the variation in the residual values 
increased as the fitted values increase. A common remedy for this is to model the 
natural logarithm of DAP instead. However, modelling the data in this way results in 
a multiplicative relationship between DAP and the explanatory variables. This is 
perhaps less intuitive and more challenging to interpret physically than an additive 
model, but the model on the log scale provides a better fit to the data and was 
therefore retained. 
 
One nonlinear relationship evaluated and subsequently rejected was based on a 
physical model of the imaging process. This is described as 
 
ReDAeFLFLDAP Wtframes
Wt
ratetime ++∗+=
++ )()(
0
2211 )()( βγβγβ , 
  
where DAP is the case dose area product, Wt is the patient weight, FLtime is the case 
fluoroscopy time, FLrate is the fluoroscopy frame rate, and DAframes is the number of 
DA frames acquired. The βi’s and the γi’s are regression coefficients, and we assume 
R ~ N(0,σr2). However, this more complicated model did not provide a better fit to the 
data, and so it was abandoned in favor of the simpler linear relationship for ln(DAP) 
given in Eq. (1). 
 
We expected that the patient’s weight may affect the radiation administered 
differently for the two stages of the procedure (due to the different tube voltages used 
in fluoroscopy and digital acquisition). Accordingly, we initially incorporated weight-
by-fluoroscopy frame and weight-by-digital acquisition frame interaction terms. We 
found that neither played a significant role in predicting DAP. An additional concern 
was whether DAP depended on the cardiologist performing the procedure. To test this 
notion, indicator variables representing cardiologists were included in the model. 
However, the inclusion of cardiologists did not explain a significant portion of the 
variation in the DAP values for either imaging system and so this factor was excluded. 
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In the end, the model that provided the best fit to the data on both the Philips and the 
Toshiba systems was of the form  
 
RDAFLFLWtDAP framesratetime ++++= )()*()()ln( 3210 ββββ ,   (1) 
 
We give the final fitted models in Sec. 6.4.1. 
 
6.3.3 Control chart methodology 
We propose to monitor the imaging systems using the residuals from the DAP 
regression models. Specifically, we monitor the quantities 
ln(DAP)observed−ln(DAP)predicted for each new CA case. We address the two objectives 
discussed in Sec. 1A using  
 
• An individuals control chart of the residuals and 
• An EWMA control chart for the residuals where extreme values identified in 
the individuals chart are excluded. 
 
We use the residuals from phase I to determine the control limits for the two charts. 
We illustrate this in Section 6.3.4. In phase II, for each case, we calculate the 
estimated residual, denoted by irˆ  for case i, using the fitted model and then add the 
residual to the individuals control chart; a plot of ir
  vs i. If the observed residual falls 
outside the chart control limits, we flag the individual case as outlying and investigate 
possible reasons for the unexpectedly large or small radiation dose for case i. 
 
If the observed residual falls inside the control limits on the individuals chart, we add 
the residual value to the exponentially weighted moving average control chart with 
the following updating formula:(Lucas and Saccucci 1990)  
 
 iE  = ( ) 1ˆ 1i ir Eλ λ −+ −  
Chapter 6:  Monitoring Radiation Use in Cardiac Angiography 147 
 
        = ( ) ( ) ( )2 31 2 3ˆ ˆ ˆ ˆ1 1 1 ...i i i ir r r rλ λ λ λ λ λ λ− − −+ − + − + − +  
        = ( ) ( )
1
0
0
ˆ1 1
i
j
i j
j
r Eλ λ λ
−
−
=
− + −∑  
where λ is a smoothing constant and 0<λ≤1. In our context, irˆ  is the model residual 
for case i and E0 is the starting value that we set to zero. Note that the EWMA, as the 
name suggests, is a weighted average of the residuals for all past cases, where the 
weights decrease exponentially for cases further in the past. To monitor the process, 
the EWMA chart is a plot of Ei vs. i. If the EWMA chart signals, i.e., falls outside 
some prespecified control limits, we suspect a systematic and persistent change in the 
imaging process (equipment output, selection of views, use of collimation, etc.). We 
recommend a smoothing constant λ = 0.1, a typical choice in EWMA implementation. 
We address this choice of λ further in Appendix A. 
 
By removing extreme residual values before plotting the EWMA, we keep the roles of 
the two charts separate. The individuals chart is designed to detect individual outliers 
for which the observed DAP is markedly different to that expected for the given 
parameters, while the EWMA chart detects systematic and persistent shifts in the 
average DAP. For this reason, our reaction to any signals on either the individuals or 
EWMA charts should be very different. As it turns out in this application, signals on 
the individuals chart were often due to data recording errors, such as transposing 
height and weight measurements. By filtering the residuals that contribute to the 
EWMA, we introduce a data quality check that reduces the chance that the EWMA 
will signal systematic problems due to simple data errors. 
 
To implement the proposed monitoring methodology, we must set control limits, and 
in the case of the EWMA, select a reasonable value for λ. For individuals control 
charts, the control limits are usually set at ±3 standard deviations away from the 
average. We use the standard deviation [e.g., an estimate for σr in model (1)] and 
average of the residuals from the phase I data. Since the residuals come from a linear 
regression model, the average is zero. 
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The control limits for the EWMA chart are slightly more complicated. One option is 
to use (Crowder 1989)  
ˆ
2r
k λσ
λ
±
−
 
 
where k is a constant determined by the user, λ is the smoothing constant, and σr is the 
residual standard deviation from the regression model (1). The choice of k is driven by 
the desired in-control average run length (ARL), which is defined as the average 
number of cases before the EWMA signals (i.e., goes outside the control limits) (see 
Appendix A for more details). 
 
6.3.4 Phase I analysis 
We assume that phase I data come from a stable (i.e., in-control) process and we use 
these data to set up the control charts that will be used prospectively in phase II. In 
practice, using the phase I data to arrive at a final regression model and set up the 
control charts is an iterative process since we are concerned that the phase I data may 
come from an unstable process (Amis, Butler et al. 2007). To achieve a final 
regression model that best predicts the process, an initial model must be created. Next, 
we  
• Plot the residuals from this model on an individuals control chart with control 
limits set at ±c rσˆ , where c is a constant (and is normally taken to be 3) and rσˆ is 
the residual standard deviation. 
• Plot the filtered residuals on the EWMA chart, as described in Sec. 6.3.3. 
• Remove any cases that suggest the process was not stable if reasons can be 
found. This could include cases whose residuals lie outside the control limits on 
the individuals chart or series of cases that result in a signal on the EWMA 
chart. 
• Refit the regression model to the remaining data. 
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• Repeat these three steps until (almost) all of the residuals fall within the control 
limits. 
We illustrate this process with the Toshiba phase I data. Fitting the model (1) to the 
phase I data gives a residual standard deviation ( rσˆ ) of 0.291, so we set the control 
limits for the individuals chart at ±0.873. Recall that the average of the residuals is 
zero, so the chart is centered on zero. Crowder (Crowder 1989) described how to 
determine λ and k, and hence how to set EWMA control limits that will minimize the 
out-of-control ARL for a specified shift in the process mean, based on a given in-
control ARL. We selected a smoothing parameter of λ = 0.1 and an in-control ARL of 
800 for the Toshiba system (roughly one year’s worth of CA cases and equal to the 
time between mandated major tests of the equipment), which resulted in control limits 
of ±0.2024. We give a more thorough explanation of how these limits are derived in 
Appendix A. Figure 6.1 shows both the individuals and the EWMA charts from the 
original phase I. 
 
 
 
Figure 6.1: Individuals and EWMA control charts from original Toshiba phase I data. 
 
Next, we examine the control charts to see if there is any evidence of instability. The 
individuals chart (left panel) shows a small number of out-of-control points, but with 
±3σ limits, a normality assumption, and over 700 CA cases, this is to be expected. The 
EWMA chart (right panel) is more worrying. We see a signal above the upper control 
limit, followed by a signal below the lower control limit. Since the number of cases in 
phase I is reasonably large and because the in-control ARL is 800 cases, a signal is 
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again not that unexpected (even for a stable process). However, further investigation 
is warranted. The period between August 4, 2009 and September 22, 2009 when the 
EWMA drops consistently corresponds to the time period when the Philips system 
was not in use, and hence all cardiologists were using the Toshiba system. It seems 
that when all of the cardiologists use one imaging system, the process does not behave 
as it usually does. The two groups of cardiologists who typically use different systems 
also have different habits when using the same system. This realization suggested 
changing the Toshiba phase I dates to exclude the time period when only the Toshiba 
system was in service. This change in phase I dates necessitated the construction of a 
new Toshiba regression model and the recalculation of control limits. With the new 
phase I data, the residual standard deviation increased slightly to 0.3033 and so the 
control limits for the individuals chart are now ±0.910 and the control limits for the 
EWMA are now ±0.2040. The individuals and EWMA charts for the new Toshiba 
phase I dates are given in Figure 6.2. We now conclude that the remaining phase I 
data could reasonably have come from a stable process and we move on to phase II. 
 
 
Figure 6.2: Individuals and EWMA control charts from reduced Toshiba phase I data. 
 
The phase I construction of control limits for the Philip’s system required no iteration 
and we do not show the resulting phase I control charts here. The residual standard 
deviation from the regression model was 0.2417, resulting in individuals chart control 
limits of ±0.725. We selected an in-control ARL of 400 for the Philips system (again 
this corresponds to 12 months of CA cases), which resulted in EWMA control limits 
of ±0.1490. 
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6.4   Results 
6.4.1 Phase II Analysis 
We demonstrate the monitoring approach using the phase II data for both the Philips 
and the Toshiba systems. In actual application, we would build the phase II control 
charts in real time as patients undergo the imaging procedure. The regression models 
we used as a result of the model building described in Section 6.3 are as follows: 
 
Toshiba:  
ln(DAP) = 0.666 + 0.0162*(Wt) + 0.00584*(FLtime*FLrate) + 0.00175*( DAframes) 
2R  = 68.3%, ˆrσ  = 0.303264 
 
Philips:  
ln(DAP) = 0.825 + 0.0191*(Wt) + 0.00567*(FLtime*FLrate) + 0.00122*( DAframes) 
2R  = 83.3%, ˆrσ  = 0.241710 
 
As mentioned in Sec. 6.2.1, the purpose of constructing regression models and using 
the residuals is to reduce the variation in the plotted data; hence, making the charts 
more sensitive to systematic process changes. In Table 6.2, we see reductions of 
approximately 66% for the Philips system and 48% for the Toshiba system. 
 
Table 6.2: Standard deviations of raw data and residual values for both imaging systems. 
System ln(DAP) St. Deviation Residual St. Deviation 
Philips FD10 0.7212 0.2417 
Toshiba Cci – FPD 0.5799 0.3033 
 
Next, we plot the control charts for the phase II data with the control limits as derived 
in phase I. The phase II control charts for the Toshiba system are given in Figure 6.3. 
Because there were no out-of-control points identified by the individuals control 
chart, no cases were omitted in the construction of the EWMA chart. As is evidenced 
by the significant increasing trend in the EWMA chart in Figure 6.3, the process 
seems to have shifted upward at the start of the phase II period. Since the EWMA 
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remains (mostly) positive, it appears that the upward shift is sustained. In other words, 
we found that the DAP values in this period were larger than expected, even after 
adjusting for the factors in the regression model. In real time, we would have 
examined the imaging system carefully when the signal on the EWMA chart first 
occurred. 
 
 
Figure 6.3: Individuals and EWMA control charts of Toshiba phase II residuals. 
 
A possible explanation for the shift in the process lies in what happened to the 
imaging equipment between the phase I and phase II periods. The equipment was 
relocated to a new cardiac imaging facility; in so doing, it was disassembled into its 
major components and reinstalled in a new location. During the reinstallation process, 
the imaging equipment was fully recalibrated. Although a standardized process, the 
complexity of the system is such that it is likely there were minor inconsistencies in 
the performance of the systems between the two periods (as evidenced by the data). 
 
For the Phillips system, we see a different pattern on the charts shown in Figure 6.4. 
There are several unusually large residuals shown on the individuals chart. Further 
retrospective investigation of these cases failed to reveal any clear reasons for the 
unusual residuals. However, had the charts been constructed in real time the 
investigation would have been more timely and reasons may have been found. The 
right panel of Figure 6.4 gives the EWMA control chart for the same data with the 
four outliers from the individuals chart removed. 
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Figure 6.4: Individuals and EWMA control charts of Philips phase II residuals. 
 
Looking at the EWMA chart in Figure 6.4, we see that the process exceeds the upper 
control limit around October 13, 2010 and drops below the lower control limit around 
December 11, 2010. An explanation exists for the first signal on the EWMA. It was 
during this time period that only the Philips system was in use, and hence all 
cardiologists were performing CA procedures on the Toshiba system. As described in 
Section 6.3.4, when all of the cardiologists use one system, the process does not 
behave as it usually does. This suggests that while we found no substantial differences 
between cardiologists on a single system, there appears to be a substantial difference 
between cardiologists when grouped by their preferred imaging system. Generally, the 
cardiologists who regularly use the Toshiba system have an inherently lower average 
DAP than those who normally use the Philips system (taking into account the frame 
rate difference between the two systems). With regard to the second signal, to 
determine whether deterioration in the performance of the imaging system has 
occurred, or whether some other factor is responsible, an investigation to search for 
the cause of this drift is necessary. 
 
6.5   Discussion 
Driven largely by improvements in technology and clinical understanding, the 
practice of medical imaging is dealing with increasingly complex procedures (Amis, 
Butler et al. 2007). While it can be argued that this change has resulted in substantial 
improvements in healthcare, recent events in the United States also reveal a 
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corresponding increase in the opportunity for failures of the overall imaging process 
resulting in significant and unnecessary risk increases for individual patients and the 
population as a whole (U.S. Food and Drug Administration). As was the case with the 
brain perfusion CT cases, these failures are not constrained to malfunctions of the 
imaging equipment but can arise due to unintended and unacknowledged changes in 
the imaging process (Wintermark and Lev 2010). 
 
At present, the recommendation of most professional bodies is for ionizing radiation 
based imaging equipment to undergo regular performance assessments. For the type 
of equipment used in cardiac angiography (as noted in this paper), this testing is 
normally performed every 12 months using standardized protocols (Causer, Einsiedel 
et al. 2005). However, most testing procedures are designed to be independent of the 
patient, assessing discrete aspects of the performance of the equipment with emphasis 
placed on image quality (resolution and contrast) and radiation output. The limitation 
of this process is that it does not take into consideration the potential for non 
catastrophic failures to occur (that may result in radiation output increases) at a point 
in time between the major performance assessments, nor does it account for 
unintended variations (specifically increases) in radiation use arising from changes in 
clinical practice or system protocols. For angiography systems, this might include 
frame rate changes, changes in collimation practice, and use of different (less efficient 
dose vs. clinical yield) imaging projections. 
 
Although it is possible that certain discrete and significant changes (equipment 
failures and protocol changes, for example) would be detected promptly by imaging 
staff, the sophistication of newer digital imaging systems (e.g., CT scanners and 
cardiac and vascular angiography systems) is such that modest changes in radiation 
output may be overlooked due to the imaging system’s inherent ability to compensate 
for patient load and hence detector input variation. The process proposed here 
addresses these concerns by supplementing the conventional testing program with a 
secondary process that makes use of clinically derived data acquired routinely by 
most imaging services as part of their regulatory obligations. 
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The success of the proposed monitoring scheme depends critically on the quality of 
the data and the fitted regression model. In this example application, the routine 
capture of the factors of interest such as patient weight and frame rate was not 
introduced until September 2008. As such, these data were not always recorded, or 
were occasionally recorded improperly. Accordingly, in phase I, approximately 40% 
of the cases could not be used to estimate the parameters for the final regression 
models. Later, in phase II, far fewer cases were missing factor values, but there were 
still occasionally errors that became clear upon closer inspection of particular data 
records. To utilize this monitoring methodology at its full potential, it is important to 
keep complete and accurate documentation of all cases. 
 
To maintain the effectiveness of the proposed methodology, the models and control 
limits should occasionally be updated to allow for accepted process changes such as 
technological improvements or changes in clinical practice. We recommend refitting 
the model and updating the control limits whenever a substantial process change has 
taken place. A regression model update may also be required if the process signals 
frequently, or for prolonged periods of time. 
 
When an update of the regression model and control charts is deemed warranted, we 
are faced with the difficult questions of how much data we need. From a statistical 
perspective, more data are better as this will allow us to better model the relationship 
between the response and the factors and estimate the unexplained variability. 
However, waiting until a large amount of data is available delays the application of 
the monitoring. We propose a compromise. To get the monitoring started quickly, we 
initially use the first 20 cases, only to estimate a new model intercept term (β0), which 
is estimated as the original β0 estimate minus the average residual (from the original 
model) for the 20 cases. In other words, until we have more data, we assume that the 
effect of the factors remains the same and only the average DAP value has changed. 
Once we have collected additional new cases, say at least 100, we can investigate to 
see if a new regression model is necessary. 
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In our example, we decided to base the monitoring on only cases with CA procedures. 
We investigated including other procedures in the model building but were unable to 
construct a single model that was appropriate for more than CA procedures. An 
alternative idea that we did not pursue here is to build a separate model for each 
procedure and then construct the two control charts using estimated residuals from 
each model, standardized to have the same variability. This approach assumes that if 
the imaging system drifts, then the effect is the same across all procedures included in 
the monitoring. 
 
The methodology that we propose here can be applied to any measured output, such 
as cumulative air kerma, from a high volume imaging process. If the volume is low, 
then the monitoring procedures are likely to be ineffective since it will take a long 
time relative to performance standards to detect any process shifts. 
 
The chief value of the proposed monitoring scheme is that it operates in real time and 
will detect underlying shifts in average DAP levels as quickly as possible. There is 
substantial administrative cost due to the requirement to maintain the records for each 
case and to review the charts looking for signals. The charting can be easily 
automated using standard software such as EXCEL. 
 
6.6   Conclusions 
The process outlined in this paper uses two control charts, informed by clinically 
derived data, to monitor the use of radiation by system. It is offered as a supplement 
to existing equipment performance assessment programs. The benefit of this process 
is twofold; first, as the data are captured and analyzed on a case by case basis, data 
errors can be identified and addressed promptly and, second, small sustained shifts in 
the output of the imaging system (arising from equipment performance drift or 
changes in imaging practice) can be identified. Although performance of the example 
charts provided in this paper may appear overly sensitive, the minor inconvenience 
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caused by investigating the signals arising is a small price to pay when compared to 
the benefits for patients (and associated personnel). 
 
Appendix 
Appendix A: EWMA Charts 
Assuming a Guassian model for the residuals, we can derive the properties of the 
combined individuals and EWMA control charts using a Markov chain approximation 
(Lucas and Saccucci 1990). The approximation suggests that for an in-control average 
run length of 400 and rσˆ = 0.24, the EWMA control limits should be set at ±0.1490, 
and for an in-control average run length of 800 and rσˆ = 0.30, the control limits 
should be set at ±0.2040. This coincides very closely with what Crowder et al. 
(Crowder 1989) suggests when  1σˆ  above or below the mean is the magnitude of 
the shift in the process that must be detected quickly. 
 
We can also use the Markov chain approximation to illustrate how quickly we expect 
the EWMA to detect a persistent shift in the mean DAP. Denoting the mean μ and 
standard deviation σ, we let μδ = μ±δσ. Thus, when we speak of a  1σˆ  shift in the 
mean (i.e., δ = 1), we mean that the average of the residuals has increased or 
decreased by 1 standard deviation and is hence given by μ1 = μ±σ. Recall that these 
residuals are from a regression model where ln(DAP) is the response, and so a shift in 
the mean refers to a shift on the log scale. 
 
Figure 6.5 plots the ARL of the Toshiba system vs. δ (the number of σˆ -shifts in the 
mean) when we assume the residuals are normally distributed. Three lines are 
depicted. Each represents the change in ARL for common values of λ (EWMA 
smoothing constant). We used λ = 0.1, and so any discussion below is in reference to 
the dashed line. 
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Figure 6.5: Average run length as a function of mean shift for different values of λ. 
 
The results shown in Figure 6.5 give the change in ARL using the proposed 
monitoring scheme, where outlying points detected on the individuals control chart 
are not included in the EWMA. Assuming the control limits on the individuals chart 
are set at ±3σˆ , we found that there is very little difference between the ARL of the 
proposed monitoring scheme and the EWMA where all points are included. 
 
We can use the results in Figure 6.5 to quantify how quickly we expect to detect 
systematic changes in the average ln(DAP) for the Toshiba system. Table 6.3 gives 
the ARL for specific values of δ and gives the resultant actual shift in the average 
DAP for the Toshiba system. Note that for a clearer understanding of this concept, the 
information in this chart has been transformed from the log scale to the actual DAP 
scale. For instance, Table 6.3 suggests we can expect that a  1σˆ  shift in the average 
ln(DAP) will, on the average, signal as out-of-control in approximately 18 cases, and 
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that a shift of this magnitude translates into a shift in the average DAP of 6.8 Gy cm2, 
an increase of approximately 35%. 
 
Table 6.3: ARL for various shifts in the mean DAP value for the Toshiba CA  
data with λ = 0.1 
δ  startµ  endµ  % increase ARL 
0 19.3 19.3 0 800 
0.5 19.3 22.5 16.4 59.1 
1 19.3 26.1 35.4 18.4 
1.5 19.3 30.4 57.6 10.8 
 
Figure 6.6 explores the best choice of the smoothing constant λ as a function of the 
size of shift in the mean ln(DAP) values. We define best as the value of λ that yields 
the smallest ARL when the ln(DAP) mean has shifted while still having fixed in-
control (i.e., no mean shift) ARL. Figure 6.6 suggests λ = 0.1 is optimal for a mean 
shift of δ = 0.84. 
 
Figure 6.6: Optimal smoothing constant λ to detect different sized mean ln(DAP) shifts. 
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It is of interest to compare the performance of our proposed EWMA chart based on 
filtered model residuals with the previously suggested methods such as using only an 
individuals control chart based on the raw data (Gerard, Grandhaye et al. 2009). It is 
well known that an individuals chart is good at detecting large shifts in the process, 
while an EWMA chart is better suited to detecting small to medium sustained shifts 
(Montgomery 2009). However, in our context to fairly compare the approaches, we 
must also consider the influence of monitoring the raw ln(DAP) values rather than 
model residuals. Assuming the model is reasonable, using residuals has the advantage 
of reducing the unexplained variation, thereby making it easier to detect process 
changes. However, in our context, this advantage is partially offset because we could 
only successfully build a model for the CA procedure and thus lose some data in our 
resulting monitoring scheme. 
 
For illustration, we consider monitoring the Toshiba system. The regression model R2 
is 0.68; thus, the standard deviation of the model residuals is 0.566 ( 21 R−≈ ) times 
the residuals of the raw ln(DAP) values. Hence, assuming process mean shifts effect 
all procedures equally, a 1 standard deviation shift in mean ln(DAP) corresponds to a 
1.77 (1/0.566) standard deviation shift in the mean of the residuals. This captures the 
effect of the modelling (assuming there is no estimation error in the model). We use 
the Markov chain approximation to determine the ARL of the two methods. To 
account for the fact that the CA procedure represents only about 60% of all the non 
rhythm related cardiac procedures, and thus that the filtered EWMA approach loses 
some data, we divide the ARL values for the EWMA by 0.6 to make them comparable 
to the individuals chart. 
 
In Figure 6.7, we compare the performance of the two approaches. For the individuals 
charts, we use the usual ±3 standard deviation unit control limits. For the approach of 
Gerard et al. (Gerard, Grandhaye et al. 2009), this results in an in-control (i.e., when 
there is no mean shift) ARL of 370. We then determine the control limit for the 
filtered EWMA so that, with the 0.6 factor adjustment, the in-control ARL is also 370. 
Figure 6.7 suggests that the proposed filtered EWMA method, despite not using all 
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the data, is superior to an individuals chart based on the raw data at detecting ln(DAP) 
mean shifts of less than about 2.5 standard deviation units. Table 6.3 quantifies the 
results numerically. For instance, for a mean shift in ln(DAP) of 1 standard deviation 
unit, we expect the filtered EWMA chart to signal, on the average, after only 7.3 
cases, while the individuals chart is expected to signal after about 44 cases. 
 
 
Figure 6.7: Comparison of the average run length for two monitoring approaches. Solid 
line—Individuals chart on raw ln(DAP). Dashed line—Combined individuals and EWMA 
chart on residuals. 
 
Appendix B: Regression Modelling 
For each case, a regression model describes the relationship between a response, such 
as log(DAP), and the measured factors or explanatory variates such as patient weight 
and fluoroscopy time. The model has the form  
 
0 1 1 ...i i p ip iy x x rβ β β= + + + +  
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where, for the i th case, yi is some function of DAP and xi1.,…,xip are functions of the 
explanatory variates. The residuals ri account for the variation in yi not explained by 
the explanatory variates. We use the available phase I data to build the model, i.e., 
choose yi and xi1.,…,xip, estimate the coefficients β0,…,βp and the residuals ri, 
determine if there are any outliers, and so on (Montgomery, Peck et al. 2006; 
Montgomery 2009). Building the model is highly iterative in that we try different 
possibilities and use the tools given in the above references to select among candidate 
models. 
 
If we can successfully build such a model, then the variation in the estimated residuals 
will be substantially smaller than the variation in the response. In phase II, if the 
process drifts, then β0 will change, resulting in a shift in the mean of the response and 
the estimated residuals. Because the variation in the estimated residuals is smaller, a 
control chart based on these residuals will detect the change more quickly than will a 
chart based solely on the response. 
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CHAPTER 7 
 
 
An Exponentially Weighted Moving 
Average Chart for Monitoring Low Event 
Rate Outcomes: Application to Lesion 
Treatment Failure in PCI  
 
Preamble 
 
As noted in the preamble of Chapter 6, appropriately designed EWMA charts have 
been shown to have performance monitoring characteristics similar to the RA-
CUSUM while providing an output that can be easily interpreted by clinicians. A 
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further advantage of the EWMA concerns the ability of this charting technique to be 
adapted to monitoring processes characterized by both continuous variables and 
binary outcomes. A benefit for the adaptation of this type of control chart into clinical 
governance applications is that clinical users are presented with a common statistical 
interface irrespective of the application as such they need only be acquainted with a 
single format of chart to understand and interpret. 
 
An unfortunate limitation of the EWMA, as proposed by Cook et al, concerns the 
minimum event rate the chart can be used to reliably monitor. In the form originally 
described, the assumptions underpinning this chart start to break down at rates under 
5%. As a number of clinical outcome indicators deemed to be of interest in 
monitoring the delivery of interventional cardiology services (see Chapters 2 and 3) 
have event rates in the range down to 1%, choice of charting tool is effectively 
confined to the RA-CUSUM.  
 
This 5% limit occurs due the distribution of the EWMA of observed outcomes which 
ceases to be sufficiently normal and symmetric for the conventional Wald interval 
based limits to be applicable. This issue has been ascribed to being a property of the 
event rate alone, however, it can be shown that both the event rate and the smoothing 
constant need to be considered in tandem when designing the chart. In this chapter a 
modification to the derivation of control limits for the EWMA chart is proposed 
which effectively address the lower event rate limitation. The performance of the 
modified chart is demonstrated in a monitoring application tracking lesion treatment 
failure in angioplasty which occurs in <2% of lesions attempted. The development of 
risk adjustment for this indicator was previously described in Chapter 5.     
 
The focus of this chapter relates primarily to the second objectives of the thesis in that 
it deals with adaptation and validation of an existing charting technique to monitor 
clinical outcomes in interventional cardiology. The chapter contributes to application 
and adaptation by developing a means of overcoming a significant limitation in an 
existing charting tool thereby permitting its application in the clinical setting.    
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This chapter has been written based on a journal paper for which I am the first author. 
It is reprinted here in the form submitted for publication. I participated in the study 
conception, conducted research, designed and implemented the statistical analysis, 
wrote the manuscript and modified the manuscript as suggested by co-authors. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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7.1   Abstract 
 
Cumulative sum (CUSUM) charts to monitor clinical outcomes in interventional 
cardiology have been previously described. Exponentially Weighted Moving Average 
(EWMA) charts have gained favour as they are statistically robust and intuitive to 
interpret. Unfortunately, conventional EWMA charts do not operate efficiently at event 
rates of <5%. We describe an innovative derivation of the EWMA control limits that 
enables these charts to be used at low event rates. 
 
Using an approach based on the derivation of the Wilsons scores method for exact 
binomial confidence intervals, we derive an alternate description of the upper and 
lower control limits for the EWMA. Effectiveness of this modified chart is illustrated 
using the clinical outcome indicator lesion treatment failure (LTF: 1.85%). 
Performance of the chart is evaluated for event rates of 2% and 8%, and for odds shifts 
of 0.25x to 4x at each event rate, using simulations based on scaled distributions of 
LTF.  
 
At event rates >5% simulations demonstrate that there is little difference in 
performance between the modified and conventional EWMA charts and the CUSUM. 
At rates of <5%. The modified EWMA performs as well as the CUSUM. At low event 
rate both charts outperform the conventional EWMA. 
 
EWMA charts have advantages over the CUSUM as they facilitate independent 
monitoring of observed and expected outcomes. We have described a modified EWMA 
chart that enhances the performance of the CUSUM with easier interpretation for the 
clinician. 
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7.2   Introduction 
 
With the adoption of SPC charts to quantitatively inform conventional hospital and unit 
level clinical governance processes (Morton, Smith et al. 2011; Smith, Rivers et al. 
2011) there is a need for these charts to be capable of conveying their message in a 
manner that is readily interpretable and actionable by general clinical staff, most of 
whom do not have strong statistical backgrounds. 
 
A chart that has shown considerable promise in this application is the Exponentially 
Weighted Moving Average (EWMA) (Grigg and Spiegelhalter 2007; Spliid 2007; 
Cook, Coory et al. 2011) as it can be set up to directly display information in a form 
that is readily understandable by clinicians. A particularly useful implementation of the 
EWMA chart was recently described by Cook et al. (Cook, Coory et al. 2011). This 
chart is constructed in such a way that it enables independent tracking of both observed 
and expected event rates, thereby facilitating better scrutiny of emerging trends in 
outcome or case mix (via the risk adjustment algorithm).  
 
A drawback with this EWMA chart, however, is that it does not exhibit sound 
operating characteristics at event rates of less than 5% (Cook, Coory et al. 2011). This 
is because the distribution of the EWMA of observed outcomes which ceases to be 
sufficiently normal and symmetric for the Wald interval based limits to be applicable. 
Although this issue is ascribed to being a property of event rate, it can be shown that 
both the event rate and the smoothing constant need to be considered in tandem (see 
Appendix A). 
 
In this paper we review the derivation of the control limits for the EWMA and propose 
an alternative formulation that enables these charts to be used effectively at low event 
rates. We demonstrate effectiveness of this modified chart by comparing its 
performance characteristics to that of the EWMA chart using conventional limits 
(Cook, Coory et al. 2011) and the risk adjusted cumulative sum chart (RA-CUSUM) 
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(Steiner and Cook 2000). To illustrate the clinical application of these charts, we apply 
them to the monitoring of lesion treatment failure (LTF) in percutaneous transluminal 
coronary angioplasty (PTCA), which has a benchmark rate at our institution of 1.85% 
(based on outcomes achieved between Jan 2003 and December 2011).  
 
7.3   Method 
 
7.3.1 EWMA Control Charts 
 
The current value of the EWMA chart (Ei) is derived by calculating a weighted average 
of sequential observations with the current observation (xi) given a weight, λ, and hence 
previous observations given geometrically decreasing weights.  
 
1)1( −−+⋅= iii ExE λλ    (1) 
 
In the form proposed by Cook et al. (Cook, Coory et al. 2011), the EWMA chart used 
for monitoring binary outcomes plots the moving average of expected results (using the 
case by case risk estimate) along with control limits derived conventionally using: 
 
)2( λ
λ
σ
−
± LEi    (2) 
 
where σ is the population standard deviation and L is a constant that controls the in-
control run length (ARL0) of the chart. An anomaly of this conventional formulation is 
that, under certain circumstances, it can deliver a negative lower control limit. In the 
clinical domain this result is non-sensible and under these circumstances (if a lower 
control limit is required) a small finite value is used lest the chart never signal a 
reduction (which would be the case if 0 was used).  
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The EWMA chart of expected outcomes (and control limits) is then overlaid with the 
EWMA of observed events. The process being monitored is then considered as 
performing within expectation while the EWMA of observed outcomes lies between 
the control limits for the EWMA chart of expected outcomes. 
 
7.3.2 Alternative EWMA Control Limits 
 
In 1927, Wilson (Wilson 1927) proposed an alternative to the commonly accepted 
(Wald) method of estimating the 100(1-α)% confidence interval for a population 
proportion p by solving the expression: 
 
σα
)(
2/
ppz −=±

   (3) 
 
for p using npp )1( −  as estimate for σ2 rather than the more conventional 
npp )ˆ1(ˆ − of the Wald method. By rearranging the equation, the 2 roots of the 
resultant quadratic provide the upper and lower confidence limits. 
 
If instead of using the standard deviation of the population (σ), the standard deviation 
of the EWMA (σz) is used (Montgomery 2009), where: 
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the expression for the confidence interval becomes: 
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By reorganising terms and solving for p, the 2 roots of this expression are found to be:  
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Alternatively, simulation can be used to determine K directly for the desired ARL0. 
 
7.3.3 Issues with Wilson’s Limits 
 
Although it has been shown that coverage for Wilson’s limits is reasonable (Henderson 
and Meyer 2001) (and certainly superior to the Wald interval (Lawrence, Cai et al. 
1999)), evaluation by Newcombe (Newcombe 1998) shows the resultant interval tends 
to be biased too close to 0.5 (a finding originally noted by Wilson (Wilson 1927)). A 
consequence of this is that a control chart based on this interval would exhibit a bias for 
signalling a reduction in event rate. To correct for this an offset odds correction (C) is 
applied to the value of Ei used to derive the control limits. The corrected value of Ei 
(Ei’) used to derive the EWMA control limits is given by: 
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'
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i
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The odds correction for Ei is chosen to ensure the control chart delivers its peak run 
length when the process is in control. A process (and empirical formula) for estimating 
the odds correction to be applied to Ei is described in Appendix B.     
 
7.3.4 EWMA Design 
 
A key consideration in design of an EWMA chart is selection of the smoothing factor 
(λ). Choice of λ involves consideration of both the size of shift to be detected (small λ, 
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small shifts) and speed of detection (large λ, faster response)(Crowder 1989). In 
accordance with the suggestions of Cook et al. (Cook, Coory et al. 2011), a λ of 0.01 
has been used. 
 
7.3.5 CUSUM Chart  
 
The particular RA-CUSUM used as the standard in this work is that described by 
Steiner et al. (Steiner, Cook et al. 2000). This chart is based on the cumulative log 
likelihood ratio. A detailed description of this chart is provided in Appendix C. In this 
study two RA-CUSUM charts are run simultaneously; one to detect a doubling in the 
odds of LTF failure while the other signals when the odds of LTF halves. In this study, 
the system of RA-CUSUM charts used is set to achieve an ARL0 equivalent to 
approximately 1000 lesions treated. 
 
7.3.6 Chart Comparison 
 
To assess performance of the various control charts (EWMA with Wald limits, EWMA 
with Wilson’s limits (unmodified and adjusted) and CUSUM), simulations were run. 
Data used as the basis for these simulations and for the clinical examples of the various 
EWMA charts relates to procedural outcomes for patients undergoing PTCA 
procedures in the cardiac catheterisation facilities at St Andrew’s War Memorial 
Hospital, Brisbane, Australia. LTF is defined as failure to successfully re-establish a 
final residual stenosis of less than 50% in the treated lesion. The status of flow and 
hence lesion outcome, is determined visually by the cardiologist during the imaging 
procedure. In total, data for 3972 consecutive revascularization procedures (5601 
lesions) performed on 3426 patients in the period from 1st January 2003 to 30th 
September 2011 were used. Across this period the average LTF rate was 1.85%. The 
LTF risk adjustment algorithm used in this study was developed within the unit for 
quality monitoring purposes (Cameron, Rivers et al. 2009). Simulations run on specific 
event rates used odds adjusted versions of the actual LTF distribution. 
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7.4   Results 
 
7.4.1 Comparison of Confidence Intervals 
 
Table 7.1 provides a summary of the confidence limits for the distribution of Eobs 
obtained using the different interval calculation methods and a base simulated LTF rate 
of 2%. Intervals corresponding to confidence limits for 95% and 99% are shown. 
Simulation has been used to provide the interval for the actual distribution of Eobs. 
Symmetry relates to the proportion of residual area outside the interval appearing 
below the lower limit (The ideal ratio is therefore 50%). This analysis shows that the 
interval coverage delivered by the Wald and Adjusted Wilson methods for 95% and 
99% limits is acceptable however, the area in the tail outside the interval for the Wald 
method is entirely above the upper bound (symmetry of 0%). The interval for the 
Unmodified Wilson interval is (as expected) drawn towards 0.5 and as a consequence 
almost all the distribution area outside the interval is below the lower bound. Coverage 
of the adjusted Wilson interval still shows some bias to 0.5 although not to the same 
extent as the Unmodified Wilson interval. 
 
7.4.2 Chart Performance 
 
Figures 7.1 (a) & (b) provide a graphical comparison of the performance of the EWMA 
chart in detecting shifts in the output of a process with an event rate of 2%. Using a 
simulation based on the SAWMH LTF model, the various intervals have been tested 
for their ability to detect process odds shifts of 0.25 to 4. The ARL0 for all charts has 
been set to 1000. Comparison of a chart using Modified Wilson limits with a RA-
CUSUM shows similar performance characteristics. Analysis of the performance of a 
chart with Wald based limits shows that when the chart is designed to deliver an ARL0 
of 1000, the chart is exceedingly slow to detect reduced event rates, peaking at an ARL 
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of >6000 lesions when the odds of LTF halves. This contrasts with the chart using 
Unadjusted Wilson limits which has a peak ARL of ~ 3000 lesions when the odds of 
LTF increases by ~70%.   
 
Table 7.1: Comparison of performance of intervals delivered using alternative methods for 
deriving control limits. Event rate of 2% used. Wald limits have been derived using the method 
described in Cook at al (Cook, Coory et al. 2011), Unadjusted Wilson limits have been derived 
using the actual event rate and Modified Wilson includes an odds correction factor for the event 
rate to compensate for interval centre bias to 0.5.   
 
  Limits Interval Tail Areas 
    Lower Upper Cover Lower Upper Symmetry 
95% CI       
 Simulated Distribution (Eobs) 
0.39% 4.14% 94.9% 2.5% 2.6% 48.8% 
 Wald 0.00% 3.95% 96.3% 0.0% 3.7% 0.0% 
 Unmodified Wilson 0.78% 5.04% 89.5% 9.9% 0.5% 95.0% 
 Adjusted Wilson 0.49% 4.27% 93.9% 3.9% 2.2% 64.2% 
99%CI       
 Simulated Distribution (Eobs) 
0.16% 5.02% 99.0% 0.5% 0.5% 48.2% 
 Wald 0.00% 4.55% 98.7% 0.0% 1.3% 0.0% 
 Unmodified Wilson 0.60% 6.49% 94.1% 5.9% 0.0% 99.8% 
 Adjusted Wilson 0.25% 5.21% 98.6% 1.0% 0.4% 74.0% 
 
Figures 7.2 (a-c) compare performance of the Wald, unadjusted Wilson and Modified 
Wilson based EWMA charting methods when used to monitor actual clinical data. 
Comparison of the performance of these charts show that the chart using Wald based 
limits suggests there are 4 signal periods where the LTF rate exceeds the control limits 
(at lesions 1011, 2280, 4065 and 4938 and running for 1, 30, 30 and 5 lesions 
respectively ). In all cases the signals relates to higher than expected LTF. For the chart 
using Unadjusted Wilson limits, there are 3 signal periods (at lesions 603, 1869 and 
4456 and running for 20, 180 and 28 lesions). In all cases the signals relates to lower 
than expected LTF. The chart using Modified Wilson limits identifies 2 periods of 
outlier performance at lesions 1948 and 4065, running for 103 and 25 lesions 
respectively. The first signal relates to a period of lower than expected LTF while the 
second is a period LTF occurred at a higher than expect rate.  
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Figures 7.1(a) & (b): Shows the detection response of the various charting methods when 
designed to have an ARL0 of 1000. Charts demonstrates the EWMA using modified Wilson’s 
limits (solid line) versus (a) CUSUM and (b) Wald (dashed red) and unadjusted Wilson’s 
(dashed blue) limits. 
 
7.5   Discussion: 
 
The marked increase in public demand for quality and transparency in health care has 
fuelled investigations such as the Queensland Public Hospitals Commission of Inquiry 
2005 (Queensland Government 2005). This inquiry specifically emphasized the 
importance of clinical audits as an ongoing evaluation tool for assessing performance 
of medical practitioners and services (Queensland Government 2005) with the 
associated Queensland Health Systems Review (Queensland Government 2005) 
recommending use of appropriate statistical techniques such as control charts as a 
means of performing this function. Responsibility for monitoring clinical performance, 
however, is not the sole domain of high level system wide monitoring programs. 
Clinical outcomes monitoring programs run at the individual unit level can play a 
significant role and offer the advantage of being able to provide feedback in clinical 
performance within shorter time frames (Smith, Rivers et al. 2011). To maximise the 
benefit offered through SPC based analysis, it is essential that the information provided 
to clinicians be presented in a form that facilitates ease of interpretation. 
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(c) Adjusted Wilson Limits
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Figures 7.2(a-c): Demonstrate application of the three intervals when used on clinical data 
(only the first 5000 lesions treated have been shown). Charts have been designed with an ARL0 
of 1000.  
 
   
Charts commonly used in clinical governance applications to monitor binary outcomes 
are the RA-CUSUM chart (Steiner, Cook et al. 2001; Grigg, Farewell et al. 2003) and 
the Variable Life Adjusted Display (VLAD) (Lovegrove, Valencia et al. 1997) or 
Cumulative Risk Adjusted Mortality/Morbidity (CRAM) (Poloniecki, Valencia et al. 
1998). Individually these charts have strengths and weakness when used in unit level 
outcomes monitoring applications. The RA-CUSUM chart proposed by Steiner et al. 
(Steiner, Cook et al. 2001), for example, is one of the most robust and efficient 
methods for detecting small sustained shifts in clinical performance (Grigg and 
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Spiegelhalter 2007), however; the charted statistic (log likelihood ratio) is neither 
intuitive nor directly interpretable by clinicians. The VLAD and CRAM charts 
overcome this drawback (through use of a statistic based directly on the accumulation 
of expected minus observed outcomes), however, the implementation of control limits 
(Sherlaw-Johnson 2005) poses some problems for interpretation. Therefore to achieve 
the dual goal of a monitoring process that is accessible by the lay clinician and 
statistical robustness, most authors propose use of a selection of charts (Rogers, Reeves 
et al. 2004; Spiegelhalter 2004; Smith, Rivers et al. 2011).  
 
The EWMA chart proposed by Cook et al. (Cook, Coory et al. 2011) appears to address 
the deficiencies inherent in both the RA-CUSUM and VLAD/CRAM charts. Analysis 
presented in this paper, however, underscores the importance of carefully considering 
the design parameters and limitations of control charts (in particular minimum event 
rate) when setting up SPC based monitoring processes.  
 
It is apparent from our analysis that EWMA charts that employ conventional Wald 
based control intervals result in a chart with significant performance deficiencies when 
used to monitor low event rate processes. Table 7.1 and Figures 7.1(b) & 7.2(c) suggest 
that a chart based on this methodology when used to monitor a clinical process with an 
event rate of ~ 2% will perform reasonably (if over sensitively) when detecting a 
deterioration in outcomes (increased event rates) but will fail to respond in a timely 
manner when the apparent or actual event rate falls. Figure 7.2(c) in particular 
highlights the deficiency of this technique at lower event rates as the lower control limit 
is non existent. While this failure mode is preferable for a chart monitoring the rate of 
adverse events, as one of the reasons for a falling event rate could be issues with data 
quality, reliance on a chart with these characteristics would significantly delay response 
to issues such as this. 
 
In comparison, charts using an unadjusted Wilson’s interval will have characteristics 
opposite to those of the Wald interval based chart. Table 7.1 and Figures 7.1(b) & 
7.2(b) suggests that, with most of the distribution area outside the interval being in the 
lower tail (due to the interval being biased to 0.5), use of this method to derive control 
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limits results in a chart that is overly sensitive to event rate declines (apparent improved 
performance) while being inefficient at signalling on increase in rates (apparent 
performance deterioration). This failure mode is potentially more dangerous that that of 
a chart employing Wald interval limits as this chart would markedly delay response to 
performance deterioration. 
 
Table 7.1 and Figures 7.1(a), 7.1(b) & 7.2(a) show that, when an appropriate correction 
is applied to the Wilson’s interval (to account for its bias towards 0.5), the resulting 
chart can be readily tuned to exhibit excellent performance characteristics. Figure 
7.1(a) suggests this chart has similar characteristics to the ‘gold standard’ RA-CUSUM 
in responding to changes in outcome.  
 
Comparison of Figures 7.2(a)-(c) suggests that EWMA charts using Modified Wilson 
limits are likely to be more conservative in identifying signal events and therefore 
would trigger fewer investigations. By contrast, use of a chart employing a Wald 
interval suggested more instances of where performance was considered to have 
deteriorated while not identifying any instances of performance improvement. In the 
example given, the Wald interval chart would have triggered three additional 
investigations for underperformance. From a clinical performance monitoring 
perspective, this is likely to have been more preferable than the result delivered by the 
chart using Unadjusted Wilson limits where no signal for underperformance were 
triggered, although there would have been two additional investigations for apparent 
performance improvement.  
  
For SPC charts to be accepted into routine clinical performance monitoring 
applications, it is imperative that they efficiently detect outlier performance while 
limiting the number of false signals. Misapplication of the Wald interval based EWMA 
chart described by Cook at al. (Cook, Coory et al. 2011) to the monitoring of a clinical 
outcome indicator such as LTF (with an event rate of ~2%) is likely to result in a high 
frequency of ‘frivolous’ investigations for suspected performance deterioration. Not 
only would a chart with this characteristic be a drain on limited resources through the 
consequent signal investigations, it is likely to contributed to reduced faith in the value 
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of SPC charts by the clinicians involved. In this regard the chart we have proposed and 
described demonstrates a clear advantage. 
 
At this point, the method used to obtain control limits for the EWMA chart using 
Modified Wilson limits using a correction factor derived using empirical techniques. 
Although we have shown that this method delivers a control chart with performance 
characteristics that compare favourably with the RA-CUSUM the exact reason this 
works is unclear. Future research will focus on providing a more analytical 
understanding of the relationship linking the control limit interval to event rate, ARL0 
and λ. 
 
7.6   Conclusion: 
 
EWMA charts have advantages over the RA-CUSUM as they provide quantitative 
feedback in a form that is easily understood by the non-statistician. Furthermore, the 
ability to independently monitor observed and expected outcomes, assists investigation 
of causes for performance change. We have described a modified EWMA chart that is 
capable of being used to monitor processes with event rates less than 5% and as small 
as 2%, an application not previously recommended for this type of chart. 
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A.  Choice of λ and Event Rate 
 
Cook et al. (Cook, Coory et al. 2011) suggest use of a Wald interval based description 
for the control limits of an EWMA is applicable to the monitoring of event rates in the 
range from 5-95% and further suggest use of λ in the range from 0.005 to 0.02. 
Simulation has been used to explore these relationships with examples given for fixed 
rates of 2% and 8%. The distribution of Eobs (the EWMA of the observed results) is 
shown in Figures 7A.1(a) and (b). It is evident from these figures that when the event 
rate is high, λ values of 0.01 and less deliver Eobs distributions that are sufficiently 
symmetric to enable the use of Wald based intervals. However, when the event rate is 
low, loss of symmetry is evident for most λ values above 0.003.  
 
 
 
 
 
 
 
 
 
Figure 7A.1(a) & (b): Distribution of Eobs resulting from the monitoring of a process with 
event rates of 2% and 8% respectively. The curves shown correspond to λ values ranging from 
0.001 to 0.018. 
 
The simulations used to provide the curves of Figure 7A.1 can be used to explore the 
effectiveness of the various methods for deriving suitable control chart limits. Figures 
7A.2(a)-(d) graphically compares the actual 95% and 99% symmetrical interval bounds 
(upper and lower 2.5% and 0.5% tail areas) for Eobs resulting from event rates of 2% 
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and 8% with limits derived using the conventional Wald, unadjusted Wilson and 
modified Wilson methods. 
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Figure 7A.2(a)-(d): Graphical comparison of the 95% (top) and 99% (bottom) confidence 
limits derived using the Wald, unadjusted Wilson and modified Wilson methods compared to 
the corresponding symmetrical bounds for the distribution of Eobs resulting from the 
monitoring of a process with event rates of 2% (left) and 8% (right). 
 
The graphs in figures 7A.2 (a) & (c) suggests that when the event rate is low (of the 
order of 2%), care must be exercised in the choice of algorithm used to determine the 
control limits as well as the value of λ. Putting aside the response of the unadjusted 
Wilson method (which exhibits a characteristic bias of the limits to 0.5), these graphs 
suggest that both the Wald and modified Wilson method would yield acceptable limits 
provided λ is sufficiently small (<0.002). However, when λ >0.002 the Wald interval 
estimation delivers limits that are too low. These graphs also suggest that selection of 
method and λ becomes particularly important when ARL0 is taken into account as the 
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discrepancies between the derived limits and the corresponding bounds on the actual 
distribution become particularly apparent (see Figure 7A.2(c)). Both graphs underscore 
the effectiveness of the modified Wilson limits, which delivers a consistent result for 
all values of λ and ARL0. 
 
The graphs in Figures 7A.2 (b) & (d) confirm that when the event rate is sufficiently 
high (in this case of the order of 8%), there is reasonable conformance between the 
control limits estimated using the various algorithms and the corresponding bounds of 
the actual distribution of Eobs. This relationship appears to hold for λ values ranging 
from 0.001 to 0.01. There is some evidence, however, that the unadjusted Wilson 
interval is still biased to 0.5 while the limits resulting from the Wald method are biased 
to 0 when ARL0 is increased and higher λ values are used. 
 
 
B.  Odds Correction for Estimation of Control Limits: 
 
The process for determining the odds correction to apply to the event rate (Ei) to correct 
for the tendency of the Wilson interval to be biased to 0.5 has two stages. 
 
In stage 1, simulation is used to explore the relationship between the odds correction C 
(from equation (7)) and the response of the EWMA chart in terms of maximum run 
length (this equates to the proportion of positive vs. negative signals being equal). The 
results of this simulation (for an Ei=1.85% and λ=0.01) is shown in Figure 7B.1. The 
run length constant, k, is used in place of zα/2 in equation (6) to control the run length. 
The value of C achieving the maximum run length for each k is termed Ck. 
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Figure 7B.1: Graph of odds correction (C) vs. proportion of negative signals for run length 
constant (k) ranging from 1 to 3. In this example, lesion treatment failure is simulated (E: 
1.85%) to generate the EWMA with λ=0.01. 
 
In stage 2, a relationship is developed linking Ck to k. This relationship is then used to 
correct Ei in equation (7) when tuning the chart to deliver the desired ARL0. The curve 
linking Ck to k for lesion treatment failure is shown in Figure 7B.2. 
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Figure 7B.2: Graphical representation of the relationship between the odds correction (Ck) and 
the run length constant (k), In this example, lesion treatment failure is simulated (event rate: 
1.85%) to generate the EWMA with λ=0.01. 
 
In the example of lesion treatment failure (with Ei~1.85% and λ=0.01), a k of 2.20 was 
found to deliver an ARL0 of 1000. For these values of Ei, k and λ a Ck of 0.6675 was 
used. 
 
In the application of monitoring LTF, where the underlying patient risk characteristics 
does not vary markedly (Ei is relatively stable), a fixed Ck was found sufficient to 
produce charts with acceptable performance characteristics. However, by repeating the 
2 stage process across a range of event rates, a generalised empirical relationship can 
be developed that links the odds correction, Ck, run length constant k and event rate Ei. 
A relationship that demonstrates reasonable characteristics for Ei <16% and λ=0.01 is: 
kE
i
k
ieE
C δγβ+α+
=
))ln((1
1  
 
where; α = -0.01107, β = -0.00665, γ = 0.17143, and δ = -0.48391. (Note: for Ei=1.85% 
and k=2.20 this formula returns a Ck of 0.6642 this compares favourably with the 
0.6675 derived using the graphical method). 
 
 
C.  CUSUM Chart 
 
Following is a brief description of the construction of a double sided RA-CUSUM 
chart similar to that attributed to Steiner et al. (Steiner and Cook 2000). For each 
successive lesion (t) treated having an estimated risk of failure (pt) and outcome (yt: 1 
for failure and 0 for success) a risk adjusted weight (wt) is calculated using the log-
likelihood formula:  
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Where, RO and RA represent the odds ratios under the null hypothesis (H0: odds ratio = 
R0) and the alternate hypotheses (HA: odds ratio = RA) respectively.  
 
The running CUSUM score (Xt) is derived by successively adding wt for each new 
patient to the accumulated score for the prior lesions. In the CUSUM method 
implemented in this study, the cumulative sum of the weighted scores for the chart 
detecting an increase in the rate of failure (RA>R0) is constrained to non-negative 
values. This has the effect of limiting the accumulation of ‘credit’ for long runs of 
favourable outcomes. The resulting calculation for the running CUSUM score (Xt) is: 
 
( )ttt wXX += −1,0max  
 
After each calculation, Xt is compared to a decision threshold h+. If Xt exceeds h+ the 
chart is said to ‘signal’ indicating there is a high likelihood that the treatment failure 
rate has increased from RO to RA.  
 
CUSUM charts intended for the detection of improved performance (RA<R0) operate in 
a similar manner, however, the accumulation of weighted scores is constrained to non-
positive values and the chart ‘signals’ when the CUSUM decreases below the defined 
h-. The resulting calculation of the running CUSUM score (Zt) is: 
 
( )ttt wZZ −= −1,0min  
 
Two charts are constructed and run in tandem with the upper CUSUM (Xt) designed to 
detect a doubling in the treatment failure rate while the lower CUSUM (Zt) to signal 
when the outcome rate halves.  
 
The value of h is critically important in determining the run lengths expected before a 
chart ‘signals’. The performance of a control chart is described in terms of the average 
number of encounters that are monitored (average run length or ARL) before the chart 
‘signals’. For each CUSUM chart, the choice of h is a trade-off between the average 
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run length to signal when the process is in-control (ARL0) and when the process is out-
of-control (ARL1). Under ideal circumstances the chart should have a very low false 
alarm rate (long ARL0) while rapidly detecting true change (short ARL1). Various 
methods can be used to determine h including the use of empirical equations, Markov 
Chain methods and simulations. 
  
 
CHAPTER 8 
 
Implementation of Multivariate Control 
Charts in a Clinical Setting  
 
Preamble  
In establishing a comprehensive monitoring program for clinical governance it is 
desirable to track changes in a number of measures simultaneously. The use of multiple 
univariate control charts, however, has the potential to increase the rate of false signal 
events due to the issue of multiple testing. To address this problem in industrial 
applications, multivariate control charts including T2 multivariate exponentially 
weighted moving average (MEWMA), and multivariate cumulative sum charts 
(MCUSUM), have been proposed and applied widely.  
 
These procedures are superior to simultaneously monitoring multiple parameters using 
several univariate control charts since the structure of correlation between 
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characteristics are captured thereby reducing the risk of false alarms. In this chapter we 
describe the adaptation of multivariate control charts to the clinical setting in an 
application monitoring the stability of radiation delivered to patients undergoing 
diagnostic coronary angiogram procedures at SAWMH. Included within this work we 
explore methods to account for missing data in measured variables in a clinical context, 
a common problem in datasets used in clinical governance applications. We 
investigated and compared the performance of the charts when different imputation 
methods were used to address the missing data problem. The results of the simulation 
study was found in favour of MEWMA and MCUSUM in presence of small shifts in 
mean of measured characteristics and sup-ported use of multiple imputation method.  
 
The focus of this chapter is on the second objective of the thesis, in which the issue of 
multiple testing is raised as a possible matter of concern when the overall performance 
of a clinical service is monitored. We propose and evaluate the use of multivariate 
control charts as a means of overcoming the statistical limitations associated with the 
use of multiple univariate control charts for the same application. This chapter 
contributes to the application and adaption of well-established charting methods from 
the industrial context to a healthcare area. Within this knowledge transfer a common 
challenge of missing data is considered.  
 
This chapter has been written as a journal article for which I am the second author. It is 
reprinted here in its entirety. I contributed in the conception and development of the 
application to the radiation monitoring context, participated in data collection, assisted 
in the interpretation of results and contributed to the preparation of the manuscript. 
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8.1   Abstract  
In most clinical monitoring cases there is a need to track more than one quality 
characteristic. If separate univariate charts are used, the overall probability of a false 
alarm may be inflated since correlation between variables is ignored. In such cases, 
multivariate control charts should be considered. This paper considers the 
implementation and performance of the T2, multivariate exponentially weighted 
moving average (MEWMA), and multivariate cumulative sum charts (MCUSUM) in 
light of the challenges faced in clinical settings. We discuss how to handle incomplete 
records and non-normality of data, and we provide recommendations on chart 
selection. Our discussion is supported by a case study involving the monitoring of 
radiation delivered to patients undergoing diagnostic coronary angiogram procedures at 
St Andrew’s War Memorial Hospital, Australia. We also perform a simulation study to 
investigate chart performance for various correlation structures, patterns of mean shifts, 
amounts of missing data, and methods of imputation. The multivariate exponentially 
weighted moving average (MEWMA) chart and the multivariate cumulative sum 
(MCUSUM) chart detect small to moderate shifts quickly, even when the quality 
characteristics are uncorrelated. The T2 chart performs less well overall, although it is 
useful for rapid detection of large shifts. When records are incomplete, we recommend 
using multiple imputation.  
 
8.2   Introduction  
Control charts are becoming widely accepted in the health domain as a means of 
monitoring processes and outcomes (Spiegelhalter, Grigg et al. 2003). To date, 
attention has mainly focused on the application of univariate control charts. In most 
clinical monitoring cases, however, there is a need to track more than one quality 
characteristic. If separate univariate charts are used to monitor each quality 
characteristic, the overall probability of a false alarm may be inflated (unless the 
control limits are adjusted accordingly) since any correlation between the variables is 
ignored. This suggests that it might be worthwhile adopting multivariate techniques.  
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In this paper we survey some of the charts available for monitoring the means of 
continuous variables. We consider their implementation and performance in light of the 
challenges faced in clinical settings. In particular, we address the fact that clinical 
records are frequently incomplete.  
The paper proceeds as follows. In Section 2 we outline the general multivariate frame-
work and explain how to construct Hotelling’s T2, the multivariate exponentially 
weighted moving average (MEWMA), and the multivariate cumulative sum 
(MCUSUM) charts. The discussion is supported by a case study involving the 
monitoring of radiation delivered to patients undergoing diagnostic coronary 
angiogram procedures at St Andrew’s War Memorial Hospital, Australia. We also 
outline the methodology of a simulation study used to investigate how each chart 
performs for various correlation structures, patterns of mean shifts, amounts of missing 
data, and methods of imputation. Results are given in Section 8.4, and we provide 
recommendations in Section 8.5 on chart selection and implementation.  
 
8.3   Methods  
8.3.1   Description of case study data  
Our dataset contains information for three variables linked to the radiation delivered to 
a patient, namely the dose area product, fluoroscopy time, and the number of digital 
images (frames) acquired during coronary angiogram procedures at St Andrew’s War 
Memorial Hospital between April 2005 and December 2008. Dose area product, 
measured in mGy-cm2, provides a measure of the total radiation to which a patient is 
exposed. It is affected by the fluoroscopy time (low radiation dose rate component of 
the study associated with positioning catheters in the heart), the number of frames (high 
dose rate documentation phase), and other procedural and clinical factors such as the 
patient’s weight. To minimise variations in dose area product associated with patient 
size, data included in the case study have been limited to female patients only. Under 
radiation safety and protection guidelines, every effort is taken to limit patient radiation 
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exposure. To this end St Andrew’s War Memorial Hospital routinely monitors and 
reviews dose area product, fluoroscopy time and frames separately in an effort to 
achieve an optimised risk versus benefit balance. Although the number of frames is 
technically discrete, we will regard it as continuous.  
 
8.3.2  A general framework for multivariate monitoring  
Let Xi be the ith vector of observations for the p variables that we want to monitor. With 
respect to the case study, Xi comprises the values of dose area product, fluoroscopy 
time and frames for the ith patient. For example, if the tenth patient had a dose area 
product of 30638 mGycm2, a fluoroscopy time of 2.56 minutes, and 622  frames were 
taken of their heart, then X10 = [30638  2.56  622]′. 
 
When the process is in-control, it is assumed that Xi follows a multivariate normal 
distribution, with mean vector µ0 and covariance matrix Σ, independent of other 
observations. That is, )(~ ,Σop
iid
i NX µ . There will be many occasions, however, where 
clinical data do not satisfy this assumption. The MEWMA chart can be designed to be 
robust against deviations from normality (Stoumbos and Sullivan 2002; Testik, Runger 
et al. 2003), and there exists a non-parametric version of the MCUSUM chart (Qiu and 
Hawkins 2003), but the T2 chart is highly sensitive to the normality assumption 
(Stoumbos and Sullivan 2002).  
 
When normality is questionable, it will often suffice to transform one or more 
variables. For example, although dose are a product and fluoroscopy time are both 
strongly right-skewed, normality appears to hold for the natural log of dose area 
product and the inverse of fluoroscopy time. Consequently, instead of creating control 
charts using the raw data, we would construct them for Xi* = [D T F] ′, where D = ln 
(dose area product), T = (fluoroscopy time) −1 and F denotes the number of frames. 
Hence, X*10 = [10.3  0.39  622] ′.  
 
The parameters µ0 and Σ can either be specified by management or estimated using a 
Chapter 8:  Multivariate Control Charts in Clinical Settings 197 
 
sample from a stable process. We assume that )(~ ,3
* Σo
iid
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The objective is to detect a shift from µ0 to µ1. The T2, MEWMA and MCUSUM charts 
consider only the magnitude of any shift and not its direction. Hence, they use only an 
upper control limit (UCL). If a statistic exceeds the UCL, the chart is said to ‘signal’, 
and the process should be investigated to determine if the signal is due to an error in the 
data, is indicative of a genuine shift, or simply the result of natural variability. 
Univariate charts and the raw data should be inspected to determine the variable(s) 
responsible for the signal and whether it is associated with a change in patterns of use 
of radiation or variation in imaging equipment performance. In terms of our case study, 
a signal would correspond to increased levels of radiation exposure.  
 
From a clinical governance perspective, deviations from a stable process must be 
identified as quickly as possible, while limiting the occurrence of false alarms. 
Performance of a control chart is described in terms of the average number of 
observations that are monitored, average run length (ARL), before the chart ‘signals’. 
For each chart, choice of the signal threshold is a trade-off between the ARL when the 
process is in-control (ARL0) and when the process is out-of-control (ARL1). Under 
ideal circumstances the chart should have a very low false alarm rate (long ARL0) 
while rapidly detecting true changes (short ARL1).  
 
Before we can construct a multivariate chart, we need to deal with any missing data. 
One solution is to use imputation, methods of which include multiple imputation 
(Rubin 1987), insertion of the sample mean, and regression-based imputation.  
 
Multiple imputation is preferred because it preserves variability in the missing values 
and performs well for small sample sizes and/or large proportions of missing data. 
Generally speaking, it involves creating 3 ≤ r ≤ 10 complete datasets, performing 
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analyses on each of these datasets, and then combining the results. For each variable 
with missing values, it is necessary to construct r imputation models. In practice, most 
researchers will not need to develop these models directly, since software, such as 
NORM (Schafer ; Schafer and Olsen 1998), is available that performs multiple 
imputation.  
 
The rates of missing data for D, T and F are 3.0%, 1.4%, and 1.5%, respectively. 
Instead of constructing control chart statistics for multiple datasets and then combining 
the results, we use multiple imputation to create five observations for each missing 
value, and we impute the average of these five values to create a single complete 
dataset.  
8.3.3   Control chart construction  
We have chosen to concentrate on the T2, MEWMA and MCUSUM charts because 
they are extensions of univariate charts commonly used to monitor clinical data, 
namely the Shewhart, the exponentially weighted moving average (EWMA) and the 
cumulative sum (CUSUM) charts. In what follows, we briefly describe how these 
charts are constructed. A more detailed explanation can be found in Montgomery 
(Montgomery 2009). See also Bersimis et al. (Bersimis, Psarakis et al. 2007) for a more 
comprehensive survey of research into multivariate charts.  
 
The T2 chart plots Ti2 = (Xi − µ0)′Σ−1(Xi − µ0) (Hotelling 1947). If µ0 and Σ have been 
specified by management or estimated using a sufficiently large sample (in excess of 
100 observations), then the UCL is 2, pαχ (Seber 2004). If they have been estimated 
using a “small” sample, the UCL depends upon whether the researcher is performing a 
retrospective (Phase I) analysis or wants to monitor future values (Phase II). The Phase 
I and II UCLs are βα,p/2,(n−p−1)/2[(n−1)2/n] and Fα,p,n−p[p(n+1)(n−1)/(n2−np)], 
respectively (Tracy N 1992), where n is the sample size.  
Construction of the MEWMA chart (Lowry, Woodall et al. 1992) requires specification 
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of a weight λ, 0 ≤ λ ≤ 1, that is used to assign importance to observations, with recent 
observations being weighted more heavily than observations more distant in time. 
Letting Zi = λ(Xi−µ0)+(1−λ) Zi−1, where Z0 = 0, it plots Zi′Σ−1Zi Zi, where ΣZi = λ/2-λ 
[1−(1−λ)2i]Σ. Prabhu and Runger (Prabhu and Runger 1997) determined the optimal 
weight and corresponding UCL for selected combinations of p, the size of the shift to 
be detected, and the desired ARL0. For cases not considered, the UCL can be obtained 
through simulation in order to achieve a desired ARL0.  
Several versions of the MCUSUM chart have been proposed (Crosier 1988). We 
consider a version proposed by Crosier (Crosier 1988). It plots (L′iΣ−1Li)1/2, where  
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and Ci = ((Li−1 + Xi −µ0)′Σ−1(Li−1 + Xi −µ0))1/2 . Crosier (Crosier 1988) recommended 
setting L0 = 0 and k = (δ′Σ−1δ)1/2/2, and we follow the convention of resetting the 
MCUSUM chart following a signal. The UCL is calculated by simulation in order to 
achieve a desired ARL0.  
Statistics were generated for all 884 records in the case study dataset using code written 
in Matlab. In Figures 8.1 to 8.3 we show the T2, MEWMA and MCUSUM charts for 
procedures performed in November 2005. The figures were produced using R 
(http://www.r-project.org/). We discuss chart interpretation in Section 8.4.1.  
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Figure 8.1: Hotelling’s T2 chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005. 
 
8.3.4   Outline of simulation study  
The simulation study considers the monitoring of Xi = [V1 V2 V3]′, where the 
correlation between variables Vi and Vj, denoted ρij, takes the values 0, 0.2 and 0.8. To 
study ARL0, we simulate data from N3(0,Σ), where Σ is in correlation form. To study  
 
 
 
Figure 8.2: MEWMA chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005.  
Chapter 8:  Multivariate Control Charts in Clinical Settings 201 
 
 
 
Figure 8.3: MCUSUM chart for the simultaneous monitoring of D, T and F for females 
undergoing a CA in November 2005.  
 
ARL1, we generate data such that the first 50 records are drawn from an in-control 
process, and the remaining records are drawn from N3(δ,Σ), where δ = [δ1 δ2 δ3]′ ≠ 0. 
We let δi be 0, 0.5 or 2, and we allow for shifts of different magnitudes amongst the 
variables. Data are generated such that Vi is missing with probability γ, where γ = 0, 
0.05 or 0.2, subject to the constraint that a record cannot have all three of its 
observations missing. When γ > 0, a complete dataset is then obtained by multiple 
imputation, imputation of the mean, or regression-based imputation. When the process 
is stable, the run length is the number of records before the chart signals. When the 
process is unstable, the run length is the number of out-of-control records before the 
chart signals. Run lengths for 10000 datasets are averaged to produce ARLs.  
 
Parameters for the multivariate charts have been chosen such that ARL0 is 
approximately 200. The UCL of the T2 chart is 12.85. We use λ =0.1 and a UCL of 
10.97 for the MEWMA chart, and k =0.5 and a UCL of 6.88 for the MCUSUM chart.  
 
In addition to creating multivariate charts, we construct separate univariate charts for 
each variable. For a particular univariate chart, we define the “overall” run length to be 
the shortest of the three run lengths. For each Shewhart chart, we use the standard 
lower and upper control limits of −3 and 3, respectively. For each EWMA chart, we use 
λ =0.1 and L = 2.814. Given these values, the control limits for the ith observation are 
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9.1/]9.01[1.0814.2 2i−± ±2.814. For each CUSUM chart we use K =0.5 and a UCL 
of 5.  
 
8.4   Results  
8.4.1   Case study  
The T2 chart (Figure 8.1) registered out-of-control signals at times 17, 25 and 34. The 
MEWMA chart first signalled at time 37 and the MCUSUM chart signalled at time 38 
(Figures 8.2 and 8.3). Since the T2 statistic only uses information from the current 
observation, investigation into the causes of the T2 signals requires inspection of only 
the 17th, 25th and 34th records. In contrast, when interpreting MEWMA and 
MCUSUM signals, we should also consider records preceding a signal.  
 
To help identify the causes of signals, we constructed Shewhart, EWMA and CUSUM 
charts for each variable. The Shewhart chart for D suggested that high values of dose 
area product may be the cause of the signals observed in the T2 chart. Moreover, X17 
=[50011 5.26 506], X25 =[67508 2.27 803] and X34 =[84965 7.14 816.2]. In each case, 
the dose area product is considerably higher than the stable mean of exp (9.5) =13360 
mGy·cm2 . The MEWMA and MCUSUM signals are perhaps due to the high dose area 
product in X34, but it is also interesting to note that the EWMA chart for F exhibited an 
increasing trend starting at observation 20. T was stable during November 2005. There 
were no false alarms associated with any of the EWMA or CUSUM charts, or with the 
Shewhart charts used to monitor D and T. However, the Shewhart chart for F generated 
a false alarm at time 14. The number of frames (955) is reasonable when considered 
simultaneously with the dose area product of 28283 mGy·cm2 and the fluoroscopy time 
of 3.7 minutes. Moreover, an increasing trend in F does not begin until several 
observations later. As an aside, 6 of the 44 records from November 2005 required 
imputation. F was imputed in X9,  X23,  X24 and  X34, T was imputed in X26, and D was 
imputed in X27.  
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Starting around May 2006, there was a sharp increase in number of signals across all 
types of charts, both multivariate and univariate. This was due to a change in 
equipment and processes used at St Andrew’s War Memorial Hospital. If monitoring 
the situation in “real time”, we would have allowed the process to stabilise, before re-
estimating µ0 and Σ to determine parameters appropriate for the changed conditions.  
8.4.2   Simulation Study  
In this section we summarise broad trends. Tables of results for all charts, combinations 
of parameters, and types of imputation are available upon request from the 
corresponding author.  
 
In keeping with our choice of parameters, if γ = 0, we expect a false alarm every 200 
records, on average. As the amount of missing data, and hence imputation, increases, so 
too does ARL0. For example, when γ = 0.2 and multiple imputation is used, ARL0 is 
approximately 300 for the T2 chart, and approximately 400 for the MEWMA and 
MCUSUM charts. For almost all scenarios considered, using separate univariate charts 
resulted in a quicker false alarm than using the multivariate counterpart.  
 
Regardless of correlation structure, the MEWMA and MCUSUM charts detect small to 
moderate shifts significantly quicker than the T2 chart. For small shifts, the MCUSUM 
chart marginally outperforms the MEWMA chart. For large shifts, the performance of 
all charts is essentially the same.  
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Figure 8.4: Plot of ARL1 versus ||δ|| for the T2, MEWMA and MCUSUM charts, given ρ12  =  
ρ13  = ρ23  = 0.2. Results are shown for the cases where no data are missing (γ = 0) and when γ = 
0.2. In the latter case, MI has been used to impute for missing values. 
 
The charts are slower to detect changes as the amount of imputation performed in-
creases. However, the effect is negligible for large shifts. The T2 chart is most 
affected by imputation. The MEWMA and MCUSUM charts are affected to the same 
extent. Figure 8.4 is representative of the trends described above. It plots ARL1 versus 
the shift size, as summarised by 23
2
2
2
1|||| δδδδ ++= . 
 
When there is little or no correlation between the variables, using multiple Shewhart 
charts detects small shifts more quickly than a T
2 
chart. In contrast, the MEWMA 
charts detects small shifts almost as quickly as multiple EWMA charts, and the 
MCUSUM chart is actually superior to multiple CUSUM charts, even when the 
variables are completely uncorrelated. When the variables are highly correlated, the 
multivariate charts tend to detect an unstable process more quickly than multiple 
univariate charts. The multivariate charts are slower when the means of all three 
variables have shifted by the same amount. 
  
If at least one pair of variables is highly correlated, small shifts are detected most 
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quickly when the average has been imputed. However, under these conditions, 
imputing the average produces the worst ARL0. For example, when γ =0.2, ρ12 =0.2, ρ13 
=0.2 and ρ23 =0.8, ARL0 is 160 if the average is imputed. When multiple imputation 
and regression-based imputation are used, ARL0 is 422 and 510, respectively. If a large 
amount of imputation is required, multiple imputation tends to produce better results 
than regression-based imputation, but the choice of imputation technique is largely 
irrelevant if interest lies in detecting moderate to large shifts.  
8.5   Discussion  
When there is more than one quality characteristic to be monitored, we advise using 
multivariate charts to avoid excessive false signals associated with using separate 
univariate charts. Of the charts considered in this paper, the MCUSUM chart showed 
the best overall performance. However, it is only marginally superior to the MEWMA 
chart, with differences becoming negligible for moderate to large shifts. Indeed, many 
clinicians may feel that the ability of the MCUSUM chart to detect small shifts quicker 
than the MEWMA chart is out weighed by the increased complexity of its construction. 
This is especially pertinent given that many statistical software packages do not include 
an in-built function for creating MCUSUM charts. We recommend strongly against 
relying on the T
2 
chart. However, if the data follow a multivariate normal distribution, 
then the T
2 
chart can be used in a supplementary manner for the purposes of quickly 
detecting large shifts, as demonstrated in our case study.  
 
Our case study highlighted some standard transformations that can be used when data 
do not follow a normal distribution. If multivariate normality is questionable and 
transformations prove unsatisfactory, then the MEWMA chart should be used. In this 
case the clinician should follow the design recommendations in Stoumbos and H. 
(Stoumbos and Sullivan 2002) or Testik et al. (Testik, Runger et al. 2003).  
 
In addition to having a skewed distribution, dose area product is strongly related to 
patient weight, with heavier patients exposed to higher levels of radiation, on average. 
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As such, what is considered a “normal” dose area product depends upon the patient’s 
size. Since weight was only recorded for approximately 4% of the patients in the case 
study dataset, it wasn’t feasible for it to be used as another covariate in our charts. As 
such, we used gender as a surrogate measure of weight, constructing charts for only the 
females. Partitioning records in this way is useful if the distribution of one or more of 
the quality characteristics is multimodal. If setting up an ongoing multivariate chart for 
the case study, in the absence of weight data, we would continue to monitor records for 
males and females separately.  
 
Multivariate charts are known to perform well for a moderate number of variables. 
However, as the number of variables increases they become less efficient in detecting 
shifts. If more than ten variables are to be monitored, we recommend using principal 
components analysis to reduce the dimensionality of the problem. Details on this 
procedure with respect to control charts can be found in Bersimis et al. (Bersimis, 
Psarakis et al. 2007).  
 
Supplementary use of univariate charts can be used to investigate the cause(s) of 
multivariate signals. They can be used to examine the behavior of individual variables 
and to identify the direction of any shift(s). If the signal is associated with an 
improvement, management should make efforts to maintain whatever procedures 
precipitated the change. If a signal suggests an undesirable change, investigations 
should be con-ducted to determine whether the signal is a result of a genuine 
deterioration in the process, a mistake in the data collection process, or the result of 
natural variability.  
 
If data are missing, we recommend using multiple imputation to create complete 
datasets, particularly if a large amount of imputation is required. In our study, we 
imputed the average of five observations for each missing value to create a single 
complete dataset. An alternative approach would be to use multiple imputation to 
create five distinct datasets, calculate statistics for each dataset, and plot the average of 
the statistics. This method is more difficult to implement and interpretation of signals 
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becomes more complicated.  
 
We advise caution when using imputation based on the sample mean or regression 
because these methods artificially reduce variability and may also distort relationships 
between variables. We strongly advise against deleting incomplete records. 
Considering our case study, if X34 had been discarded on account of the number of 
frames being missing, then the unusually large dose area product associated with that 
record would have been overlooked.  
 
Because imputation reduces the amount of variability in the data, it has the effect of 
increasing both ARL0 and ARL1. While the former is not considered a problem, a 
higher ARL1 is less desirable. This effect can be countered somewhat by setting a 
lower UCL than would be used for a dataset with no missing values.  
 
When estimating Σ in the case study, we used the sample covariance matrix. An 
alternative approach uses the differences between successive vectors of observations 
(Holmes and Mergen 1993). This is analogous to using the moving range to estimate 
the standard deviation. In this case the estimator of Σ is VVS n ′= − )1(21  , where V is a  
p×(n−1) matrix, the ith column of which is given by Xi+1−Xi, for i =1,2,...,n−1. If 
successive observations are independent, this estimator should be used because it 
results in a chart that is better able to detect sustained shifts in the mean vector 
(Sullivan and Woodall 1996). It should not be used if observations are auto correlated 
because it results in a large false alarm rate (Capilla 2009).  
 
We considered continuous clinical data. If the institution wants to monitor multiple 
discrete quality characteristics, a multi-attribute chart should be used instead. There has 
been less research into multi-attribute charts, but the interested reader is referred to 
Patel (Patel 1973), Lu et al. (Lu 1998) and Skinner et al. (Skinner, Montgomery et al. 
2003).  
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CHAPTER 9 
 
Bayesian Change Point Detection in 
Monitoring Cardiac Surgery Outcomes  
 
Preamble  
Clinical governance has been markedly enhanced through the application of statistical 
process control tools and methods to enhance detection of significant changes in the 
outcomes achieved by clinical services being monitored. Once change is detected, 
effective governance systems employ a structured process to investigate possible 
causes for the apparent change in outcome contributing to the signal. This investigation 
usually involves reviewing patient records to; validate the quality of data used in 
running the control chart and identify any marked changes in patient case mix, system 
of care or allocation of recourses before questioning clinician performance. However, a 
fundamental characteristic of control charts, particularly those employed to monitor 
‘rare events’, is that the signaling of change invariably occurs some time after the 
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actual point at which the process changed. As this lag time between change and signal 
is invariably unknown, signal investigation can be hampered as the cases requiring 
review are ill-defined. The ability to accurately estimate the time at which the 
outcomes delivered by a clinical process changed can therefore make a substantial 
contribution to improving the efficiency of signal investigation by limiting the 
number of cases for review.  
To illustrate the effectiveness of change point detection in a clinical setting we 
retrospectively apply this method to two instances of where well defined changes in 
clinical practice are known to have impacted on clinical outcomes. In the first example, 
changes in an outcome indicator tracking post surgical bleeding in patients undergoing 
Coronary Artery Bypass Graft (CABG) surgery is investigated while in the second 
example changes in the incidence of major adverse cardiac events (MACE) at 12 
months post Percutaneous Transluminal Coronary Angioplasty (PTCA) were explored. 
In both cases the outcome rate of patients undergoing these procedures were monitored 
using Bernoulli EWMA and CUSUM control charts. Following signals in the 
respective control charts, the time of changes were estimated using a Bayesian 
approach. The observed coincidence of obtained estimates for the time of change and 
the timing of known potential causes supported change point investigation.  
The focus of this chapter is on the second and third objective of the thesis as it deals with 
the development and refinement of statistical tools, including change point indicators, 
which can be used to support the clinical governance application of SPC to efficiently and 
effectively monitor for changes in clinical outcomes and clinician performance This 
chapter contributes to application as well as method. Within this study, concept of 
change point estimation within an industrial context is adapted and applied in a 
healthcare area.  
 
This chapter has been written as a journal article for which I am second author. It is 
reprinted here in its entirety. I was involved in the conception of the paper, identified 
potential clinical applications for the tools, sourced data used in the example analysis, 
assist with discussion, comments on manuscript and editing. 
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9.1   Abstract 
 
Precise identification of the time when a clinical process has changed, a control chart's 
signal, enables clinicians to search for a potential special cause more effectively. In 
this paper, we develop a change point estimation method for Bernoulli processes in a 
Bayesian framework. We apply Bayesian hierarchical models to formulate the change 
point model and Markov Chain Monte Carlo to obtain posterior distributions of the 
change point parameters. The performance of the Bayesian estimator is investigated 
through applications on clinical data. We monitor outcomes of cardiac surgery and 
angioplasty procedures using Bernoulli EWMA and CUSUM control charts. We then 
identify the time of changes prior signals obtained from charts. Study of the known 
potential causes of changes in the outcomes reveals that estimated change points and 
shifts in the known causes are coincident. 
 
9.2   Introduction 
 
A control chart monitors behavior of a process over time by taking into account the 
stability and dispersion. The chart signals when a significant change has occurred due to 
the existence of assignable causes. This signal is investigated using root causes analysis 
to identify potential causes of the change and then corrective or preventive actions are 
conducted. Following this cycle leads to variation reduction and process stabilization 
(Montgomery, 2008). The achievements obtained by industrial and business sectors 
via the implementation of a quality improvement cycle including quality control charts 
and root causes analysis have motivated other sectors such as healthcare to consider 
those tools and apply them as an essential part of the monitoring process in order to 
improve the quality of healthcare delivery. 
 
The need for modification of the tools according to health sector characteristics such 
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as emphasis on monitoring individuals and patient mix was raised by quality control 
experts and clinicians. In this regard, risk adjustment control charts have been 
developed and applied within medical contexts; see Steiner and Cook (2000), Cook 
(2004) and Grigg and Spiegelhalter (2007) for more details. However, there still exits 
a lack of communication and knowledge transfer among experts between health 
sectors and industrial and business sectors. Consideration of identified needs and how 
they are being satisfied in each sector can accelerate other sectors in their own 
research and development of effective quality improvement tools (Woodall, 2006; 
Woodall et al., 
2010). 
 
The need to know the time at which a process began to vary, the so-called change 
point, has recently been raised and discussed in the industrial context of quality control. 
Accurate detection of the time of change can help in the search for a potential cause 
more efficiently as a tighter time-frame prior to the signal in the control charts is 
investigated. 
 
A built-in change point estimator in CUSUM charts suggested by Page (1954, 1961) and 
also an equivalent estimator in EWMA charts proposed by Nishina (1992) are two early 
change point estimators which can be applied for all discrete and continuous distribution 
underlying the charts. However they do not provide any statistical inferences on the 
obtained estimates. Samuel and Pignatiello (2001) developed and applied a maximum 
likelihood estimator (MLE) for the change point in a process fraction nonconformity 
monitored by a p-chart, assuming that the change type is a step change. They showed 
how closely this new estimator detects the change point in comparison with the usual 
p-chart signal. Subsequently, Perry and Pignatiello (2005) compared the performance 
of the derived MLE estimator with EWMA and CUSUM charts. These authors also 
constructed a confidence set based on the estimated change point which covers the 
true process change point with a given level of certainty using a likelihood function 
based on the method proposed by Box and Cox (1964). This approach was extended 
to other probability distributions as well as change type scenarios. In the case of a very 
low fraction non-conforming, Noorossana et al. (2009) derived and analyzed the MLE 
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estimator of a step change based on the geometric distribution control chats discussed 
by Xie et al. (2002). 
 
An interesting approach which has recently been considered in the SPC context is 
Bayesian hierarchical modelling (BHM) using, where necessary, computational methods 
such as Markov Chain Monte Carlo (MCMC). Application of these theoretical and 
computational frameworks to change point estimation provides a way of making a set 
of inferences based on posterior distributions for the time and the magnitude of a change 
as well as assessing the validity of underlying assumptions in the change point model 
itself (Gelman et al., 2004). 
 
In this paper we consider the problem of change point estimation in process monitoring 
in a clinical setting. The two processes of interest are Coronary Artery Bypass Graft 
(CABG) surgery and Percutaneous Transluminal Coronary Angioplasty (PTCA) at St. 
Andrew's War Memorial Hospital (SAWMH), Brisbane, Australia. In the former pro-
cess the incidence of return to theater for excessive bleeding and excess blood product 
usage, defined as use of more than 10 units of blood products within the first 24 hours 
post surgery, for each patient undergoing CABG surgery are of interest. For the latter 
process, we are interested in monitoring the 12 month major adverse cardiac event 
outcome rate of patients undergoing PTCA. 
 
To monitor the processes, two control charts, a Bernoulli CUSUM and a Bernoulli 
EWMA, are applied. We then construct the Bayesian estimators for Bernoulli obser-
vation data. The change points prior to signals of the control charts are identified and 
investigated for the two datasets. In Section 9.3 we describe the problem of monitoring 
and change point detection of CABG data and in Section 9.4 the angioplasty data are 
investigated. We then summarize and discuss the implication of the methodology and 
its application in Section 9.5. 
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9.3   Cardiac Surgery Data 
 
9.3.1 Data Description 
 
This analysis involved the review of prospectively collected data acquired as part of an 
ongoing quality monitoring program conducted by the cardiac surgical unit of SAWMH. 
Ethical approval was gained to undertake collection of these data. In total, records re-
lating to 1971 consecutive isolated CABG procedures performed in the period from 
December 2002 to January 2010 were available for analysis. All procedures were per-
formed by seven experienced cardiac surgeons. Details recorded for each procedure 
included patient demographic and preoperative co-morbidity details, comprehensive 
procedural details and post procedural outcomes including major adverse events dur-
ing the term of the admission. 
 
9.3.2 Process Monitoring 
 
Excessive post-operative bleeding following CABG surgery can be physiological and/or 
technical in origin. Clinical practice in these cases is first to administer blood products 
(whole blood, platelet concentrates, or fresh frozen plasma) to replace lost blood while 
the natural clotting mechanism has time to deal with the bleeding. However, if blood 
loss continues, the patient may be returned to the operating theatre to check for tech-
nical problems with the suture lines. As both actions carry increased risk to the patient 
(infection risk and operative complications), monitoring the rate of patients requiring 
intervention to deal with excessive bleeding is of interest in ensuring the continued 
quality of a cardiac surgical service. 
 
To cover the two treatments mechanisms, monitoring of both excess blood product 
usage (patients requiring in excess of 10 units of blood products in the first 24 hours 
after surgery) and re-operation for excess bleeding are variables of interest. Figure 9.1 
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shows the rate of high blood product use and re-operations for the 1971 patients in the 
period from December 2002 to January 2010. 
 
 
 
Figure 9.1: Exponentially weighted moving average graphs (with smoothing constant of 
0.01) tracking the incidence of patients returning to theatre for re-operation for bleeding 
related issues and cases requiring excess blood product utilisation (>10 units)in the first 24 
hours post CABG surgery. Data is drawn from cardiac surgical procedures performed at 
SAWMH in the period 2002-2010. 
 
Although it has been shown that the inclusion of risk adjustment in control charts mon-
itoring clinical outcomes has the potential to improve their performance (by accounting 
for known sources of variation), in the case of blood product use and/or excess bleeding 
there is no recognised risk-adjustment algorithm; see Steiner and Cook (2000), Cook 
(2004) and Grigg and Spiegelhalter (2007) for more details. Clinical performance of the 
cardiac surgical service is, however, subject to a formalised morbidity and mortality 
review process and this did not identify any significant variation in either case mix 
or the underlying risk factors that would normally be expected to be associated with 
variations in outcome such as process of care, patient age, sex, case complexity, etc. 
For the ith patient, we observe (yRi,yBi) where yRi,yBi ∈ (0,1). This leads to a dataset of 
Bernoulli data. It enables us to monitor the rates of each patient instead of monitoring 
grouped data in which the detection of the change is postponed to when n> 1 patients 
are observed (Reynolds and Stoumbos, 1999). In this setting, we assume 
)i(p ~ Bernouly RRi  and )i(p ~ Bernouly BBi .  
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To monitor the probability of an event, we refer it as "rate", hereafter, based on 
Bernoulli data, we considered two well-established control chart procedures, Bernoulli 
CUSUM (Steiner and Cook, 2000; Page, 1954) and Bernoulli EWMA (Somerville et al., 
2002). Alternatives for monitoring Bernoulli data based on counting observations be-
tween two events in which the observations assumed to have a geometric distribution 
may also be of interest. This approach was applied to Shewhart (Xie et al., 2002; Goh, 
1987; Benneyan, 2001), CUSUM (Bourke, 1991; Chang and Gan, 2001) and EWMA 
(Yeh et al., 2008) control charts. However they were found inappropriate if the rate is 
not low and the detection of a decrease in the rate is also of interest (Yeh et al., 2008). 
The disadvantage of geometric distribution based charting is that the observation is 
not plotted on the chart until an event occurs. This may cause delay in the change 
detection and ineffectiveness of root causes analysis particularly when the detection 
of a decrease in event rate is of interest. In contrast, in Bernoulli based charts the 
observations are plotted as soon as they have been observed. 
 
A Bernoulli CUSUM monitors an in-control rate, p0 say, using a CUSUM score Wi 
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and the +1p  and 
−
1p  are an increased and a decreased rate, respectively, that the chart is 
designed to detect. If +iX  (
−
iX ) exceeds a specified decision threshold h
+ (h-) then the 
control chart signals that an increase (a decrease) in the Bernoulli rate has occurred. 
As shown in Figure 9.1, the rates of re-operation and use of blood products seems 
to be relatively stable for the 568 patients undergoing CABG during 2004 and 2005. 
The associated rates, Rp0ˆ = 0.021 and Bp0ˆ  = 0.018, of this segment were therefore 
considered as the in-control rates for the chart construction. The event rates for the 
subsequent 1072 patients were monitored by control charts using these rates. 
 
We constructed the CUSUM chart to detect a doubling and a halving of the odds ratio, 
)1/(
)1/(
11
00
pp
pp
−
−  ={0.5,2}, in the in-control rates (0.021, 0.018) and have an in-control average 
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run length ( 0ˆLRA ) of approximately five years (1500 procedures). This setting and 
initializing the chart at zero, ±0X = 0, led to decision intervals of 
)87.2,37.3(=±Rh  and )68.2,22.3(=
±
Bh  for the re-operation and blood products, 
respectively. As two sided charts were considered, the negative values of h— were 
used. The associated CUSUM scores were obtained )014.0,027.0(−=±RiW  and 
)678.0,665,9( −=±RiW  where yi is 0 and 1, respectively, for the re-operation 
variable, and )010.0,020.0(−=±BiW and )682.0,672.0( −=
±
BiW where yi is 0 and 1, 
respectively, for the blood products variable. 
 
In a Bernoulli EWMA cumulative values of observations are obtained through 
1)1( −×λ−+×λ= iii ZyZ , where Z0 = p0, and plotted in a chart with ZApUCL σ+=
+
0  
and ZApLCL σ−=
+
0 , where λ−
λ
×−=σ
1
)1( 00
2 ppZ . We set λ = 0.05 since the in-
control rates were low ( Rp0ˆ = 0.021, Bp0ˆ  = 0.018); see Somerville et al. (2002) for 
more details. A± were calibrated so that the same in-control average run length 
( 0ˆLRA ) as the Bernoulli CUSUM was obtained. The resultant chart had 
15.4=±RA  and 25.4=
±
RA . A negative lower control limit in the Bernoulli EWMA 
was replaced by zero. 
 
We constructed the charts in the R package (http://www.r-project.org). The obtained 
Bernoulli CUSUM and EWMA control charts are shown in Figure 9.2. According to 
the CUSUM chart (Figure 9.2-al) the rate of re-operation among patients who had 
undergone CABG surgery was in-control; however the EWMA signalled (Figure 9.2- 
a2) at the 32nd patient as an increase in the rate was detected. This signal was held for 
the next two patients and then the re-operation rate returned to the in-control state. 
 
The behavior of the rate of excess blood product use seemed different between the two 
charts. The Bernoulli CUSUM chart (Figure 9.2-b1) first signalled at the 61st and then 
at the 71st observations and remained out-of-control over the next 34 patients. This was 
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followed by two signals for the 128th – 144th and 158th – 183rd patients. Later, a signal was 
identified at the 529th patient. This signal was extended to the rest of observations as a 
long-term increase in the rate was detected by the CUSUM chart. Although the 
CUSUM never returned to the in-control state, the Bernoulli EWMA chart (Figure 9.2- 
b2) detected 12 short-term signals followed by in-control periods. The signal periods 
were 14-15, 32-36, 41-45, 531-564, 721-731,789-790, 800-801, 812-813, 982-983, 990-
1001, 1052-1056 and 1058-1064, each indicating that an increase in the rate occurred. 
The shortest signal period contained two observations, whereas the longest included 34 
observations. As seen in Figure 9.2-b2, three quarters of the signals were detected in 
the second half of the observations in the Bernoulli EWMA chart, beginning with the 
531st patient. This was close to the patient detected by the Bernoulli CUSUM chart 
at the start of the long-term increase in the rate of the blood products (number 529). 
 
9.3.3 Change Point Detection 
 
Statistical inferences for a quantity of interest in a Bayesian framework are described 
as the modification of the uncertainty about their value in the light of evidence, and 
Bayes' theorem precisely specifies how this modification should be made as below: 
 
Posterior ∝  Likelihood x Prior, (9.2) 
 
where "Prior" is the state of knowledge about the quantity of interest in terms of a 
probability distribution before data are observed; "Likelihood" is a model underlying 
the observations, and "Posterior" is the state of knowledge about the quantity after 
data are observed, which also is in the form of a probability distribution. 
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Figure 9.2: Bernoulli CUSUM and EWMA control charts for the re-operation (a1-2) and the 
use of blood products (b1-2) variables over 1072 patients underwent CABG surgery during 
2006-2010. 
 
This structure is expendable to multiple levels in a hierarchical fashion, so-called 
Bayesian hierarchical models (BHM), which allows to enrich the model by capturing 
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all kind of uncertainties for data observed as well as priors. In complicated BHMs it is 
not easy to obtain the posterior distribution analytically. This analytic bottleneck has 
been eliminated by the emergence of Markov chain Monte Carlo (MCMC) methods. In 
MCMC algorithms a Markov chain, also known as a random walk, is constructed whose 
stationary distribution is the posterior distribution of the parameters. Samples gener-
ated from a long run of the Markov chain using a proposal transition density are drawn 
from posterior distributions of interest. Some common MCMC methods for drawing 
samples include Metropolis-Hastings and the Gibbs sampler, see Gelman et al. (2004) 
for more details. 
 
Consider a Bernoulli process yi, i = 1, ..., T, that is initially in-control, with independent 
observations coming from a Bernoulli distribution with a known rate p0. At an unknown 
point in time, 'r, the Bernoulli rate parameter changes from its in-control state of p0 
to p1, p1 = p0+δ, and p1 ≠ p0. The Bernoulli process step change model can thus be 
parameterized as follows: 
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Assume that the process yi is monitored by a control chart that signals at time T. We 
assign a normal distribution with mean of 0 and standard deviation of )1(6 00 pp −×  as 
a prior distribution for δ. This normal prior is truncated to -p0 and 1 — p0 due to 
expected values of p1 . This is a reasonably diffuse prior for the magnitude of the 
change in an in-control Bernoulli rate as the control chart is sensitive enough to detect 
very large shifts and estimate associated change points. See Gelman et al. (2004) for 
more details on selection of prior distributions. We place a uniform distribution on the 
range of (1, T) as a prior for  τ, the time of the step change in the in-control rate. 
 
To run the model and obtain posterior distributions of the time and the magnitude 
of the changes following signals from the charts we used the R2WinBUGS interface 
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(Sturtz et al., 2005) to generate 100,000 samples through MCMC iterations in Win- 
BUGS (Spielgelhalter et al., 2003) for all signals with the first 20000 samples ignored as 
burn-in. We then analyzed the results using the CODA package in R (Plummer et al., 
2010). See Appendix for the step change model code in WinBUGS. It should be noted 
that the posteriors can also be obtained analytically. 
 
Figure 9.3: Posterior distributions of the time 1- (1) and the magnitude 8 (2) of the change in 
the rate of re-operation detected by the Bernoulli EWMA control chart at the 32nd patient who 
underwent CABG surgery. 
 
As shown in Figure 9.2, the Bernoulli EWMA chart detected an early out-of-control 
state in the rate of re-operation for patients who had undergone CABG surgery proce-
dure, at around the 39th observation, where the CUSUM did not alarm. The posterior 
distributions of the time, τ, and the magnitude, δ, of the detected change are shown in 
Figure 9.3. As seen in Figure 9.3-1, the distribution of T is bimodal concentrating on 
the 11th and the 28th patients. Having two modes in the obtained posterior distribution 
implies that there were two step changes and consequently two change points in this 
subset of the observation. Figure 9.3-2 shows that the resultant posterior distribution 
of δ is a unimodal distribution with 0.14 as the mode and 0.24 as the mean. This 
distribution also may be a mixture of two (slightly) different distributions for the two 
changes. 
 
To investigate the cases with two changes, we developed a multiple change point model. 
In this scenario, we assume that at an unknown point in time, i, the Bernoulli rate 
changes from its in-control state of p0 to p1, p1 = p0+δ1, and p1 ≠ p0. For a period of 
time, the process follows the parameter p1 and then at an unknown point in time, τ2, it 
changes to p2, p2 = p1+δ2, and p2 ≠ p1. Similar to the step change model, we used a 
normal distribution with mean of 0 and standard deviation of )1(6 00 pp −×  for τ1 and 
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τ2, and a uniform distribution on the range of (1, τ2) and (τ1, T) for δ1 and δ2 as 
prior distributions. See Appendix for the multiple change model code in WinBUGS. 
 
Table 9.1, row one, shows the resultant estimates for the multiple change point model 
following the first signal obtained by the Bernoulli EWMA chart. Change point analysis 
was followed for all signals, which contain at least ten in-control observations prior to 
the signal, provided by the Bernoulli CUSUM and EWMA charts. The shorter subsets 
were merged with the preceding signals. The multiple change point model was applied 
 
Table 9.1 Posterior distributions (mode, sd.) and credible intervals (CI) of the change point 
parametersr and 8 following signals from the Bernoulli CUSUM (h± = (3.37,2.87) and h± = 
(3.22, 2.68)) and EWMA (λ= 0.05, A± = 4.15 and A± = 4.25) charts on the rate of re-operation 
and the use of blood products over 1072 patients who underwent CABG surgery during 2006-
2010. Standard deviations are shown in parentheses. 
 
 
where it was appropriate. Since the posteriors tended to be asymmetric and skewed 
the mode of posteriors was used. These are reported in Table 9.1 as estimates of 
the change point parameters (7, 8). Applying the Bayesian framework enables us to 
construct probability based intervals for these parameters. A credible interval (CI) is 
an interval which involves those values of highest posterior probability density of the 
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distribution of the parameter of interest. Table 9.1 also presents 50% and 80% credible 
intervals for the estimated time of the changes, one or multiple, for all signals. 
 
The multiple change point model identified two increases of sizes 0.106 and 0.131 at 
the 11th and the 28th patients, respectively, within the first 32 observations. This 
result pinpoints the inability of EWMA control charts to detect a change in very early 
observations, which has been labelled by researchers as Fast Initial Response (FIR). 
To overcome this, several techniques have been proposed and investigated; see Steiner 
(1999) and Knoth (2005) for more details. 
 
As seen in Table 9.1, the mode of the posterior distribution obtained from the first 
signal of the CUSUM chart on the blood products (61) reports the 11th patient as the 
time of the change which is identical to the time provided through the first signal of the 
EWMA. This case also addresses the FIR problem in CUSUM charts; see Montgomery 
(2008) for more details. 
 
According to Table 9.1, the estimates of the time of the changes prior to the signals in 
the EWMA chart at the 128th and the 158th patients propose that the changes occurred 
in the last observed patient and the chart detects the shift immediately, whereas for the 
signals at the 61st and the 529th (first change) they indicate that the chart detects the 
changes with a long delay. Comparing the estimates of the magnitude of the change in 
conjunction with the time is the key point here. Having relatively large and small sizes 
of changes for the former and latter signals, respectively, implies that any increase in 
the magnitude of a change improves the performance of immediate change detection 
of the chart and therefore the change point model tends to address the signal as the 
change point. In contrast, if a small shift occurs in the process, the EWMA chart 
detects the change with delay, but the change point model tends to identify the real 
time. 
 
The multiple change point model was found appropriate for one of five signals obtained 
from the Bernoulli CUSUM chart on the blood products. The modes reported that 
two consecutive changes occurred at the patients number 480 and 528 prior with an 
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associated signal at the 529th patient. This signal was also detected by the EWMA 
chart with a delay of two patients. Although different subsets of observations were used, 
the same change point model was found appropriate and almost the same estimates 
obtained for τs. The minor differences can be seen in associated standard deviations 
and δˆ s. 
 
The multiple change point model also identified two changes prior to the signal at the 
patient number 71 in the EWMA chart. In this case, the signal and 10 observations 
prior to the signal were obtained. For signals highlighted by an asterisk in Table 9.1, 32 
and 789, although bimodal posterior distributions were obtained for τ, a step change 
point was reported since the modes are very close. 
 
Figure 9.4: Exponentially weighted moving average graph (with smoothing constant of 0.01) 
for rates of patients for whom Aprotinin was used in CABG surgery during 2006-2010 at 
SAWMH. 
 
Incorporating the obtained change points with the signals of the Bernoulli CUSUM 
and EWMA charts shifts the focus of experts' efforts in root causes analysis from a 
biased time frame to a time closer to when the changes really occurred in the rate of 
interest. It also reveals changes ignored by other charting methods. To investigate this, 
we focus on some signals and associated change point estimates. We then compare the 
results with changes that occurred in the use of the drug Aprotinin (Trasylol, Bayer), 
the known potential cause. Aprotinin is used during complex surgical procedures, such 
as CABG surgery, to reduce bleeding. 
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As seen in Table 9.1, an early increase in the rate of blood products was identified 
at the 11th patient, who had undergone CABG surgery in January 2006, where the 
CUSUM alarmed at the 61' patient in March 2006. An identical change point was 
also obtained following the first signal of the EWMA chart on the rate of re-operation. 
This change coincides with the time, early 2006, when there was a temporary drop 
in the use of Aprotinin. This reduction occurred following publication of work by 
Mangano et al. (2006) that linked Aprotinin use to an increased risk of post procedural 
complications including death. Figure 9.4 shows this reduction. However, following 
a review of adverse outcomes in the surgical unit's regular morbidity and mortality 
meeting, where no significant effect was detected, this reduction was not sustained and 
therefore the rate of blood products decreases to in-control range as Aprotinin use 
increased. 
 
The second identical change point which was identified following signals of the 
CUSUM and EWMA charts on the blood products, is at patient number 480, who 
underwent surgery in late September 2007. As seen in Figure 9.2-bl, the CUSUM 
shows a stable increase in the rate. Again, the change point associated with the 
increase in use of blood products matches with changes in the use of Aprotinin At 
this time, follow-up studies supported the results reported by Mangano et al. (2006) 
and the U.S. Food and Drug Administration (FDA) recognized this risk in late 
October 2007 (US). This warning was followed by the withdrawal of Aprotinin by 
Bayer in early November 2007 (http://www.trasylol.com/). This action had an 
immediate impact on the routine use of Aprotinin at SAWMH as seen by the large 
drop in Figure 9.4. It should be noted, however, that it is also worthwhile to 
investigate other potential causes of changes in the rate of blood products using the 
process described by Mohammed et al. (2004). 
 
Chapter 9:  Change Point Estimation Control Charts 229 
 
9.4   Angioplasty Data 
 
9.4.1  Data Description 
 
This analysis involved the review of prospectively collected data acquired as part of an 
ongoing quality monitoring program conducted by the interventional cardiology unit of 
St Andrew's War Memorial Hospital, Brisbane, Australia. As with the cardiac surgical 
data, ethical approval was gained to undertake collection of these data. In total, data 
for 2104 index PTCA procedures performed in the period from May 2002 to December 
2006 with 12 month follow-up data were available for analysis. Any instance of a patient 
requiring a PTCA procedure within 12 months of the index procedures was treated as a 
complication of the initial PTCA (as such they were not counted separately). All 
procedures were performed by five experienced interventional cardiologists. Data were 
entered into a purpose-designed database which stored patient demographic and pre-
operative co-morbidity details, comprehensive procedural details including number and 
type of stents used, and outcomes including major adverse events during the admission 
of the procedure as well as at 30 days and 12 months post procedures. 
 
9.4.2  Process Monitoring 
 
Two measures commonly used to assess the outcome for patients following PTCA are 
the rate of subsequent revascularisation procedures, either repeat PTCA or CABG, 
involving the target lesion (TLR) and the rate of any major adverse cardiac event 
(MACE) defined as any instance of TLR, myocardial infarction or death (Ajani et al., 
2008). Common time intervals after the procedure at which the TLR or MACE rates 
are quoted are 30 days and 12 months following the index procedure. 
 
Study of PTCA outcomes frequently involves a patient's pre-operative risk factors. In 
this regard, risk adjusted monitoring procedures are recommended; see Steiner and 
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Cook (2000), Cook (2004) and Grigg and Spiegelhalter (2007) for more details. How-
ever risk adjustment is not followed here since the demographics of the patients who 
underwent coronary angioplasty and the characteristics of the procedure were relatively 
stable through the period of observation. Therefore the variation caused by the case 
mix is unlikely to have significantly contributed to any detected shifts in the outcome, 
particularly, when low risks were obtained through current risk models. 
 
Similar to the first study, for ith patient, we observe (yTi,yMi) where yTi,yMi ∈ (0,1). This 
leads to two datasets of Bernoulli data. We assume )i(p ~ Bernouly TTi  and  
)i(p ~ Bernouly MMi . As discussed in Section 9.3.2, we first considered Bernoulli 
CUSUM and EWMA control charts. According to Figure 9.5, the rates of TLR and 
MACE seem to be stable from the middle of 2003 to the end of 2004 for 598 patients. 
Therefore the associated rates, 020.0ˆ0 =Tp  and 040.0ˆ0 =Mp , of this segment were 
considered as the in-control rates for the chart construction and the subsequent 982 
patients were monitored by the resultant control charts. 
 
In the same way as discussed in Section 9.3.2, we calibrated the CUSUM charts to 
detect a doubling and a halving of the odds ratio in the in-control rates ( 020.0ˆ0 =Tp  
and 040.0ˆ0 =Mp ) and have an in-control average run length ( 0ˆLRA ) of five years, 
approximately. This setting led to an 0ˆLRA  of 2250 patients, and the decision intervals 
of  3.27) (3.78, =±Th and  )(4.60,4.07 =
±
Mh for TLR and MACE, respectively. As two 
sided charts were considered, the negative values h- were used. The associated CUSUM 
scores obtained were  010)(-0.020,0. =±
iT
W  and  683)(0.673,-0. =±
iT
W where yi is 0 and 
1, respectively, for TLR, and  020)(-0.039,0. =±
iM
W and  672)(0.653,-0. =±
iM
W where yi is 0 
and 1, respectively, for MACE. In the Bernoulli EWMA we set λ= 0.05 as the in-
control rate is low and obtained 50.4=±TA and 05.4=
±
MA  for TLR and MACE such 
that the same in-control average run length ( 0ˆLRA =2250) was satisfied. 
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Figure 9.5: Exponentially weighted moving average graphs (with smoothing constant of 
0.01) for rates of patients who underwent CABG or PTCA on the lesion target of the 
angioplasty procedure (TLR) and the rate of patients who experienced either TLR or heart 
attack or died (MACE). Data is drawn from cardiac surgical procedures performed at 
SAWMH in the period 2002-2006. 
 
The constructed Bernoulli CUSUM and EWMA control charts are shown in Figure 
9.6. According to the CUSUM chart (Figure 9.6-al), the rate of TLR among patients 
who had undergone angioplasty was in-control except for two short periods of time 
including 575-578 and the last three patients of the dataset, 980-982. After the signal, 
the CUSUM chart returned to the in-control state; however the associated statistic of 
the Bernoulli CUSUM in detection of an increase in the rate ( +iX ) tended to remain 
away from the center and never became zero. The Bernoulli EWMA for TLR signalled 
at four periods of observations. The first pair includes six observations in the periods 
301-302 and 307-310 whereas the second pair contains eight observations in the periods 
570-572 and 575-579. As seen in Figure 9.6-al, the last signal in the EWMA chart is 
almost identical to the patients first detected as out-of-control in the CUSUM chart.  
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Figure 9.6: Bernoulli CUSUM and EWMA control charts for TLR (a1-2) and MACE (b1-2) 
variables over 982 patients underwent angioplasty during 2005-2006. 
 
The behavior of the rate of MACE among patients who had undergone angioplasty 
seemed different between the two charts. The Bernoulli CUSUM chart (Figure 9.6-b1) 
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first signalled an increase in the rate at the 552nd patient and remained out-of-control 
for the remaining patients. In contrast, the Bernoulli EWMA chart (Figure 9.6-b2) 
detected four short-term signals followed by in-control periods. The signal periods were 
326-328, 557, 570-571 and 575-577, each implying that an increase in the rate occurred. 
The shortest signal period contained one observation, whereas the longest included 
three observations. As seen in Figure 9.6-b2, the beginning of the second signal, an 
increase in the rate of MACE, detected by the Bernoulli EWMA is almost identical to 
the starting time of the long-period signal detected by the Bernoulli CUSUM chart. 
 
Table 9.2: Posterior distributions (mode, sd.) and credible intervals (CI) of the change point 
parameters 1- and 8 following signals from the Bernoulli CUSUM (h± = (3.78, 3.27) and h± = 
(4.60, 4.07)) and EWMA (λ = 0.05, A± = 4.50 and A± = 4.05) charts on TLR and MACE 
variables over 982 patients undergone angioplasty during 2005-2006. Standard deviations are 
shown in parentheses. 
 
 
 
9.4.3  Change Point Detection 
 
We applied the change point model proposed in Section 9.3.3 to the TLR and MACE 
data. As discussed, either a step change point or multiple change point model was 
allowed. Table 9.2 presents the posterior distributions and associated credible intervals 
for the time and the magnitude of the change points following signals of the Bernoulli 
CUSUM and EWMA charts on TLR and MACE variables. See Section 9.3.3 and 
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Appendix for details on the MCMC method and implementation. 
 
The mode of the posterior distribution of the time of the first signal detected by the 
CUSUM in the rate of TLR suggested that the change occurred at the 550th patient, 
25 patients earlier than the observed signal. This estimate and the magnitude of the 
change were confirmed when the step change point model was implemented over a 
different subset of data (311 to 570) prior to the second pair of signals obtained from 
the EWMA chart. 
 
Figure 9.7: Exponentially weighted moving average graph (with smoothing constant of 0.01) 
for rates of patients who DES was used for in angioplasty procedure during 2005-2006 at 
SAWMH. 
 
The multiple change point model was found appropriate for the second signal 
provided by the CUSUM in TLR. The model suggested that a small increase in the 
rate occurred at the 904th patient and then a relatively large increase occurred at the 
971st which was followed by the signal. Having two changes points prior to the signal 
poses a need for recalibration of the causal analysis around the process. 
 
The mode proposed the 298th patient as the change point related to the signal at patient 
301 in the EWMA chart. However care should be taken regarding the associated mag-
nitude as a diffuse posterior distribution was obtained (highlighted by double asterisks 
in Table 9.2). 
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Implementation of the multiple change point model for the only signal at patient 552 
of the Bernoulli CUSUM chart on the MACE data reported the 299th and the 550th  
patients as the change points. The former was also identified as a change point if a 
shorter subset of data is used when the first signal of the Bernoulli EWMA, at patient 
326, is taken into consideration. The mode of the posterior proposed the later point as 
the change point when a step change point model was applied to the signal at patient 
557 in the EWMA. Thus although different subsets of observations were used, almost 
the same estimates were obtained for the parameter τs. The minor differences can be 
seen in associated standard deviations and the magnitude of the changes ( δˆ s). 
 
For the signal at patient 570 in the CUSUM and EWMA charts, highlighted by an 
asterisk in Table 9.2, although bimodal posterior distributions were obtained for τ, the 
step change point model was reported since the modes are too close to each other and 
no more informative results can be provided by the multiple change point model. 
 
As discussed in Section 9.3.3, having the change points beside the signals leads to 
more efficient root causes analysis efforts. To show this advantage of change point 
detection, we , here, focus on some signals and associated change point estimates. We 
compare the obtained estimates with changes in use of drug-eluting stents (DES), the 
known potential factor influencing the rate of MACE (Stone et al., 2004). A DES is a 
coronary stent placed into narrowed, diseased coronary arteries that slowly releases a 
drug to block cell proliferation. The stent is placed within the coronary artery by an 
interventional cardiologist during an angioplasty procedure. 
 
As seen in Table 9.2, an identical change point at the 300th patient, who underwent 
angioplasty procedure in mid August 2005, was obtained following the first signals of 
the CUSUM and EWMA charts on the rate of MACE. This time of change coincides 
with a reduction in the use of DES across the second half of 2005, see Figure 9.7. 
 
As one of the major benefits of DES over conventional bare metal stents (BMS) is a 
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reduction in the rate of late restenosis, a slow decline in their use and a shift back 
to BMS, may contribute to an increase in the rate of MACE although this was not 
sufficient to induce signals in TLR alone (a component of MACE). The decline in 
use of DES in late 2005 and early 2006 appears to be linked with an increase in the 
number of reports such as that by Bavry and colleagues at the November 2005 American 
Heart Association meeting linking the use of DES to a possible increase the risk for 
late thrombosis (reported in Bavry et al. (2006)). Concerns were reinforced at the 
European Society of Cardiology in Barcelona in September 2006 when similar results 
(particularly those of the Swedish Coronary Angiography and Angioplasty Registry) 
were presented, see Daemen et al. (2007) and Lagerqvist et al. (2007). This behavior 
can be seen as the source of following signals and estimated change points. As shown in 
Table 9.2, although different signals were obtained by the EWMA and CUSUM charts 
for TLR and MACE in early (patient 552), mid (patient 557) and end (patients 570 and 
575) of February 2006, the real change point was identified as occurring on 6 February 
2006 (patient 550). This change point matches with a larger drop in the use of DES at 
SAWMH in the same time, as can be seen in Figure 9.7. 
 
9.5   Conclusion 
 
Control charts play an essential role in improvement of quality of healthcare deliv-
ery. The chart signals when a significant change has occurred due to the existence of 
assignable causes. This signal is investigated using root causes analysis for identifying 
potential causes and then corrective or preventive actions are conducted. Identification 
of the time when a process has changed enables process owners to run their investiga-
tion for special causes more effectively. Indeed, knowing the change point restricts the 
search efforts to a tighter window of observations and related variables. 
 
In this paper we first studied the rate of patients who had undergone re-operations for 
bleeding and whom were administered more than 10 units of blood products following 
their CABG surgery. We applied Bernoulli CUSUM and EWMA control charts to 
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1072 CABG procedures over 2006-2010. The behavior of the charts was discussed. We 
then developed a Bayesian change point model to identify the time when the potential 
changes in the underlying rate occurred prior to signals. Either a step or a multiple 
change model was used depending on which was found more appropriate. Posterior 
distributions of the time and the magnitude of the changes were constructed using 
MCMC method and the estimates were reported. To assess the reliability of estimates, 
the changes in use of Aprotinin as a known potential cause were compared with the 
obtained estimates. The coincidence of change points obtained from Bayesian posteriors 
and the changes occurring in the use of Aprotinin confirmed the capability of change 
point detection in root causes analysis. 
 
In the second study we monitored the rate of patients experiencing adverse events 
including re-operation, heart attack and death in the follow-up period of angioplasty. 
Similar to the first study, the Bernoulli CUSUM and EWMA charts were applied and 
change points prior to signals were estimated. In the same manner, root causes analysis 
was conducted considering the use of DES as a source of changes. Shifts in the use of 
DES were matched to the estimated time of changes identified by the Bayesian posterior 
estimates. 
 
Although these investigations were implemented off-line for a restricted range of related 
factors, the obtained results supports the role of change point detection in process 
monitoring and root causes analysis. It could be considered as a plug-in procedure 
following signals obtained by control charts in an on-line monitoring program to provide 
more specific and probabilistic information which may lead to more productive efforts 
in assignable causes identification. 
 
However, prior to practice, further investigation to validate the performance of the 
proposed change point estimator over various change scenarios is required. Meanwhile, 
modification of the change point model to capture the underlying patent mix in moni-
toring hospital outcomes is essential. 
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Appendix 
Step change model code for blood products 
 
model { 
for(i in 1 : RL ){ 
x[i] ∼ dbern(pl [i]) 
pl [i] =p0+delta*step (i-change) } 
tau=sqrt (1/ (6*p0(1-p0))) 
delta ∼ dnorm(0, tau)I(-0.0176,0.982) 
change ∼ dunif(1,RL)} 
 
 
Multiple change model code for blood products 
model { 
for(i in 1 : RL ){ 
x [i] ∼ dbern(p2 [i] ) 
p2 [i] =p0+delta1*step(i-change1)*step(change2-i)+delta2*step (i-change2) 
p2 [i] i-min(pl [i] , 0.999) } 
tau=sqrt (1/ (6*p0 (1-p0)) 
deltal ∼ dnorm(0, tau)I(-0.0176,0.982) 
delta2 ∼ dnorm(0, tau)I(-0.0176,0.982) 
changel ∼ dunif(1,change2) 
change2 ∼ dunif(changel,RL)} 
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CHAPTER 10 
 
 
Use of Quantitative Feedback to Drive 
Change in Clinical Practice 
 
Preamble 
 
Whilst a primary goal for monitoring clinical performance is the identification of 
instances of underperformance (see the Bristol Inquiry), it is also important to 
consider how best to influence clinicians to continually strive to improve clinical 
practice. In this chapter, we explore the use of a process of regular audit and feedback 
of quantitative data and analyze the impact this has on influencing clinicians to alter 
their practice. The example given concerns the introduction of annual personalized 
radiation use reports to a group of cardiologists performing cardiac imaging 
procedures. Feedback of this data was originally introduced to quantify the impact of 
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a government mandated education program (conducted in October 2001) that the 
cardiologists had to undertake to enable them to use the imaging equipment. Analysis 
of the pattern of change in radiation use, associated with the education and feedback 
interventions, at both a cohort and individual clinician level, suggests that education 
alone is not sufficient to deliver improved outcomes. Our findings, which were linked 
to behavior modification theory via the theory of planned behavior, suggest that the 
introduction of regular personalized performance feedback is an essential component 
of strategies designed to modify clinical performance and deliver improved patient 
outcomes.  
 
Additional to the study’s core findings related to change management, this chapter 
also serves to demonstrate that control charts can be used in healthcare applications 
other than the proactive monitoring of the stability of a process in the absence of 
intended external change. In this study, we make use of the power of sequential 
monitoring to characterize the consequence of introduction of a change agent (routine 
performance audit and feedback). In this regard, control charts are shown to be 
effective in two ways; first, the control charts are used to confirm the significance of 
impact that the provision of feedback has had on radiation use (at both the overall 
cohort and individual clinician levels) and second, the charts were shown to be useful 
in identifying when the change took place in relation to the timing of the provision of 
education and introduction of feedback. 
The focus of this chapter is on the third objective of the thesis as it deals with the use of 
quantitative analysis to influence changes in clinical outcomes and clinician performance 
This chapter contributes primarily to application.  
 
This chapter has been written as a journal article for which I am first author. It is 
reprinted here in its entirety. I was responsible for the conception and conduct of 
research, design and implement statistical analysis, wrote manuscript, modified 
manuscript as suggested by co-authors and reviewers 
 
Software used in the analysis of data and construction of graphs presented in this 
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paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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10.1   Abstract 
 
In this paper we undertook an evaluation of the benefits of radiation education with 
and without feedback reporting in altering clinician radiation use behaviour in 
performing coronary angiography. 
 
Work involves a retrospective review of radiation use (fluoroscopy time in coronary 
angiograms) performed between July 1996 and December 2005 by ten cardiologists to 
assess the impact of various interventions aimed at minimising radiation risk. The 
impact of interventions such as education and audit/feedback were correlated against 
radiation use using Cumulative Sum and Cumulative Expected minus Observed 
charts. 
 
Baseline radiation use subject to standard guidelines was stable. Group performance 
charts show a modest transient improvement in radiation use associated with an 
education intervention alone. However, regular detailed personalised feedback 
comparing an individual’s radiation use to group and external benchmarks was 
successful in achieving sustained reduction in overall radiation use. For individual 
participants, significant improvement was noted in seven of ten cardiologists.     
 
Although an improved theoretical understanding of effective radiation hygiene 
strategies might contribute to reduced radiation use, this study suggests that regular 
detailed quantitative feedback supporting education is an effective tool in altering 
radiation use in coronary angiography. Understanding triggers that stimulate change 
in clinician behaviour is critical to the design of systems to optimise clinical 
performance. Confidentially reported benchmarking systems may be a useful tool to 
alter clinician behaviour.     
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10.2   Introduction 
 
Quantitative performance monitoring has been accepted in many industries, 
particularly manufacturing, as an essential step in the quality improvement cycle. 
Although a number of approaches for quality improvement have been applied within 
the health care industry including provider education, audit and feedback (Beck CA, 
Richard H et al. 2005), the effects of these approaches have been inconclusive 
(Jamtvedt, Young et al. 2006). In addition, interventions intended to change clinical 
practice are rarely designed using a theory-based approach (Eccles, Grimshaw et al. 
2005). Radiation risk management in clinical practice is an illustration of this 
approach with most professional guidelines (American College of Radiology 1999; 
Bashore, Bates et al. 2001; Hirshfeld, Balter et al. 2005) typically only emphasising 
the role of education as the prime intervention. In regard to audit processes, there has 
also been considerable debate within the healthcare industry about the relative merits 
of confidential/peer review reporting systems when compared with public 
performance reporting (Guru, Fremes et al. 2006). Education and guidelines are often 
proposed as effective strategies to influence clinician behaviour. However, previous 
work by others (Jamtvedt, Young et al. 2006), suggests that an appropriately managed 
audit and feedback program may more successfully achieve greater long term 
sustained improvement. 
 
The recent increased use of radiation based imaging modalities in cardiology has 
heightened awareness of total individual radiation exposure. During the diagnosis and 
treatment of chronic illnesses such as coronary artery disease, patients often undergo a 
series of imaging procedures most of which involve the use of ionizing radiation 
(Gerber, Carr et al. 2009). Increased sensitivity of cardiologists to the issue should be 
fuelled by reports suggesting that man-made radiation has equalled natural radiation 
as a source of human exposure (with exposure from medical sources being the major 
contributor) (Mettler, Thomadsen et al. 2008). The detrimental effects of radiation 
have long been understood with published evidence of severe x-ray induced injuries 
appearing as early as one month after x-rays were discovered (Inkret, Meinhold et al. 
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1995). Precise risks associated with medical radiation are, however, unknown but 
some perspective can be gained from one recent estimate (Redberg and Walsh 2008) 
suggesting that up to 2% of all new cancer cases in the USA might be due to 
computerised tomography (CT) use alone.  
 
To address this issue, professional bodies responsible for establishing and maintaining 
standards of clinical practice (American College of Radiology 1999; Bashore, Bates et 
al. 2001; Hirshfeld, Balter et al. 2005) and regulators charged with controlling the use 
of ionizing radiation (Queensland Government ; Australian Government 2008) have 
implemented strategies aimed at ensuring that the benefits derived from the various 
radiation based procedures significantly outweigh the risks involved. A common and 
often dominant requirement for most radiation risk minimization programs is regular 
user education (American College of Radiology 1999; Bashore, Bates et al. 2001; 
Hirshfeld, Balter et al. 2005; Kuon, Empen et al. 2005; Rehani 2007). In spite of these 
efforts, however, studies continue to demonstrate poor awareness amongst physicians 
and radiologists of the radiation doses associated with the procedures they commonly 
request or perform (Jacob, Vivian et al. 2004; Correia, Hellies et al. 2005; Thomas, 
Parnell-Parmley et al. 2006).  
 
Behaviour modification theorists (Eccles, Grimshaw et al. 2005), however, suggest 
that reliance on a single intervention strategy, such as education, is flawed. The 
“Theory of Planned Behaviour” (Perkins, Jensen et al. 2007), for example, builds on 
the concept that for change to take place three factors need to be considered and 
addressed; an individual's perceptions concerning the advantages and disadvantages 
of performing a particular behaviour the perceived importance of the change to 
‘significant others’ (and how much the individual values the opinions of these others 
regarding the alternative behaviour), and whether or not the objective behaviour is 
possible. Programs built around education alone may address the first factor but not 
factors two or three. It is possible that addition of a program of audit and feedback of 
both group and individual performance can not only reinforce the belief that outcomes 
are important to others but also demonstrate that change is possible by providing 
comparison to realistic benchmarks of excellence. 
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In this study we evaluate the effectiveness of annual personalised confidential 
quantitative feedback as an adjunct to radiation protection education intervention in 
stimulating change in radiation use by a group of experienced cardiologists 
performing coronary angiography in a single centre. Through this analysis we seek to 
better understand the combination of interventions that may be a useful in modifying 
clinician behaviour.     
 
 
10.3   Methods 
 
10.3.1 Radiation Safety Interventions: 
 
The entire cardiology group involved in this study undertook a 4-hour long 
compulsory radiation safety training course in October 2001 comprising both theory 
and practical elements. The requirement for cardiologists to undertake this course 
arose out of the introduction of the Queensland Radiation Safety Act 1999 
(Queensland Government). Under this legislation cardiologists intending to use 
irradiating apparatus must be licensed to administer radiation to patients. Subsequent 
to this course, the Radiation Safety Officer at St Andrew’s War Memorial Hospital 
(SAWMH) introduced a number of radiation feedback mechanisms to provide all of 
the cardiologists with confidential quantitative information concerning comparative 
individual and group radiation use. The data provided was specific to the individual 
clinician’s performance in the main procedural subclasses performed in the SAWMH 
cardiac imaging facility (diagnostic coronary angiography, studies of coronary artery 
bypass grafts, angioplasty procedures, electrophysiology studies and device implant 
procedure). Table 10.1 provides a summary of the information provided to each 
cardiologist at the various intervals. Data was categorised into procedure type with the 
information regarding each procedure comprising an analysis of the radiation metric 
available. As described in this table, the content of the feedback varied at each 
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interval, however, it was delivered in the form of a written report containing graphical 
and tabular data that compared the individual clinicians radiation use (procedural 
volume along with median and inter-quartile range) for each of the procedural sub 
classes in which they were involved. In addition to the radiation use information 
shown in Table 10.1, the feedback in 2004 and 2005 also outlined a range of strategies 
that could be applied to reduce radiation use as well as comparisons with external 
benchmarks (where available).    
 
10.3.2 Study Data 
 
Records available for review related to adult diagnostic coronary angiography (CA) 
imaging procedures undertaken at SAWMH in the period from January 1997 to 
December 2005. Data for each procedure comprised basic patient details (age and 
gender), a measure of radiation use in the form of total case fluoroscopy time (FT) as 
well as clinical diagnostic details describing the extent of any disease present. It is 
acknowledged that more sophisticated measures of radiation use are available such as 
number of frames acquired, dose area product, peak skin dose and effective dose, 
however, these were not recorded in the period prior to the radiation safety course in 
October 2001 and hence were not available for study. In any event as general practice 
at SAWMH is for the cardiologist to have direct control over the use of fluoroscopy, 
measures of FT will better reflect clinician attitude to radiation use. Due to the 
variation in radiation dose associated with differing levels of case complexity (Smith 
and Rivers 2008), analysis of radiation use over time was limited to only those cases 
with minimal disease burden. 
 
To allow trends to be fully analysed, only procedures performed by cardiologists 
working consistently throughout the entire study period were included. Therefore, of 
the 32 cardiologists performing procedures in the SAWMH Cardiac Catheter Theatre 
(CCT) during the period of study, 22 were excluded as they: commenced after 
January 1997 (4), ceased work at SAWMH around the time of the education 
intervention (2), made only sporadic use of the facilities (4) or were very low volume 
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(<10 cases per year) users of the facility (12). Therefore, in total, procedures 
performed by 10 experienced cardiologists (accounting for 77% of the total CA 
volume) have been considered. Across the period of study, procedures were 
performed in two identically configured image intensifier equipped catheterisation 
laboratories. Towards the end of 2004, a third catheterisation laboratory employing a 
digital flat panel detector was commissioned. After applying the various inclusion 
criteria, the study involved analysis of radiation use in 2029 procedures with 1012 
procedures occurring before delivery of the education. Analysis of patient data 
relating to these procedures did not reveal any major trend in either patient age or 
gender throughout the period of this study. 
 
Table 10.1: Summary of personalised feedback provided to cardiologists. Current year’ 
refers to analysis of data for procedures performed in the 12 months prior to the feedback 
report while ‘Previous year’ relates to the 12 months prior to that. The radiation metrics 
comprised summaries of fluoroscopy time (FT), digital acquisition frame count (DA), and 
dose area product (DAP).  
 
Feedback 
Date 
Individual  Group 
Annual 
Volume 
Current 
Year 
Previous 
Year  
Annual 
Volume 
Current 
Year 
Previous 
Year 
Nov-01 Yes FT -  Yes FT - 
Nov-02 Yes FT  Yes FT - 
Nov-03 Yes FT & DA  Yes FT & DA 
Nov-04/05 Yes FT, DA & DAP*  Yes FT, DA & DAP* 
 
 
For this study, the benchmark defining high radiation use has been set at a FT 
equivalent to the 75th percentile of the group radiation use in the period prior to the 
mandated radiation safety training course (a level of 2.8 minutes of FT per case). Use 
of the 75th percentile FT value as a benchmark level conforms to the model proposed 
for the establishment of diagnostic reference levels in radiology (Australian 
Government 2008). An additional sensitivity analysis was performed to assess the 
impact of using alternative threshold values such as the median and 25th percentile FT 
values.  
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10.3.3 Data Analysis 
 
Clinician radiation use summaries (median and interquartile range) were determined 
for the two periods pre- and post-radiation safety training. These data were analysed 
to determine whether differences existed in overall use patterns. While this analysis is 
useful in determining the significance of changes in radiation use between the two 
periods it does not provide any indication of the timing of any changes.  
 
To provide this analysis, techniques taking into account procedure date have been 
used to explore the change in frequency of cases exceeding the defined benchmark 
over time. The graphical techniques used involve the cumulative expected minus 
observed (E-O) chart (Lovegrove, Valencia et al. 1997) and cumulative sum 
(CUSUM) chart (Kestin 1995).  
 
The cumulative E-O chart is a very basic form of CUSUM chart. As the description 
implies, the chart is derived by cumulatively summing the difference between the 
expected and observed outcomes of a procedure. The expected outcome in this 
analysis is the average probability that a case will involve a FT exceeding the stated  
benchmark while the observed outcome is either 1 or 0 depending on whether it 
actually does (or doesn’t). As we have used the 75th percentile FT (2.8 minutes) as our 
benchmark, the expected probability is 0.25. This type of chart is good for visual 
inspection as it shows, over time, how many events more or less have been observed 
compared to what was expected 
 
The CUSUM chart is constructed by cumulatively summing the difference between 
the observed and expected values related to the parameter being monitored. The 
resultant sum is compared to a predefined decision threshold (‘h’) and is said to signal 
when the threshold is breached (this normally triggers a review of the factors 
contributing to the outcome change). After a signal (and subsequent investigation) the 
CUSUM is reset to zero and monitoring continued. The chart used in this analysis is 
the double sided CUSUM described by Steiner et al. (Steiner and Cook 2000) which 
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is based on the log likelihood ratio. The log likelihood ratio is derived using the 
expected and observed outcomes described previously. As applied in this analysis, 
these charts provide a running statistical analysis, updated after each procedure, that 
simultaneously tests the hypotheses that the odds of a case involving prolonged 
fluoroscopy time has doubled or halved. 
 
These charts were selected for their abilities to identify subtle sustained changes in a 
process with the E-O chart being used for its ease of interpretation while the CUSUM 
provides a more robust statistical analysis of the significance of any change.  
 
Data from the 1012 procedures performed prior to delivery of the education were used 
to establish baseline measures for individual cardiologists and group performance. As 
such, the cardiologists acted as their own controls for individual and group 
performance analysis. For the CUSUM chart, the ‘h’ value (alarm level) for the two 
charts has been set at an average run length to signal while in control (ARL0) of 5 
years. This design criterion results in an ‘h’ value of 4.4 for charts monitoring group 
performance with a doubling or halving in the odds being reached with average run 
lengths of 11 weeks and 24 weeks, respectively.    
 
10.3.4 Statistical Notes 
 
Due to the skewed nature of the data distributions in this study, the median and 
interquartile range have been used to describe population central tendency and 
dispersion. The Mann Whitney ‘U’ test has been used to assess the difference between 
two patient populations. In all cases, a statistical significance level of 5% has been 
used. 
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10.4   Results 
 
Table 10.2 provides a summary of the individual FTs for cardiologists prior to and 
following radiation safety education (October 2001) and introduction of radiation use 
feedback (annually from November 2001). Analysis shows that median FT for the 
group decreased significantly from 2.1 min to 1.7 min (p<0.001). On an individual 
basis, absolute radiation use per case decreased for all cardiologists, but the change 
was not significant for three.  
 
Table 10.2: Analysis of radiation use by individual clinicians pre- and post-
radiation safety training course. Conducted in November 2001. FT (min) are 
expressed as the median and inter-quartile range.  
 
Cardiologist Pre Education Post Education p Value n FT (min) n FT (min) 
C1 69 2.1 (1.7-2.7) 75 1.7 (1.5-2.1) <0.001 
C2 56 2.7 (2.2-3.5) 102 2.3 (1.9-3.5) 0.006 
C3 123 1.4 (1.2-1.9) 131 1.3 (1.1-1.8) ns 
C4 152 2.1 (1.8-2.8) 160 1.6 (1.4-2.4) <0.001 
C5 154 1.8 (1.5-2.5) 106 1.5 (1.3-2.0) <0.001 
C6 124 2.1 (1.8-2.8) 199 1.8 (1.4-2.4) <0.001 
C7 63 2.1 (1.9-3.2) 50 2.0 (1.6-2.4) ns 
C8 160 2.0 (1.6-2.7) 100 1.5 (1.3-1.9) <0.001 
C9 87 2.5 (2.1-3.4) 78 2.0 (1.8-2.5) 0.005 
C10 24 2.4 (1.9-3.3) 16 2.2 (1.8-3.1) ns 
Overall 1012 2.1 (1.6-2.8) 1017 1.7 (1.4-2.4) <0.001 
 
 The E-O chart (Figure 10.1) and CUSUM chart (Figure 10.2) show trends in 
radiation use for the cardiology group from January 1997 to December 2005. The top 
chart in Figure 10.2 is a running test assessing whether the odds of a patient 
undergoing a procedure involving an FT exceeding the target threshold has doubled; 
while the lower chart tests whether the odds have halved. In the period prior to the 
radiation safety training intervention (October 2001) the radiation use pattern of 
SAWMH clinicians was relatively stable. The two alarm signals (alarm level 
breaches) noted in the pre education period of the CUSUM charts are most likely due 
to the accumulation of random chance events. Consideration of the CUSUM design 
shows an ARL0 of 5 years was used and as such some false alarm signals are to be 
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expected even when the process is in-control. Reference to the E-O chart confirms 
that these alarm signals were correlated with short term clusters of high FT cases. 
Additional graphs for cardiologist C3, C6 and C8 have been included in Figure 10.1 
to highlight variation in individual response to interventions.  
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Figure 10.1: Cumulative E-O chart showing FT for all cardiologists over a period of nine 
years (January 1997 to December 2005). Also shown are the trends in FTs for Cardiologists 3, 
6 and 8. The mandatory radiation safety training course occurred in October 2001 (dotted 
line). Timing of provision of personalised feedback is indicated by the letter ‘A’.  
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Figure 10.2: Double sided CUSUM chart monitoring changes in rate of FTs exceeding the 
entire cardiologist group benchmark time (75th percentile). Radiation safety training course 
indicated by the vertical dotted line with timing of personalised feedback indicated by the 
letter ‘A’. Solid dots indicate that the alarm limits have been reached, at which point the chart 
has been reset to zero and monitoring continued.  
 
The sensitivity analysis assessing the impact of using the median and 25th percentile 
FTs as threshold values yielded CUSUM and E-O charts identifying changes in 
radiation use consistent with that identified in Figures 10.1 and 10.2. These additional 
charts suggest that the change in radiation use was reflected across the entire spectrum 
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of fluoroscopy times (not just at the high end). Due to the similarity of results 
provided by these additional charts they have not been included separately.  
 
 
10.5   Discussion 
 
Review of data presented in Table 10.2 suggests that significant change in overall 
radiation use, as indicated by FT, has been achieved in the four years following the 
radiation safety training course (p<0.001). At an individual level, a reduction in FT 
has been noted by all cardiologists with seven achieving reductions that were 
significant (p<0.05). This bulk analysis of data, however, is misleading as it could be 
interpreted that education alone was the change agent (the point in time used to 
stratify the two groups of data). Reference to the E-O (Figure 10.1) and the CUSUM 
(Figure 10.2) charts provides a clearer identification of when change took place and 
for how long the change was sustained. These charts show that in the first few months 
following radiation safety training, there was a rapid favourable impact on FT. This 
initial change was not sustained, however, and the graphs indicate a return to the pre-
education FT levels. From the group perspective, sustained change in radiation use 
does not appear to have been established until some time after the second personalised 
feedback report in November 2002 (with the first signal occurring August 2003). 
There was also a delay between the third personalised feedback report and a reduction 
in radiation use. These delays in radiation reduction are suggestive of a gradual 
change in the cardiologists’ behaviour. A more discrete time point of change is 
difficult to detect for a group of 10 individuals since each cardiologist would be 
exploring different ways of performing CA in light of receiving feedback regarding 
their individual radiation use. The improvement in performance, however, was 
sustained for the remaining period of analysis.  
 
For individual cardiologists, the response to the various change interventions has been 
markedly different. The E-O charts for cardiologists C3, C6 and C8 respectively show 
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no effect, delayed improvement and prompt change in response to the education 
intervention. The response of C3 needs to be highlighted as this individual started 
with the lowest FT and as such may have already been operating as efficiently as is 
possible without compromising clinical practice. For C8, it is possible that education 
alone was a sufficient trigger to stimulate change while for C6 the additional 
encouragement to change coincided with the provision of quantitative feedback and 
the likely demonstration that group use of radiation was changing. However, it cannot 
be discounted that other factors may have influenced practice change over this period. 
For example, some of the cardiologists in this study perform cardiac imaging 
procedures in other facilities. Therefore it is conceivable that techniques used to 
reduce radiation may have been transferred from other hospitals to SAWMH on an 
individual basis. In addition, heighted awareness of radiation protection issues 
brought about through local legislative changes (Queensland Government 1999) and 
the release of key practice standards, guidelines and reports (American College of 
Radiology 1999; ICRP 2000; Bashore, Bates et al. 2001) within the same time period 
as the education intervention might have also heightened the cardiologists’ awareness 
of radiation use and therefore could have contributed to a change in behaviour. 
 
While this study has been limited to analysing trends in FT associated with low 
disease burden diagnostic coronary angiography, it will be important to determine 
whether the radiation awareness strategy and reporting system translates into dose 
reductions in more complex angiography cases, angioplasty and electrophysiology 
studies where higher levels of radiation use are expected. The magnitude of the 
absolute dose reduction is small but cardiology patients typically undergo multiple 
imaging and intervention procedures with potential for large cumulative doses. 
Physicians should attempt to minimise dose at all exposure points and this type of 
radiation awareness strategy might have potential value for broader algorithms to 
minimise patient, clinician and associated procedural staff risk by promoting lower 
radiation interventions where feasible.  
 
One conclusion that might be drawn from this evidence is that knowledge of radiation 
risk or of effective radiation reduction strategies does not necessarily in itself lead to a 
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better appreciation of individual case based radiation issues or alternately may not 
translate into a clear motivating factor or mechanism for behaviour change. Programs 
relying predominantly on guidelines and education may not be the most effective 
course of action to reduce radiation use, although these factors may be prerequisites 
for a successful change environment or intervention. Studies on individual behaviour 
modification (Eccles, Grimshaw et al. 2005; Perkins, Jensen et al. 2007) and clinical 
outcomes improvement (Guru, Fremes et al. 2006; Fung, Lim et al. 2008) indicate the 
need for additional interventions to promote change.  
 
As for how the cardiologists were practically able to reduce their radiation use, the 
education course delivered in October 2001 covered strategies that could be employed 
to reduce case radiation use. This information was reinforced through a practical 
session conducted as part of the education program. Although the full list of radiation 
use reduction techniques covered included some that would not be expected to have a 
direct effect on case fluoroscopy use (such as collimation, frame rate selection and 
projection orientation), other techniques such as reducing the number of views 
employed, minimising the x-ray on time and maximising use of the last image hold 
facility do have clear links to FT. As noted in the description of material provided to 
the cardiologists in their annual feedback, the information provided included both 
summaries of individual radiation use (comparing this to internal and external 
benchmark data) as well as supplementary material that reiterated the radiation risk 
reduction strategies presented in the initial education and practical sessions. It is likely 
that the combination of information on personal comparative radiation use and 
recommendations on how to reduce this use (without impacting on clinical outcomes) 
was an important component in driving change in this instance.    
 
Private or confidential reporting systems do not utilise the “name and shame” 
behaviour attributed to public reporting. Private reporting systems of this type provide 
objective benchmarking, tools to reinforce practice and represent a collegiate form of 
education that employs a team approach with a focus on continued improvement. All 
the cardiologists in this study were highly experienced with long established 
behaviour patterns for performing angiography. It appears that the benchmarking 
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system gave each participant a mechanism to challenge their own established patterns 
of behaviour and a motivation to change.  
 
Our study has not explored the factors that motivated change in the cardiologist group 
but an analysis of these factors is planned. Motivation to improve patient outcomes is 
likely to underlie all successful changes but factors specific to this intervention such 
as competitive behaviour, demonstration of feasibility of improvement, quantitative 
tools and team support for the change process may be relevant. Removal of barriers to 
change and patterns of behaviour might also have facilitated improvement.  
 
Quantitative confidential individual performance reporting against group and reported 
benchmarks was an effective tool for initiating and sustaining change in radiation use 
amongst a group of experienced cardiologists. This intervention appeared superior to 
previous approaches employing guidelines and general radiation safety education.  
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CHAPTER 11 
 
 
Impact of Quantitative Feedback and 
Benchmark Selection On Radiation Use By 
Cardiologists Performing Cardiac 
Angiography  
 
Preamble 
 
In chapter 10 we used the Theory of Planned Behavior to support the concept that 
provision of regular benchmarked personalized performance feedback is a key 
component of strategies aimed at delivering improved patient outcomes. The feedback 
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described in Chapter 10, made use of peer cohort derived data to provide clinicians 
performance benchmarks on an annual basis. There is a body of literature, however, 
that describes the benefit of providing feedback, temporally and physically closer to 
the point of care. These benefits include improved opportunity for linking action with 
outcome as well as heightening awareness of issues related to data quality and 
completeness. In this chapter we extend our previous work to explore the impact of 
increasing the frequency of feedback by providing benchmarked performance data at 
the conclusion of each case.  
 
The study described in this chapter again dealt with the modification of clinician 
radiation use during diagnostic cardiac angiography. Clinicians performing these 
procedures at St Andrew’s War Memorial Hospital were approached to participate in 
the study. Those consenting to take part were randomly assigned to one of two 
groups; the first group was provided only with case clinical details (patient 
characteristics and clinical findings) while the second group was additionally 
provided with comprehensive case based radiation data which was compared to 
cohort derived 75th percentile benchmarks (a common target used in national radiation 
monitoring programs) . 
 
Control charts were used to track for subtle changes in clinician performance in 
response to the feedback. Evaluation of the group and individual clinician control 
charts revealed that, in general, the group blinded to their radiation use data reduced 
their radiation use throughout the course of the study while the group receiving 
radiation data generally deteriorated in performance. Explanation for the observed 
results for Group 1 was linked to the Hawthorne Effect while Goal Setting Theory 
(GST) was suggested as a possible justification for the response of Group 2. Under 
GST, to be effective at driving improvement, objectives should be both specific and 
challenging. This study suggests that while a 75th percentile benchmark may be 
effective at identifying outlier underperformance, if it is the sole comparator used, it’s 
routine user may contribute to the deterioration in performance of those performing 
better than the benchmark.   
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The focus of this chapter is on the third objective of the thesis as it deals with the use of 
quantitative analysis to influence changes in clinical outcomes and clinician performance 
This chapter contributes primarily to application.  
 
This chapter has been written as a journal article for which I am first author. It is 
reprinted here in its entirety. I was responsible for the conception and conduct of 
research, design and implement statistical analysis, wrote manuscript, modified 
manuscript as suggested by co-authors and reviewers 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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11.1   Abstract  
Audit and feedback of both group and individual data provided immediately after the 
point of care and compared to realistic benchmarks of excellence have been 
demonstrated to drive change. This study sought to evaluate the impact of immediate 
benchmarked quantitative case based performance feedback on the clinical practice of 
cardiologists practicing at a private hospital in Brisbane, Australia. 
 
Feedback on radiation usage during coronary angiography was provided on an annual 
versus case-by-case basis. Participating cardiologists were assigned to one of two 
groups: Group 1: received patient and procedural details for review; Group 2: 
received Group 1 data plus detailed radiation data relating to the procedures and 
comparative benchmarks.   
 
In Group 2, Linear-by-Linear Association analysis suggests a link between change in 
radiation use and initial radiation dose category (p=0.014) with only those initially 
‘challenged’ by the benchmarks showing improvement. Those not ‘challenged’ by the 
benchmarks deteriorated in performance with those starting well below the 
benchmarks showing greatest increase in radiation use. Conversely, those blinded to 
their radiation use (Group 1) showed general improvement in radiation use throughout 
the study with those performing initially close to the benchmark showing greatest 
improvement. 
 
This study shows that the use of non-challenging benchmarks in case based radiation 
risk feedback does not promote a reduction in radiation use, indeed it may contribute 
to increased doses. Paradoxically, cardiologists who are aware of performance 
monitoring but blinded to individual case data appear to maintain, if not reduce, their 
radiation use. 
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11.2   Introduction  
 During the course of diagnosis and treatment of chronic illnesses (e.g. coronary 
artery disease), patients often undergo a series of imaging procedures involving 
ionising radiation (Einstein, Weiner et al. 2010; Gerber, Carr et al. 2009). The recent 
increased use of ionising radiation based imaging in cardiology has heightened 
awareness of the potential issues associated with the total cumulative radiation dose 
received by patients and the need to minimise individual procedure radiation 
exposures without compromising diagnostic yield. To address this issue, professional 
bodies responsible for establishing and maintaining standards of clinical practice 
(American College of Radiology 1999; Bashore, Bates et al. 2001; Hirshfeld, Balter et 
al. 2005) and regulators charged with controlling the use of ionizing radiation 
(Queensland Government ; Australian Government 2008) have implemented 
strategies directed at ensuring that the benefits derived from undergoing radiation 
based procedures continue to significantly outweigh the risks to patients and 
providers.  
 
In the past, practice guidelines have predominantly relied on education as the main 
intervention for radiation risk reduction (American College of Radiology 1999; 
Bashore, Bates et al. 2001; Hirshfeld, Balter et al. 2005). Printed education materials, 
in particular, have shown little effect in improving professional practice (Grimshaw, 
Shirran et al. 2001; Fremantle, Harvey et al. 2003). Although a number of approaches 
for quality improvement have been applied within the health care industry including 
provider education, audit and feedback (Beck, Richard et al. 2005), the effects of the 
majority of these approaches have so far been minimal or inconsistent (Jamtvedt, 
Young et al. 2006). Audit and feedback of both group and individual data, however, 
have been demonstrated to drive change when providing a comparison to realistic 
benchmarks of excellence (Perkins, Jensen et al. 2007). In addition, feedback 
provided immediately after the point of care, has been shown to have a more 
significant effect on changing clinical practice (Mugford, Banfield et al. 1991).  
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In a previous study, we confirmed that in isolation, education is not a sufficient 
stimulus to ensure cardiologists reduce their radiation use in cardiac imaging 
procedures (Smith, Foster et al. 2011). Instead, we demonstrated that a program of 
annual personalized feedback, comparing an individual cardiologist’s summary 
radiation use to peer group benchmarks had greater long term benefit in terms of 
sustained radiation risk reduction (Smith, Foster et al. 2011).  
 
In this study we build upon the previously conducted program of annual radiation 
usage feedback, by providing cardiologists with more frequent and detailed 
information on their radiation usage. We hypothesised, based on behavioural theory 
(Perkins, Jensen et al. 2007), that increasing the frequency of comparative radiation 
use data would reinforce the motivational factors that lead to these shifts in clinical 
practice.  
 
To explore this issue, we developed site specific radiation metric benchmarks for 
coronary angiograms using methodology modelled on that employed by the United 
Kingdom National Radiological Protection Board (NRPB) (Hart, Hillier et al. 2009) 
and Australian Radiation Protection and Nuclear Safety Agency (ARPANSA). 
Participating cardiologists were randomised to one of two groups. While at the 
completion of each study both groups received clinical details of the procedure, one 
group was provided with additional case specific radiation data, compared against 
relevant (but low performance) radiation metric benchmarks. A third group of 
cardiologists, not receiving any feedback data, was used as a control. Individual 
cardiologist and cardiology group radiation use was then analysed using statistical 
process control charts to assess impact of the feedback strategy. 
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11.3   Methods And Patients 
 
11.3.1 Study population  
 
The study population was drawn from patients undergoing cardiac imaging 
procedures at SAWMH in the period from March 2009 to October 2011. A subgroup 
of procedures, comprising patients undergoing diagnostic coronary angiography 
(Hardcastle) procedures, with or without left ventriculograms, by the participating 
cardiologists was drawn from the total population. These data were filtered to remove 
incomplete records and inconsistent outliers as these would impact on the 
performance of the control charts, potentially obscuring the ability to detect small 
shifts in radiation use. DCA procedures included in this study were performed on two 
different imaging systems; a Philips Allura Xper FD10 system (Philips Medical 
Systems, Best, Netherlands) and a Toshiba Infinix CCi – FPD system (Toshiba 
Medical Systems Corporation, Tokyo, Japan).  
 
11.3.2 Study design 
 
Data for this project was divided into three phases: Phase 1 was the 12 month period 
leading up to the commencement of the study (March 2009 to March 2010); Phase 2 
the 12 months of the study (March 2010 to March 2011) and Phase 3, the 6 months 
after conclusion of the feedback component of the study (March 2011 to October 
2011). Data from Phase 1 was used to establish baseline performance measures of 
radiation use for each cardiologist and cardiology group. 
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11.3.3 Feedback mechanism 
 
A total of fourteen experienced cardiologists consented to receive feedback data on 
each case as part of the study. These cardiologists were randomly assigned to one of 
two groups (Group 1 and Group 2) for the term of the project. The process used to 
assign the cardiologists ensured a spectrum of baseline performance featured in the 
two groups. While both groups, at the end of each procedure, were provided with 
patient and procedural details (e.g. confirmation of procedure type and diagnostic 
findings) for review, one group (Group 2) also received detailed data on the radiation 
used in that procedure along with comparative benchmark data including estimates of 
patient stochastic and deterministic risk. Provision of this information is intended to 
provide point of care quantitative performance feedback. 
 
The radiation benchmark data provided for comparison in each case represented the 
3rd quartile of pooled radiation use data for Phase 1. The benchmark data was adjusted 
for relevant patient characteristics such as weight and gender using a model developed 
in Phase 1. An example of the feedback provided is shown in Figure 11.1. 
 
Procedures performed by two cardiologists electing not to participate in the receipt of 
feedback were assigned to a third group (Group 3). Data for these procedures acted as 
a default control for the project as they were not influenced by either form of 
feedback or the perception of active performance monitoring.  
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Patient Details: 
MRN ######### FIN 2638091 
Last Name #### First Name #### 
Date of Procedure 01 - May - 09 Gender Female 
Age 75 
Height 162 Weight 57 
Body Surface Area 1.63 Body Mass Index 22.48 
Rest Heart Rate 69 
Procedure Details 
Prim  Interventionalist ###### 
Sec  Interventionalist Primary Cardiologist Date 
Radiographer #######  CCT Procedure Room CCT3 (Phillips FD20) 
Case Description: Diagnosis: 
CCT Procedure CA Vessel Disease Status Minor CAD 
Other CCT Procedure Valve Disease Status 
CCT  Px Comments Rhythm Related  Px 
Complications System Configuration: 
In Lab Comps None Fluoro Frame Rate 15 
Other In Lab Comp Digital  Acq Frame Rate 15 
CCT Outcome Post Comp LV Gram Frame Rate 15 
Radiaton Details 
Radiaiton Measures: Benchmark Measures: 
Fluoro Time ( mm.mm ) 1.47 Fluoro Time ( mm.mm ) 3.40 
Number Frames 658 Number Frames 759 
D A P  (Gy.cm2) 22.00 D A P  (Gy.cm2) 25.22 
Effective Dose (mSv) 4.00 Effective Dose (mSv) 4.59 
Radiation Risk Estimates 
Cancer Risk Estimate: Skin Injury Risk: 
Induction Incidence 0.010% Peak Skin Dose ( Gy ) 0.13  Gy 
Mortality Incidence 0.008% %  Erythema Dose 6.5 % 
CCT Procedure Data Confirmation 
######## 
1
ion Details 
ion easures: 
 
Figure 11.1: Example of the detailed feedback provided to cardiologists at the conclusion of 
each case. Data in the top half of the form; Patient and Procedural Details was provided to all 
cardiologists in Groups 1 and 2, while the lower half of the form; Radiation Details and Risk 
Estimates, was provided to only those cardiologists assigned to Group 2. 
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11.3.4 Radiation metrics 
 
Radiation use in DCA procedures consists of two components; the first involves 
imaging while the cardiologist manipulates a catheter into position in the patient’s 
heart prior to injecting a radio opaque dye into the coronary arteries to enable 
visualization of vessel disease. This component, typically referred to as fluoroscopy, 
involves a low radiation exposure mode of operation of the equipment. The second 
component involves documentation of the injection of contrast agent down the 
arteries. This commonly involves acquiring low statistical noise, high resolution 
images at a higher radiation exposure. This aspect of the procedure is typically 
described as the digital acquisition (DA) mode. The total study radiation exposure is 
then a combination of the exposures resulting from the fluoroscopy and DA modes of 
operation. In this study, radiation use was documented using three measures relating 
directly to cardiologist decisions on how each case was performed: 
 
Fluoroscopy time (FT): FT is the total time that fluoroscopy is used during an 
imaging or interventional procedure. Procedural FT has been linked to proficiency in 
coronary angiography (Hillock, Smyth et al. 2006) and is actionable by the 
cardiologist as demonstrated in a previous study (Smith, Foster et al. 2011).  
 
Digital acquisition time (DAT): DAT is the total time used by the cardiologist in 
documenting the study. DAT was preferred to the more traditional digital acquisition 
frame count as the two imaging systems used in the study had different configuration 
characteristics; the Toshiba System offered the selection of 10 or 15 frames per 
second (with most procedures performed at the lower rate) while the Philips system 
offered only a 15 frame per second option for DCA procedures. This measure directly 
relates to decisions by the cardiologist concerning the number of separate projections 
used to document the case, the number of imaging runs employed and the length of 
each run. This measure will also be impacted by the decision to use low dose 
fluoroscopy grab facilities on the imaging systems to replace the higher dose 
acquisition mode. 
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Weighted radiation time (WRT): In this study, WRT has been used as the overall 
measure of radiation use in a DCA case. It was derived by combining the total case 
FT with the case DAT which is weighted by a factor of 10 to reflect the higher dose 
rate of this mode.  
 
Although Dose Area Product (Davies, Kaple et al.) was recorded for each case, this 
was not ultimately used as this exhibits significant variation not directly tied to 
cardiologist practice. For example, procedural DAP is heavily influenced by patient 
size, imaging practice choices of the radiographer (e.g. field collimation) and imaging 
system configuration. On this last point, the two imaging systems delivered different 
DAP rates due to the frame rate limitations mentioned previously. This issue was 
further exacerbated when the Philips imaging platform received a significant upgrade 
during the course of the study that resulted in a substantial drop in DAP (of the order 
of a 40% reduction). This change, however, did not impact upon WRT as this is 
independent of the actual dose output of the imaging platform(s). 
 
The distribution of each measure in Phase 1 was analysed, and FT, DAT and WRT, 
were found to be non normal. A Box-Cox analysis was performed and for DAT and 
WRT, a logarithmic transform was found to be sufficient to normalise the distribution 
of the data while for FT a Box-Cox transform (Sakia 1992) with a coefficient of -
0.6573 was required. 
 
As the cardiologists participating in the study had markedly different baseline 
measures of radiation use, the data for each contributor was converted to a standard 
normal distribution using: 
c
ci
i s
xxX )( −=   (11.1) 
 Where Xi is the standardised radiation metric value, xi is the raw transformed 
(normalised) value and cx  and sc are the mean and standard deviation of the Phase I 
radiation values for cardiologist c. In doing this, the data for each cardiologist could 
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be pooled so that variations in participant contribution rate over time would not 
unduly drive variations in the control charts. 
 
Throughout the course of this study, there were no changes in case complexity that 
would account for shifts in the distribution of radiation use by individual 
cardiologists. 
  
11.3.5 Monitoring radiation use 
 
Exponentially Weighted Moving Average (EWMA) charts were used to monitor for 
variations in the pattern of use of radiation by individual cardiologists and cardiologist 
groups. The EWMA chart is a form of statistical process control chart that is ideally 
suited to the detection of small sustained shifts in a process (Montgomery 2008).  
 
EWMA charts were constructed using the following updating formula: 
 
1)1( −⋅−+⋅= iii EXE λλ   (11.2) 
 
where λ is the smoothing constant, Ei is the updated value of the EWMA arising from 
sequential radiation metric observation Xi and Ei-1 is the previous value of the EWMA. 
Control limits were derived using Crowder (Crowder 1989): 
 
λ
λσ
−
±
2r
k    (11.3) 
 
where k is a constant determined by the user and σr is the standard deviation of the 
Phase 1 data (equal to 1 for a standardised distribution). The EWMA charts of the 
transformed metric data have been designed with control limits to optimally detect a 
5% shift in the radiation use patterns. For FT, DAT and WRT, this magnitude of 
change translates to a shift of 25% of the standard deviation of the normalised 
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distributions. For the chart under consideration a 25% shift is optimally detected with 
an ARL of 1000 cases (the approximate throughput of each arm of the study for 12 
months) using a λ of 0.01 and a k value of 2.3. 
 
11.3.6 Motivation to change radiation use 
 
To evaluate the impact of the 3rd quartile benchmark as a motivator stimulating 
clinicians to improve their use of radiation, clinicians in Group 2 were first assigned 
to one of three categories based upon their Phase 1 average radiation use compared to 
the pooled distribution of Phase 1 radiation data. Clinicians recording a result less 
than the lowest quartile were categorised as having a ‘Low’ initial radiation use while 
those falling into the upper quartile (i.e. greater than the benchmark) were seen as 
having ‘High’ radiation use. Remaining clinicians were allocated to an ‘Intermediate’ 
category. The Phase 2 data for each case was then categorised according to whether it 
was above or below the relevant clinician’s Phase 1 average. Note, reference to 
average refers to the average of the normalised distributions for each radiation 
measure. Impact of the relevant Phase 2 strategies on each group was then quantified 
using Pearson’s Chi Squared statistic and a test of Linear-by-Linear association to 
explore trends. Data obtained in the first three months of Phase 2 was excluded from 
this analysis as clinicians required adequate time to stabilise changes in their practice 
in response to the feedback. This analysis was repeated for Groups 1 and 3. 
 
11.3.7 Ethical statement 
 
Approval for this study was obtained from the UnitingCare Health Human Research 
Ethics Committee (Reference Number: 200922). The registry from which the 
procedural details including radiation data was extracted is regarded as an audit 
activity and as such did not require individual patient consent before being used for 
the analysis described. Cardiologists, however, were consented prior to receiving case 
based feedback as part of this study. 
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11.4   Results 
 
Figures 11.2-11.4 chart the radiation use patterns for the three radiation use measures 
(FT, DAT and WRT) throughout the course of the study. In each figure, graphs are 
charted representing the pattern of radiation use by the three groups of cardiologists 
analysed in the study. Charts showing the variation in radiation use for each measure 
for each individual cardiologist were plotted, however, only the summary charts are 
shown. In each figure, Group 1 represents the overall pattern of radiation use for 
cardiologists receiving patient and procedural details only, Group 2 represents the 
pattern of radiation use of cardiologists receiving feedback of patient, procedural and 
radiation details and Group 3 is the aggregated response for cardiologists who 
received no feedback at all.  
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Figure 11.2: EWMA control charts monitoring impact of the various levels of feedback on 
the normalised Fluoroscopy Time for the three groups of cardiologists (Group 1: patient and 
procedural data, Group 2: radiation data + patient and procedural data, Group 3: no feedback). 
Feedback provided in Phase 2 only. Phase 1 – pre study period used to establish monitoring 
baselines, Phase 2 – study phase during which participants received feedback described in 
Figure 11.1, Phase 3 – post feedback period. 
 
Chapter 11:  Impact of Benchmark Selection on Driving Change 280 
 
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
12
-M
ar
-0
9
11
-A
pr
-0
9
11
-M
ay
-0
9
10
-J
un
-0
9
10
-J
ul
-0
9
09
-A
ug
-0
9
08
-S
ep
-0
9
08
-O
ct
-0
9
07
-N
ov
-0
9
07
-D
ec
-0
9
06
-J
an
-1
0
05
-F
eb
-1
0
07
-M
ar
-1
0
06
-A
pr
-1
0
06
-M
ay
-1
0
05
-J
un
-1
0
05
-J
ul
-1
0
04
-A
ug
-1
0
03
-S
ep
-1
0
03
-O
ct
-1
0
02
-N
ov
-1
0
02
-D
ec
-1
0
01
-J
an
-1
1
31
-J
an
-1
1
02
-M
ar
-1
1
01
-A
pr
-1
1
01
-M
ay
-1
1
31
-M
ay
-1
1
30
-J
un
-1
1
30
-J
ul
-1
1
29
-A
ug
-1
1
28
-S
ep
-1
1
Procedure Date
EW
M
A
Phase 1 Phase 2 Phase 3
Group 1
Group 2 Group 3
 
Figure 11.3: EWMA control charts monitoring impact of the various levels of feedback on 
the normalised Digital Acquisition Time for the three groups of cardiologists (Group 1: 
patient and procedural data, Group 2: radiation data + patient and procedural data, Group 3: 
no feedback). Feedback provided in Phase 2 only. Phase 1 – pre study period used to establish 
monitoring baselines, Phase 2 – study phase during which participants received feedback 
described in Figure 11.1, Phase 3 – post feedback period.  
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Figure 11.4: EWMA control charts monitoring impact of the various levels of feedback on 
the normalised Weighted Radiation Time ( FT + 10 * DAT) for the three groups of 
cardiologists (Group 1: patient and procedural data, Group 2: radiation data + patient and 
procedural data, Group 3: no feedback). Feedback provided in Phase 2 only. Phase 1 – pre 
study period used to establish monitoring baselines, Phase 2 – study phase during which 
participants received feedback described in Figure 11.1, Phase 3 – post feedback period. 
 
As expected, the control chart for each radiation metric; FT, DAT and WRT, exhibits 
reasonable stability during the Phase 1 period.  
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For FT (Figure 11.2), the chart of Group 1 cardiologists first signals a reduction in 
radiation use within 6 months of the commencement of Phase 2. Although the chart 
returns to being within the control limits for a number of months it again signals a 
reduction at 10 months, a status it retains for nearly the remainder of Phase 2. 
Following cessation of the feedback component of the study, the chart for this group 
returns to the Phase 1 level. By comparison, the chart for Group 2 cardiologists (those 
receiving radiation feedback in addition to patient and procedural data) remains 
within the control limits throughout Phase 2. At 3 months after the end of Phase 2, 
however, the chart momentarily signals an increase in FT, a pattern that repeats within 
the remainder of the Phase 3 monitoring period. The chart for Group 3 cardiologists 
shows very little variation, remaining well within the control limits throughout the 
period of study.  
 
The trends identified for DAT (Figure 11.3) follows a similar pattern to FT. The chart 
of Group 1 cardiologists first signals a reduction in radiation use at approximately 7 
months of the commencement of Phase 2. This chart, however, remains outside the 
lower control limits for the remainder of the study (indicating a sustained reduction in 
DAT by these cardiologists). By comparison, Group 2 remains within the control 
limits throughout Phase 2. The chart then exhibits a trending increase in DAT 
throughout Phase 3, ultimately signalling a significant shift to higher DAT just prior 
to termination of the study. Again, the Group 3 chart remains within the control limits 
throughout the study period.  
 
As WRT is strongly influenced by the digital acquisition component of a study, it is 
no surprise that charts tracking WRT for the three groups of cardiologists (Figure 
11.4) follow similar patterns to that noted for DAT. The only differences being that 
the chart for Group 2 cardiologists signals more promptly after the end of Phase 2 
while the chart for Group 1 cardiologists hovers around the lower control limit (rather 
than exhibiting a sustained marked shift).  
 
Evaluation of the effectiveness of providing feedback using a benchmark based on the 
3rd quartile of group performance as a motivator for clinicians to minimise their 
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radiation use identified similar patterns for the three radiation measures evaluated. As 
such, for brevity, only details for WRT are provided (see Figure 11.5). For Group 2 
clinicians, a trend to decreased radiation use in the ‘High’ category is evident with 
41% of Phase 2 cases in this category being above the respective Phase 1 clinician 
averages (a reduction of 8%). Conversely, it is apparent that for clinicians falling into 
the ‘Low’ category, 64% of Phase 2 cases were above the respective Phase 1 averages 
(an increase of 14%). Analysis using Pearson’s Chi Squared statistic suggests there is 
a significant pattern to the overall distribution of outcomes (p=0.047) while Linear-
by-Linear Association analysis supports a link between reduction in radiation use and 
initial radiation dose category (p=0.014). For Group 1 clinicians (represented in only 
the ‘Low’ and ‘Intermediate’ categories), response to feedback (with only clinical 
data), suggests that clinicians in the ‘Intermediate’ category demonstrated greatest 
response (only 29% of Phase 2 cases above the respective Phase 1 averages). 
Clinicians in the ‘Low’ motivation group did not appear to alter their practice (51% of 
Phase 2 cases above the respective Phase 1 averages). For Group 3, no significant 
change was noted. 
 
11.5   Discussion 
 
Our expectation in undertaking this study was that cardiologists, when provided with 
case by case feedback of their comparative radiation usage and estimated consequent 
risks, would be stimulated to decrease the amount of radiation on-time involved in 
their cardiac angiographic imaging procedures over time. In formulating this 
hypothesis, we considered the possibility that a number of cardiologists might already 
be using the minimum possible radiation dose that could be employed without 
compromising diagnostic yield and that no further improvements might be achieved.  
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Figure 11.5: Plot for WRT showing change in radiation use against category of individual 
cardiologist initial (Phase 1) average radiation use. Initial use categories are defined as; ‘Low’ 
- clinicians with Phase 1 average results < 25th percentile of overall Phase 1 data, 
‘Intermediate’ - clinicians with Phase 1 average between 25th and 75th percentile of overall 
Phase 1 data and ‘High’ - clinicians with Phase 1 average > 75th percentile of overall Phase 1 
data. Change in radiation use is expressed as the proportion of Phase 2 procedures with a 
radiation record more or less than the Phase 1 average for individual cardiologists. A 95% 
confidence interval is shown for each proportion. 
 
 
The EWMA charts for each radiation measure, however, reveal a potentially different 
result. The control charts suggests that Group 1 participants (those receiving clinical 
data only) actually appear to have reduced their radiation use overall across the 
feedback phase (Phase 2) of the study. In contrast, for Group 2 it is apparent that 
provision of benchmarked radiation feedback, in the form described, on a case by case 
basis, did not act as a stimulus for cardiologists to reduce radiation use during Phase 
2. Indeed in some instances radiation use by individual cardiologists appears to have 
increased.   
 
Of further note is that in Phase 3, the 6 months after cessation of the provision of any 
feedback, both groups (1 and 2) appear to have exhibited a shift to increased radiation 
use. Group 2 (the group receiving radiation feedback) signalled a shift to higher 
radiation use patterns on all metrics analysed (up 5% over the baseline measures) 
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while Group 1 appears to have returned to FT levels consistent with the pre-study 
baselines while DAT and WRT values have remained low (although these have 
returned to slightly higher values than those recorded in Phase 2 of the study). 
 
One possible explanation for the results of Group 2 relates to the nature of the 
feedback provided. By definition, for most cardiologists the actual doses delivered 
were less than the benchmark in 75% of cases and for higher performers, these 
benchmarks were not a level to which they aspired. Use of 3rd quartile radiation data 
as a benchmark, therefore, did not sufficiently challenge cardiologists to improve their 
performance and indeed may have acted to give them a perception of outperformance, 
in effect providing tacit approval to relax their efforts in dose reduction. This 
interpretation is consistent with findings from goal setting theory (Locke and Latham 
2002) where greatest effect is reported when the achievement of the goal (in this case 
the radiation benchmark) is challenging. Limited positive effect, if any, is noted, when 
achievement of the goal is easy or extremely difficult. In addition, consideration of 
control theory (Gardner, Whittington et al.) would also suggest that because there was 
no discrepancy between the message provided by the feedback to participants and the 
behavioural goal (lower radiation risk) then there may have been no motivation to 
change. Relevant to this point is a separate research project that also included 
participants involved in the current study, which investigated motivating factors that 
lead to change in clinical practice (Ryan and Horrigan 2011). In relation to the use of 
audit and feedback models for radiation usage, one key motivating factor for change 
in a clinician’s practice was knowledge of how their performance compared to that of 
their peers’. This had provided a meaningful and motivating mental reference-point 
for most of the participants. This form of feedback was not part of the feedback to 
Group 1 participants in the current study. Secondly, participants who expressed 
idealism beliefs, (i.e., those that were highly motivated to reduce radiation risk) were 
more likely to have lower actual radiation usage. In relation to the current study, the 
benchmark chosen could have attenuated the effect of this belief by providing an 
unchallenging target or aspirational level. 
 
Chapter 11:  Impact of Benchmark Selection on Driving Change 285 
 
In the group that did not receive radiation benchmark data, these cardiologists were 
being constantly reminded (through the provision of case by case clinical data) that 
their radiation use was being monitored but received no feedback as to how their 
radiation use compared to benchmark. As such, this may be a classic example of the 
Hawthorne Effect (Adair 1984), where the fact that they were being observed (albeit 
blinded to the actual performance data) was sufficient to encourage them to maintain 
or improve their efforts at radiation risk reduction. 
 
One final observation, concerns the radiation data for Group 3 (those not participating 
in the study). With the exception of DAT (which showed a slight increase during 
Phase 2), radiation use for this group appeared relatively constant over the entire term 
of the study. This suggests that unlike Groups 1 and 2, there were no confounding 
factors that may have influenced this group’s performance. 
 
The findings of this study have significant consequences for quality improvement 
strategies employing comparison with benchmarks as a means of stimulating 
improvements in performance. The analysis summarised in Figure 11.5 provides an 
interesting insight into the potential effect of using a benchmark that does not 
sufficiently challenge recipients of the feedback to improve performance. While this 
analysis suggests that the provision of benchmarked feedback can be successful in 
improving performance in those identified as negative performance outliers (those in 
the ‘High’ radiation use category), a finding that indicates that this form of feedback 
has little effect on those performing moderately well (‘Intermediate’ category) while 
being linked to potential performance deterioration in high achievers (those already 
performing significantly better than benchmark) is a major concern. Great care must 
therefore be taken regarding the context in which the feedback is provided and the 
attributes of the benchmarks chosen. Whilst selection of a low performance hurdle as 
a benchmark may aid in the identification of significant underperformers, the use of a 
benchmark that does not sufficiently challenge clinicians to perform, may only serve 
to encourage mediocrity in performance. In our study, when clinicians were presented 
with radiation use data compared to a ‘poor’ benchmark only those clinicians 
challenged by the benchmark appear to have been stimulated to modify their practice. 
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The remaining clinicians either reduced their efforts to maintain low levels of 
radiation use or did not change.  
 
Goal setting theory (Locke and Latham 2002) warns, however, that the use of a 
benchmark that sets unreasonable outcome expectations may not drive the desired 
improvement in performance. Use of unrealistic benchmarks may only result in 
disengagement of clinicians with the quality improvement process and contribute to 
gaming of data (and no change in actual performance or outcome).   
 
An acknowledged limitation of the study is the relatively small number of 
cardiologists involved. For this reason, these findings cannot be immediately 
generalized to the broader community based on the outcomes of this study alone. The 
findings, however, are of sufficient importance to suggest that a more detailed 
analysis of the role of benchmarks in optimising quality improvement is warranted.  
 
11.6   Conclusion 
 
Assuming the goal of benchmarking and performance feedback is to deliver overall 
clinical outcomes improvement, quality monitoring and improvement processes may 
need to incorporate a system with two process targets. The first target would assist in 
the identification of service providers suspected of delivering less than satisfactory 
performance. An example of this target is the 75th percentile reference level used by 
the NRPB and ARPANSA. Based on goal setting theory, the second target would 
define an aspirational level of performance which would serve to challenge service 
providers to strive for excellence. Given the degree of variation in baseline 
performance observed, individual aspirational level benchmarks might need to be 
considered. If structured correctly, use of a dual target system would act across the 
entire continuum of service provider performance to drive overall quality 
improvement.  
 
Chapter 11:  Impact of Benchmark Selection on Driving Change 287 
 
Funding  
 
This work was supported by a Research Industry Partnership Program (RIPP) grant 
through the Queensland Government Smart State Initiative [grant number IPF206]. 
 
 
Chapter 11:  Impact of Benchmark Selection on Driving Change 288 
 
Bibliography 
Adair, J. G. (1984). "The Hawthorne Effect - A Reconsideration of the 
Methodological Artifact." Journal of Applied Psychology 69(2): 334-345. 
American College of Radiology (1999). ACR standard for diagnostic medical physics 
performance monitoring of radiolgraphic and fluoroscopic equipment. 
Standards. Reston, VA, American College of Radiology: 167-169. 
ARPANSA. "National Diagnostic Reference Level Fact Sheet."   Retrieved 10th 
December 2011, from http://www.arpansa.gov.au/ 
Australian Government (2008). RPS 14.1 - Safety Guide for Radiation Protection in 
Diagnostic and Interventional Radiology (2008). D. o. H. a. Ageing, 
Australian Government. 
Bashore, T. M., Bates, E. R., Berger, P. B., Clark, D. A., Cusma, J. T., Dehmer, G. J., 
Kern, M. J., Laskey, W. K., O'Laughlin, M. P., Oesterle, S., et al. (2001). 
"American College of Cardiology/Society for Cardiac Angiography and 
Interventions Clinical Expert Consensus Document on cardiac catheterization 
laboratory standards. A report of the American College of Cardiology Task 
Force on Clinical Expert Consensus Documents." J Am Coll Cardiol 37(8): 
2170-2214. 
Beck, C. A., Richard, H., Tu, J. V. and Pilote, L. (2005). "Administrative Data 
Feedback for Effective Cardiac Treatment: AFFECT, a cluster randomized 
trial." JAMA 294(3): 309-317. 
Crowder, S. (1989). "Design of Exponentially Weighted Moving Average Schemes." 
Journal of Quality Technology 21(3): 155-155. 
Davies, R. R., Kaple, R. K., Mandapati, D., Gallo, A., Botta, D. M., Jr., Elefteriades, 
J. A. and Coady, M. A. (2007). "Natural history of ascending aortic aneurysms 
in the setting of an unreplaced bicuspid aortic valve." Ann Thorac Surg 83(4): 
1338-1344. 
Einstein, A. J., Weiner, S. D., Bernheim, A., Kulon, M., Bokhari, S., Johnson, L. L., 
Moses, J. W. and Balter, S. (2010) "Multiple Testing, Cumulative Radiation 
Dose, and Clinical Indications in Patients Undergoing Myocardial Perfusion 
Chapter 11:  Impact of Benchmark Selection on Driving Change 289 
 
Imaging." Jama-Journal of the American Medical Association 304(19): 2137-
2144. 
Fremantle, N., Harvey, E. L., Wolf, F. and et al. (2003). Printed educational materials: 
effects on professional practice and health care outcomes (Cochrane Review). 
The Cochrane Library. Oxford, Update Software. 
Gardner, B., Whittington, C., McAteer, J., Eccles, M. P. and Michie, S. (2010). 
"Using theory to synthesise evidence from behaviour change interventions: the 
example of audit and feedback." Soc Sci Med 70(10): 1618-1625. 
Gerber, T. C., Carr, J. J., Arai, A. E., Dixon, R. L., Ferrari, V. A., Gomes, A. S., 
Heller, G. V., McCollough, C. H., McNitt-Gray, M. F., Mettler, F. A., et al. 
(2009). "Ionizing radiation in cardiac imaging: a science advisory from the 
American Heart Association Committee on Cardiac Imaging of the Council on 
Clinical Cardiology and Committee on Cardiovascular Imaging and 
Intervention of the Council on Cardiovascular Radiology and Intervention." 
Circulation 119(7): 1056-1065. 
Grimshaw, J. M., Shirran, L., Thomas, R., Mowatt, G., Fraser, C., Bero, L., Grilli, R., 
Harvey, E., Oxman, A. and O'Brien, M. A. (2001). "Changing provider 
behavior: an overview of systematic reviews of interventions." Med Care 39(8 
Suppl 2): II2-45. 
Hardcastle, R. A. (1997). "CUSUM: a credible method for the determination of 
authorship?" Sci Justice 37(2): 129-138. 
Hart, D., Hillier, M. C. and Wall, B. F. (2009). "National reference doses for common 
radiographic, fluoroscopic and dental X-ray examinations in the UK." Br J 
Radiol 82(973): 1-12. 
Hillock, R. J., Smyth, D. W. and Elliott, J. M. (2006). "Proficiency in coronary 
angiography: local experience and college requirements." Heart Lung Circ 
15(3): 163-167. 
Hirshfeld, J. W., Jr., Balter, S., Brinker, J. A., Kern, M. J., Klein, L. W., Lindsay, B. 
D., Tommaso, C. L., Tracy, C. M., Wagner, L. K., Creager, M. A., et al. 
(2005). "ACCF/AHA/HRS/SCAI clinical competence statement on physician 
knowledge to optimize patient safety and image quality in fluoroscopically 
guided invasive cardiovascular procedures: a report of the American College 
Chapter 11:  Impact of Benchmark Selection on Driving Change 290 
 
of Cardiology Foundation/American Heart Association/American College of 
Physicians Task Force on Clinical Competence and Training." Circulation 
111(4): 511-532. 
Jamtvedt, G., Young, J. M., Kristoffersen, D. T., O'Brien, M. A. and Oxman, A. D. 
(2006). "Does telling people what they have been doing change what they do? 
A systematic review of the effects of audit and feedback." Qual Saf Health 
Care 15(6): 433-436. 
Locke, E. A. and Latham, G. P. (2002). "Building a practically useful theory of goal 
setting and task motivation. A 35-year odyssey." Am Psychol 57(9): 705-717. 
Montgomery, D. C. (2008). Introduction to statistical quality control. Hoboken, NJ, 
Wiley. 
Mugford, M., Banfield, P. and O'Hanlon, M. (1991). "Effects of feedback of 
information on clinical practice: a review." BMJ 303(6799): 398-402. 
Perkins, M. B., Jensen, P. S., Jaccard, J., Gollwitzer, P., Oettingen, G., Pappadopulos, 
E. and Hoagwood, K. E. (2007). "Applying theory-driven approaches to 
understanding and modifying clinicians' behavior: what do we know?" 
Psychiatr Serv 58(3): 342-348. 
Perkins, M. B., Jensen, P. S., Jaccard, J., Gollwitzer, P., Oettingen, G., Pappadopulos, 
E. and Hoagwood, K. E. (2007). "Applying Theory-Driven Approaches to 
Understanding and Modifying Clinicians' Behavior: What Do We Know?" 
Psychiatric Services 58(3): 342-348. 
Queensland Government. (9th July 2008). "Radiation Health - Legislation, standards 
and policies."   Retrieved 10th April 2009, 2009, from 
http://www.health.qld.gov.au/radiationhealth/legislation/default.asp. 
Ryan, C. and Horrigan, L. (2011). Factors influencing clinical decision making and 
attitudes to radiation exposure for cardiologists. Unpublished Research. 
Brisbane, Australia: St Andrew’s Medical Institute, sami@institute.org.au. 
Sakia, R. M. (1992). "The Box-Cox Transformation Technique: A Review." Journal 
of the Royal Statistical Society. Series D (The Statistician) 41(2): 169-178. 
Smith, I. R., Foster, K. A., Brighouse, R. D., Cameron, J. and Rivers, J. T. (2011) 
"The role of quantitative feedback in coronary angiography radiation 
reduction." Int J Qual Health Care 23(3): 342-348. 
  
 
CHAPTER 12 
 
 
Optimising Clinical Practice  
 
Preamble 
 
In Chapters 10 and 11 we explained observed changes in clinician behavior when 
provided with quantitative performance feedback in terms of the Theory of Planned 
Behavior and Goal Setting Theory (GST). The example used in both cases involved 
evaluation of the provision of benchmarked feedback as a means of influencing 
clinicians to reduce their use of radiation in performing diagnostic coronary 
angiography. Although both studies had radiation use reduction as their clinical 
objective, at no stage in either study were clinicians specifically directed on how this 
reduction was to be achieved. Although general strategies dealing with radiation risk 
reduction were provided to the clinicians as part of their annual feedback, both studies 
left decisions on how they changed their clinical practice to achieve radiation use 
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reduction to the creativity of the individuals concerned. It is evident from the data 
presented in the previous chapters that there is substantial variation in radiation use 
amongst the clinicians evaluated, and although there has been an overall trend to 
lower radiation use in response to the provision of feedback considerable variation has 
remained. 
 
Diagnostic coronary angiography is a complex operator directed imaging procedure 
performed in order to assess the patency of the cardiac arteries. In conducting the 
procedure, the cardiologist injects a radio opaque dye into a patient’s coronary arteries 
and records the resultant patterns of flow in the various vessels. As imaging involves 
the use of ionizing radiation, every effort is taken to ensure the radiation related risks 
to both clinical personal and patient are minimized.  
 
A factor contributing to the complexity of DCA is the manner in which the coronary 
vessels wrap around the outside of the heart in a complex but essentially common 
pattern. The process of building up a diagnostic assessment of the coronary anatomy, 
therefore, requires that the cardiologist image the patient from a number of directions 
in order to adequately assess each individual artery segment (imaging each segment in 
profile without overlap). Although previous studies have separately looked at what 
projections are required to perform a comprehensive assessment of the coronary 
arteries and the radiation risks associated with the commonly used projections, to date 
no study has looked at how the imaging process should be achieved so as to optimally 
balance the acquisition of clinical information against the cost to the patient (and 
personnel) in terms of radiation exposure. 
 
The objective of the study described in this chapter is to develop a sequence of 
projections that can be used by cardiologists to optimally perform a coronary 
angiogram while minimizing the risks to both the patient and themselves.   
The focus of this chapter is on the third objective of the thesis as it deals with the use of 
quantitative analysis to influence changes in clinical outcomes and clinician performance 
This chapter contributes primarily to application.  
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This chapter has been written as a journal article for which I am first author. It is 
reprinted here in its entirety. I was responsible for the conception and conduct 
research, design and implementation of the cost benefit algorithm, undertook 
statistical analysis, drafted the manuscript and modified the manuscript as suggested 
by co-authors and reviewers. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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12.1   Abstract 
 
Radiation safety principles dictate that imaging procedures should minimise the 
radiation risks involved without compromising diagnostic performance. This study 
defines a core set of views that maximises clinical information yield for minimum 
radiation risk. Angiographers would supplement these views as clinically indicated.  
 
An algorithm was developed to combine published data detailing the quality of 
information derived for the major coronary artery segments through use of a 
common set views in angiography with data relating to the dose area product and 
scatter radiation associated with these views.  
 
The optimum view set for the left coronary system comprised 4 views (Left Anterior 
Oblique (LAO) with cranial (Cr) tilt, shallow Right Anterior Oblique (AP-RAO) 
with caudal (Ca) tilt, RAO with Ca tilt and AP-RAO with Cr tilt) while for the right 
coronary system 3 views were identified (LAO with Cr tilt, RAO and AP-RAO with 
Cr tilt). An alternative left coronary view set including a left lateral achieved 
minimally superior efficiency (<5%) but at ~ 8% higher radiation dose to the patient 
and 40% higher cardiologist dose.  
 
This algorithm identifies a core set of angiographic views that optimises the 
information yield and minimises radiation risk. This basic data set would be 
supplemented by additional clinically determined views selected by the angiographer 
for each case. The decision to use additional views for diagnostic angiography and 
interventions would be assisted by referencing a table of relative radiation doses for 
the views being considered. 
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12.2   Introduction 
 
In 1977 the International Commission on Radiological Protection (ICRP) put 
forward three basic guiding principles aimed at minimising the detrimental impact 
radiation has on society (International Commission on Radiological Protection 
1977). Since that time these principles of justification, optimisation and limitation 
have been developed into the foundation of most state, national and international 
legislation dealing with radiation protection.  
 
In the medical context, the principle of optimisation requires that all exposures to 
patients (and staff) arising from imaging procedures be kept as low as reasonably 
achievable (ALARA). This objective is particularly important in cardiac imaging as 
although the absolute radiation dose from an individual coronary angiography 
procedure might be relatively low, patients with cardiac disease often undergo 
multiple imaging procedures which can lead to substantial cumulative exposures 
(Bedetti, Botto et al. 2008).   
 
Due to the potential for high cumulative radiation doses, strategies that minimise the 
radiation contribution at each point in the imaging journey should be pursued 
(Einstein, Moser et al. 2007; Chen, Einstein et al. 2010). For complex operator 
directed imaging procedures such as diagnostic coronary angiography (DCA) and 
interventions, this approach involves close examination of not only the technology 
related aspects of the procedure (namely the imaging system and its set-up) but also 
how the equipment is used to achieve the clinical objective.  
 
Numerous papers have been written reviewing the radiation exposures delivered to 
individuals undergoing cardiac imaging procedures and those involved in the 
conduct of these procedures (Betsou, Efstathopoulos et al. 1998; Harrison, 
Ricciardello et al. 1998; Wilde, Pitcher et al. 2001; Efstathopoulos, Karvouni et al. 
Chapter 12:  Optimising Clinical Practice 297 
 
2004; Paisley, Eatough et al. 2004). What is immediately apparent in reviewing this 
literature is that there is tremendous variation in clinical practice, technology and 
technique with a consequence that the results reported by the various authors 
regarding the radiation risks for these procedures vary substantially. Information 
presented by Mettler et al. (Mettler, Huda et al. 2008) for example, shows that DCA 
is associated with an average radiation exposure of 7mSv (with doses ranging from 
2mSv to 15.8mSv being reported) while Kim and Miller (Kim and Miller 2009) 
suggests that the average dose to cardiologists performing DCA is of the order of 
5µSv per case (but might vary by as much as three orders of magnitude for the same 
type of procedure).  
 
The level of exposure received by patients undergoing DCA procedures is 
substantially greater than that reported by Mettler et al. (Mettler, Huda et al. 2008) 
for patients undergoing common medical imaging procedures such as an X-ray of the 
chest (0.02mSv), abdomen (0.7mSv) and thoracic spine (1mSv). Only patients 
undergoing complex fluoroscopy (up to 70mSv) and computer tomography (up to 
15mSv) procedures receive doses rivalling DCA.  
 
Partridge and Slaughter published work in 1986 that analysed the information 
gathering process in DCA and proposed a standard set of projections (supplemented 
by extra views at the discretion of the experienced operator) for the efficient 
collection of diagnostic information in cardiac angiography. This evaluation was 
largely based on deriving clinical information and did not balance the clinical 
information yield with the radiation consequence of the selection of projections. 
Papers, such as those by Kuon et al. (Kuon, Dahm et al. 2004) has shown that 
significant dose reduction can be achieved in situations where multiple view options 
exist by selecting the view with the lowest per unit exposure.  
 
The purpose of this study is to use information from the available literature on 
clinical information yield for various angiographic projections and merge this with 
data relating to the radiation consequence of these views to derive a core set of 
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projections that simultaneously optimises clinical information yield for minimum 
radiation risk. This analysis will encompass both consideration of the radiation risk 
to the patient as will as the cardiologist arising from a DCA. 
 
12.3   Methods 
 
An algorithm was developed to provide an efficiency score for a combination of 
radiographic views by integrating published data detailing the clinical image quality 
of information derived for the major coronary artery segments through use of the 
common views in angiography with data relating to the dose area product (DAP), 
scatter radiation and effective dose (E) for these views. Abbreviations and acronyms 
used in the tables, figures and text of this paper are summarised in Table 12.1. 
 
Table 12.1: Table of abbreviations and acronyms. 
 
Term Acronym 
Coronary Arteries  
 Left Anterior Descending LAD 
 Left Circumflex LCX 
 Left Main LM 
 Obtuse Marginal OM 
 Posterior Descending Artery PDA 
 Posterior Left Ventricular PLV 
 Right Coronary Artery RCA 
Projections  
 Antero-Posterior AP 
 Caudal Ca 
 Cranial Cr 
 Left Anterior Oblique LAO 
 Left Lateral LL 
 Right Anterior Oblique RAO 
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12.3.1 Image Quality Information:  
The information quality yield for each segment delivered by each projection is taken 
from the work by Di Mario and Sutaria (Di Mario and Sutaria 2005) and is shown in 
Table 12.2. As this paper deals with the selection of a set of views for standard 
coronary angiography, analysis involving coronary artery bypass graft studies has 
not been included. The only enhancement to this data involves the inclusion of a 
segment weighting score (wj) that reflects the relative importance of achieving a 
diagnostic outcome for that segment. Values for wj of 1.5 were allocated to high 
priority segments while the remaining segments were each assigned a value of 1.  
 
12.3.2 Radiation Data:  
Radiation data reflecting the Time-Adjusted Radiation Exposure (DAP Rate in 
mGy.cm2.s-1) and Mean Operator Radiation Exposure (Scatter Rate in µSv.h-1) has 
been derived from the work by Kuon et al. (Kuon, Dahm et al. 2004). Use of this 
information allows the DAP and scatter dose to the clinician for each view to be 
estimated for each projection in Table 12.2 using interpolation (these data are for 
uncollimated use of the imaging system). The E contribution for each projection is 
then derived by using conversion factors estimated from the data provided in the 
work of Stern et al. (Stern, Rosenstein et al. 1995). Rather than use the Stern tables 
to derive absolute conversion factors relating DAP to E, for the purposes of the 
evaluation conducted in this study it was sufficient to derive a relative weighting 
factor. As a relative conversion factor is used, the resultant effective dose rate 
estimate does not have the SI unit of Sieverts and instead the term Units is used. 
Table 12.3 details the relative DAP, E and scatter dose contributions from each 
projection. For ease of calculation and as relative dose contributions are sufficient, 
the scatter and E factors for each projection used in the calculation have been 
normalised to the lowest value (referred to in Table 12.3 as the Normalised E or 
Scatter Rates).  
Chapter 12:  Optimising Clinical Practice 300 
 
 
Table 12.2: Image quality scores for each coronary anatomical segments by projection. 
These data are drawn from the work of Di Mario and Sutaria (Di Mario and Sutaria 2005). 
The system used by Di Mario and Sutaria translates to the classification of a view that is not 
recommended as 0, occasionally useful as 1, very useful as 2 and the ideal view is rated as 
3.  
 
  Projection 
Angulation 
Pr
io
rit
y 
LA
O
/C
a 
A
P-
R
A
O
/C
a 
R
A
O
/C
a 
A
P-
R
A
O
/C
r 
LA
O
/C
r 
LL
 
LA
O
 
R
A
O
 
LAO(+)/RAO(-)  45 -15 -37 -15 37 90 50 -37 
Cr (+)/Ca (-)  -30 -30 -35 40 30 0 0 0 
Segment  
LM ostium 1.5 2 1 1 3 3 0 0 0 
LM bifurcation 1.5 3 3 2 0 0 0 0 0 
LAD proximal 1.5 2 2 3 2 2 1 0 0 
LAD mid 1 0 1 1 3 2 2 0 0 
LAD distal 1 1 1 3 1 0 3 0 2 
LAD/diagonal  1 2 1 0 2 3 0 0 0 
LCX proximal 1 1 3 3 0 0 0 0 0 
LCX distal 1 1 1 2 3 2 1 2 0 
OM bifurcation 1 2 3 2 0 0 0 1 0 
RCA proximal 1.5 0 0 0 1 3 0 2 0 
RCA mid 1 0 0 0 0 1 3 2 3 
RCA distal/crux 1 0 0 0 3 3 0 2 0 
PDA 1 0 0 0 3 2 0 1 2 
PLV 1 1 0 0 3 2 1 1 0 
 
For the purpose of this study, it has been assumed that the time spent delivering 
radiation during the fluoroscopy and fluorography components of the study are 
equally divided between each projection. Although this may not be strictly valid for 
fluoroscopy, it has been shown that this component of a study accounts for less than 
15% of the total radiation dose delivered in a DCA (Smith and Rivers 2008) and as 
such variations from the assumption will make little difference to the overall 
analysis. The use of normalised dose rates in both the analysis of patient dose and 
clinician scatter dose also aids to generalise the analysis as it removes dependence of 
the results on actual dose rates and hence imaging platform set-up and mode of 
operation of the equipment (assuming different imaging systems respond in similar 
manners to changes in radiographic load). 
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Table 12.3: Radiation weighting factors by projection. Data for the Time-Adjusted 
Radiation Exposure (DAP Rate in mGy.cm2.s-1) and Mean Operator Radiation Exposure 
(Scatter Rate in µSv.h-1) has been derived from the work of Kuon et al. (Kuon, Dahm et al. 
2004) using linear interpolation. Data for the relative weights converting DAP Rate to E 
(Units) has been derived from the work of Stern et al. (Stern, Rosenstein et al. 1995). 
 
 Projection 
Radiation Factor 
LA
O
/C
a 
A
P-
R
A
O
/C
A
 
R
A
O
/C
a 
A
P-
R
A
O
/C
r 
LA
O
/C
r 
LL
 
LA
O
 
R
A
O
 
DAP Rate (mGy.cm2.s-1) 46.5 20.0 44.8 45.5 60.7 28.0 30.0 15.1 
Relative E Weight/DAP 2.0 2.1 2.1 1.5 1.7 0.9 2.2 2.1 
E (Units) 93.0 42.0 94.0 68.3 103 25.2 66.0 31.7 
Normalised E Rate 3.69 1.67 3.73 2.71 4.09 1.00 2.62 1.26 
Scatter Rate (µSv.h-1) 680 160 306 440 671 630 600 94 
Normalised Scatter Rate 7.23 1.70 3.26 4.68 7.14 6.70 6.38 1.00 
 
 
12.3.3 Algorithm Description. 
1. For each coronary segment the mean dose adjusted quality score (Vj) is 
calculated by averaging the ratio of the information quality score (qij) divided 
by the radiation exposure for each projection (Ri). This is used as a quality 
‘benchmark’ for that segment in each subsequent projection combination 
evaluated.  
2. For each projection combination, the total dose adjusted quality score 
normalized using the quality ‘benchmark’ for each segment (Vj), across all 
included views is calculated 
3. The total ‘efficiency’ score for each projection combination (Qset) is then 
adjusted using a weighting factor based on the proportion of contributing 
segments with the maximum quality score. 
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The resultant algorithm can be expressed as: 
  
∑∑
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1  (1) 
 
Where:  N is the total number of views considered in the algorithm 
 Ri is the radiation exposure (in terms of DAP) from view i,  
 qij is the information quality score of information on segment j from view i,  
 wj is the relative importance of segment j,  
 nseg is the number of segments being evaluated,  
 nmax is the number of segments recording a maximum quality factor, and  
 nv is the number of views involved. 
 
The algorithm was designed to derive an overall quality score for a set of projections 
(Qset) by summing together the quality weighted radiation scores for each vessel 
segment. The individual quality scores for each vessel segment is derived by 
dividing the quality score provided by a particular view (qij/Ri) by the average 
quality weighted radiation score provided for all views of that segment (Vj). This 
aspect of the algorithm delivers scores greater than one for a particular view of a 
segment that delivers a quality score greater than the average quality score of all 
views for a segment while a score of less than one results when the view ‘performs’ 
more poorly than the average. The addition of the weighting factor nmax/nv enhances 
the algorithms bias towards ensuring that a view set that achieves ideal visualisation 
in all relevant segments is identified. In addition, view combinations were eliminated 
entirely if any individual coronary segment failed to achieve a score greater than 0. 
 
To test the validity of the algorithm in combining measures of radiation (ratio scale) 
and quality (ordinal scale), a sensitivity analysis was performed to assess the impact 
on view selection that would result through the application of different weighting 
mechanisms for the qij values (one using the square, the other using the square root 
of qij).   
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12.4   Results 
 
The overall effect of the proposed algorithm is to bias the Q score to delivering the 
optimum compromise between the number of views used, the quality of information 
derived using those views and the radiation dose delivered in obtaining this 
information. All possible view combinations for the left and right coronary systems 
were evaluated separately and the Q score for each view set was plotted against 
radiation dose measures for visual interpretation. Graphs relating to the evaluation of 
patient E and scatter dose to the cardiologist for the left and right coronary systems 
are shown in Figures 12.1(a & b) and 12.2(a & b) respectively. Table 12.4 provides 
the top five ranked view set combinations in order of decreasing efficiency (Q Score) 
for both patient E and scatter dose to the cardiologist for imaging of the left and right 
coronary systems. In addition to the Q Score for each combination of views, this 
table includes an index of the total dose (patient E and scatter) as well as the number 
of segments visualised with an ‘ideal’ rating (out of 8 for the left and 5 for the right).  
 
Analysis of the optimum view combinations for imaging of the two coronary 
systems for both E and Scatter reveals that when scatter to the operator and E are 
separately considered slightly different view combinations are identified in each 
system. When patient E is considered, the optimum view set identified by the 
algorithm for the left coronary system comprised 5 views (Left Lateral (LL), Left 
Anterior Oblique (LAO) with cranial (Cr) tilt, shallow Right Anterior Oblique (AP-
RAO) with caudal (Ca) tilt, RAO with Ca tilt and AP-RAO with Cr tilt). The set of 
views ranked second in this analysis comprised 4 views, omitting the LAO with Cr. 
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Figure 12.1: Graphs of Q Score against E Score (a measure related to effective dose) for the 
Left and Right coronary systems. Highlighted is the view set recommended as being optimal 
for imaging of the Left and Right coronary systems (corresponds respectively to the ‘*’ and 
‘+’ sets in Table 12.4). 
 
 
Figure 12.2: Graphs of Q Score against Scatter Score (a measure related to operator scatter 
dose) for the Left and Right coronary systems. Highlighted is the view set recommended as 
being optimal for imaging of the Left and Right coronary systems (corresponds respectively 
to the ‘*’ and ‘+’ sets in Table 12.4). 
 
Closer inspection of these two view sets shows that the higher ranked set achieves 
ideal ratings for all 8 vessel segments while the second ranked set achieves only 7 
ideal ratings (visualisation of the LAD diagonal being rated as very useful). When 
operator scatter dose is considered, the optimum set of views comprises only 3 
views, omitting the LL view from the set of views ranked second in the patient E 
analysis. The set of views ranked second in the scatter analysis, is similar to the view 
set ranked first in the patient E analysis, with omission of the LL. This view set 
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ranks third in the patient E analysis. In reviewing the results of the scatter and E 
analysis simultaneously, the set of combining an LAO/Cr, shallow RAO/Cr, 
RAO/Ca and shallow RAO/Ca ranks 3rd on the list for E (5% less efficient and 8% 
less dose when compared to the set ranked 1st) and 2nd on the list for scatter dose (5% 
less efficient but 40% more dose when compared to the set ranked 1st).  
 
Applying a similar review of the projections sets for the right coronary system 
identified a 3 view set the LAO with Cr tilt, RAO and AP-RAO with Cr tilt as being 
the optimum combination when scatter to the operator is balanced with clinical 
information yield. However, when clinical information yield is traded against patient 
dose a 4 view set, comprising the same 3 views found in the scatter set with a LL 
projection, is identified. This set of views ranks 3rd when scatter dose is considered 
(20% less efficient at 50% higher scatter dose) while the optimum scatter biased 
view ranks 4th when E to the patient is considered (3% less efficient at 11% lower E).     
 
When the impact of alternative weighting mechanisms for the qij scores was assessed 
it resulted in negligible change in the evaluation of left and right system views. For 
scatter dose to the clinicians, this aspect of the analysis demonstrated no meaningful 
change to the ranking of the sets of views. For E to the patient, however, when 
greater emphasis was placed on the quality of information (through squaring the q 
scores), the view combinations we have recommended for imaging both the left and 
right systems moved up the rankings (from 3 to 2 for the left and 4 to 2 for the right). 
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Table 12.4: Table summarising the top 5 ranked view set combinations in order of 
decreasing efficiency (Q Score) for patient effective dose and cardiologist scatter dose for 
imaging of the left and right coronary systems. The number in brackets after the rank 
shows the ranking of that view set in the list for the alternative radiation measure. Vmax 
represents the number of segments visualised with at least one view rated as ideal (out of 8 
for the Left and 5 for the Right). The core set of views recommended for the Left coronary 
system is identified with a ‘*’.the core set of views recommended for the Right coronary 
system is identified with a ‘+’. 
Factor  
(System) Rank 
Q 
Score 
Dose 
Score Vmax Projection Combination 
Effective Dose: 
(Left) 1 (7) 6.31 13.20 8 
LL, LAO/Cr, AP-RAO/Cr, 
RAO/Ca, AP-RAO/Ca 
 2 (8) 6.13 9.10 7 
LL, AP-RAO/Cr, RAO/Ca, AP-
RAO/Ca 
 3 (2)
* 6.02 12.20 8 LAO/Cr, AP-RAO/Cr, RAO/Ca, AP-RAO/Ca 
 4 (1) 5.98 8.10 7 
AP-RAO/Cr, RAO/Ca, AP-
RAO/Ca 
 5 (13) 5.96 16.89 8 
LL, LAO/Cr, AP-RAO/Cr, 
RAO/Ca, AP-RAO/Ca, LAO/Ca 
(Right) 1 (3) 2.33 9.06 5 LL, LAO/Cr, AP-RAO/Cr, RAO 
 2 (8) 2.29 11.68 5 
LL, LAO/Cr, LAO, AP-RAO/Cr, 
RAO 
 3 (36) 2.28 7.80 5 LL, LAO/Cr, AP-RAO/Cr 
 4 (1)+ 2.27 8.06 5 LAO/Cr, AP-RAO/Cr, RAO 
 5 (40) 2.24 10.42 5 LL, LAO, LAO/Cr, AP-RAO/Cr 
Scatter Dose: 
(Left) 1 (4) 5.38 9.64 7 
AP-RAO/Cr, RAO/Ca, AP-
RAO/Ca 
 2 (3)
* 5.12 16.78 8 LAO/Cr, AP-RAO/Cr, RAO/Ca, AP-RAO/Ca 
 3 (8) 4.52 24.02 7 
LAO/Cr, AP-RAO/Cr, RAO/Ca, 
AP-RAO/Ca, LAO/Ca 
 4 (12) 4.50 16.88 8 
AP-RAO/Cr, RAO/Ca, AP-
RAO/Ca, LAO/Ca 
 5 (19) 4.50 17.78 7 
LAO/Cr, AP-RAO/Cr, RAO/Ca, 
AP-RAO/Ca 
(Right) 1 (4)+ 1.87 12.82 5 LAO/Cr, AP-RAO/Cr, RAO 
 2 (6) 1.63 19.20 5 LAO/Cr, LAO, AP-RAO/Cr, RAO 
 3 (1) 1.50 19.52 5 LL, LAO/Cr, AP-RAO/Cr, RAO 
 4 (13) 1.44 12.06 5 LAO, AP-RAO/Cr, RAO 
 5 (23) 1.43 20.05 5 
LAO/Cr, LAO/Ca, AP-RAO/Cr, 
RAO 
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12.5   Discussion 
 
Application of the ALARA principle to DCA procedures requires the striking of a 
balance between the competing needs of effectively obtaining accurate and reliable 
information about coronary anatomy and disease state and low radiation risk to the 
patient. Due to the operator directed nature of cardiac angiography, this goal is 
achieved by ensuring the technical performance of the imaging platform is 
appropriate for the purpose (image quality is appropriate for the clinical needs) and 
through optimisation of the clinical information gathering process. This also 
highlights an added complexity of this type of procedure where the radiation risk is 
not solely incurred by the patient but, in part, is shared (through scattered radiation) 
by those directly involved in the conduct of the procedure. 
 
As a feature of the analysis performed is to heavily bias in favour of projection 
combinations that provide sound visualisation of each major vessel segment of the 
left and right coronary systems, comparison of the top ranked views in each category 
largely comes down to a comparison of the radiation dose weighted efficiency of 
each combination and the radiation dose concerned (scatter dose to the clinician and 
E to the patient). In undertaking this analysis, it has been assumed that although 
more than one view is usually required to perform quantification on a stenosis, in 
many instances only one view is required to determine whether a stenosis is 
clinically significant (Partridge and Slaughter 1986). Additional review of each set of 
views will therefore focus on the ability of the combination to provide identification 
of disease only in all major vessel segments. 
 
Analysis of projection combinations for imaging the right coronary system depicted 
in the graphs of Figures 12.1(b) & 2(b) comes down to a choice between performing 
the procedure at minimum scatter dose to the operator or minimum E to the patient. 
Of the two view sets ranked highest for these two measures, the resulting analysis 
shows that the optimum scatter biased combination (which includes the LAO/Cr, 
RAO and AP-RAO/Cr projections) ranks 4th on the Q ordered list of E biased 
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projections. However, when the scatter biased list is reviewed the optimum E 
projection set (comprising the same 3 views and a LL) ranks 3rd, delivering in excess 
of 50% more scatter radiation to the operator. It is this factor, coupled with 
knowledge that both sets of views provide ideal visualisation of each of the 5 vessel 
segments evaluated, that sways recommendation of the scatter biased projection set 
(comprising LAO/Cr, RAO and AP-RAO/Cr projections). 
 
Similar, analysis of the left coronary system projection combination selection 
depicted in Figures 12.1(a) & 12.2(a) also compels a choice between minimising 
scatter dose to the operator and minimising E to the patient. If E is used as the 
radiation measure, optimum information efficiency yield is achieved through the use 
of five views; LAO/Cr, LL, AP-RAO/Ca, RAO/Ca and AP-RAO/Cr. When scatter 
dose to the cardiologist is considered, the projection combination identified 
comprises only three views, omitting the LL and LAO/Cr from the views identified 
for E. Review of the data for the E projection combination analysis reveals that the 
scatter biased combination is ranked fourth, having only marginally lower efficiency 
(5.98 units vs. 6.31 units) but with markedly lower E (~40% less due to the omission 
of the 2 views). By comparison, the five view combination identified when E is 
considered, ranks seventh in the table of scatter biased combinations (an efficiency 
score of 4.32 vs. 5.38), delivering some 2.4 times more scatter (23.48 units vs. 9.64 
units). An issue for the three view set, however, is that it achieves ideal ratings in 
only 7 of 8 vessel segments (the LAD diagonal being rated only as very useful). In 
reviewing the results of the scatter and E analysis simultaneously, the set of views 
appearing to offer the best compromise between patient dose, scatter dose to the 
operator and information yield is one that combines an LAO/Cr, shallow RAO/Cr, 
RAO/Ca and shallow RAO/Ca. This achieves ideal ratings in all 8 vessel segments, 
ranking third on the list for E (5% less efficient and 8% less dose when compared to 
the set ranked first) and second on the list for scatter dose (5% less efficient but at 
40% more dose when compared to the set ranked first due to inclusion of the 
LAO/Cr). 
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In both cases the overall bias against sets of projections that include a LL view, as 
well as other views where the detector is on the left side of the patient, should not be 
a surprise. Although the LL projection provides clear visualisation of coronary 
segments such as the distal LAD and mid RCA, the substantial scatter dose ‘penalty’ 
of this view and other views with the detector on the patient’s left, weighs heavily 
against any projection set in which they are included. This finding is supported in the 
literature where warnings concerning the operator scatter dose from steep LAO and 
LL projections are common (Vano 2003; Kuon, Dahm et al. 2004). Although not 
considered in the datasets employed in this study, consideration could be given to 
inclusion of a right lateral (RL) projection in place of the LL. Reference to the 
radiation data of Kuon et al. (Kuon, Dahm et al. 2004) suggests that the scatter 
radiation ‘cost’ to the operator of the RL projection is approximately 30% of the LL 
(190µSv.hr-1 vs. 630µSv.hr-1) although the DAP is marginally higher (~ 10%).    
 
Comparison of the views identified in this analysis with those suggested by Partridge 
and Slaughter (Left: LAO/Cr, LAO/Ca, LAO, LL, RAO and RAO/Ca, Right: 
LAO/Cr, LAO, LL and RAO/Ca)) shows considerable difference. Acknowledging 
that the exact views recommended by Partridge and Slaughter vary in their 
angulations when compared to the views we have used, their projection sets appear 
quite well down on the evaluation lists based on the Q scores for patient E and 
scatter dose (ranked >100 in each evaluation). This can be attributed to a 
combination of the number of views they have suggested for the left (6 vs. 4) and 
right (4 vs. 3) systems and the side of the patient on which the imaging system is 
positioned for these views. As previously identified, the set of views we propose are 
comprised largely of projections where the detector is on the patient’s right side. 
This effectively minimises scatter dose to the clinician. This contrasts with the 
Partridge and Slaughter sets where 4 of 6 views used for the left system and 3 of 4 
views for the right system are on the patient’s left.  
 
Although not explicitly evaluated in this study, if it is assumed that a similar volume 
of contrast-media is used in the acquisition of data for each projection, strategies that 
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lead to a reduction in the number of views taken can also be expected to have a 
proportional impact on the total volume of contrast-media used in a study. Use of an 
optimised projection set for cardiac angiography could therefore be expected to have 
a flow on beneficial effect in terms of minimising the risk of contrast-medium 
induced nephropathy (CIN), particularly in high risk patient groups. It must be 
emphasised however, that total contrast-media volume is only one of a number of 
factors (including hydration, diabetic status and renal dysfunction) that has been 
linked to the risk and severity of CIN (Gomes, Blaya et al. 2003). 
 
While the intent of this paper is to identify a core set of imaging projections for use 
by clinicians seeking to minimise radiation risk in diagnostic angiography it must be 
emphasised that controlling the number and orientation of views employed goes only 
part way to addressing the overall issue of risk minimisation. Radiation risk 
reduction in operator directed procedures such as cardiac angiography is achieved 
through a multifaceted approach that involves optimisation of equipment use and 
conduct of the case by the clinical team. For example, substantial dose reduction 
(both E and scatter) can be achieved by making active use of collimation and 
ensuring the fluoroscopy and fluorography frame rates as well as the detector 
entrance dose rates in these modes are as low as necessary for the clinical task 
(Kuon, Dorn et al. 2003; Kuon, Glaser et al. 2003). Furthermore, scatter dose to the 
cardiologist can be significantly reduced through use of appropriate personal 
protective equipment as well as table, floor and ceiling mounted operator shielding. 
  
After considering the combined constraints of optimum information yield at 
minimum risk to the patient and cardiologist it is recommended that the following 
views be included in the core imaging set: 
Right coronary system: LAO/Cr, RAO and AP-RAO/Cr 
Left coronary system: LAO/Cr, AP-RAO/Ca, RAO/Ca and AP-RAO/Cr 
In sequencing the views for the left coronary system, it is further recommended that 
the study commence with the LAO/Cr view followed by the AP-RAO/Ca as this will 
ensure efficient imaging of the LM ostium and bifurcation is completed before 
moving to the other segments.  
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Our method has been primarily directed at developing an algorithm for identify sets 
of views to efficiently detect disease in the major vessel segments of an average 
patient undergoing diagnostic coronary angiography. The view sets suggested will 
need to be supplemented by additional projections once the presence of disease is 
identified to facilitate planning an intervention. For example, the RAO/Cr view 
might provide more diagnostic information than an AP/Ca in a patient with LAD and 
LAD Diagonal disease. A left or right lateral might be useful in assessment of mid or 
distal LAD disease. A LAO/Ca might provide important information in assessment 
of ostial LAD or LCX disease. The additional views to be used, while guided by the 
anatomy, should be selected keeping in mind the radiation consequence of the 
various options (see Kuon et al. (Kuon, Dahm et al. 2004) for detailed exposure 
tables). 
 
 
12.6   Conclusion 
 
A core set of angiographic views has been identified that optimises the conflicting 
requirements of maximising diagnostic information yield and minimising both 
patient and operator radiation risk. The core view sets would be supplemented by 
additional clinically determined views selected by the angiographer for each case. 
The selection of additional views might be assisted by a relative radiation dose table 
(for example Table 12.3). This analysis highlights the operator radiation ‘penalty’ 
associated with the LL projection, ultimately recommending alternative angiographic 
view sets that achieve similar clinical performance without inclusion of this view.     
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CHAPTER 13 
 
 
Use of Graphical Statistical Process Control 
Tools to Monitor and Improve Outcomes in 
Cardiac Surgery  
 
Preamble 
 
Whilst the primary objective of this thesis has been the development and 
implementation of statistical methods to monitor and improve the outcome of patients 
undergoing interventional cardiology procedures, it is important to demonstrate that 
these tools and techniques have broader clinical applicability. This chapter serves to 
highlight how these same techniques can be adapted to other clinical areas. The 
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example described in this chapter concerns the development and implementation of a 
clinical outcomes monitoring program in cardiac surgery. To illustrate how this process 
is effective in informing clinical governance processes we focus on the development of 
a risk adjusted monitoring scheme for a clinical outcome indicator (COI) tracking the 
management of bleeding related issues post surgery. This is one of a suite of COIs that 
have been developed for cardiac surgery. For the purposes of monitoring, the event of 
interest was converted to a binary outcome based on whether the patient experienced 
excessive bleeding (requiring transfusion of more than 10 units of blood in the first 24 
hours post surgery) or was returned to theatre for bleeding or tamponade. The value of 
this indicator is that it is marker of haemostatic issues during surgery that might reflect 
surgical technique. 
 
This chapter describes the rational behind the selection of the COI, development of the 
risk adjustment model and design of the control charts. Discussion of the investigation 
of signal events associated with this COI clearly demonstrate how a structured 
investigation process can contribute to the identification of issues impacting on clinical 
outcome and how this information might then be used to provide an evidence base for 
decisions to modify clinical practice. 
The focus of this chapter is on the third objectives of the thesis as it demonstrates how the 
performance evaluation provided by sequential charts can be used to monitor clinical 
performance. The main contribution of this chapter is to knowledge adaptation and 
application, promoting methods drawn from the industrial domain and demonstrating 
their application to the clinical context. 
This chapter has been written as a journal article for which I am the principal author. 
It is reprinted here in its entirety. I was responsible for the conception of the paper, 
statistical analysis, writing manuscripts and addressing the reviewer's comments. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
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Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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13.1   Abstract 
 
Graphical Statistical Process Control (SPC) tools have been shown to promptly 
identify significant variations in clinical outcomes in a range of health care settings. 
We explored the application of these techniques to qualitatively inform the routine 
cardiac surgical morbidity and mortality (M&M) review process at a single site. 
 
Baseline clinical and procedural data relating to 4774 consecutive cardiac surgical 
procedures, performed between the 1st January 2003 and the 30th April 2011, were 
retrospectively evaluated. A range of appropriate performance measures and 
benchmarks were developed and evaluated using a combination of Cumulative Sum 
(CUSUM) charts, Exponentially Weighted Moving Average (EWMA) charts and 
Funnel Plots. Charts have been discussed at the unit’s routine M&M meetings. Risk 
Adjustment (RA) based on EuroSCORE has been incorporated into the charts to 
improve performance.  
 
Discrete and aggregated measures, including Blood Product/Reoperation, major acute 
post-procedural complications and Length of Stay/Readmission <28 days have proved 
to be usable measures for monitoring outcomes. Monitoring trends in minor 
morbidities provides a valuable warning of impending changes in significant events. 
Instances of variation in performance have been examined and could be related to 
differences in individual operator performance via individual operator curves.  
 
SPC tools facilitate near “real-time” performance monitoring allowing early detection 
and intervention in altered performance. Careful interpretation of charts for group and 
individual operators has proven helpful in detecting and differentiating systemic 
versus individual variation.  
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13.2   Introduction 
 
Over the past decade, statistical process control (SPC) techniques have proven to be 
effective tools for use in quantitatively informing clinical governance processes. Their 
application has been validated in the monitoring of performance across a broad 
spectrum of levels from individual clinicians to nation wide services. In most reported 
applications, however, they have been used for specific clinical events such as 
hospital infections (Benneyan 1998; Quesenberry 2000; Morton, Whitby et al. 2001), 
cardiac surgery (Morton, Smith et al. 2011; Novick, Fox et al. 2001; Spiegelhalter, 
Grigg et al. 2003; Rogers, Reeves et al. 2004; Rogers, Ganesh et al. 2005) and 
intensive care mortality (Cook, Steiner et al. 2003; Cockings, Cook et al. 2006; Cook, 
Duke et al. 2008) and major adverse cardiac events in interventional cardiology 
(Smith, Rivers et al. 2011; Kunadian, Dunning et al. 2008; Matheny, Ohno-Machado 
et al. 2008). 
 
Having recognised the potential of these tools, Cardiac Surgeons at St Andrew’s War 
Memorial Hospital (SAWMH) have been keen to explore the use of SPC to enhance 
the hospital’s existing clinical governance processes. In this context, a range of key 
clinical outcomes indicators (COIs), analyzed using a variety of complimentary 
graphical charting techniques, were developed for presentation and discussion at the 
unit’s bi-monthly morbidity and mortality meetings (M&M). The SPC charts have 
been adapted to provide an early warning mechanism capable of identifying changes 
in the process of treatment in advance of significant deterioration in outcomes results.  
 
The effectiveness of these tools will be illustrated using, as an example, the 
identification of a significant variation in clinical outcomes in late 2010. At that time, 
a chart monitoring a combined endpoint of blood product use in excess of 10 Units or 
reoperation for tamponade or bleeding (BP/Reop) signalled that a shift to a higher rate 
had been detected. The resultant systematic analysis identified issues around the use 
of two antifibrinolytics, aprotinin (Trasylol, Bayer AG) and tranexamic acid (TXA: 
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Cyclokapron, Pharmacia & UpJohn Inc.) and then explored the impact that their 
changing patterns of use had on the COI of interest and clinical outcomes. 
 
13.3   Methods 
 
13.3.1 Data: 
 
Analysis for the quality monitoring process used as the example in this study involved 
data drawn from registries containing clinical information on 4774 admissions for 
primary (86%) and repeat coronary artery bypass grafting (CABG: 46%), valve 
(33%), combined (CABG & valve: 18%) or other cardiac operations performed at 
SAWMH between 1st January 2003 and 30th April 2011.  
 
For each patient, demographic and co-morbidity data was collected at the time of 
procedure along with comprehensive details of the surgery performed and procedural 
outcome. Details of the patient’s subsequent hospital experience, including procedural 
and pre-discharge complications were also collected. Specific outcome indicators 
such as readmission and death were followed to 30 days post procedure.   
 
Prior to October 2008, data was captured manually using the Australasian Society of 
Cardiac and Thoracic Surgeons (ASCTS) data form circa 2001. Selected data fields 
were then transcribed into a dedicated purpose built registry for audit and review. 
From October 2008, a new registry was commissioned to accommodate a 
comprehensive suite of data including current ASCTS dataset (see: 
www.ccretherapeutics.org.au/research/ascts.html) and factors required for calculation 
of EuroSCORE (see www.euroscore.org). This collection and use is regarded as an 
audit activity and the UnitingCare Health Human Research Ethics Committee deemed 
that a formal ethical review was not required.  
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To ensure data quality, clinical information coded on forms by the perfusionist during 
surgery is reviewed and validated by an experienced data manager before entry into 
the electronic procedures registry. Data is entered into the registry once the patient is 
discharged from hospital and all details relating to the admission are available 
(records are updated as needs be to include relevant post discharge information such 
as readmission within 30 days). Where possible, data is ‘tested’ using algorithms that 
compare observed and expected outcomes and event data. Such tests cover fields 
linked to the COIs monitored as part of the clinical performance review process and 
include data used in the various risk adjustment models and models for continuous 
data such as length of stay and bypass (and cross clamp) time. Where extreme outlier 
events are identified (i.e. those where the outcome is not as expected) the record is 
pulled for review. Finally, cases featuring criteria matching a review template (usually 
those in which key adverse events have taken place) are raised for review at the units 
bi-monthly M&M meeting.             
 
13.3.2 Blood Product Use & Reoperation for Bleeding (BP/Reop): 
 
The use of control charts to monitor re-operation for excessive bleeding after cardiac 
surgery has been proposed by others (Wolfe, Bolsin et al. 2007), however, the COI of 
interest in the SAWMH monitoring program relates to a compound endpoint coupling 
together use of blood (Fresh Frozen Plasma, Platelets and Packed Cells) in the first 24 
hours post surgery or a return to theatre for bleeding or tamponade related issues. The 
primary intention for monitoring an indicator based on these parameters is not for any 
issue specifically relating to adverse outcomes for the patient arising from blood 
product use or reoperations although it is clear that there is a link between these 
factors (Ranucci, Bozzetti et al. 2008; Bhaskar, Bidstrup et al. 2009; Slight, Nzewi et 
al. 2009). In the context of the clinical quality monitoring program, this measure is 
viewed as a surrogate marker for technical issues that occur during surgery, an 
application supported by Vivacqua et al. (Vivacqua, Koch et al. 2011) who proposed 
technical reasons as being the dominant cause of bleeding following cardiac surgery.  
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The use of 10 Units of blood as a threshold arose out of an early evaluation of blood 
product use by the cardiac surgical unit when the monitoring process was being 
established. This analysis showed that 68% of surgeries did not involve the use of 
blood products while 5.3% of surgeries required 10 Units or more (CABG: 2.7%, 
valve: 6.2% and CABG & valve: 8.2%). A compound measure was proposed, rather 
than two individual processes, to simultaneously monitor the two main mechanisms 
used to manage excessive bleeding post-surgery which eliminates what would be the 
first investigation step if either of the individual charts signaled as well as reducing 
the potential for gaming. At that time, reoperation for bleeding and tamponade 
occurred in approximately 3-4% of surgeries (CABG: 1.9%, CABG & valve: 3.1%, 
valve: 4.3%). So as to ensure a balance between the two process measures comprising 
the COI (ensuring that neither dominated the monitoring process), it was deemed 
necessary to set the blood use threshold at a level sufficient to achieve a similar rate. 
This results in a chart that is equally sensitive to changes in the rate of both 
reoperation and blood product utilization. This would not be the case if the underlying 
rate of the two measures was markedly different. For a compound measure based on 
reoperation (4%) and use of any blood products (32%) would be comparatively 
insensitive to a doubling in the rate of reoperations as the overall measure would only 
increase from a combined 36% to 40%. A review of blood product use at the time 
suggested that 10 Units of blood in the first 24 hours after surgery was, therefore, an 
appropriate threshold for this purpose.    
 
13.3.3 SPC Charts: 
 
Many different types of control chart have been used in clinical monitoring 
applications. Those presented for discussion at the SAWMH M&M meetings include 
cumulative sum (CUSUM) (Steiner, Cook et al. 2000; Steiner, Cook et al. 2001) and 
Exponentially Weighted Moving Average (EWMA) charts (Cook, Coory et al. 2011) 
for unit level analysis. Funnel plots (Spiegelhalter 2002; Spiegelhalter 2005) are 
employed for individual surgeon and surgical team comparison. With all SPC charts, 
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choice of design parameters (e.g. benchmark rates, control limits, etc) is established in 
consultation with the users and only after careful consideration of the actions to be 
taken should an alarm be signaled. In this application, performance benchmarks for 
each chart were initially based on data for the period 1st July 2005 to 31st December 
2007, a period when aprotinin was widely used. During the review process arising 
from the signal investigation in August 2010, the benchmark period was revised to 1st 
July 2008 to 1st July 2010, a period when TXA had replaced aprotinin. 
 
A brief description of the various charts routinely used is provided in the Appendix, 
but for brevity, the remainder of this paper focuses only on EWMA charts  
 
13.3.4 EWMA Chart Design Parameters: 
 
When appropriately designed, EWMA charts are an efficient means of detecting 
changes in outcome of a process (Montgomery 1991). The current value of the 
EWMA chart (Ei) is derived from the previous value of the EWMA (Ei-1) by 
calculating a weighted average of sequential observations with the current observation 
(xi) given a weight, λ, and previous observations effectively given geometrically 
decreasing weights using the formula: 
 
iE  = λ xi + (1- λ) E i-1 
 
The EWMA control chart used for monitoring of binary outcomes, plots the moving 
average of expected outcomes (derived using the case by case risk estimate). Control 
limits for the EWMA chart are set to achieve a predefined false alarm rate. The 
establishment of this parameter, known as the in-control run length (ARL0), is a 
balance between the need to rapidly detect true shifts in performance while 
minimizing the incidence of false alarms. For the EWMA charts used in this analysis 
control limits have been set to achieve an ARL0 resulting in on average one false 
alarm signal per 1000 surgeries. See Cook et al. (Cook, Coory et al. 2011) for details 
on derivation of the control limits. 
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This EWMA chart of expected outcomes (and control limits) is then overlaid with the 
EWMA of observed events. The chart therefore conveys to the reader a representation 
of the current event rate of the process being monitored along with the expected rate 
and measure of acceptable variation (defined by the EWMA of the case by case risk 
estimate and associated confidence interval). The process being monitored is then 
considered as performing within expectation while the EWMA of observed outcomes 
lies within the expected chart’s control limits. 
 
The main advantage of the EWMA over other sequential charting tools (such as the 
CUSUM) is its ease in interpretation and its ability to track both changes in the 
observed and expected outcomes independently. This chart is primarily used for group 
review, however, it can also be applied to analyze the performance of a single team or 
individual clinician when required. 
 
13.3.5 Risk Adjustment: 
 
The performance of SPC monitoring significantly improves through the application of 
well calibrated risk adjustment (RA) (Steiner, Cook et al. 2000; Steiner, Cook et al. 
2001; Benneyan and Borgman 2003; Grigg, Farewell et al. 2003; Spiegelhalter, Grigg 
et al. 2003). Conversely, an ill fitting RA is known to introduce bias into the 
monitoring process (Steiner, Cook et al. 2000; Cook, Steiner et al. 2003; Grigg, 
Farewell et al. 2003; Woodall 2006). As such, site specific RA algorithms were 
developed using patient demographic, co-morbidity and procedural data from the 
representative benchmark periods. Logistic regression analysis was used to identify 
the optimum parameter set for the RA models. Calibration and discrimination of the 
risk models was assessed using Hosmer-Lemeshow (H-L) goodness of fit and area 
under the receiver operating curve (AUC) measures. As antifibrinolytic drugs have a 
major impact on bleeding in cardiac surgery, use of the drugs aprotinin and TXA were 
factored into the regression analysis at the appropriate intervals as described below.  
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13.3.6 Analysis of TXA: 
 
The changing patterns in use of aprotinin and TXA was tracked via EWMA charts. 
The decline in use of TXA from June 2009 to July 2010 was due to concerns of a 
possible link to increased adverse outcomes. These concerns focussed on an anecdotal 
report from another Brisbane hospital linking use of TXA with a possible increase in 
patient seizures post surgery, a possibility supported by Murkin et al. (Murkin, Falter 
et al. 2011) in regard to high-dose TXA use (median TXA dose 140mg/kg, range 61-
259mg/kg). This issue was raised at an M&M meeting in mid 2009, and although no 
evidence of a link was found in the SAWMH patient population (median TXA dose 
49mg/kg, range 10-100mg/kg) , a decision was made by the surgeons to reduce TXA 
use. To quantitatively assess the link between TXA and adverse events post cardiac 
surgery at SAWMH, propensity score (Caliendo and Kopeinig 2008) based analysis 
(nearest neighbour (1:1) matching without replacement and bootstrapping (N=100)) 
was used. The propensity analysis included data from cases performed after the 1st 
October 2008 and matched surgeries in which TXA was used against a control group 
based on the likelihood of receiving the drug. Outcomes compared include 
complications such as: new arrhythmias, deep sternal infections, neurologic 
complications (coma and permanent/temporary stroke), new renal failure, pulmonary 
complications (including pleural effusion, pneumonia, pneumothorax, prolonged 
ventilation, pulmonary embolism, chest infection and acute pulmonary oedema), 
unplanned returns to theatre, extended intensive care unit stay (ICU > 96 hours), 
extended hospital length of stay (POLOS > 21 days), and death within 1 month of 
surgery. The rate of intra-operative variations (IOV defined as bleeding, myocardial 
dysfunction, perfusion problems and other undefined events) with particular attention 
given to intra operative bleeding (IO Bleed) were also compared. 
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13.4   Results 
 
Table 13.1 summarises the factors identified in the logistic regression analysis as 
being related to BP/Reop. These factors were used in the respective RA models. The 
Model1 coefficients are for the original benchmark period (1st July 2005 to 31st 
December 2007) while the Model2 coefficients are for the updated benchmark period 
(1st July 2008 to 1st July 2010). Note that in Model1, aprotinin use is reflected as a 
coefficient while in the second period TXA appears (in this period, aprotinin is no 
longer being used). Calibration (H-L C Statistic) and discrimination (AUC) for the 
two RA models is also confirmed in Table 13.1. This analysis highlights the role that 
various factors play in relation to blood product use. For example, use of blood 
products appears linked to older age groups, cases involving valve surgery and 
surgery on the aorta, patients with a history of prior cardiac surgery and the use of 
antiplatelet drugs within 7 days of surgery. Countering these factors, higher pre-
operative haemoglobin and use of antrifibrinolytics appear to be associated with a 
lower use of blood products.       
 
Figure 13.1 is the EWMA plot of the observed incidence BP/Reop. The graph also 
plots the use of aprotinin and TXA. Key events impacting on the use of these drugs at 
SAWMH are identified. The first major increase in BP/Reop (from 4% to 12%) was 
associated with publication of the Mangano paper (Mangano, Tudor et al. 2006) in 
January 2006 which triggered a drop in the use of aprotinin. The next major peak in 
BP/Reop (~17%) occurred in December 2007 following cessation of aprotinin use and 
prior to the adoption of TXA. The incidence of BP/Reop then declined as TXA use 
increased. A peak in TXA use (~70%) corresponded to a fall in the rate of BP/Reop to 
~10%. Following discussions at an M&M meeting in June 2009 surrounding a 
potential link between TXA use and seizures post surgery, TXA use declined until its 
use largely stopped in August 2010. During this time, the incidence is BP/Reop 
steadily increased to more than 20%. Note the ‘spikes’ in BP/Reop associated with the 
falls in use of aprotinin and TXA in early 2006, late 2007 and August 2010. In both 
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cases of where aprotinin and TXA use ceased, the rate of BP/Reop settled back to 
lower rates after brief transient highs.   
 
Table 13.1: Logistic regression (β) coefficients used in the two risk models. Age at Operation 
and Pre-Operative Haemoglobin are continuous variables, the remainder are binary with a 1 
allocated when the characteristic is present and a 0 otherwise.  
 
Factor Model1 Model2 
Age at Operation* 0.020 0.036 
Valve Surgery 0.526 0.263 
Aortic Surgery 1.494 0.985 
Pre-Operative Haemoglobin* -0.015 -0.019 
Aprotinin -0.853 Not Used 
TXA Not Used -0.767 
Antiplatelets within 7 days 0.607 0.304 
Prior Cardiac Surgery 0.745 1.086 
Constant -2.422 -2.429 
AUC 0.74 (SE=0.06) 0.74 (SE=0.05) 
H-L C Statistic 14.35 (p=ns) 4.63 (p=ns) 
 
* Continuous variables 
 
 
Figure 13.1: Chart showing the proportion of surgeries involving a transfusions of >10 units 
and or reoperation (BP/Reop) compared against the proportion of patients receiving aprotinin 
or TXA. The graph shows an initial rate of BP/Reop of 5% with aprotinin used in 
approximately 80% of surgeries to October 2007. Key events impacting on the use of 
aprotinin and TXA at SAWMH are shown. Reference to Mangano relates to publication of 
the paper by Mangano et al. dealing with the risk associated with aprotinin in cardiac surgery 
(Mangano, Tudor et al. 2006). The withdrawal of aprotinin was associated with the (BART) 
study (Fergusson, Hebert et al. 2008). 
 
Figure 13.2 plots the incidence of BP/Reop overlaid on the control chart employing 
RA Model1. Note the overestimation of risk in the period associated with TXA. 
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Figure 13.3 plots the incidence of BP/Reop overlaid on the control chart employing 
RA Model2. Note the impact of recalibration to the TXA period on results from the 
aprotinin era. The pattern of BP/Reop can clearly be linked to changes in use of TXA 
(note how the observed incidence of BP/Reop conforms to the graph describing the 
expected rate during the ‘Data Period’ for RA Model2). The odds ratio for various 
intra- and post-operative complications is shown in Figure 13.4. 
 
 
Figure 13.2: EWMA Control chart for BP/Reop using RA Model1. Shown on the graph is the 
observed rate of BP/Reop (solid black line) overlaying the expected rate of BP/Reop defined 
by the risk model. Control limits for the expected rate of BP/Reop have been set to deliver an 
ARL0 of 1000 cases. Boundaries of the data for establishing RA Model1 are shown. 
 
 
Figure 13.3: EWMA Control chart for BP/Reop using RA Model2. Shown on the graph is the 
observed rate of BP/Reop (solid black line) overlaying the expected rate of BP/Reop defined 
by the risk model. Control limits for the expected rate of BP/Reop have been set to deliver an 
ARL0 of 1000 cases. Boundaries of the data for establishing RA Model2 are shown.  
 
Chapter 13:  Monitoring Bleeding in Cardiac Surgery 330 
 
 
Figure 13.4: Propensity score based analysis of intra- & post- operative adverse events in 
cases involving TXA compared to cases in which TXA was not used.  Filled diamonds 
indicate factors for which the odds ratio is significantly different to one. 
 
 
13.5   Discussion 
 
In this study, use of SPC charts tracking a COI coupling together blood product use and 
reoperation for tamponade and bleeding identified a significant increase in the rate of these 
events. Once the EWMA chart signalled, a structured review of potential issues contributing 
to the signal of the outcome indicator commenced. This investigation followed the pathway 
summarised in Figure 13.5, which is a review process agreed upon by the surgeons when the 
monitoring program was established. 
 
As data quality (lowest level in the ‘triangle’ for signal investigation) is monitored 
continuously throughout the data acquisition and entry process, evaluation rapidly progressed 
to assessing whether case mix and other factors effecting risk had remained stable and the RA 
model adequately reflective of the clinical process being monitored. In so doing, changes in 
the use of antifibrinolytics were considered as these are included in the risk model. At the 
time of initial signalling, the RA model (Model1) only included the drug aprotinin (TXA had 
not been in regular use up to that point). During this review, the opportunity to revise the risk 
model was taken and as a consequence the new model, using a temporally more proximal 
benchmark period, dropped aprotinin in favour of TXA only.    
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Figure 13.5: Signal investigation process – adapted from Mohammed et al. 2004 
(Mohammed, Rathbone et al. 2004).   
 
While accounting for the process change through the revised risk model has not entirely 
addressed the signal, the resultant charts do show that the surgeons were able to adapt their 
technique to manage the incidence of BP/Reop (the chart reverted to being well within the 
control limits defining satisfactory performance). 
 
One consequence of this investigation was the opportunity to explore concerns surrounding 
possible complications, particularly neurological events (including seizures), associated with 
the use of TXA (Martin, Wiesner et al. 2008; Murkin, Falter et al. 2011). Concerns over the 
potential adverse consequences associated with TXA use appears to have been at the core of 
the decision by most surgeons in the unit to reduce use of this drug. Unlike aprotinin, 
however, which was withdrawn from use rapidly when Bayer Pharmaceuticals Corporation 
ceased distribution following publication of the "Blood Conservation Using Antifibrinolytics 
in a Randomized Trial" (BART) study (Fergusson, Hebert et al. 2008), TXA use gradually 
declined from June 2009, with the last surgeons ceasing routine use in July 2010. Preliminary 
propensity score analysis suggests that TXA was not associated with any increase in the 
documented major morbidities and confirms its link with a lower risk of intra-operative 
variations (which includes bleeding) and lower blood product use. 
 
An interesting observation from the two charts (Figures 13.2 and 13.3) concerns the 
comparative performance of aprotinin and TXA at reducing bleeding and reoperations in 
cardiac surgery. As the RA model in Figure 13.2 includes aprotinin but not TXA, the 
predicted and observed EWMA charts for the period when TXA was used (April 2008 to July 
2010) suggests that the BP/Reop rate would have been 15% compared with the 10-12% 
achieved. Conversely, as the RA model in Figure 13.3 includes TXA but not aprotinin, 
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reflection on the period when aprotinin was in high use (up to October 2007) suggests the 
BP/Reop rate would have been 15% compared with the 5-10% achieved. This finding is in 
accordance with the findings of others (Diprose, Herbertson et al. 2005; Mannucci and Levi 
2007). 
 
13.6   Conclusion 
 
The analysis presented here demonstrates the potential value of SPC in clinical 
governance applications. We have demonstrated the use of these tools through 
exploration of signals arising from risk-adjusted monitoring using control charts of a 
clinical outcome indicator which was created by combining rates of blood product use 
and reoperation for bleeding and tamponade. Maximum benefit from using these 
charts is derived when they are included in a structured process that has full 
agreement and active participation from the clinicians involved. Use of these tools can 
enhance the conventional M&M process. Careful collection of quality data including 
information on the timing of key clinical and non-clinical events enables clinicians to 
readily identify and explore factors contributing to significant changes in outcome.  
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Appendix: 
 
Statistical Process Control (SPC) concerns the application of statistical methods and 
procedures to the analysis of inherent variability in the outputs of a process in order to 
ensure the outcomes delivered by that process are maintained or improved. A key tool 
of SPC is the control chart. Many types of statistical process control charts have been 
used in clinical performance monitoring applications. Due to the relative strengths and 
weaknesses of the range of charts available (rapid response to large shifts vs. 
sensitivity to small changes, ease of interrelation vs. statistical robustness), some 
authors have proposed use of a combination of charts to optimise the monitoring 
process (Rogers, Reeves et al. 2004; Spiegelhalter 2004). A strength of sequential 
monitoring using these charts is the ability to construct a motoring system that senses 
changes in outcome on a “near real time” basis (provided data are entered and 
analysed promptly). As such they are suitable for use in an “alarm” or “early 
warning” system. The following is a brief outline provides a more detailed 
explanation of the charts used in this study. 
 
CUmulative SUM (CUSUM): When appropriately designed, Risk Adjusted (RA) 
CUSUM charts (Steiner, Cook et al. 2000; Steiner, Cook et al. 2001) are the most 
efficient form of chart at detecting small persistent shifts in a process. The chart is 
constructed by cumulatively summing the difference between the observed and 
expected values of the parameter being monitored. The RA CUSUM described by 
Steiner et al, this difference is expressed as the log likelihood ratio (Steiner and Cook 
2000). The resultant sum is compared to a predefined decision threshold (‘h’) and is 
said to signal when the threshold is crossed (this normally triggers a review of the 
factors contributing to the outcome change). After a signal the CUSUM may be reset 
to zero and monitoring continued. The charts used at SAWMH are double sided 
CUSUM charts. These charts simultaneously test the hypotheses that the odds of an 
event occurring has doubled or halved (although other values can be used). 
Establishment of the decision threshold ‘h’ for these charts is a balance between the 
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need to rapidly signal a shift in performance against the rate of false alarms that arise 
due to chance. This chart was used for group performance review. 
 
Exponentially Weighted Moving Average (EWMA): When appropriately designed, 
EWMA charts can be as efficient as CUSUM charts at detecting changes in outcome 
of a process. Two versions of the EWMA chart are used in monitoring applications at 
SAWMH:  
1. Derivation of version one of the EWMA chart is broadly described in the methods 
section of this paper. For a more in depth understanding of the charts see Cook et 
al. (Cook, Coory et al. 2011). 
2. Version two is used for continuous variables. In this form the distribution of data 
is first normalised (using for example the Box-Cox transform). Using an algorithm 
predictive of the outcome being monitored, a residual is derived which is then 
plotted on a Shewhart chart (to identify and correct outliers). An EWMA chart of 
the residual is then constructed. See Stevens et al. for more details (Stevens, 
Steiner et al. 2011). 
  
The main advantage of the EWMA over the CUSUM is its ease in interpretation. The 
use of both charts is proposed, however, as the CUSUM contributes the more robust 
statistical analysis. This chart is primarily used for group review, however, it is also 
applied for targeted individual clinician analysis when required. 
 
Funnel Plots: Funnel Plots (Spiegelhalter 2002; Spiegelhalter 2005) are a useful 
technique for comparison across a number of surgeons or institutions. The graph is 
constructed by plotting the measure of performance (as a percentage) for each surgeon 
or surgical team under review against the number of cases performed (the 
denominator for the percentage). The performance benchmark and exact binomial 
limits are calculated and plotted for all possible values for the number of cases and 
used to create the familiar funnel plot appearance. Performance is deemed as being 
consistent with the benchmark when the plotted result falls within the funnel. This 
chart is used for individual surgeon review. 
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CHAPTER 14 
 
 
Validation of the Use of Cardiopulmonary 
Bypass Duration as a Marker for Cardiac 
Surgical Performance 
 
Preamble 
 
As with Chapter 13, this chapter provides a practical demonstration of how the 
processes and tools described in the preceding chapters of this thesis can be brought 
together to contribute to an effective and efficient clinical governance system. The 
example described in this chapter concerns the development and use of a clinical 
outcome indicator that is sensitive to a sustained drift in the cardiopulmonary bypass 
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duration (CPBD) experienced by patients undergoing cardiac surgery. Cardiopulmonary 
bypass is a technique used in cardiac surgery whereby the function of a patient’s heart 
and lungs is temporarily assumed by a mechanical support system thereby enabling the 
heart to be stopped for better surgical access. As the mechanical support system used in 
cardiopulmonary bypass exposes the patient’s blood to an external circuit, there is the 
potential for the blood to be damaged. This damage can result in an increased incidence 
of a range of adverse events for the patient post surgery including death as well as 
pulmonary, renal and neurologic complications.  
 
In this chapter we described the development of a monitoring process based on CPBD. 
This parameter was identified using a similar process to that described in Chapters 2 
and 3. As CPBD is a continuous variable, the control charts used were based on the 
exponentially weighted moving average (EWMA) chart method described in Chapter 6. 
During the process of monitoring, the chart detected a marked increase in procedures 
experiencing unexpectedly long CPBD. The signaling of this chart triggered a 
structured review process as outlined in Chapters 3 and 13. This review rapidly 
eliminated data quality and case mix changes as a issues of concern. Attention was then 
focused on process of care, which revealed that across the period of monitoring there 
had been a number of changes in clinical practice and the environment (the hospital had 
undergone a program of redevelopment which included the introduction of a number of 
new facilities and technologies). Change point analysis (similar to that described in 
Chapter 9) was applied to the EWMA chart and the timing of change of this chart was 
compared to the points of change identified in the control charts documenting the 
patterns of potential change agents. This process effectively identified the expanded use 
of intra operative echocardiography during cardiac surgery as the most likely factor 
responsible for the increase in CPBD. Finally, this chapter describes the use of 
propensity score matching as a means of addressing treatment selection bias when 
investigating the clinical consequence of change agents. 
The focus of this chapter is on the third objectives of the thesis as it demonstrates how the 
performance evaluation provided by sequential charts can be used to monitor and 
positively influence clinical performance. The main contribution of this chapter is on 
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knowledge adaptation and application, promoting methods drawn from the industrial 
domain and demonstrating their application to the clinical context. 
This chapter has been written as a journal article for which I am the principal author. 
It is reprinted here in its entirety. I was responsible for the conception of the paper, 
statistical analysis, writing manuscripts and addressing the reviewer's comments. 
 
Software used in the analysis of data and construction of graphs presented in this 
paper included SPSS (SPSS Statistics for Windows, Version 17.0. Chicago, Illinois: 
SPSS Inc) and Microsoft Excel (Microsoft Excel. Standard Edition 2003. Redmond, 
Washington: Microsoft Inc). Unless otherwise stated, code for simulations required to 
construct and evaluate the performance of control charts and risk adjustment 
algorithms and undertake or support other specific analysis were written in Just 
BASIC (Just Basic. Version 1.01. Framingham, Massachusetts: Shoptalk Systems) 
and Excel.  
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14.1   Abstract 
 
Cardiopulmonary Bypass Duration (CPBD) has been identified as an independent 
predictor of morbidity and mortality after cardiac surgery. We propose 
implementation of a process utilizing statistical process control (SPC) techniques to 
monitor for persistent systemic changes in CPBD. 
 
SPC charts were used to sequentially monitor CPBD. To improve monitoring 
sensitivity a regression model was built to predict expected CPBD with monitoring 
based on the difference between observed and expected CPBD. Factors included in 
the regression model comprised surgeon, patient age, surgery on thoracic aorta, 
number of distal anastomoses, use of “T” or “Y” grafts, number of valves, combined 
valve and graft surgery, history of prior cardiac surgery and EuroSCORE predicted 
risk. A model involving these factors had a correlation coefficient of 0.972 (p<0.001). 
This technique, when retrospectively applied to clinical data, identified a number of 
cases in which individual CPBDs could be considered unexpected. In March 2010 the 
chart signalled a significant increase in CPBD, change point analysis suggested the 
change occurred in December 2009. Systematic review of the causes of the signal did 
not reveal any issues with data quality or variation in case mix. Analysis identified 
more pervasive use of intra-operative transoesophageal echocardiograpy as the 
probable cause of the increase in CPBD.    
 
The technique we describe can rapidly identify persistent small changes in CPBD. 
When used in a structured governance framework, we have demonstrated how control 
charts can assist in identifying causes of these changes and attend to the resultant 
impact. 
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14.2   Introduction 
 
To actively ensure the continued clinical excellence of the cardiac surgical unit at St 
Andrew’s War Memorial Hospital (SAWMH) a governance system employing 
graphical statistical process control charts has been implemented to provide feedback 
to the unit’s bi-monthly morbidity and mortality (M&M) meetings. In establishing 
this process, the unit carefully selected a range of clinical outcome indicators (COIs) 
to track service delivery and monitor patient outcomes. Criteria for selection of these 
indicators included a requirement that they be easily interpretable and actionable by 
the clinicians as well as accurate and adequate markers of the quality of care 
(Shahian, Edwards et al. 2007). 
 
One such indicator is cardiopulmonary bypass duration (CPBD). The detrimental 
effects of CPBD are well established (Murphy and Angelini 2004). While all surgery 
can elicit an inflammatory response, the effect is greatly magnified in cardiac surgery 
(Cremer, Martin et al. 1996) due to the ongoing exposure of heparinized blood to non-
endothelial surfaces, the trauma of the pump and the scavenging of blood from the 
pericardium and pleura that is returned to the pump (Jewell, Akowuah et al. 2003; 
Kaza, Cope et al. 2003) as well as the occurrence of microemboli and foreign material 
in the CPB circuit (Djaiani, Fedorko et al. 2004).  
 
A number of studies have linked prolonged CPBD to an increased incidence of 
adverse outcomes following cardiac surgery. For example, longer CPBD has been 
associated with an increase in cerebral microemboli (Brown, Moody et al. 2000) and 
is an independent predictor of early stroke (Hogue, Murphy et al. 1999). Salis et al. 
(2008) drew a link to a range of adverse events including death, pulmonary, renal and 
neurologic complications, multi-organ failure, reoperation for bleeding and multiple 
blood transfusions (Salis, Mazzanti et al. 2008). A recent meta-analysis demonstrated 
a correlation between CPBD and acute kidney injury (Kumar, Suneja et al. 2012). 
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Nissinen et al. (2009) explored cross clamp time (XCT) as well as CPBD and while 
finding both to be independent predictors of immediate postoperative death, only 
CPBD could be linked with 30 day mortality among patients who underwent isolated 
procedures (Nissinen, Biancari et al. 2009).  
 
The purpose of this study is to validate the monitoring of CPBD using statistical 
process control (SPC) charts as an efficient and effective means of detecting changes 
in cardiac surgical performance. To demonstrate the application of this chart, we 
provide an example of a signal indicating a significant increase in CPBD that 
occurred in March 2010 and describe the subsequent investigation. Systematic review 
of the potential causes of this signal did not reveal any issues with data quality or 
variation in case mix, however, analysis did suggest more pervasive use of intra-
operative transoesophageal echocardiograpy as the probable cause. 
 
 
14.3   Methods 
 
14.3.1 Data: 
 
During the period 1st November 2008 to 1st November 2011, 1559 patients underwent 
cardiac surgical procedures at St Andrew’s War Memorial Hospital (SAWMH), 
Brisbane, Australia. Surgeries were performed by 8 experienced consultant cardiac 
surgeons. The procedures comprised coronary artery bypass graft (CABG, 41%), 
Valve (39%), combined CABG and Valve (18%) and other cardiac surgical 
procedures. The patient population (males: 70%) had a median age of 70 (range: 17-
93) at the time of surgery. A summary of patient characteristics is provided in Table 
14.1. 
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Table 14.1: Patient characteristics and operative details 
Characteristic N (%) * Median (Range) 
Procedure    
 Operations  1559  
 Patients  1550  
Demographics    
 Gender Male 1094 (70.2%) 
 Age Male * 69 (17-93) 
  Female * 74 (31-91) 
Patient Factors    
 Chronic pulmonary disease  11 (0.7%) 
 Extracardiac arteriopathy  222 (14.2%) 
 Neurological dysfunction  89 (5.7%) 
 Previous cardiac surgery  236 (15.1%) 
 Serum creatinine >200 µmol/ L  10 (0.6%) 
 Active endocarditis  0 (0%) 
 Critical preoperative state  23 (1.5%) 
 EuroSCORE *  4.8% (0.9%-90.4%) 
Cardiac Factors    
 Unstable angina  10 (0.6%) 
 LV Dysfunction Normal 1248 (80.1%) 
  Mild/Moderate 260 (16.7%) 
  Severe 22 (1.4%) 
  Unknown 29 (1.9%) 
 Recent myocardial infarct  189 (12.1%) 
 Pulmonary hypertension  87 (5.6%) 
Operation Factors     
 Operative Status Elective 1311 (84.1%) 
  Urgent 230 (14.8%) 
  Emergency 16 (1%) 
  Salvage 2 (0.1%) 
 Type of Surgery CABG Only 638 (40.9%) 
  Valve Only 608 (39%) 
  CABG + Valve 278 (17.8%) 
  Other 35 (2.2%) 
 Cardiopulmonary Bypass Duration (minutes)  85 (11-316) 
  % >240 min 1.2%  
 Cross Clamp Time (minutes)  64 (11-285) 
  % >150 min 3.4%  
 Surgery on thoracic aorta  172 (11%) 
 Postinfarct septal rupture  0 (0%) 
Other     
 Preoperative haemoglobin *  138 (70-178) 
 Preoperative diabetes  373 (23.9%) 
  Antiplatelets within 7 days pre surgery   1019 (65.4%) 
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Data for analysis in this study was collected as part of the cardiac surgical unit’s 
routine quality monitoring program. All information collected was entered into a 
dedicated, purpose designed data registry. The data registry is regarded as an audit 
activity that does not require patient consent. The UnitingCare Health Human 
Research Ethics Committee deemed that a formal ethical review was not required. 
Where applicable, standard definitions consistent with those of the Australasian 
Society of Cardiac and Thoracic Surgeons have been used 
(http://www.ccretherapeutics.org.au/research/ascts.html). Data collection, validation 
and entry into the registry was undertaken by experienced data managers. 
 
For each patient, demographic and co-morbidity data was collected at the time of 
surgery along with comprehensive details of the surgery performed. Details of the 
patient’s subsequent hospital experience, including intensive care unit and hospital 
lengths of stay and peri-procedural and pre-discharge complications were also 
collected. Specific clinical outcome indicators (COIs) such as readmission and death 
were followed to 30 days post-procedure while post-discharge death (to 12 months) 
was identified by matching records with the Queensland Death Registry. 
 
14.3.2 Monitored Variable: 
 
The target variable for monitoring in this study, CPBD, is defined as the total number 
of minutes the patient spent on cardiopulmonary bypass. Unlike the majority of 
instances of control chart use in clinical performance monitoring applications, which 
deal with binary outcomes (e.g. hospital infections (Morton, Mengersen et al. 2010; 
Morton, Mengersen et al. 2010; Morton, Whitby et al. 2001; Morton 2003; Morton 
2006; Morton 2007), cardiac surgical outcomes (Morton, Smith et al. 2011; Novick, 
Fox et al. 2001; Spiegelhalter, Grigg et al. 2003; Rogers, Reeves et al. 2004; Rogers, 
Ganesh et al. 2005) and intensive care mortality (Cook, Steiner et al. 2003; Cockings, 
Cook et al. 2006; Cook, Duke et al. 2008)), CPBD is available as a continuous 
variable. Initial analysis showed the distribution of CPBD to be non-normal (see 
Figure 14.1) and as such it was not suited to control chart monitoring in its raw form. 
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For monitoring purposes, therefore, CPBD was normalised through use of a Box-Cox 
transform (Sakia 1992) with a power parameter of -0.240 (CPBD’).  
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Figures 14.1(a) & (b): Left plot is the distribution of raw CPBD values. Right plot shows the 
normalised CPBD distribution along with the distribution of residuals.  
 
 
14.3.3 Control Chart Paradigm: 
 
Control charting for process monitoring has two phases (Montgomery 2008). In Phase 
I, a set of data is retrospectively examined to derive the control limits and build charts 
which balance sensitivity to the nature of the changes to be detected with the 
incidence of false signals. In Phase II, the charts are used to prospectively monitor the 
process in real time, with the intention that an agreed investigation protocol (and 
possibly corrective action) is initiated if the charts signal (a control limit is breached) 
that the process has changed. A logical point for the delineation between Phase I and 
Phase II occurred in late 2009 when the hospital commissioned two new cardiac 
operating theatres as part of a major hospital wide redevelopment.  
 
Monitoring based on these timeframes (Phase I – prior to 31st December 2009), was 
therefore used to detect any impact on CPBD’ arising due to the structural, technical, 
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work practice and environmental changes arising as a result of or in association with 
the redevelopment process.  
 
14.3.4 Monitoring Process: 
 
The goal of this project was to develop and describe the use of a scheme for 
monitoring CPBD’ in cardiac surgery. The proposed ongoing performance monitoring 
method is capable of identifying unexpectedly long or short CPBDs for individual 
patients, as well as detecting persistent changes in the average of CPBD’.  
 
These two complimentary objectives are achieved by monitoring CPBD’ using a 
combination of individuals and exponentially weighted moving average (EWMA) 
control charts. Although tempting to monitor raw CPBDs directly, as there is 
substantial variation due to known factors (e.g. surgeon, type of surgery) using such a 
plot would result in a loss of sensitivity to small changes.  
 
To improve performance of the charts, variations in CPBD’ are accounted for using a 
multiple linear regression model to predict the target variable with control charts then 
constructed using the residual values (actual CPBD’ minus predicted CPBD’). A 
detailed description of the methodology used is provided by Stevens et al. (Stevens, 
Steiner et al. 2011). 
 
The simultaneous use of two control charts is particularly useful as the outliers 
flagged by the individuals chart can be investigated for possible data capture errors. In 
doing this the EWMA chart is better able to detect real changes in CPBD’ without 
undue influence from extreme outliers. 
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14.3.5 Regression Model for CPBD’: 
 
Considerable trial and error was involved in building the regression model to predict 
CPBD’. Ultimately a regression model for CPBD’ of the form: 
∑
=
⋅+=
n
i
ii FCPBD
1
0' ββ  
was used where n is the number of factors (Fi) included in the model, βi are the factor 
regression coefficients and β0 is a constant. Included in the model are a number of 
factors known to impact on the time taken to perform surgery. These include; surgeon 
(F1: categorical), number of distal anastomoses (F2: ordinal), number of valves (F3: 
ordinal), prior history of cardiac surgery (F4: binary), patient age at time of surgery 
(F5: continuous) , use of “T” or “Y” grafts between segments of arterial conduit (F6: 
binary), EuroSCORE predicted risk (F6: continuous), other cardiac surgery (F7: 
binary) and combined CABG + valve surgery (F8: binary).  
 
As the intention of the monitoring process is to focus on underlying shifts in CPBD’, 
a surgeon parameter (F1) has been included to account for noticeable difference in 
their bypass times. If left unaccounted for, there is the potential for variations in 
CPBD’ to be driven predominantly by changes in surgeon workload rather than 
changes in technique.   
 
14.3.6 Design of Charts: 
 
Individuals Chart: The chart monitoring for unexpectedly long, or short, CPBD’ is a 
conventional Shewhart chart of residuals. As the residuals come from a linear 
regression model, the average is zero. Control limits for this chart are set at ± 3 
standard deviations based on Phase 1 data. 
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EWMA Chart: EWMA charts can be constructed using both continuous (Stevens, 
Steiner et al. 2011) and binary outcome (Cook, Coory et al. 2011) variables. The chart 
is constructed using the following updating formula: 
 
1)1( −⋅−+⋅= iii ExE λλ  
 
where λ is the smoothing constant, Ei is the updated value of the EWMA arising from 
observation xi and E i-1 is the previous value of the EWMA. In the charts monitoring 
CPBD’, xi are the residuals arising from each surgery. Control limits for continuous 
data (in this case CPBD’) are derived using (Crowder 1989): 
 
λ
λσ
−
±
2r
k  
 
where k is a constant determined by the user and σr is the residual standard deviation 
from the regression model. For the monitoring of CPBD’, a λ of 0.02 was chosen to 
optimally detect shifts of the order of 0.25 σ in CPBD’ (see Crowder (Crowder 1989) 
for details). The choice of k is driven by the desired in-control average run length 
(ARL0), where ARL is defined as the average number of procedures before the 
EWMA signals (i.e. breaches the control limits). In this application, an ARL0 of 1000 
cases (~2 years) has been used resulting in a k of 2.5.  
 
For EWMA charts tracking binary outcomes, the EWMA chart is constructed using a 
0 or 1 for xi depending on the absence or presence of the event being monitored. 
These charts have been constructed using a λ of 0.01 (Cook, Coory et al. 2011). 
 
14.3.7 Change Point Detection: 
 
An important aspect of control chart monitoring is the determination of the point in 
time at which a process changes. Identification of this time allows more rapid 
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investigation of the circumstances that led to the change including the potential 
sequencing of events. For the monitoring CPBD’ (a continuous variable), change 
point estimation employed the 2-sample t statistic method (Montgomery 2008) while 
for binary outcome charts a maximum likelihood estimator approach was adopted 
(Pignatiello and Samuel 2001).   
 
 
14.3.8 Cardiac Surgery Process Changes: 
 
Within the time frame of this study, a number of significant process changes occurred. 
These included a significant reduction in use of tranexamic acid (TXA), introduction 
of anaesthetist-directed intra-operative transoesophageal echocardiography (IO-TOE), 
and expansion in use of IO-TOE (directed by both cardiologists and anaesthetists) to 
cover a broader spectrum of procedures including non-valve related cardiac surgery  
 
Significant changes identified in CPBD were evaluated in the context of changes in 
pattern of these factors. Change point analysis was applied if changes in pattern were 
noted. This review employed additional regression analysis to identify factors of 
significance. To account for treatment bias, propensity score (Caliendo and Kopeinig 
2008) based analysis (nearest neighbour (1:1) matching without replacement and 
bootstrapping (N=100)) was used to quantitatively assess the impact on patient 
outcomes associated with the use of TXA and IO-TOE. 
 
14.3.9 High CPBD Residual: 
 
To confirm the importance of monitoring longer than expected CPBD, an odds ratio 
(OR) based analysis was performed comparing the outcomes for cases where the 
residual is in the upper quartile of the population (Q4) with that for the remaining 
population (Q1-3). Outcomes compared include intra-operative variations (IOV, 
bleeding, myocardial dysfunction, perfusion problems and other undefined events) 
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and a range of post-operative complications such as: new arrhythmias, deep sternal 
infections, neurologic events (coma and permanent/temporary stroke), new renal 
failure, pulmonary complications (including pleural effusion, pneumonia, 
pneumothorax, prolonged ventilation, pulmonary embolism, chest infection and acute 
pulmonary odema), unplanned returns to theatre, prolonged intensive care unit stay 
(ICU > 96 hours), prolonged hospital length of stay (LOS > 21 days), and death 
within 30 days and 12 months of surgery. 
 
OR based analysis was also used to explore links between cases with longer than 
expected CPBD’ and use of TXA and IO-TOE. 
 
14.4   Results 
 
The distribution of Phase I CPBD data prior to and following application of the Box-
Cox transform is highlighted in Figures 14.1(a) and (b). Note skewed nature of the 
distribution of raw data shown in Figure 14.1(a). Median bypass time is 85 minutes 
with a range from 11 to 316 minutes. Figure 14.1(b) depicts the transformed CPBD 
distribution (corrected for the mean offset) compared to a plot of the CPBD’ residuals. 
Both sets of observed frequencies have been overlaid with normal distributions of the 
same mean (0 in both cases) and standard deviation as the corresponding observed 
distributions (σt = 0.132, σr = 0.076).  
Figure 14.2: Plot of predicted (using the regression model) versus observed CPBD’. 
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A plot of predicted against observed CPBD’ is shown in Figure 14.2. Correlation of 
observed and predicted CPBD’ values is confirmed using Pearson’s correlation 
coefficient (p<0.001). Data used for this plot relates to surgeries performed prior to 
January 2010. 
 
The relevance of monitoring prolonged CPBD is evidenced in Figure 14.3 which 
shows the OR for major peri- and post-operative complications for Phase I Q4 CPBD 
residual cases compared with cases with a residual appearing in Q1-3. This comparison 
suggests that cases appearing in Q4 are associated with significantly more intra-
operative variations, have a higher rate of neurological events and pulmonary 
complications post-surgery, spend longer in ICU and hospital during recovery, are 
more likely to experience unplanned returns to theatre and have a higher rate of death 
at 30 days and 12 month. This figure also provides comparison of the distribution of 
EuroSCORE predicted risk for Q4 and Q1-3 procedures. This comparison shows that 
there was no significant difference in pre-operative risk profile for patients involved 
in procedures appearing in Q4 vs. Q1-3 (p=0.082, Mann-Whitney U test). This result is 
significant as the risk of a number of post-operative complications including 
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prolonged recovery in ICU and hospital have been linked to higher EuroSCOREs 
(Toumpoulis and Anagnostopoulos 2005; Hirose, Inaba et al. 2009).    
 
The Individuals CPBD’ residual Shewhart chart is shown in Figure 14.4. CPBD’ 
results for Phase I are delineated from Phase II and residual values falling outside the 
3 σ limits are highlighted. Cases in which the CPBD was not recorded are given a 
residual value of 0, these are shown on the graph along the origin. It is apparent from 
this graph that the frequency of CPBD’ residuals above the upper control limit has 
increased in the initial period of Phase II.  
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Figure 14.3: Odds ratio comparison of outcomes for surgeries with residual CPBD’ in Q4 vs. 
Q1-3 for Phase I procedures (95% confidence intervals are shown). Shown are comparisons for 
peri- and post- procedural events as well as major process changes. Open diamonds indicate 
no significance found while closed diamonds indicate significance at p<0.05, p<0.01 and 
p<0.001 using (*), (**) and (***) respectively. Also compared are the EuroSCORE predicted 
risks for the two groups (p=0.082, Mann-Whitney U test).  
 
 
Figure 14.5 shows the EWMA chart for data presented in Figure 14.4. The graph 
shows the Phase I period to be indicative of a process that is delivering outcomes that 
are within expected bounds. It is apparent in Phase II, however, that the residual 
CPBD’ has shifted to a higher value. Evaluation of the of the distribution of CPBD’ 
residuals in Phases I and II shows that the drift to increased residuals (which translates 
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to an increase of approximately 5.5% in CPBD from a case complexity adjusted 
average of 83.9 minutes to 88.6 minutes) is attributable to a general shift to longer 
CPBDs rather than an increase in the number of high outliers. Change point analysis 
suggests the increase in CPBD took place around the 19th December 2009. 
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Figure 14.4: Shewhart Control Chart of CPBD’ residuals for individual Phase I and Phase II 
surgeries. Upper and Lower control limits are set at ± 3 σr of the Phase I data (+/- 0.227). 
Open dots represent surgeries with CPBD’ falling outside the control limits or where no 
bypass time was recorded (in which case the CPBD’ is shown as 0). Short dashed line is at the 
19th December 2009 and corresponds to the point in time identified as the statistical change 
point for CPBD’. 
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Figure 14.5: EWMA of CPBD’ residuals. Control limits are based on Phase I data (+/- 
0.019). Short dashed line is at the 19th December 2009 and corresponds to the point in time 
identified as the statistical change point for CPBD’. 
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Figure 14.6 charts variations in significant events during the period of monitoring. 
Use of TXA declined throughout Phase I and Phase II with a marked drop in use 
occurring in July/August 2010, well after the change point for CPBD. There was a 
marked increase in IO-TOE use at the start of Phase II, while change point analysis 
confirms an increase in IOVs occurred after the change in CPBD (10th March 2010 vs. 
19th December 2009) and as such, IOV is unlikely to be have caused the increase in 
CPBD. The sequencing of these events suggests, however, that CPBD or the agent 
driving changes in CPBD may have contributed to the increase in IOVs. The marked 
change in IO-TOE use was identified to have occurred in early November 2009. This 
time frame corresponds to the commissioning of two TOE units for dedicated use in 
cardiac surgery and use of IO-TOE shifting from being exclusively cardiologist-
directed for complex valve cases to include use by cardiologists and appropriately 
certified anaesthetists in cases which also included non-valve surgeries. Rates for IO-
TOE in CABG Only, Valve Only and CABG & Valve procedures increased from 1% 
to 45%, 45% to 78% and 27% to 71% from Phase I to Phase II. 
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Figure 14.6: EWMA chart tracking variations in TXA use, use of IO-TOE and incidence of 
intra-operative variations during the period of monitoring. Also highlighted on the graph is 
the change point for CPBD (19th December 2009) and the date on which the possibility of a 
link between CPBD and IO-TOE was first discussed with senior clinicians. 
 
Along with the analysis of peri- and post-operative complications , Figure 14.3 also 
depicts the result of an evaluation of IO-TOE and TXA use in Phase I and association 
of these factors with prolonged CPBD. This analysis suggests that while there does 
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not appear to be any link between TXA use and prolonged CPBD (OR=1.07), use of 
IO-TOE does appear to be strongly associated with prolonged CPBD (OR=2.34, 
p<0.001). To further evaluate which, if any, of the factors under consideration (IO-
TOE, TXA and IOV) contributed to the variation detected by the control chart, each 
factor was individually included in the regression model (using Phase I data) and the 
control charts re-compiled using the revised residual values. This analysis eliminated 
both TXA use and occurrence of IOVs as potential contributing factors as application 
of the updated regression model did not effect the EWMA chart’s signal. This finding 
is consistent with the results suggested by the change point analysis. This contrasts 
with the changes noted with the Phase II signal when IO-TOE was factored into the 
regression model as shown in Figure 14.7. Although not totally addressing the 
increase in CPBD’ between January 2010 and April 2010, the revised model largely 
addresses the increase in the remainder of Phase II after this period. 
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Figure 14.7: EWMA of CPBD’ residuals following inclusion of IO-TOE as a factor in the 
regression model. Control limits are based on Phase I data. Short dashed line is at the 19th 
December 2009 and corresponds to the point in time identified as the statistical change point 
for CPBD’. 
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Figure 14.8: Result of propensity score matched analysis. OR (with 95% confidence 
intervals) shown for peri- and post- outcomes for cases involving IO-TOE compared with 
those where IO-TOE was not used. Open diamonds indicate no significance found while 
closed diamonds indicate significance at p<0.05, p<0.01 and p<0.001 using (*), (**) and 
(***) respectively. 
 
The result shown in Figure 14.7 suggests that IO-TOE was a contributor to prolonging 
CPBD. To evaluate the clinical significance of the use of IO-TOE, analysis of peri- 
and post-procedural outcomes and complications, using propensity score matched 
datasets was employed. This analysis matched cases based on the likelihood of use of 
IO-TOE. The result of this analysis is summarised in Figure 14.8. This suggests that 
of the outcomes and complications assessed, IO-TOE was associated with a only a 
significant increase in post-operative pulmonary complications (pleural effusion, 
pneumonia, pneumothorax, prolonged ventilation, pulmonary embolism, chest 
infection and acute pulmonary odema).   
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14.5   Discussion 
 
Investigations such as the 2001 inquiry into paediatric cardiac surgery at the Bristol 
Royal Infirmary (The Bristol Royal Infirmary Inquiry 2001) and the Queensland 
Public Hospitals Commission of Inquiry 2005 (Queensland Government 2005) have 
led to an increased emphasis on the implementation of systems that ensure the 
delivery of clinical services of an acceptable quality. Building on more than 15 years 
of robust outcome-focused peer review, the cardiac surgical unit at SAWMH has 
proactively explored the innovative application of SPC tools to augment the 
traditional M&M review approach to driving quality outcomes.  
 
A key part of this process has been the establishment of a core set of clinical outcome 
indicators (COIs) that track the overall ‘health’ of the unit’s performance. Due to the 
relatively low rate of major complications (death ~ 1.5%), selection of COIs for 
monitoring using SPC has tended to focus on markers that can act as early warning 
indicators of system performance deterioration or change. The application of SPC in 
this context addresses the findings of Carthey at el (Carthey, de Leval et al. 2001) 
who identified that an increase in the incidence of ‘near miss’ type events in complex 
systems as providing evidence of an overall deterioration in performance that, if left 
unaddressed, might lead to a clustering of catastrophic events. 
 
One indicator considered for inclusion in the SAWMH cardiac surgical unit’s 
monitoring processes is CBPD. As this is recorded as a continuous variable, it offers 
unique challenges in terms of developing and implementing a generalisable 
monitoring process that accounts for case complexity.   
 
14.5.1 CPBD as a Performance Indicator: 
 
Following the principles outlined by Shahian et al, (Shahian, Edwards et al. 2007) 
indicators used for monitoring clinical quality should accurately reflect the 
Chapter 14:  Monitoring Bypass Duration in Cardiac Surgery 361 
 
performance they are intended to measure; adequately reflect the quality of care, and 
be easily interpretable and actionable by providers. By underscoring the link between 
longer than expected CPBD (upper quartile of residuals) and poorer outcomes for 
patients, the analysis presented in Figure 14.3 demonstrates that CPBD satisfies these 
requirements.  
 
Based on the data analysed in this study, patients undergoing surgeries that were 
characterised with unexpectedly long CPBD experienced a higher rate of intra-
operative variations (bleeding and perfusion defects, p<0.001) and appear to be at 
greater risk of neurologic events (p=0.009) and pulmonary complications (p<0.001) 
post-surgery. The combination of these outcomes may contribute to patients 
experiencing longer stays in ICU (p=0.003) and hospital (p=0.02). Despite having 
initial EuroSCOREs that are not statistically different, at 1 months these patients have 
higher odds of death and 30 days and 12 months (OR=6.5, p=0.006 & OR=3.1, 
p=0.017). In part these findings support the findings of Salis et al. (2008) (Salis, 
Mazzanti et al. 2008), although we did not identify any significant link with 
reoperation for bleeding while the changing pattern in use of TXA rendered any 
observations regarding blood transfusion meaningless. 
 
Although it is apparent a link exists between bypass duration and increased risk to the 
patient following cardiac surgery, as the unit’s median CPBD is 85 minutes and the 
‘safe’ limit of 240 minutes suggested by Nissinen et al. (2009) (Nissinen, Biancari et 
al. 2009) is exceeded in only 1.2% of surgeries, it is unlikely there will be any 
significant adverse event rate attributable to (changes in) CPBD alone. Therefore, 
aside from any direct effect prolonged bypass might have on the incidence of post 
procedural adverse events, as CPBD can be impacted not only by the critical 
condition of the patient but also technical difficulties during the operation (Nissinen, 
Biancari et al. 2009), it can also be viewed as a “near miss” marker and therefore an 
independent indicator of the stability of the processes underpinning cardiac surgical 
performance. 
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14.5.2 Monitoring CPBD: 
 
This analysis demonstrates that it is possible to establish a control chart based 
monitoring process for CPBD. When applied to the SAWMH data, the charts 
demonstrated stability across the Phase I period. Shortly after the commencement of 
Phase II, the chart indicates that there was a significant increase in CPBD of 
approximately 5.5%. This change, was sustained until early 2011, at which time 
CPBD returned to the Phase I levels. 
 
As stated previously, motivation for selection of Phase I was to enable assessment of 
the impact of changes to the systems of treatment and care arising from the hospital 
redevelopment. In this regard, the charts and accompanying analysis do suggest that 
some aspect of the redevelopment (and associated capital acquisition program) may 
have contributed to the identified shift in patient outcomes.  
 
Having identified a change in CPBD, the next step undertaken was a structured 
review of the processes delivering this result. Initial stages of this review focused on 
issues of data quality and case mix. In both aspects these factors were eliminated as 
contributing factors as the data is subject to critical review upon entry (with no 
evidence of data quality issues over the period in question) and the case mix in the 
unit remained relatively constant throughout the period of monitoring. Attention was 
therefore given to evaluating environmental issues, process of care factors and 
clinician contribution to the outcomes. 
 
Analysis of the rate of significant intra- and post- operative events suggests that 
across the Phase I and II periods of monitoring, there has been an increase in both 
IOVs and certain major post-operative complications. Timing of these changes, 
however, does not seem to correlate precisely with the increase noted in CPBD. The 
IOV chart, for example, appears to increase some months after the change in CPBD. 
Another factor, noted in Figure 14.6, that was thought to have some bearing on CPBD 
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was decline in use of TXA. Changes in TXA do seem to have some relationship with 
both IOVs and post-procedural complications, although again the timing of changes in 
these factors and CPBD was not closely related. Regression analysis effectively 
eliminated both IOVs and TXA as being related to the CPBD increase. 
 
As noted previously, the end of Phase I coincided with the commissioning of two new 
cardiac operating theatres at SAWMH, both equipped with the capacity to offer IO-
TOE. At around this time, anaesthetist directed IO-TOE gained acceptance. When 
combined, these two events resulted in a marked increase in use of IO-TOE, up from 
20%-30% in Phase I to a peak of 60%-70% in Phase 2 (see Figure 14.6). This increase 
was noted in all cardiac surgeries including CABG procedures. Analysis of the 
relationship between IO-TOE use and prolonged CPBD (Figure 14.3) suggests this is 
a potential contributing factor to the signal and when IO-TOE is factored into the 
CPBD’ prediction model, the resultant control chart returns to being within the 
control limits. This confirms suspicions that IO-TOE is the likely contributor to the 
noted increase. The residual transient increase in the EWMA chart of Figure 7 (after 
revision of the CPBD’ model to include IO-TOE) for the period January 2010 to April 
2010 is likely to stem from the use of data from Phase I. As this was a period when all 
IO-TOE was under the control of experienced cardiologists, any impact on CPBD 
associated with the use of IO-TOE will be compounded by the change to a higher 
proportion of procedures being covered by inexperienced non-cardiology operators 
and any associated training impact.. The decline in CPBD’ residual after June 2011 is 
likely due to heightened awareness of the use of CPBD as a COI (through discussion 
at the unit’s M&M meetings) and a combination of a reduction in use of IO-TOE 
(from 70% down to 55%) and continued improved proficiency on the part of the non-
cardiology users. 
 
14.5.3 Impact of IO-TOE Use: 
 
Although it is likely that IO-TOE use has resulted in a ‘transient’ increase in CPBD, it 
is also apparent that this has not resulted in a proportional increase in the major 
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negative consequences attributed to prolonged CPBD. Propensity score based analysis 
suggests that of the major complications reviewed, IO-TOE is associated with only an 
increase in pulmonary complications post surgery. This finding is consistent with the 
known complications of TOE reported by others (Flachskampf and Klinghammer 
2010). Concerning the trend to a higher rate of IOVs under IO-TOE (p=0.06), it is 
unclear, whether this is a causal effect or if IO-TOE has merely facilitated IOV 
detection. 
 
 
14.6   Conclusion 
 
The process outlined in this paper uses two control charts, informed by clinically 
derived data, to monitor for variations in a quality process indicator (CPBD) during a 
large scale transition in a service-level’s system of delivering care. The characteristics 
of CPBD as a COI are generalisable to other service-lines and are recommended to 
enhance existing clinical performance monitoring and improvement programs. 
Through the use of a two chart monitoring and improvement system, CPBD 
continuous data can be captured and analysed on a case by case basis, thereby 
offering a mechanism for identifying and addressing data and individual procedural 
anomalies promptly. Through use of the EWMA chart, significant small sustained 
shifts in CPBD arising from changes in imaging practice can be identified and their 
effects managed. We have demonstrated the effectiveness of this system in the 
clinical setting by its integration with a service-level quality assurance program.  
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CHAPTER 15 
 
 
Conclusion 
 
The overarching goal of the research undertaking in preparing this thesis was the 
development of a systematic scientific process for ensuring the delivery of excellence 
in interventional cardiology. Implicit in this objective was the desire for the system 
developed to have broader applicability and as such be transferable to other clinical 
domains. At the core of this research was the adaptation of existing, well-established 
and accepted statistical quality control and improvement techniques from the 
industrial context to healthcare. To this end, a logical set of research questions were 
raised and practically addressed in the setting of a hospital offering a range of clinical 
services including diagnostic and interventional cardiology and cardiac surgery. In 
addressing the questions raised, issues relating to the choice of outcome measures, 
tools for monitoring clinical outcomes and the governance use of quantitative 
information to monitor and improve clinical practice have been dealt with. The 
findings of this work, detailed in Chapters 3 to 14 of this thesis, are summarised in the 
following sections of this chapter and are mapped back to the original research 
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objectives. This chapter concludes with a brief discussion of possible future areas of 
research. 
 
15.1   Research Findings 
 
To achieve the stated goal, the program of research was divided into three main 
objectives. These are briefly discussed in the following subsections, where we link 
achievement of these objectives to the outcomes of research conducted and described. 
 
15.1.1 Objective 1: Performance Measures for PCI 
 
This component of research dealt with the identification of a set of clinical outcome 
measures that could be used to quantify the quality of clinical performance of an 
interventional cardiology service. This aspect of research involved three main 
components: 
 
Objective 1(a) Performance Measures: In Chapters 2 and 3 we identified a 
comprehensive set of criteria that could be used to characterise clinical outcome 
indicators suitable for the task of tracking the quality of a clinical service. These 
characteristics included the requirement that the indicators be measureable and 
actionable, have sufficient frequency of occurrence to enable the use of statistical 
process control techniques and cover a time frame extending from the point of care to 
post discharge recovery. When these criteria were applied to interventional 
cardiology, outcome indicators appropriate to the task were identified, these included; 
successful treatment of each lesion attempted, patient success (success in treating all 
lesions attempted in a patient), post procedural/pre-discharge complication rate and 
the rate of target lesion revascularisation and major adverse cardiac events at one 
month and twelve months post procedure. In addition to these measures of patient 
outcome, Chapters 2 and 6 identified radiation use in performing cardiac imaging as 
being a useful performance measure as the stochastic risk (cancer induction) and risk 
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of deterministic injury (erythema, epilation and desquamation) associated with 
exposure to ionising radiation has the potential for significant short and long term 
health implications for patients undergoing cardiac diagnostic and interventional 
procedures. 
 
Objective 1(b) Risk Adjustment: A major difference impacting on the translation of 
statistical monitoring and improvement processes from the industrial to the healthcare 
setting is the presence of factors inherent in the patient that are known to impact upon 
their outcome. To account for known sources of variation, monitoring tools have been 
adapted to adjust for variations in patient risk by comparing the observed and 
expected outcomes. In Chapter 4 we explored the importance of using a risk 
adjustment algorithm that exhibits sound discrimination and calibration for the patient 
cohort being monitored. In this chapter we use as an example the APACHE II 
algorithm which was developed for audit applications in the intensive care unit where 
it is intended to be predictive of the risk of death. In the SAWMH patient population 
this model was shown to possess adequate discrimination but significantly over 
predict the risk for individual patients. A simple process involving a non-linear 
(power function) recalibration of the raw APACHE II risk estimates was described for 
adapting this algorithm to the patient cohort and improvement in performance of the 
modified monitoring process was demonstrated. One reason for using an example in 
intensive care to demonstrate calibration issues of an existing risk model for SPC is 
that there are very few universally accepted risk models in interventional cardiology. 
This issue was the subject of Chapter 5 in which we describe the development and 
application of a risk model for the outcome indicator of lesion treatment failure. 
 
Objective 1(c) Issues of Data Quality: Use of quantitative performance management 
systems is critically dependent on the accuracy and completeness of data used in the 
monitoring process. This aspect of the project was touched upon in Chapters 6 and 8. 
In Chapter 6, which explored the monitoring of equipment performance stability in 
cardiac imaging, a process for monitoring radiation use in cardiac imaging procedures 
was described in which patient and imaging process factors are used to predict the 
overall quantum of radiation expected to result from an imaging procedure. This 
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chapter describes how comparison of the observed and expected case radiation levels 
can be used to identify inconsistencies in the quality of the data. In Chapter 8, which 
was primarily concerned with the adaptation of multivariate control charts to health 
care applications, issues were encountered with missing data. Various options for 
dealing with missing data were discussed and best practice was identified using 
simulated scenarios.  
 
 
15.1.2 Objective 2: Control Charts for Monitoring PCI Outcomes 
 
This component of research dealt with the development and validation of charting 
tools to be used to monitor clinical performance in PCI. Work in this was addressed 
through two main activities: 
 
Objective 2(a) Control Chart Selection: This aspect of research, described and 
discussed in Chapters 2, 3, 6 and 7 involved a review of the range of control charts in 
common use in health care applications. A key consideration in the selection of 
charting tools was identified as the need for these tools to not only be efficient at 
identifying possible performance variations but also to be easily interpretable by the 
general clinician user. At the time Chapter 3 was written, no one charting tool was 
identified as offering a suitable solution. As such the use of a two chart system was 
described that employed the ‘Steiner’ double sided CUSUM chart (using the log 
likelihood ratio as the test statistic) for the statistical detection of change in parallel 
with the VLAD (using the accumulation of events more or less than expected across 
the monitored period) for ease of interpretation by clinicians. Chapter 3 also explored 
the issue of peer group performance comparison and advocated the use of risk 
adjusted funnel plots for comparisons between individual clinicians. Subsequent to 
the preparation of Chapter 3, work by others had validated the use of an innovative 
charting method based on the use of a system of EWMA charts to simultaneously 
track observed and expected outcomes delivered by the process being monitored. 
Control limits are then constructed around the chart of expected outcomes with 
Chapter 15:  Conclusion  374 
 
unexpected performance being signalled when the chart of observed performance 
exceeds the defined limits. An unfortunate limitation of this system is that it is not 
validated for event rates of less than 5%. As a number of the outcomes identified in 
Chapter 3 occur at rates less than this threshold, this limitation precludes the use of 
EWMA charts in the form originally proposed. Chapter 7 addresses the lower event 
rate limitation issue by revisiting derivation of the control limits, replacing the 
conventional (symmetrical) Wald interval limits with limits derived using a Wilson 
interval approximation (with an offset to account for the offset bias to 0.5). 
 
While most of the indicators proposed in Chapter 3 are in the form of binary events, 
the various measures used to document radiation use can be considered as being in 
the form of continuous variables. The versatility of the EWMA chart was used in 
Chapter 6 which described the development of a charting system based on a 
combination of a conventional Shewhart and EWMA charts to deliver a system 
sensitive to variations in the performance drift of cardiac imaging platforms. As 
identified under Objective 1 (c), the first phase of this analysis (involving the 
Shewhart chart) also provides a data quality check as outlier residual values 
(observed minus expected dose area product results) act as a trigger to investigate 
potential data errors. 
 
Objective 2(b) Issues of Multiple Testing: As the establishment of a comprehensive 
performance monitoring program has the potential to involve the simultaneous 
tracking of a number of clinical outcome indicators, Chapter 3 discussed the need to 
strike a balance between the desire to implement a broad based monitoring program 
and the increased likelihood of falsely signalling a change in performance through 
over testing. This issue was addressed in Chapter 8 which described the adaptation of 
multivariate control charts to monitor radiation use in cardiac imaging procedures. 
Multivariate control charts have the potential of limiting the false alarm rate inherent 
in the use of system of multiple univariate charts since any correlation between the 
variables is ignored. The process described involved the development of a single test 
statistic that incorporated the three routinely collected (and potentially correlated) 
continuous radiation measures that document the time taken to position catheters in a 
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patients heart, document the state of disease when radio opaque contrast is injected 
and describe the total quantum of radiation delivered. Superiority of the multivariate 
statistic obtained by combining the three measures was compared to the performance 
of the three measures in isolation and found to have advantages. 
 
15.1.3 Objective 3: Use of SPC in Clinical Governance 
 
This component of research dealt with how the analysis and interpretation of 
information obtained through the monitoring process can be used to maintain and 
improve clinical performance in PCI.  
 
While the work discussed in earlier chapters of this thesis has clearly demonstrated 
that when designed appropriately, a system of clinical outcome indicators monitored 
through the application of control charts can be used to effectively identify drift in 
the performance of processes delivering a clinical outcome, to be of maximum 
benefit in a clinical governance framework it is important to identify the point in time 
at which a change took place. This is the subject of Chapter 9, which described and 
evaluated a Bayesian estimator to determine the ‘true’ time of change of EWMA and 
CUSUM control charts used to monitor outcomes of a clinical process. This study 
validated the use of the Bayesian change point indicator by confirming coincidence 
between known potential causes of change and the detected change points of 
processes monitoring excess blood product usage in patients undergoing cardiac 
surgery and the incidence of major adverse cardiac events in patients following PCI.  
 
Having addressed the issues of what outcomes should be monitored (Objective 1) and 
what tools should be used for the purposes of evaluation (Objective 2) the question of 
how best to use the quantitative information to maintain and potentially improve 
outcomes was dealt with in Chapters 10 to 12. In Chapter 10, we evaluated the 
provision of regular quantitative personalised feedback as a means of stimulating 
clinicians to optimise their clinical practice. The example used dealt with the 
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provision of benchmarked radiation use in which a clinicians were provided with 
annul reports detailing their radiation use with that of their peer group. The analysis 
of the impact of this program demonstrated that feedback was an important 
component of a systematic program for monitoring and improving outcomes. We 
linked the observed findings to behaviour change theory via the Theory of Planned 
Behaviour (TPB). Under TPB, it is postulated that three matters need to be addressed 
to ensure a change in behaviour; the individual must see a benefit in achieving the 
change, the individual must identify that achieving change is important to significant 
others and the individual must accept that change is possible. We concluded that 
while existing education and legislative mechanisms may address the first two 
change components, the provision of feedback showing what is possible within the 
local cohort is a powerful motivator for achieving change .  
 
Having established that quantitative feedback is an important component of a 
governance strategy designed to optimise clinical performance, in Chapter 11 we 
then discussed a program of research that explored the impact of providing 
benchmarked feedback closer to the point of care. In essence the study divided a 
cohort of clinicians performing cardiac angiography into two equal groups with one 
half provided with patient details only while the remainder provided with details of 
their case based radiation use compared to appropriately adjusted 3rd quartile 
benchmark data (similar methodology to that used by the National Radiological 
Protection Board in the United Kingdom and the Australian Radiation Protection and 
Nuclear Safety Agency in Australia). The study found that the group blinded to their 
radiation use improved their performance overall while the group receiving 
benchmarked data increased their radiation metrics. The outcome of this study for the 
group receiving radiation data was linked to Goal Setting Theory (GST) which 
suggests that for a benchmark to be effective at driving change it must be achievable 
but challenging. In this regard, use of a 3rd quartile benchmark only was deemed not 
to be a sufficient challenge. For the group receiving clinical feedback only, we 
attributed the improvement noted to the Hawthorne Effect (change that arises through 
participation in a study rather than due to the intervention). This study suggests that 
while use of a 3rd quartile benchmark may be useful in identifying underperformance, 
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change management theory in the form of GST suggests that there is a role for setting 
aspirational benchmarks in order to encourage improvement. 
 
A question arising out of Chapters 10 and 11 concerned the range in documented 
radiation use amongst clinicians performing coronary angiography. In Chapter 12 we 
described the development and application of an algorithm that combined a 
qualitative assessment of information yield for each imaging projection commonly 
used in cardiac angiography with estimates of the effective dose to the patient and 
scatter dose to the clinician. The outcome of this study was a set of projections that 
could be employed by clinicians to optimally balance the competing needs of 
diagnostic performance and minimum radiation risk (to both the patient and 
clinician).  
 
The overall aim of this objective was the validation of a systematic approach to 
employing statistical process control techniques to monitor a suite of identified 
outcome indicators to ensure the quality of clinical outcomes delivered by a unit 
performing interventional cardiology. A broad framework for such a system was 
introduced in Chapter 3. To achieve maximum engagement, it was recommended that 
the proposed system be clinician lead rather than one driven solely by an 
administrative or legislative agenda. Key aspects of the system included the need for 
clinicians to be involved in all aspects of establishment of the process with a clear 
understanding by all concerned of the structured review process that would be 
triggered as a consequence of a change in outcome being signalled. Chapters 13 and 
14 demonstrate how a statistical process control based governance process can work 
to monitor and improve outcomes in the clinical setting. In Chapter 13 we described 
the development of risk adjusted control charts to monitor post surgical bleeding and 
demonstrate how these can be used to provide important information concerning 
changes in clinical practice. This chapter also reinforced the structured review process 
associated with a signal event and how this can be used to identify and deal with 
changes in the process of care (in this instance, the use of anti-fibrinolytic drugs). This 
chapter also demonstrates the type of analysis that can be brought to bear to address 
questions surrounding changes in the process of care, specifically the use of 
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propensity matched data sets to explore concerns about the use of alternative 
treatments. The analysis presented in Chapter 14 also provided an example drawn 
from cardiac surgery. In this instance the use of statistical process control tools in a 
structured governance system was used to proactively monitor for the consequences 
of an intended change in the process of care when the hospital commissioned a new 
operating theatre complex equipped with a range of innovative technologies. The 
example demonstrated how the control charts were able to detect a significant shift in 
bypass times for patient undergoing cardiac surgery and how the use of a structured 
review process, assisted by change point analysis was able to identify the likely cause 
of the change.   
 
15.1.4 Contribution to Method 
 
The agenda for research into methods for evaluating and improving the performance 
of health services is long standing, with reports of physicians as long ago as 1864 
reacting derisively to the release of data comparing death rates in English hospitals 
(Iezzoni 1997). At that time, it was argued that the analysis performed had used 
questionable statistical methods and had failed to adequately account for the 
differences in patient characteristics. Although the publication of English hospital 
death rates took place almost 150 years ago, suspicion of the statistical methods and 
criticism around failure to adequately addresses differences in patient complexity still 
persist. A goal of this research has therefore been to ensure, as best as possible, that 
the tools and processes developed are able to be understood and interpret by the 
average clinician. With this in mind, the contribution to method made by this thesis 
can be considered as being in four categories: 
 
Control Charts for Healthcare Applications: While initial work in this thesis identified 
the need to use a combination of CUSUM and VLAD charts to provide sound 
statistical evaluation of clinical performance and intuitive feedback to clinicians, the 
EWMA chart has evolved to be a universal tool that is capable of fulfilling both 
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requirements. A further advantage of the EWMA chart is that it can be readily 
adapted to the task of monitoring both binary outcomes (e.g. success or failure of a 
procedure) and outcomes measured on a continuous scale (e.g. time a patient spends 
on cardiopulmonary bypass). In dealing with applications involving a binary outcome, 
Chapter 7 addresses a basic limitation of the Wald based control limits for the EWMA 
by proposing an alterative derivation of the control limits based around the Wilson’s 
interval. For continuous data, Chapters 6 and 14 describe the development of a 
EWMA based monitoring process that uses clinically derived data to monitor the 
stability of a clinical process, in so doing, the charting process extends the concept of 
risk adjustment to deal with data in this form.  
 
Change Point Detection: Efficient investigation of signals occurring during the 
monitoring of a clinical process is substantially enhanced when the point in time at 
which the process changed can be defined. In Chapter 9 we described the 
development of a Bayesian estimator to identify the time when the potential changes 
in the underlying rate occurred prior to signals. The efficiency of this process in a 
clinical setting was confirmed through retrospective application in two examples 
where the timing of clinical practice changes were know to have impacted on 
outcomes.  
 
Clinical Practice Optimisation: An undesirable consequence of cardiac imaging 
procedures is the increased risk of cancer induction faced by patients as a result of 
exposure to ionising radiation. In Chapter 12 we describe the development and 
outcome of an algorithm that combines information from published sources to 
identify a set of imaging projections capable of adequately documenting a normal 
diagnostic cardiac angiography study at the lowest risk to both patient and clinicians 
(as angiography is an operator directed procedure they are present in the room during 
the imaging procedure).    
 
Clinical Governance Processes: In Chapters 3 and 13 we describe the development 
and implementation of a systematic approach to driving the maintenance and 
improvement of quality of healthcare services. The process identified is based on the 
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use of a suite of clinical outcome indicators monitored via of range of statistical 
process control tools within a governance framework that features performance 
feedback to participating clinicians. The process is designed and run in close 
consultation with clinicians to ensure optimal engagement and understanding of the 
process and the consequences arising should deviation from accepted performance be 
identified. A key feature of this process is that it must both limit exposure to 
underperformance and encourage learning from identified ‘true’ excellence. In 
Chapter 10 we confirmed a link between quantitative benchmarked feedback with 
improved clinical performance (in diagnostic angiography), explaining the result 
using the ‘Theory of Planned Behaviour’. While Chapter 11 was intended to build on 
this work, it resulted in a finding that suggested poorly considered benchmarks might 
contribute to a decline in standards in certain subgroups of the monitored cohort. This 
work concluded that although minimum performance standards have a place for 
detecting underperformance, application of ‘Goal Setting Theory’ suggests a need for 
aspirational targets to be used to encourage performance improvement.     
 
15.1.5 Contribution to Application 
 
At the outset it is important to acknowledge that the body of work presented in this 
thesis builds on the substantial efforts done over many years by others in developing 
and validating statistical methods to support quality monitoring and improvement in 
the industrial domain. For almost as long, many others have worked diligently to 
address the many confounding differences between health care and industry to adapt 
these tools in to the clinical setting. The contribution this thesis makes is to extend the 
use of statistical process control techniques from the monitoring of isolated single 
measures of performance through the use of univariate control charts to deliver a 
structured process capable of monitoring and improving the performance of a clinical 
service. As such the major contribution made by this work goes to the application of 
statistical techniques to support a structured clinical governance processes. 
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Chapter 3 described the broad framework for the use of statistical process monitoring 
to underpin quality monitoring and improvement in interventional cardiology. This 
chapter also proposed a set of meaningful and actionable clinical outcome indicators 
for monitoring the overall quality of delivery of angioplasty services. Chapters 4 and 
5 dealt with the refinement of the monitoring process through the adaptation and 
development of risk models. Chapter 4 demonstrated the need to ensure that 
commonly accepted risk models were appropriately calibrated to the local cohort 
being monitored (offering a simple process for performing this task) while Chapter 5 
described use of Bayesian techniques to develop an outcome indicator specific risk 
model when an off-the-shelf algorithm is not available. Chapter 6 provided an 
important contribution to the field of radiation risk minimisation (particularly in 
complex cardiac imaging procedures) by demonstrating how routinely collected case 
based clinical data could be used to enhance the monitoring of stability of 
performance of the cardiac imaging process thereby enhancing the overall safety of 
this practice. The work described in Chapter 8 extends the use of multivariate charts 
from the industrial domain to monitoring applications in healthcare. In some aspects 
the example applications used in Chapters 6 and 8 offer two different processes for 
delivering a similar outcome. Chapter 9 provides validation of change point 
estimation as a valuable tool to assist in the investigation of signals arising form 
control charts with application of this work being highlighted as a cornerstone of the 
investigation into changes in cardiopulmonary bypass duration identified in Chapter 
14.   
 
While a number of the examples used in this thesis dealt with the retrospective 
application of SPC to prospectively collected data to demonstrate how the use of these 
tools and techniques could have identified circumstance of deterioration in clinical 
performance, we have also demonstrated extension of the use of these tools to monitor 
for the effectiveness of change interventions. This capability was used to enhance the 
analysis provided in Chapters 10 and 11 which assessed the timing and impact of the 
provision of education and feedback interventions aimed at encouraging clinicians to 
modify their practice. 
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A case for the overall effectiveness of an SPC backed clinical governance program 
was provided in Chapters 13 and 14. Both cases provided examples arising form the 
implementation of such a program into cardiac surgery. Chapter 13 in broad terms 
mirrors the process described in Chapter 3 which involved interventional cardiology. 
In both chapters the charts were used to identify points of change of the respective 
processes (post surgical bleeding in Chapter 13 and bypass duration in Chapter 14). 
Monitoring provided by the charts subsequent to the identification of change 
demonstrated that the provision of data to the clinicians in a structured manner clearly 
played a role in influencing their performance.    
 
15.2   Future Research 
 
Where appropriate in each Chapter of this thesis, potential areas of development and 
future research have been explicitly and implicitly identified. Extensions identified 
can be categorised broadly under each of the objective headings; performance 
measures for PCI (specifically issues of data quality), control charting methods, issues 
related to clinical governance and potential health services research. 
 
15.2.1 Data Quality 
 
In the signal investigation protocol outlined by Mohammed et al. (Mohammed, 
Rathbone et al. 2004) it is recommended that the initial response of a governance 
system to the identification of a substantial shift in clinical performance is a review of 
the quality of data used in the monitoring process. Such an investigation leads in two 
directions; it can focus on the accuracy of the available data (ensuring information 
relating to outcomes and risk adjustment accurately represents the actual chain of 
events) and it can involve a review of the completeness of data capture (including any 
impact or biases missing data may have on the monitoring process). 
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Data accuracy: As identified above, the signal investigation process suggested by 
Mohammed et al. involves five sequential stages of investigation. In essence, 
however, these five stages can be logically grouped into two distinct categories; 
validation (centred on issues to do with data quality and case mix) and root cause 
investigation (structure of resources, process of care and clinician performance). 
There is nothing, however, that mandates that addressing any or all of these steps 
must take place after a signal is detected, indeed the signal investigation process could 
be expedited through the implementation of processes that run in ‘real’ time to track 
the stability of these factors. In particular implementation of mechanisms that address 
data quality and case mix stability in an ongoing review process could substantially 
speed up the investigation process, allowing focus to rapidly shift to analysis of 
aspects of the process dealing with patient care. Systems such as those described in 
Chapter 6 which identify inconsistencies in the data through analysis of the 
differences between observed and expected outcomes might offer some assistance. 
Another approach to the data quality issue is the application of acceptance sampling 
plans as suggested by Assareh (Assareh 2012). Development and evaluation of these 
tools is strongly recommended with a view to their potential integration into 
electronic medical record and electronic registry systems. A necessary extrapolation 
of this work is to develop an understanding of the tolerance of the clinical outcomes 
monitoring processes to issues of data quality (see also section 15.2.4). Whilst every 
effort should be made to ensure that data is as consistent and accurate as possible 
research in this area would provide a better understanding of the boundaries that need 
to be set around data quality to achieve optimum (cost) efficiency.  
 
Data completeness: Whilst every effort is taken to ensure that the data used to support 
clinical governance processes is complete, due to resource constraints this is usually 
not the case. Missing data was one of the issues identified and briefly dealt with in 
Chapter 8. As a result of this review, we strongly advised against ignoring records 
which feature missing data and cautioned against using methods such as imputation 
based on the sample mean or regression as these artificially reduce variability. 
Multiple imputation (Rubin 1987) was identified as the preferred method of dealing 
with this problem as it preserves variability in the missing values and performs well 
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for small sample sizes and/or large proportions of missing data. The issue of missing 
data and how to deal with it, becomes particularly relevant when outcomes 
monitoring is extended into the post discharge period. An issue not fully dealt with in 
Chapter 8 concerns the characteristics of the missing data. Preliminary work in this 
area suggests that the impact of incomplete follow-up is might be influenced by the 
nature of the missingness of the data. Work by Kristman et al. (Kristman, Manno et 
al. 2005) explored the level of missingness that could be tolerated in the presence of 
data missing completely at random (MCAR: missingness is independent of the 
exposure, confounders or the outcome), missing at random (MAR: missingness is 
dependent on the exposure and confounders but not the outcome) and missing not at 
random (MNAR: missingness is dependent on the outcome). Preliminary analysis 
suggests that in the case of MCAR and MAR use of imputation has the effect of 
increasing both the in-control (ARL0) and out-of-control (ARL1) run lengths as it 
reduces the amount of variability in the data. While the former is not considered a 
problem, a higher ARL1 is less desirable as this might lead to unacceptable delays in 
responding to true changes in performance. However, in the presence of data MNAR, 
such as might be found in long term outomes where there is the possibility that 
patients may be lost to follow-up due to death (which is an endpoint of interest) there 
is the potential for this bias to adversely impact upon the performance of a monitoring 
process. A potential solution to this issue would be to monitor, and correct for, this 
bias using the known characteristics of patients captured at the time of treatment (all 
patients) and at follow-up (those with successful follow-up). The methodology for 
achieving this is the subject of future research which will draw upon the experience 
gained by others in dealing with incomplete follow-up data sets associated with, for 
example, longitudinal studies (Dufouil, Brayne et al. 2004; Kristman, Manno et al. 
2005). 
 
15.2.2 Control Charting Methods 
 
Multivariate charts for RA binary outcomes: As identified in Chapters 2 and 3, a 
consequence of establishing a service wide monitoring program involving a 
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comprehensive range of clinical outcome and service delivery attributes is the 
increased opportunity for false alarms to arise due to the issue of multiple testing 
(Bland and Altman 1995). To minimise this risk, a balance must be struck between 
the desire to implement a broad based monitoring program and the increased 
likelihood of falsely signalling a change in performance through over testing. In this 
thesis we have dealt with this issue by identifying a core, minimum set of 
performance attributes and focused monitoring on these. As a possible means of 
addressing this problem, in Chapter 8, we explored the adaptation of multivariate 
control charts to performance monitoring in the clinical setting. This example 
application demonstrated and compared use of the Hotelling’s T2 (Hotelling 1947), the 
multivariate exponentially weighted moving average (MEWMA) (Lowry, Woodall et 
al. 1992), and the multivariate cumulative sum (MCUSUM) (Crosier 1988) charts. In 
the example application of Chapter 8, which dealt with the monitoring of radiation use 
in cardiac imaging procedures, the three metrics monitored were represented as 
continuous (normally distributed) variables as this is a fundamental requirement of the 
charting methods evaluated. In healthcare, however, most outcomes are measured in 
terms of binary events (survival vs. death, success vs. failure) or number of events 
occurring in a sample. Further exacerbating this issue is that in most instances, the 
event rates for outcomes of interest can be low (1-5%) with the likelihood of these 
outcomes being subject to variation on a case by case basis due to known factors (risk 
adjustment). Adaptation of multivariate charting methods to cater for the various 
types of data commonly encountered in healthcare is a recommended area of further 
research.  
 
EWMA charts for low event rates: As identified in Chapters 6 and 7, the EWMA 
chart is proving to be a very versatile and informative graphical tool for use in 
performance monitoring applications in healthcare. Not only is the chart relatively 
straightforward to implement and able to convey information in a form that is easily 
interpretable by clinicians, it can be shown to have signal detection performance as 
good as other charting methods such as the CUSUM. Unfortunately, in the form 
proposed by Cook et al. (Cook, Coory et al. 2011) use of the EWMA chart to monitor 
binary outcomes with an event rate of less than 5% is not recommended due to the 
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inherent characteristics of the Wald based control limits. Although we have offered a 
solution to this problem (based on a Wilson’s interval approach), the technique we 
have derived has a number of empirical aspects that, although addressing the 
fundamental issue, make routine use of the chart more complex. Further work in 
developing alternative derivations of the control limits of the EWMA chart for use in 
monitoring applications where event rates are less than 5% is encouraged. Such 
methods might focus on alternative enhanced theoretical derivation of the control 
limits or hybrid charting techniques. The former approach might explore approaches 
focussing on deriving a better description of the distribution of the EWMA function.  
 
15.2.3 Clinical Governance 
 
Complex Risk Models: Algorithms commonly used for estimating the risk a patient 
faces of experiencing an outcome (death, morbidity etc) largely utilise factors inherent 
in the patient alone. Conventional wisdom attributes the systematic failure to deliver 
an intended outcome to the skill of the physician involved. Vincent et al. (Vincent, 
Moorthy et al. 2004) expands on this concept by extending the scope of the factors 
contributing to a clinical outcome to also include aspects of communication, 
teamwork, resources, operative environment and decision making. In a sense these 
aspects align with the ‘upper’ three stages of the signal investigation process proposed 
by Mohammed at al (Mohammed, Rathbone et al. 2004) which was referred to in 
section 15.2.1 as the “root cause analysis phase” of investigation. An area of research 
that is recommended is the exploration of the extent to which team and environmental 
factors contribute to patient outcomes. Elements of this work have already been 
touched upon by Grutterink et al. (Grutterink, Van der Vegt et al. 2012) who 
attributed mutual recognition by team members of each other's expertise as a factor 
contributing to positive team performance while Pisano et al. (Pisano, Bohmer et al. 
2001) has linked team characteristics to the speed and success of the adoption of new 
clinical procedures and technologies. These findings are supported by preliminary 
work on cardiac surgical blood product use in which marked variations in 
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performance can be linked to the presence or absence of a stable team while the 
model used in the monitoring of bypass duration described in Chapter 13 had to 
include a factor to account for surgeon variations in order to allow focus on the 
process of care. Similarly, while it is well known that the imaging platform has a 
dominant role to play in the level of radiation used in a cardiac imaging procedure 
(hence the reason behind room specific algorithms in Chapter 6) work done in the 
analysis of radiation use by cardiologists in performing coronary angiograms and 
angioplasty procedures appears to suggest that the radiographer (a member of the 
imaging team) also has an influence over the level of radiation used. This work may 
evolve to the development of risk models and charting processes that are based on not 
only patient characteristics but also characteristics of the clinician (or clinical team) 
and environment. Such systems may improve statistical monitoring programs by 
allowing focus to be shifted to key elements of the care process other than the 
clinician. 
 
15.2.4 Health Services Research 
 
The work presented in this thesis has focussed largely on the use of measures of 
clinical outcome and process to monitor and drive improvement in the quality of 
service experienced by patients. The underlying premise for this work has been that 
efforts to reduce the incidence of adverse events and poor outcomes will result in an 
optimisation of the expenditure of resources in delivering the clinical service. Studies 
such as those by Eappen et al. (Eappen, Lane et al. 2013) and Krupka et al. (Krupka, 
Sandberg et al. 2011), however, appear to indicate that under defined circumstances, 
efforts to improve patient outcomes might actually have a negative impact on a 
hospitals revenue with Krupka et al. (Krupka, Sandberg et al. 2011) suggesting that 
this impact could be as high as $US1.2M in lost revenue per 1% fall in adverse 
events. Although these results appear to arise due to an artifact of the hospital funding 
model involved and ignore the wider societal impact of adverse events and poor 
outcomes, they do serve to raise questions concerning the cost and cost impact of 
programs aimed at monitoring and improving patient outcomes. Areas of potential 
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future research could, therefore, address issues relating to the question of cost and 
cost efficiency in the delivery of quality healthcare. This work might focus on two 
closely related issues; impact of the use of cost related measures as indicators of 
performance and an evaluation of the cost effectiveness of programs aimed at 
monitoring and improving clinical outcomes. 
 
Regarding the inclusion of measures of cost as performance indicators, preliminary 
work has been done in this area looking at evaluating the potential of a multi-
dimensional analysis approach to evaluating clinical performance. One of these 
projects has explored the use of a two dimensional funnel plot to evaluate and 
compared lesion treatment success rates by individual clinicians against the cost 
incurred in delivering treatment. In this preliminary analysis, the cost metric used was 
in terms of radiation exposure delivered, however, metrics linked to number and type 
of stents deployed or net revenue per case could be employed. Similarly, evaluations 
in cardiac surgery involving utilisation of resources (theatre time, hospital length of 
stay, adoption and use of innovative technologies, use of blood products and 
antifibrinolytics etc) and outcome achieved has yielded some interesting results and 
suggest that these evaluations can contribute to an improvement in both the cost 
effectiveness and performance of a clinical service.  
 
With regards the second issue, a question needing to be addressed concerns the 
overall cost effectiveness of the implementation and ongoing operation of a 
comprehensive quality monitoring and improvement program. Programs such as that 
outlined in this thesis are expensive with a major component being attributed to 
efforts involved in ensuring comprehensive, complete and high quality data. To 
optimise the impact of these monitoring and improvement programs, a number of 
questions need to be addressed. These include; the link between data quality and 
performance of the monitoring system (i.e. what level of data quality is required to 
deliver a system that performs effectively and efficiently), what is the cost of 
achieving the required data quality, and what is the cost in achieving incremental 
gains in the outcomes delivered by a service through the implementation of a 
comprehensive monitoring program. The added complexity in this is that the outcome 
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gains (and costs in achieving these gains) might depend on the initial quality of the 
service into which the program is being introduced. As identified in the analysis 
concerning the introduction of quantitative feedback, in certain circumstances, 
improvement may not reasonably be possible (e.g. in the case of a clinician or service 
delivering a high standard of care) whereas for others, quite substantial improvements 
might be achieved for a modest investment in time and effort. Overall, however, an 
analysis exploring the optimisation of return on investment of quality monitoring and 
improvement programs such as those described in the thesis is warranted. 
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